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Summary 
Genetic screening to improve obesity treatment outcomes is available despite the lack of conclusive 
evidence, specifically for Caucasian South Africans, in this regard.  
 
The aim of this study was to investigate the association between genotype (seven polymorphisms) and 
body mass index (BMI), health and lifestyle indicators in a cross-sectional sample of overweight/obese 
Caucasian adults (n=133), as well as the association between genotype and weight loss outcomes following 
an intervention (n=88) using a quasi experimental study design (time-series).  The intervention consisted of 
a 24-week conservative weight loss programme that included dietary, physical activity and behavioural 
components. 
 
The primary null hypothesis for the cross-sectional sample, namely that there is no association between 
genotype and BMI, has not been rejected.  A number of the secondary/exploratory hypotheses were 
rejected of which the most plausible associations (based on support by the literature and a physiological 
basis for the findng) are: 1) the mutant TT homozygotes of the GNB3 C825T polymorphism may have a 
higher risk to develop the metabolic syndrome (MetS) as they had significantly higher fasting triglyceride 
and glucose levels, a higher number of traits that met the diagnostic cut-off criteria for MetS and higher 
number of these subjects was diagnosed with MetS compared to the wild-type C-allele carriers; and 2) 
subjects with mutant alleles of either the FTO rs1421085 or rs17817449 polymorphisms may have poorer 
eating behaviours (a higher rigid control, habitual and emotional disinhibition, perceived hunger and 
internal locus for hunger) and higher intake of high-fat foods.   
 
The primary null hypothesis for the intervention sample, namely that there is no association between 
genotype and weight loss outcome, was not rejected for the FABP2 Ala54Thr, INSIG2 rs7566605, FTO 
rs1421085, ADRB3 Trp64Arg and GNB3 C825T polymorphisms.  However, it was rejected in some instances 
indicating the following associations: 1) The wild-type TT homozygotes of the FTO rs17817449 
polymorphism lost significantly more weight during the first two months of the program compared to the 
mutant allele carriers (this is a novel finding); 2) The wild-type Arg16Arg homozygotes of the ADRB2 
Arg16Gly polymorphism lost significantly more weight during the first month of the program compared to 
the mutant allele carriers (this finding is supported by one other intervention study); 3) Subjects with a 
mutant C-allele of the INSIG2 rs7566605 polymorphism and a mutant Gly16-allele of the ADRB2 Arg16Gly 
polymorphism lost significantly less weight over the six month intervention period (this is a novel gene-
gene interaction finding).  A number of secondary/exploratory hypotheses were rejected, of which the 
most plausible finding include that the improvement in emotional disinhibition in the wild-type TT subjects 
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of the FTO rs1421085 polymorphism was associated with a more pronounced decrease in BMI over the six 
month weight loss period. 
 
The integration of the results from this study with the literature indicates that there is insufficient evidence 
at this stage for genetic screening of the polymorphisms investigated in this study and the provision of 
evidence-based personalized recommendations for weight loss in obese individuals.  It is recommended 
that these associations should be viewed as priority in future research.  
 v
Opsomming 
Genetiese sifting om die resultate van vetsug behandeling te verbeter is beskikbaar ten spyte van ‘n tekort 
aan genoegsame bewyse, spesifiek ten opsigte van Kaukasiërs van Suid-Afrika.  
 
Die doel van hierdie studie was om die assosiasie tussen genotipe (sewe polimorfismes) en liggaamsmassa 
indeks (LMI), gesondheid en lewenstyl indikatore in ‘n dwarssnit (cross-sectional) steekproef van 
oorgewig/vetsugtige Kaukasiër volwassenes (n=133) te ondersoek, asook die assosiasie tussen genotipe en 
gewigsverlies uitkomste na afloop van ‘n intervensie (n=88) in ‘n kwasi-eksperimentele studie ontwerp (tyd-
reeks).  Die intervensie het bestaan uit ‘n 24-week konserwatiewe gewigsverlies program met dieet, fisieke 
aktiwiteit en gedragskomponente. 
 
Die primêre nul hipotese vir die dwarsnit steekproef, naamlik dat daar geen assosiasie tussen genotipe en 
LMI is nie, is nie verwerp nie.  ‘n Aantal sekondêre/spekulatiewe hipotesis is verwerp waarvan die mees 
geloofwaardige assosiasies (gebasseer op ondersteuning van die literatuur en ‘n fisiologiese basis vir die 
bevinding) die volgende insluit: 1) die mutante TT homosigote van die GNB3 C825T polimorfisme het 
moontlik ‘n hoër risiko vir die ontwikkeling van die metaboliese sindroom (MetS) aangesien hulle 
betekenisvolle hoër vastende trigliseriede en glukose vlakke gehad het, ‘n grooter aantal kenmerke gehad 
het wat aan die diagnostiese afsnykriteria vir MetS voldoen en ‘n grooter aantal van hierdie persone was 
met MetS gediagnoseer in vergelyking met die wilde-tipe C-alleel draers; en 2) persone met die mutante 
allele van die FTO rs1421085 of rs17817449 polimorfismes het moontlik ‘n swakker eetgedrag (‘n hoër 
rigiede kontrole, gewoonte en emosionele disinhibisie, waarneembare honger en interne lokus van honger) 
en ‘n hoër inname van hoë-vet voedsel.  
 
Die primêre nul hipotese vir die intervensie steekproef, naamlik dat daar geen assosiasie tussen genotipe 
en gewigsverlies uitkomste is nie, is nie vir die FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, ADRB3 
Trp64Arg en GNB3 C825T polimorfismes verwerp nie. Dit was egter in sommige gevalle vir die volgende 
assosiasies verwerp: 1) Die wilde-tipe TT homosigote van die FTO rs17817449 polimorfisme het 
betekenisvol meer gewig in die eerste twee maande van die program verloor in vergelyking met die 
mutante alleel draers (dit is ‘n nuwe bevinding); 2) Die wilde-tipe Arg16Arg homosigote van die ADRB2 
Arg16Gly polimorfisme het betekenisvol meer gewig gedurende die eerste maand van die program verloor 
in vergelyking met die mutante alleel draers (hierdie bevinding word ondersteun deur een ander 
intervensie studie); 3) Persone met ‘n mutante C-alleel van die INSIG2 rs7566605 polimorfisme en ‘n 
mutante Gly16-allele van die ADRB2 Arg16Gly polimorfisme het minder gewig tydens die ses maande 
intervensie periode verloor (dit is ‘n nuwe geen-geen interaksie bevinding).  ‘n Aantal sekondêre/ 
spekulatiewe hipoteses is verwerp, waarvan die mees geloofwaardigste bevinding insluit dat ‘n verbetering 
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in emosionele disinhibisie van die wild-tipe TT persone van die FTO rs1421085 polimorfisme geassosieer 
was met ‘n meer prominente daling in LMI oor die ses maande gewigsverlies periode.  
 
Die integrasie van die resultate van hierdie navorsing met die literatuur dui aan dat daar op hierdie stadium 
onvoldoende bewyse vir genetiese sifting en die voorsiening van bewys-gebasseerde persoonlike 
aanbevelings vir gewigsverlies in vetsugtig individue bestaan vir die polimorfismes wat ondersoek is.  Dit 
word aanbeveel dat hierdie assosiasies as prioriteit in toekomstige navorsing beskou moet word.   
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Chapter 1 
 
Introduction 
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1.1 Problem identification and motivation for study 
 
In 2003, the World Health Organization (WHO) estimated that globally more than 1 billion adults were 
overweight with at least 300 million being obese (WHO 2003).  Obesity has reached epidemic proportions 
in many countries and is still escalating at an alarming rate world-wide, affecting children and adults in both 
developed and developing countries, including South Africa (WHO 2003, WHO 2010, DoH 2007).    
 
According to the second South African Demographic and Health Survey (SADHS), obesity prevalence (BMI ≥ 
30 kg/m2) in adult South Africans older than 15 years is 8.8% for men and 27.4% for women, while a further 
21.0% men and 27.5% women are overweight (BMI≥25 and <30 kg/m2) (DoH 2007).  For women obesity is a 
problem across all races with the prevalence being 24.8% for Indian, 13.7% for Caucasian, 26.5% for 
Coloured and 28.5% for Black females.  The obesity prevalence for Caucasian males (23.0%) is higher than 
the prevalence for Indian (10.9%), Coloured (14.9%) and Black (7.1%) men (DoH 2007).  A comparison of 
the weight status results from the first (conducted in 1998) to the second SADHS (conducted in 2003) 
revealed that this situation has remained unchanged over the five year period (DoH 2007). 
 
The high overweight and obesity prevalence is concerning as it is known that obesity is associated with 
increased morbidity and mortality risk (Brown et al. 2009).  Obesity is an intermediate risk factor for the 
development of chronic diseases of lifestyle (CDLs) including cardiovascular disease, stroke, cancer and 
Type 2 diabetes (WHO 2005, WHO 2008, Brown et al. 2009).  These chronic and life-threatening diseases 
are often accompanied by a range of other non-fatal but debilitating conditions such as infertility, 
dermatological problems, respiratory difficulties, osteoarthritis and gout that affect the immediate quality 
of life (Brown et al. 2009).  Furthermore, obese individuals often have to contend with factors such as social 
stigmatization and discrimination, especially in Western societies, that contribute to psychological 
problems (Simon et al. 2006).  These include the development and progression of a low self-esteem, body 
image problems, binge eating (Stunkard & Sobal 1995), loss of self-confidence, depression and lower levels 
of happiness (summarized by Franz 1998). 
 
Because of the negative consequences associated with obesity, research has extensively focussed on the 
development and implementation of various obesity prevention and treatment/management strategies, 
which is still ongoing (Aronne et al. 2009, Wolf & Woodworth 2009).  However, despite these efforts to 
address the problem and the fact that it has been shown that small weight losses of five to ten percent of 
initial weight are associated with clear health benefits (Seagle et al. 2009), the prevalence of obesity 
remains high in many countries and is still increasing worldwide (WHO 2010).  This situation can be 
ascribed to the fact that prevention and treatment/management of obesity have proven not to be simple 
tasks most probably due to the heterogeneous nature of the disease that has yet to be fully elucidated 
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(Rosmond 2004, WHO 2000, Dahlman & Arner 2007).  Although it is known that obesity results when 
energy intake chronically exceeds energy expenditure, creating a positive energy balance (Papas et al. 
2007), the pathophysiology of the condition is complex (Romao & Roth 2008) and the causes of the positive 
energy balance are multifactorial.  It is now acknowledged that effective obesity prevention and 
management should address the root causes of the condition that can include any combination of genetic, 
metabolic, biochemical, psychological, physiological and environmental factors (Rosmond 2004).  In terms 
of environmental factors, the concept ‘obesogenic’ environment has emerged to describe aspects of the 
built and social environments that promote the adoption of ‘obesogenic’ behaviour that includes the 
consumption of large portion size meals, unhealthy high-fat and refined carbohydrate diets and physical 
inactivity (Bouchard 2007).  However, it is well known that not all individuals living in an obesogenic 
environment and engaging in obesogenic behaviour will gain weight (Loos & Rankinen 2005, Chung & Leibel 
2008).  Furthermore, it has also been observed that obese individuals following the same obesity treatment 
strategies do not necessarily react the same to this treatment (Kaput & Rodriguez 2004, DeBusk et al. 2005, 
Hainer et al. 2008, Reilly & DeBusk 2008).  Studies on monozygotic and dizygotic twin pairs have confirmed 
that exposure to the same controlled environment has led to the same weight loss in response to a weight 
reduction programme in twins carrying identical genes (monozygotic twins).  However, differences in 
weight loss between twin pairs or in dizygotic twins are clearly evident (Bouchard et al. 1994, Hainer et al. 
2000).  Although the fact that heritability does contribute anything from 5% to 90% to the variation in 
human adiposity (Loos & Bouchard 2003, Romao & Roth 2008) has long been recognized, the advent of 
nutritional genomics in the early 2000s provided a new perspective on this relationship (Loktionov 2003, 
Kaput & Rodriguez 2004).  The nutritional genomics perspective proposes that when individuals engage in 
the same obesogenic behaviour, those who have genetic mutations that promote the development of 
obesity will gain more weight and probably develop obesity, while those without the genetic predisposition 
for obesity will gain little if any weight (Loos & Bouchard 2003, Loos & Rankinen 2005, Chung & Leibel 2008).   
 
The challenge posed by the nutritional genomics perspective lies in the fact that any number and 
combination of susceptibility genes may be interacting in numerous ways with any combination of 
environmental and other health factors to result in the obese phenotype (Chung & Leibel 2008, Marti et al. 
2008, Romao & Roth 2008).  To date a large number of candidate genes and genetic markers that are 
associated with a variety of obesity-related phenotypes have been identified (Rankinen et al. 2006).  
According to the latest obesity gene map, the number of human obesity quantitative trait loci (QTLs) for 
obesity-related phenotypes is 253 generated from 61 genome-wide scans.  A total of 52 of these genomic 
regions are supported by two or more studies.  From candidate gene studies, 426 positive associations with 
obesity related phenotypes have been reported for 127 candidate genes.  Of these candidate genes, 22 
have shown associations with obesity-related phenotypes in at least five studies (reviewed by Rankinen et 
al. 2006).   
 4 
It has been proposed that the science of nutritional genomics could result in gene based susceptibility 
screening for a specific phenotype, also referred to as predictive genetic testing (PGT). PGT refers to the 
screening of healthy individuals in the general population to identify those who are at risk of developing a 
multifactorial chronic disease such as obesity, cancer, heart disease etc. based on the presence of mutant 
polymorphisms in several genes (Evans et al. 2001). Furthermore, genetic screening could also be used to 
predict individual response to treatment in those with already developed risk factors or diseases.  The 
outcomes of genetic screening are subsequently applied to personalize nutrition (Joost et al. 2007), 
involving genotype tailored dietary recommendations for the individual in order to prevent, treat or even 
cure a disease (Boehl 2007).  Proposed benefits of genotype-based personalized nutritional advice for 
chronic conditions such as obesity include the following:  Firstly, genotyping for early identification of at risk 
individuals without manifested risk factors, may result in early introduction of targeted prevention when 
compared to current practices of identification and consequent treatment of manifested risk factors for 
diseases (DeBusk et al. 2005, Joost et al. 2007, Stover & Caudill 2008).  Joost et al. (2007) maintain that 
such preventative advice may be especially beneficial for conditions that are known to have a long latency 
period in the development of associated complications.  Secondly, Joost et al. (2007) argue that genotype 
based disease prevention/treatment may result in more cost-effective treatment as successful 
interventions can be targeted at those who are most likely to benefit from them.  Thirdly, genotype results 
may motivate at risk individuals to change their lifestyle to comply with necessary dietary advice (Joost et al. 
2007).  It is thus proposed that genetic screening will enable dietitians and other health professionals to 
ultimately move away from generalized nutrition recommendations to prescribing more genotype-based 
personalized diets and other lifestyle recommendations to prevent/treat disease (DeBusk et al. 2005, 
Trujillo et al. 2006).   
 
Although genetic screening has been used effectively in the past to screen for relatively uncommon 
monogenic disorders, it has become increasingly available on the market for chronic disease 
prevention/management.  In many countries, including South Africa, companies have started marketing 
genetic screening, through health care providers or directly to the public, even in the form of home-testing 
kits (DeBusk et al. 2005, Jakobsdottir et al. 2009, www.dnadiet.co.za).  The tests are often accompanied by 
customized recommendations for the intake of specific vitamins and foods according to each individual’s 
genotype (www.quackwatch.org).  There is no doubt that economic forces played a role in creating a strong 
drive for the increased availability of genetic screening (Baird 2001).  Baird (2001) comments that in 
countries where there is sufficient wealth to provide a potential market of consumers, inappropriate 
overuse could become a challenge. 
  
In light of these developments it is important to emphasize that as is the case with all clinical practice in 
dietetics, genetic screening for personalization of dietary recommendations for obesity 
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prevention/treatment needs to be evidenced-based (Gray & Gray 2002).  In 2002 Nieters et al. (2002) 
mentioned that research regarding the link between obesity related genes, phenotype markers and 
environmental factors (e.g. dietary intake and physical activity) and how this would translate into 
formulation of effective obesity prevention and management strategies at lifestyle level, was still in its 
infancy. At the time it was also suggested by a number of researchers that these questions should become 
the focus of nutritional genomics research worldwide (Patterson 1999, Kaput & Rodriguez 2004).  Loktionov 
(2003) mentioned that these questions should be investigated in humans using association or linkage 
studies with obesity phenotypes or even better, in actual intervention studies to assess the effect of 
genotype on the response to dietary and possibly other life-style changes, bearing in mind the genetic 
heterogeneity amongst different race groups.  Although the effect of some candidate genes on weight loss 
outcomes have been investigated since these suggestions were made (reviewed by Hainer et al. 2008), the 
latter authors concluded that the evidence is not yet sufficient to support evidence-based practice in this 
field and recommend that more research is necessary before effective personalized obesity prevention or 
treatment (weight loss diets) strategies for obese individuals can be suggested.  More specifically, although 
associations for 127 candidate genes with one or more obesity phenotype indicator have been reported, 
the effect of only very few of these genes on weight loss outcomes have been investigated in clinical trials 
(Hainer et al. 2008).  None of the trails that have been completed were conducted on South Africans.   
 
For the contention of Simopoulos (2010) that “every physician and other relevant health care professionals 
will need to utilize genetic information to recommend diet, physical activity and pharmacotherapy” to 
become reality as part of evidence-based practice for obesity prevention/treatment in South Africa, 
research among South African population groups in this regard is imperative.  Such research will also 
contribute to informing health care professionals and the public regarding the appropriateness of currently 
available genetic screening for obesity prevention/treatment. 
   
 
1.2 Aims and objectives 
 
Aim: 
To investigate the association between genotype and BMI, health and lifestyle indicators as well as weight 
loss outcomes in overweight/obese Caucasian1 adults2. 
 
 
                                                 
1
 A parallel group of South African Zulu overweight/obese adults is currently under investigation 
2 These genotype associations were investigated in a cross-sectional and an intervention sample (see Section 3.1 for detail). 
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Objectives: 
Cross-sectional sample of overweight/obese Caucasian South African adults: 
1. To determine and describe the physical health of subjects in terms of the prevalence of metabolic 
syndrome (MetS) and each MetS trait.  
2. To describe the association between BMI and health (perceived weight history, MetS prevalence, MetS 
traits and psychological health) and lifestyle (physical activity, dietary intake and eating behaviour) 
indicators. 
3. To investigate the association between genotype and BMI, health and lifestyle indicators: 
 Determine the genotype and allele frequencies of the following obesity-related polymorphisms: 
FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, FTO rs17817449, ADRB3 Trp64Arg, ADRB2 
Arg16Gly and GNB3 C825T.   
 Determine the association between genotype and BMI, health and lifestyle indicators.   
 Determine the effect of the interaction between genotype and health and lifestyle indicators on 
BMI. 
 
Intervention sample of overweight/obese Caucasian South African adults: 
4. To assess the effectiveness of a conservative weight loss programme in terms of  
 Weight and BMI reduction over the total 24 week intervention period. 
 Changes in selected health and lifestyle indicators that were the focus of strategies included in the 
weight loss programme from baseline to 16 week follow-up.   
5. To investigate the association between genotype and conservative weight loss outcomes: 
 Determine the association between genotype and treatment outcome (change in weight and BMI) 
at four, eight, 12, 16 and 24 weeks of the intervention period. 
 Determine the effect of the interaction between genotype and change in process outcomes 
(selected health and lifestyle indicators that were the focus of strategies included in the weight 
loss programme) on change in BMI over the 24 week intervention period. 
 
 
6. To integrate the genotype associations found in objectives 3, 5 and existing evidence to elucidate the 
potential role of genetic screening for polymorphisms included in this study in the formulation of 
personalized obesity treatment strategies for overweight/obese Caucasians.    
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1.3 Definition of terms 
 
For the purposes of this research health and lifestyle indicators reflect the following (see Chapter 3 for 
details): 
Health indicators:  
 Physical health: MetS traits (waist circumference, blood pressure, glucose, triglyceride and HDL levels.) 
and the diagnoses of MetS. 
 Weight history: perception of weight during childhood, adolescence and young adulthood. 
 Psychological health: general psychological well-being, depression and self-esteem. 
 
Lifestyle indicators: 
 Physical activity: Work, sport and leisure-time physical activity 
 Dietary intake: Frequency of intake of energy-dense indicator food groups namely high fat foods, take-
away foods, energy-dense snacks and energy-dense drinks. 
 Eating behaviour: Dietary restraint, disinhibition and perceived hunger. 
 
Conservative treatment refers to a six month weight loss programme consisting of dietary, physical activity 
and behavioural strategies (see p132 for details) 
 
Weight loss outcomes refer to:   
 Treatment outcomes: Changes in weight and BMI over a 24 week intervention period. 
 Process outcomes: Changes in selected health (psychological health) and lifestyle (physical activity and 
eating behaviour) indicators that were the focus of strategies included in the weight loss programme 
 
 
1.4 Outline of thesis 
 
In Chapter 2 a review of the literature is presented that firstly focuses on a brief overview of the etiology of 
obesity followed by an in depth discussion of each gene and polymorphism investigated in this study 
(literature up until January 2010 were included).  This is followed by a detailed description of the methods 
and experimental procedures used in this study in Chapter 3.  The results, discussion and conclusions of the 
cross-sectional sample to meet objectives 1 to 3 of this study are presented in Chapter 4.  The results, 
discussion and conclusions of the intervention sample to meet objectives 4 and 5 follow in Chapter 5.  
Finally, an integrative discussion of Chapters 4 and 5 to meet objective 6 is presented in Chapter 6.  The 
references for all the above-mentioned Chapters appear in Chapter 7.   
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Chapter 2 
 
Literature review 
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The etiology of obesity, including the genetics of obesity, are the core concepts discussed in the first section of 
this literature review.  The focus in the first section is on the role of dietary intake, physical activity, the built-
environment, socio-economic status, education, culture, behavioural, psychological and biological factors in 
obesity development.  Following this, the genetics of obesity, including monogenic and polygenic forms thereof 
are described.  The discussion on each gene included in this research, provides specific reference to the 
characteristics of the gene, the protein expressed by the gene and the physiological function thereof, the 
mutation(s) selected for investigation in this research as well as the functionality of the mutation and the 
reported genotype and allele frequencies.  This is followed by tabulated summaries and discussions on the 
association of each selected mutation with weight status, fat distribution, glucose homeostasis, plasma lipid 
profile, blood pressure and outcome of weight loss intervention programmes.   
 
2.1 Etiology of obesity 
 
Obesity results when energy intake chronically exceeds energy expenditure, creating a positive energy balance 
(Papas et al. 2007).  However, the pathophysiology of obesity is complex (Romao & Roth 2008) and the causes of 
the positive energy balance are multifactorial and not fully understood, with several lifestyle factors manifesting 
together in a genetically susceptible individual to produce weight gain and obesity development (Rosmond 2004, 
WHO 2000, Dahlman & Arner 2007).  In almost all cases obesity development is characterized by an interaction 
between genetics and environmental factors over time (Romao & Roth 2008).   
 
The extra energy from a positive energy balance is stored as fat in adipose tissue and results in gradual weight 
gain over years and consequent development of obesity (Dahlman & Arner 2007).  According to the WHO (2000) 
gaining weight can be divided into the following three phases: 
 A pre-obese static phase during which long-term energy balance is experienced and weight remains constant. 
 A dynamic phase during which weight gain occurs as a result of a prolonged positive energy balance. This 
phase may continue for several years and is often recognized by considerable fluctuations in weight (weight-
cycling) as the individual tries to lose weight.  During this phase an energy imbalance of as little as 80 kJ in 
excess per day can cause a 0.89 kg body weight gain in an average person per year or 4.4 kg in five years 
(Cohen 2008).  The rate of weight gain can eventually decrease as a result of physiological adaptations such 
as changes in basal metabolic rate (WHO 2000).   
 An obese static phase during which energy balance is regained, however this energy balance now occurs at a 
higher weight than the weight held during the pre-obese static phase, as a result of the weight gain that 
occurred in the dynamic phase (WHO 2000).  In the obese static phase the body appears to defend this new 
(higher) body weight referred to as the new “settling point” (Peters 2006).  During adult life several settling 
points are defended by the body as individuals go through dynamic weight gain phases followed by a weight 
stable phase (WHO 2000).   
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According to Bouchard (2007) the potential contributors to the higher obesity prevalence seen over the past 
decades can be grouped under four major headings, namely the built environment, social environment, 
behaviour and biology.  Built environment factors contribute to obesity development when it causes physical 
inactivity and high energy consumption e.g. increased use of automobiles, building design favouring increased 
access to fast-food outlets and lack of safe sidewalks.  The social environmental factors that increase the risk for 
obesity development include marketing, advertising and cultural influences.  Together the built and social 
environments result in the phenomenon that is referred to as the ‘obesogenic’ environment in both developed 
and in most developing areas of the world.  This obesogenic environment promotes the adoption of obesogenic 
behaviour that includes the consumption of large portion size meals, high-fat diets, high sugar intake, many 
hours spent watching television, playing video games or sitting at a computer.  Consequently, in a population 
exposed to this obesogenic environment and that partakes in the same obesogenic behaviour, those with a 
higher biological predisposition to develop obesity (with genetic polymorphisms favouring weight gain) will gain 
more weight.  However, in comparison to them, others with an intermediate, very low or non-existent 
predisposition will gain less or no weight respectively (Bouchard 2007).   
 
2.1.1 Dietary intake 
 
Experimental studies in animals and humans have repeatedly shown that dietary factors, especially fat and 
energy intake, are associated with obesity development (WHO 2000).  The term, obesogenic foods, has been 
used to collectively refer to those components in the diet that might cause obesity.  However, at this point in 
time no standard definition for obesogenic foods is available.  Dietary components referred to as obesogenic by 
various authors, include the following: a higher intake of energy-dense food (Black & Macinko 2008), fats (Bray 
et al. 2004a, Rosmond et al. 2004), refined carbohydrates (Gross et al. 2004), high-fructose corn syrup (Bray et al. 
2004b), sweetened beverages (Malik et al. 2006, Gibson 2008, Wolff & Dansinger 2008) and a low carbohydrate 
diet (<47% of total energy) (Merchant et al. 2009).  Furthermore, eating fast foods (Black & Macinko 2008), 
eating away from home (McCrory et al. 1999, Popkin 2006), eating larger portions sizes (Nielsen & Popkin 2003, 
Popkin 2006) and an inappropriate meal pattern and snacking (Popkin 2006, Marín-Guerrero et al. 2008, Howell 
et al. 2009) may be referred to as obesogenic eating behaviours.  A discussion of these dietary components and 
the association thereof with the development of obesity is presented in the following sections.   
 
Macronutrient content of diet 
It is well known that the extent to which excess energy is stored depends on the macronutrient content of the 
diet as the metabolic and physiologic characteristics and effects of the different macronutrients differ (Table 2.1).  
When excess energy is consumed, priority for oxidization goes to those macronutrients with no or limited 
storage capacity within the body.  Alcohol is always oxidized first because it is toxic to the body and the body has 
no storage capacity for it.  Second in line for oxidation is protein, as the body has a limited storage capacity and 
because amino acid balance is tightly regulated so that any excess is oxidized.  Carbohydrate is third in line, as 
the body can store only limited amounts of carbohydrates in the form of glycogen in the liver and muscle tissue 
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(WHO 2000, Peters 2006).  Liver glycogen can be released to keep blood glucose levels constant for instance 
during overnight fasting, while muscle glycogen supplies glucose to working muscles (Peters 2006).  In humans, 
excess carbohydrates are not usually stored as fat.  However, this can occur when the diet supplies very little fat 
and excessive amounts of carbohydrates over time.  Last in line is fat, as the body has virtually an unlimited 
storage capacity for fats in the adipose tissue, while fat intake does not markedly increase fat oxidation, thus 
favouring adipogenesis.  It is also important to note that the storage of fat requires very little energy and the 
storage process is thus highly energy efficient.  Thus, when considering the metabolism of the macronutrients, it 
is evident that dietary fat intake favours fat storage when a positive energy balance exists for the mentioned 
reasons (WHO 2000, Peters 2006).   
 
Table 2.1:  Metabolic and physiologic characteristics and effects of macronutrients 
 Protein Carbohydrates Fat 
Ability to bring eating to an end High Intermediate Low 
Ability to suppress hunger High High Low 
Contribution to daily energy intake Low High High 
Energy density Low Low High 
Storage capacity in the body Low Low High 
Metabolic pathway to transfer excess intake to another compartment Yes Yes No 
Autoregulation (ability to stimulate own oxidation on intake) Excellent Excellent Poor 
From WHO (2000). 
 
Fat intake 
A higher fat intake has previously been associated with a higher BMI in Black South Africans (Kruger et al. 2002, 
Vorster et al. 2000).  Possible explanations for the link between obesity development and a high-fat intake may 
include the fact that dietary fat provides more energy per gram when compared to the other macronutrients 
(Peters 2006).  Consequently, passive overconsumption can easily occur when individuals are exposed to high-
fat foods.  Furthermore, the high palatability that fat provides to a meal has a stimulatory effect on food intake.  
In addition it is thought that the signals controlling appetite and food intake may be too weak or too delayed in 
response to a fatty meal to control food intake.  Consistent high intake of fatty foods may overwhelm these 
signals and influence long-term regulatory processes stimulating an inability to respond to overeating (WHO 
2000). 
 
Palatability  
Sweetness and fat promote the palatability of foods, which is associated with increases in the rate of eating and 
the sense of hunger during meals (WHO 2000).  Fat provides a pleasurable mouth feel, while sweetness provides 
the easy and most powerful recognisable enjoyable tastes.  It has been shown that obese women prefer fat-
sweet mixtures which may be a contributing factor to weight gain (WHO 2000).  In a review article by Mattes 
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(2008) it was indicated that the consumption of palatable foods is associated with a greater energy intake and 
weight gain.   
 
Carbohydrate intake 
It has been shown that diets providing between 290 to 310g of carbohydrates per day (between 47 to 64% of 
total energy per day) are associated with the lowest risk for overweight or obesity (Merchant et al. 2009).  
However, a low carbohydrate diet consisting of less than 47% of total energy intake seems to be associated with 
obesity development (Merchant et al. 2009).  Such a low carbohydrate diet would normally provide more fat 
compared to the higher carbohydrate diet to make up the energy composition.  As summarized in Table 2.1, 
carbohydrates, especially complex and low GI carbohydrates have the ability to suppress hunger and have a 
lower energy density and storage capacity in the body compared to fat (WHO 2000).   
 
High fructose corn syrup 
It has been argued that the increased production and intake of high fructose corn syrup (HFCS) may be 
associated with the increasing prevalence of obesity (Bray 2008, Duffey & Popkin 2008).  Since the 1970s, lower 
farming prices have led to a decrease in the price of maize, making it an inexpensive starch that could be 
converted in to a highly sweet and very cheap liquid known as HFCS, using the new isomerase technology.  HFCS 
is now commonly used in the manufacturing of soft drinks and other highly processed foods.  Therefore, since 
the early 1970s a steep rise in HFCS was noticed in the food supply chain (Bray 2008).  It is evident that HFCS has 
rapidly replaced sugar in manufactured products such as sports drinks, high-fat milk, salad dressings, sweetened 
coffee and tea, hamburgers, breads, cereals and desserts and almost entirely replaced the sugar in fruit juices 
and soft drinks (Bray 2008, Duffey & Popkin 2008).  From a review of 12 studies by Bray (2008) it was evident 
that 10 indicated a positive association between HFCS containing soft drinks and energy intake.  The author 
concluded that soft drink consumption usually adds additional kilojoules to the daily energy consumption, as 
individuals normally do not lower the intake of another food to compensate for the energy content of the soft 
drink (Bray 2008).  Furthermore, data from the United States of America indicates that less water and milk are 
consumed at this point in time, while regular soft drinks and beer are the first and second most frequently 
consumed beverages (Nielsen & Popkin 2004, Popkin 2006, Wolf et al. 2008).   
 
Fast-foods 
The consumption of fast-foods may also be associated with greater weight gain and obesity development 
(Duffey et al. 2007, Larson et al. 2009).  Although it can be argued that fast-foods were available 50 years ago 
when obesity prevalence was very low, today many individuals do not consume fast-foods as an occasional meal 
or treat but rather include it is as a regular addition to their diet.  It is known that the accessibility and 
consumption of fast-foods has grown significantly over the past two decades with famous outlets such as 
McDonalds and Kentucky Fried Chicken spreading rapidly across the globe (Popkin 2006).  Meals from these 
outlets are often irresistible for a large section of the population, as they are intensely marketed, highly 
palatable and available at relatively cheap prices compared to other ready meals (WHO 2000).  In general, fast-
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foods are low in complex carbohydrates and micronutrients, high in fat, energy-dense, high in glycemic load, 
excessive in portion sizes and not entirely satisfying (WHO 2000, Rosenheck 2008).  Days when individuals eat at 
fast-food restaurants are characterized by a higher intake of soft drinks and chips and a lower intake of 
vegetables, cereals and milk compared to days when they do not eat at these restaurants (Paeratakul et al. 
2003).  Fast-food consumption has been associated with higher energy intakes, BMIs, greater long-term 
increases in weight and a higher risk of being obese and having a poor diet quality (Bowman & Vinyard 2004, 
Schröder et al. 2007, Stender et al. 2007, Black & Macinko 2008, Rosenheck 2008).  In a 15 year follow-up study 
it was shown that individuals who consumed fast-foods more than twice a week gained more weight over 15 
years than those who eat fast-foods less than once a week (Pereira et al. 2005).  
 
Portion size  
An increase in portion sizes of food and beverages consumed is another food environmental change that has 
occurred over the past 30 years (Cohen 2008).  It has been reported that the typical restaurant now serves 
portions that are two to five times bigger than is required for an individual to remain in energy balance (Nestle 
2003, Nielsen & Popkin 2003, Young & Nestle 2007).  Factors that contribute to this phenomenon from food 
consumed at individual’s homes, include that more food is available from the larger packaging size used together 
with the availability of larger supermarkets or warehouse stores stocking larger quantities of food (WHO 2000).  
It has been shown that obese individuals eat larger portion sizes when compared to lean individuals (Berg et al. 
2009) and growing evidence suggest that people will eat more when presented with larger portion sizes (Wardle 
2007).  
 
In Western societies the accepted norm of eating large portion sizes contributes to active overeating, thus a high 
energy intake due to eating a large amount of food.  Normally food becomes less pleasant as more is consumed, 
which is referred to as sensory-specific satiety.  However, this principle can be overridden when a shift to 
another food choice during the meal occurs.  For instance, at buffet meals overconsumption can often occur 
when a variety of foods are available.  Furthermore, the fact that individuals perceive that they get better value 
for their money when buying upsize meals or partake in all-you-can-eat buffets from restaurants and fast-food 
outlets, contributes to the intake of larger portion sizes (Gee et al. 2008).   
 
Passive excessive intake refers to the consumption of energy-dense meals.  Fisher et al. (2007) have shown that 
when individuals are presented with different starters or meals consisting of the same amount of food but with 
varying energy densities, a higher energy intake results from eating the energy-dense starters or meals.  This can 
be explained by the fact that individuals do not adjust the amount of food taken in according to the energy 
density of a meal (Fisher et al. 2007).   The fact that energy-dense foods is known to be more palatable and less 
satiating compared to low energy-dense foods (Drewnowski et al. 2004) contributes to excessive intake.  
Therefore the portion size of the food or meals eaten during the day may be small or similar to a normal size but 
a higher energy intake and consequent weight gain occur due to the energy density of the food (Gee et al. 2008).   
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Eating pattern  
The regularity of a person’s eating pattern may be associated with obesity development (Timlin & Pereira 2007, 
Howell et al. 2009).  It has consistently been shown that skipping breakfast is associated with weight gain and a 
higher risk of being obese (Timlin & Pereira 2007, Marín-Guerrero et al. 2008, Berg et al. 2009).  Individuals who 
eat a high fibre breakfast regularly have a better overall diet quality and micronutrient intake, a lower fat intake, 
less uncontrollable nibbling episodes during the day and less incidence of between meal hypoglycemia (Nicklas 
et al. 2001, Timlin & Pereira 2007).  This has also been reflected in the finding that in comparison with normal 
weight individuals, obese individuals skipped breakfast or lunch more frequently and when they do, a larger 
dinner meal is consumed (Berg et al. 2009).  A higher food intake in the morning and afternoon has been 
associated with lower total energy intake compared to a higher food intake later during day and in the evening 
as a result of skipping breakfast (De Castro 2004). 
 
Two forms of night time eating namely night eating syndrome (NES) and sleep related eating disorder (SRED), 
may be associated with obesity development (Howell et al. 2009).  In a review by Howell et al. (2009) it was 
indicated that a definite conclusion that NES causes obesity can not be made at this stage due to a lack of 
research in this area.  However, available evidence points to a possible causal relationship as NES was found to 
correlate with higher BMIs, the resistance to lose weight on weight reduction programmes and that NES is more 
prevalent in obese than non-obese individuals (Howell et al. 2009).  The association between SRED, weight gain 
and obesity has been confirmed.  Both NES and SRED are associated with an inappropriate time of eating when 
metabolic responses to food intake is different from responses to day-time eating, inappropriate food choices 
and binging (Howell et al. 2009).  Individuals with NES eat similar foods during the night as during the day, 
although they show definite preference for carbohydrate rich foods such as breads and sugars.  NES is also 
associated with being more psychologically distressed and depressed, which may influence food intake (Calugi et 
al. 2009, Olbrich et al. 2009).  On the other hand, SRED is often associated with frequent sleep walking and 
unconscious nocturnal eating that consists of specific combinations of foods, inedible substances, dangerous 
food preparation behaviour and foods high in carbohydrates and fats such as bread, pies, ice cream, chocolate, 
sweets and peanutbutter (Howell et al. 2009).  
 
2.1.2 Physical activity 
 
When considering the other end of the energy balance equation, namely energy expenditure, there is ample 
evidence that low physical activity levels relate to weight gain and contribute to the development of obesity.  In 
economically active South African adults it has been found that low physical activity levels when not at work and 
self-reported low or medium physical activity levels significantly predict obesity development (Senekal et al. 
2003). Low physical activity usually results from a combination of aspects, including no participation in formal 
exercise or sports, increased engagement in sedentary behaviours especially during leisure time, decreased 
occupational activity and decreased household activities that include activities undertaken as part of day-to-day 
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living.  Increased sedentary behaviours or physical inactivity accounts for the large documented decreases in 
energy expenditure in various populations.  These include physical passive behaviours such as watching 
television (TV), computer work, driving a car, talking to friends on telephone instead of walking to them, reading 
and other inactive daily doings (WHO 2000).  Gorden-Larsen et al. (2009) found an 8 kg higher weight gain over a 
period of 15 years in women with no leisure time walking compared to those who walk for 30 minutes a day.  
Furthermore, several studies have indicated that TV viewing is the dominant leisure time activity for many 
individuals and the amount of hours of viewing is positively associated with higher BMIs and lower levels of 
fitness (Swinburn & Shelly 2008).  Three possible explanations for this positive relationship have been suggested 
by Swinburn & Shelly (2008), including 1) TV viewing causes obesity, 2) obesity causes high TV viewing and 3) 
lower socio-economic status could be responsible for high TV viewing. It is also possible that a vicious cycle 
between these components exists.  The relationship is mediated through the availability of less time for physical 
activity, reduced resting metabolic rate and increased energy intake (Swinburn & Shelly 2008).  The increased 
energy intake results from eating high-fat and unhealthy foods while watching TV.  TV watching also increases 
exposure to the marketing of energy-dense foods and beverages which may stimulate consumption (WHO 2000, 
Swinburn & Shelly 2008).     
 
Besides the overall positive effect of regular participation in exercise or sports on energy expenditure and thus 
weight management, exercise also suppresses hunger.  Furthermore, it has been shown that individuals who 
regularly participate in moderate exercise develop an increased ability to burn fats rather than carbohydrates as 
a fuel (WHO 2000).   
 
2.1.3 Built-environment  
 
The term, built environment, refers to those elements of an individual’s external surroundings that are human-
made or modified in comparison to naturally occurring environment elements surrounding individuals (Papas et 
al. 2007).  The built environment is considered to be a contributing factor in the development of obesity when it 
creates a milieu that promotes increased energy consumption and decreased physical activity (Black & Macinko 
2008).  To have an impact on weight status, an interaction between the built-environmental factors and the 
individual takes place.  This interaction and the outcome thereof may vary for instance between men and 
women, families, family members, age groups and socio-economic status groups (Papas et al. 2007).  Papas et al. 
(2007) confirmed that 17 of the 20 studies reviewed by them showed a positive relationship between elements 
of the built environment leading to increased energy consumption and/or decreased physical activity and 
obesity development.   
 
The influence of the built environment on physical activity 
It is evident from various reviews that modernization and changing societal structures have created an 
environment that promotes a more sedentary lifestyle (Booth et al. 2005, Papas et al. 2007, Black & Macinko 
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2008).  Several elements in the built environment and neighbourhood design can affect physical activity levels.  
These include:  
 How individuals get from one place to the other with available roads, transportation systems, bicycle and 
walking paths;  
 Places where individuals spend their leisure time for example available parks and public facilities;  
 Places where individuals can exercise such as available gyms and sport clubs; and  
 Social values and perceptions including crime, traffic, reputation, aesthetics, litter, trust and capital that 
impact on individuals as to how they use their neighbourhoods (Black & Macinko 2008).   
 
In current day society the energy expended on various day-to-day living tasks is clearly less than a few decades 
ago (summarized in Table 2.2).   
 
Table 2.2:  Energy expenditure on day-to-day living tasks in current day society compared to a few decades ago. 
Day-to-day 
living task 
Current day society Consequence of current day 
society factors 
A few decades ago 
Transportation  Increased car ownership; 
 Improved public transport 
systems. 
 Travels short distances by 
car, train, bus or other 
automobiles. 
 Walked or cycled short and 
long distances. 
Household 
tasks  
 Availability of washing machines, 
tumble driers, vacuum cleaners. 
 Spends less physical activity 
on household tasks. 
 Increased activity on these 
tasks as machines were not 
available. 
Food 
preparation 
 Ready prepared food or 
ingredients for a dish; 
 Motorized and labour-saving 
kitchen equipment. 
 Spends less physical activity 
on food preparation. 
 Food procurement and 
preparation was more 
labour intensive. 
Occupation  Advancement in mechanization, 
robotics, computerizations, 
control systems; 
 More people in service, clerical, 
other professional occupations; 
 Less people in jobs such as 
forestry, mining and farming. 
 More sedentary jobs; 
 Less physically demanding 
jobs; 
 Less energy expended even 
in physically demanding 
jobs due to improved 
machinery. 
 More people in physically 
demanding jobs.  
 These occupations were 
more labour intensive than 
today.  
Electricity and 
fuels 
 Increased availability of electricity 
and other easily available fuels; 
 Central heating. 
 Decreased energy 
expended as 
thermoregulation is not 
necessary with central 
heating;  
 Decreased activity to keep 
warm. 
 No central heating 
 Collect and prepare fuels 
such as wood for heating or 
lighting. 
 
Public places Automatic time-saving devices such 
as lifts, elevators, automatic doors 
Decrease energy expended.  No such devices 
Climb stairs 
Leisure-time 
activities 
Dominated by watching TV and 
other sedentary behaviours 
Decrease leisure-time activity Decreased time spent on 
watching TV 
Summarized from WHO 2000 and Popkin 2006.   
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Other built environmental elements that have been associated with decreased physical activity levels and 
obesity development include (Booth et al. 2005, Papas et al. 2007, Black & Macinko 2008): 
 Decreased number of recreational facilities near an individual’s residence; 
 Increased distance from an individual’s residence to nearest recreational facility; 
 More daily time spent in cars and higher kilometres travelled in a car; 
 Living on a highway; 
 Living on a street with no sidewalks or with sidewalks on one side only; 
 Living in neighbourhoods with:  
- Low walkability; 
- Lower levels of greenery; 
- Increased residence density; 
- Increased population density; 
- Decreased land-use mix (residential, commercial and institutional facilities are not in close proximity of 
each other, which makes the community less walkable); 
- Increased sprawl index (model that includes residential density, land-use mix, degree of centering and 
street accessibility); 
- Barriers to physical activity such as: more crime, traffic and undesired topography (steep hills). 
 
The influence of the built environment on availability of food and food intake 
The food environment has change dramatically over the past 30 years favouring excessive energy intake and 
obesity development.  It is apparent that food has become increasingly accessible at prices that are generally 
more affordable (Wardle 2007).  This situation can be ascribed to major subsidies on feed grains, livestock 
research and livestock production (Popkin 2006).  Major advances in agricultural technology that have led to 
improved cultivation techniques, the use of fertilizers, the ability to grow a wider variety of crops that are 
disease-resistant and can tolerate problems with soil, temperature and insects also contribute to the situation 
(Cohen 2008).  The consequent dramatic increase in livestock and crop yield together with the advances in food 
technology, production and preservation, product development, transportation and storage, resulted in an 
increased per capita food availability at lower prices (WHO 2000, Cohen 2008).  Technological advancements 
and major political and economical initiatives also led to the development of high-yield oilseeds and thus high-
quality refined vegetable oils, contributing to major reduction in the cost of fats for baking and frying, margarine 
and salad oils (Popkin 2006).   
 
All these changes in food production led to the availability of food regardless of season, increased accessibility 
and consequent consumption of animal source foods, highly processed foods and edible oils, with a shift away 
from fruits, vegetables and whole grains (Popkin 2006, Cohen 2008).  It is a matter of concern that location and 
accessibility to supermarkets and fast-foods restaurants influence consumption of unhealthy and healthy foods 
and consequently weight status (summarized in Table 2.3).   
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Table 2.3:  The characteristics of the current-day food environment and associated effects on lifestyle practices and 
BMI 
Characteristics of food environment Association with lifestyle practices and BMI Reference 
 Living in neighbourhoods with:  
- ↑ fast-food restaurants 
- ↑ convenience stores 
- ↓ grocery stores 
- ↓ supermarkets 
 
 unhealthy dietary practices 
 ↑ BMI 
 ↑ obesity prevalence 
Maddock 2004 
Morland et al. 2006 
Inagami et al. 2009 
Larson et al. 2009 
 
 ↑ density (number) of fast-food 
outlets, convenience stores, 
restaurants and lunchrooms 
 ↑ accessibility of meals prepared away from 
home 
 ↑ weekly visits to fast-food restaurants 
 ↓ confidence in eating healthy foods 
 not meeting physical activity goals 
Cohen 2008 
Li et al. 2009 
 Greater distance required to travel to 
a supermarket 
 ↑ BMI 
 ↓ fruit and vegetable consumption 
 ↑ unhealthy food in diet 
Rose & Richards 2004 
Black & Macinko 2008 
Inagami et al. 2009 
Zenk et al. 2009 
 Better access to convenience stores  ↓ fruit and vegetable consumption 
 ↑ obesity prevalence 
Larson et al. 2009 
Zenk et al. 2009 
 
Additionally, chocolates, chips, sweets, soft drinks and a variety of convenience food are now available at easily 
accessible vending machines or retail outlets that do not typically sell food as their primary business such as 
video shops, petrol stations and hardware stores.  These non-food establishments often stock highly processed 
and non-perishable foods that are high in sugar and fat and of low nutritive value (Cohen 2008).  The fact that 
food prices in grocery stores and supermarkets are relatively reasonable, also results in a situation where a 
lower percentage of household income is spent on purchasing foods at these stores.  This leaves more money to 
afford the convenience of buying ready prepared food away from home (WHO 2000).  In the United States of 
America it was found that only 24% of all household food expenses went to food prepared away from home in 
1966 compared to 42% in 2006 (Cohen 2008).   
 
What is of further concern is that it is now possible to manufacture food products with virtually any textural, 
nutritional and tastes properties (WHO 2000).  Manipulation of food products have gone to such extremes that 
it is difficult for individuals to associate visual, textural or taste cues with the nutritional and energy content of 
meals.  With the increasing trend towards consuming convenient pre-packed food and dishes, individuals are 
literally losing control over the preparation of food and the nutritional content is determined by the 
manufacturers (WHO 2000).  It needs to be borne in mind that the WHO (2000) claim that the food supply is 
now literally in the hands of a small number of large multi-national companies that are more concerned about 
the production of tasty cheap foods or food products to ensure financial gains, than the nutritional content and 
health impact thereof.  For instance, processed food products rich in refined grains, added fat and added sugar 
are usually considerably cheaper per thousand kilojoules and a higher consumption level is reported for these 
foods compared to more expensive fresh fruits and vegetables (Drewnowski 2007, Bray 2008).  The calculated 
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energy cost of fresh produce such as fruit and vegetables is 10 times higher as that of vegetable oils and sugars 
(Drewnowski 2009).  Therefore, this results in a paradox of ability to spend less but eat more energy, provided 
that the energy comes from added fat and sugar (Drewnowski 2009).   
 
Finally, it needs to be considered that industrialization at global and national levels has resulted in large-scale 
urbanization as people are searching for work, a higher income and a better life (WHO 2000, Candib 2007).  
Urbanization goes hand-in-hand with high levels of unemployment, poverty, increased exposure to cheap, 
processed foods and less access to home-grown and local vegetables.  The resulting diet is high in protein, fat, 
especially saturated fatty acids, kilojoules and less in complex carbohydrates (WHO 2000, Candib 2007).  These 
dietary changes are referred to as the ‘nutrition transition’ experienced by urbanization and contributes to 
obesity development (Kruger et al. 2005, Popkin 2006).   
 
Governance 
The government of countries also play a role in addressing the problem of obesity as they make final decisions 
and enforce laws that may influence food intake and physical activity levels (WHO 2000). For instance, the 
amount of time spent in school curriculums on physical activity and nutrition teaching are prescribed by the 
Departments of Education.  Governments also influence infrastructure by allocating open spaces, previously 
used for recreational activity, to other purposes such as building apartments and shops.  Goverments have the 
power to regulate food quality and safety together with the labelling and advertising of foods.  However, many 
have failed in these tasks and consequently consumers are badly informed, confused about conflicting messages, 
and exposed to an environment favouring obesity development (WHO 2000). 
 
2.1.4 Social environment  
 
Marketing and advertising 
Food choices are influenced by messages and advertisements conveyed to the public through the media, 
including television, radio and printed material (WHO 2000).  With the commercialization of food production and 
increased competition between large multi-national food production companies and fast-food restaurants, 
marketers were employed to increase the sales of their products and thus profit (WHO 2000).  Marketing 
strategies such as “eat as much as you can” or “upsize” portion sizes at many fast-food outlets or restaurants 
create the impression amoung consumers that they will receive better value for money if making these choices 
(WHO 2000, Gee et al. 2008).  Furthermore, substantial advertising campaigns that are very convincing and 
successful are continuously launched to increase sales (WHO 2000).  It has been shown that individuals with a 
high exposure to these commercials through watching more hours of TV per day eat fast-foods more often than 
those watching less TV per day (Scully et al. 2009).  It is evident that messages relating to fast-foods, energy-
dense foods, carbonated soft drinks and other unhealthy foods far exceed those of fruit and vegetables (WHO 
2000, Rosenheck 2008).  At the same time advertisements focused on weight loss products and the very thin 
female fashion models are rife, contributing to very conflicting messages sent through the media (WHO 2000).  It 
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is important to note that programs aired and advertisements published in developing countries are rapidly 
shifting from a traditional content to a more modern Westernized content, favouring exposure of these 
populations to energy-dense foods (Popkin 2006).  
 
Cultural influences 
Cultural influences such as religious practices, peer group pressure, social gatherings, status assigned to certain 
foods and individual lifestyles all affect food selection as well as a person’s view of their weight and weight 
management (WHO 2000, Kruger et al. 2005, Candib 2007).  
 
In many industrialized countries thin women symbolize competence, success, control and sexual attractiveness, 
while obesity represents laziness, self-indulgence and a lack of power.  Therefore, women in such countries are 
inclined to be dissatisfied with their body shape, idealize being thinner and often engage in inappropriate dieting 
regimes to achieve unrealistic weight goals.  However, weight loss following such diets is usually short-lived and 
is soon followed by weight gain and more attempts to lose weight (WHO 2000).  Unsuccessful weight reduction 
attempts or the inability to maintain weight after initial weight loss could be the starting point of a never-ending 
cycle of weight gain and dieting. Weight cycling in itself has been associated with subsequent large weight gains 
(Kroke et al. 2002) and an increase in the waist-to-hip ratio in women (Rodin et al. 1990).  Senekal et al. (2003) 
have shown that the absence of weigth loss attempts in the previous year was a significant protective factor for 
the risk of obesity in economically active South Africans.  
 
In South Africa, black women are less likely to perceive themselves as being obese compared to white women, 
although more black women were actually classified as being obese compared to white women (Puoane et al. 
2002). This reflects how some cultures, including black South Africans, view fatness in women as a sign of health, 
prosperity, being attractive, sexually appealing, powerful, a good wife, cook and mother and showing that their 
husbands are good providers (Puoane et al. 2002, Puoane et al. 2005, Faber & Kruger 2005).  Weight loss or 
being thin may be associated with being more likely to die, often from a stigmatized disease such as tuberculosis 
or acquired immuno-deficiency syndrome (Puoane et al. 2002, Puoane et al. 2005).  The body image of 
Caucasian South African women is more in line with those of women in industrialized countries (Cilliers et al. 
2006).  In general, men from developing and developed countries associate “bigness” or a large body structure 
and muscularity as ideal.  Many men, therefore would not view adiposity to be a problem and would not 
attempt to lose weight as frequently as women (WHO 2000). 
 
Certain cultures or countries highly prize fitness and vitality and have a general positive attitude towards a 
healthy lifestyle.  Individuals from these cultures or countries engage in considerable amounts of vigorous 
physical activity during their leisure-time.  In contrast, individuals from other cultures or countries practice more 
sedentary lifestyles as they do not understand the importance and necessity of physical activity in being healthy 
(WHO 2000).   
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Similarly, cooking methods and foods eaten may be culture specific with some cultures being traditionally 
inclined to have a higher fat intake.  Food, instead of its nutritive value, has been viewed over many centuries as 
a means to establish and express relationships between people and as one of the most important components 
of social gatherings such as birthdays, weddings and religious festivities (WHO 2000).  Christakis and Fowler 
(2007) have observed that obesity spreads through social networks, with friends or siblings from the same 
gender having the greatest effect on an individual’s weight gain than opposite gender friends, siblings or spouses.  
Within these social networks, normal and overweight children and adults had a higher food intake when eating 
together with friends or family compared to having a meal with a stranger (De Castro 1994, Salvy et al. 2007, 
Salvy et al. 2008, Salvy et al. 2009).  The possible explanation behind this is that individuals are more likely to 
attend to their food intake in the company of strangers as they still need to be accepted and make an impression 
on them.  However, the accepted and well-known relationships that exist with family and friends may lead to 
care-free overconsumption (Salvy et al. 2009).  Furthermore, an individual may recognize a higher food intake or 
weight gain seen in friends, partners or siblings as a type of “permission” to also indulge or gain weight as it is 
the norm within their social network and will thus be accepted by their peers (Christakis & Fowler 2007).  This 
may also explain the fact that being married incurs a risk for a higher BMI and waist circumference in South 
African Blacks (Malhotra et al. 2008). 
 
2.1.5 Socio-economic status and education  
 
When considering the socio-economic status (SES) of an individual, factors such as income, education, 
occupation as well as place of residence (urban or rural) are usually taken into account.  These indicators may 
influence weight status independently or in combination and therefore studies referring to the effect of SES may 
include any one or combination of these indicators (WHO 2000).   
 
In developed countries it has been consistently shown that individuals with a lower SES or individuals from 
households with a lower SES have a greater risk of being obese (Ulijaszek 2007, Brennan et al. 2009, Drewnowski 
2009).  However, in many developing countries, thin adults are stigmatized as being poor while overweight or 
obesity is viewed as a symbol of affluence (WHO 2000).  Therefore, in developing countries more affluent 
individuals have a higher risk for being obese, while those with a low SES usually have a decreased obesity risk 
(WHO 2000, Drewnowski 2007, Ulijaszek 2007).  In both developed and developing countries the increased 
obesity risk associated with either low or high SES is more profound in women and not always applicable to 
males (Drewnowski 2007).  It is also now evident that as affluence in some developing countries has grown, the 
relationship between SES and obesity has changed towards a similar picture seen in developed countries, with 
low SES being associated with obesity (WHO 2000).  Because the population in the current study reflects an 
urban developed community, the focus of the rest of this section is on the association between SES and weight 
status in developed countries.  The relevant studies have mostly been executed in the United States of America, 
Canada, Australia, England, France and other European countries (Drewnowski 2009).   
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Possible explanations for the association between lower SES and obesity in developed countries are related to 
the fact that these individuals are more likely to consume energy-dense diets that are high in energy, refined 
grains, sugar, salt, total fats and saturated fats and low in micronutrients and fibre (Mendoza et al. 2007, 
Drewnowski 2007, Drewnowski et al. 2007, Black & Macinko 2008, Savage et al. 2008, Drewnowski 2009, 
Monsivais & Drewnowski 2009, Townsend et al. 2009).  It is further evident that energy-dense diets are less 
expensive and very palatable, while actually consisting of less food (in weight) when compared to low energy-
dense diets (Drewnowski & Darmon 2005, Maillot et al. 2007).  The lower satiating power of energy dense diets 
may result in passive overeating (Drewnowski & Darmon 2005, Drewnowski 2007).  In a review by Darmon and 
Drewnowski (2008) it has been shown that individuals with a low SES specifically have higher intakes of white 
bread, rice, potatoes, organ meats, fried, canned or stewed meat, sausages, fried fish, eggs, full cream milk, 
animal fats, sugar, sweetened beverages and beer.  In contrast, individuals from a higher SES consume more 
whole grains, higher quality lean meats, fish, low-fat dairy products, nuts, fresh vegetables and fruits and wine 
(Kirkpatrick & Tarasuk 2003, Drewnowski 2007, Darmon & Drewnowski 2008).  Furthermore, a larger variety of 
fruits and vegetables with more lettuce based salads, melons and berries were consumed by high income 
households, while low income households preferred less expensive fruits and vegetables such as bananas and 
potatoes (Drewnowski 2007).   
  
The consumption of energy-dense diets by individuals with a low SES has been associated with higher weight 
gains over a six year period and higher BMIs (Savage et al. 2008).  It was also shown that obese individuals, when 
compared to normal weight individuals, usually consume energy-dense diets (Ledikwe et al. 2006, Drewnowski 
2007).  The purchase of unhealthy, energy-dense foods by individuals with a low SES is inherently driven by the 
lower cost thereof, but is also linked to the perception that healthy foods are more expensive and unaffordable 
(Giskes et al. 2002, Turrell & Kavanagh 2006).  Recent research in South Africa points to the fact that a healthy 
diet is more expensive than an energy-dense unhealthy diet (Temple et al. 2010; Temple & Steyn 2010).  These 
authors have shown that replacing six commonly consumed energy-dense foods (hamburger, full cream milk, 
corn flakes, brick margarine, white rice and white bread) with healthy nutrient-dense alternatives amounts to a 
10 to 60% increase in cost when compared per 100g food or a 30 to 110% increase when comparing the food per 
megajoules content.  Furthermore, a healthier alternative to a typical South African daily menu of an average 
adult was calculated to be 69% more expensive. The authors argued that the latter price difference can decrease 
by half with motivation, education and careful selection of cheaper healthy foods (Temple et al. 2010; Temple & 
Steyn 2010).  However, it has been shown that lower education levels (Monsivais & Drewnowski 2009) and 
poorer dietary knowledge of many individuals with a low SES contributes to the selection of unhealthy energy-
dense foods (Turrell & Kavanagh 2006).  In fact, lower education levels alone have been linked to a higher 
prevalence of obesity when compared to groups with higher education levels.  The WHO (2000) claims that 
individuals with higher education levels are more likely to follow dietary recommendations and adopt other risk-
avoidance behaviours than those with lower education levels.  Individuals from a high SES are usually thinner 
and characterized by having an overall better quality diet, higher educational levels and a better awareness of 
the role of nutrition in health (Drewnowski 2009).  In groups from lower SES, lifestyle choices such as smoking, 
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larger serving sizes of food and reduced physical activity were linked with obesity and poorer health (Brennan et 
al. 2009).  However, the association between nutrition knowledge and obesity prevalence is not always 
consistent.  The findings that some individuals with better nutrition knowledge still prefer eating unhealthy food 
may be linked to the fact that the long-term effect of an unhealthy lifestyle on health outcome is not well 
understood (WHO 2000).    
 
Within the South African context, Puoane et al. (2002) reported that lower BMIs in South African women were 
associated with lower education levels or no schooling.  This might be explained by the fact that these women 
tend to do more manual labour compared to their schooled counterparts.  However, when considering South 
African women with schooling, the picture is in line with global findings from developed countries namely that 
women with tertiary education had lower BMIs compared to those with no further tertiary education (Puoane et 
al. 2002).  Puoane et al. (2002) speculated that these women may have a better understanding of the impact of 
body weight on health, resulting in the negative association.  However, these authors maintain that body image 
may play a bigger role and that educated woman may endeavour to control their weight in order to conform to 
Western ideals of thinness (Puoane et al. 2002).  As far as South African men are concerned, it is evident that 
obesity is more likely to occur in those who live in urban areas, are highly educated and are white (Puoane et al. 
2002).  Gender and age-adjusted data of economically active South African adults from Asian, Black, Caucasian 
and Mixed ancestries confirms that a lower education status (≤ grade 7) is associated with an increased risk for 
obesity (Senekal et al. 2003).  However, Malhotra et al. (2008) found no association between education status 
and the risk of being obese in Black urban South Africans.  
 
A recent review indicates that the neighbourhood an individual lives in may also play a role in terms of SES 
related factors and obesity development.  Research consistently shows a link between living in an economically 
deprived neighbourhood and higher odds of being obese or having higher BMIs (Black & Macinko 2008).  Low 
income neighbourhoods usually have fewer large supermarkets, fewer supermarkets per person, a lower 
availability of healthy foods such as low-fat milk, high-fibre bread and fresh fruits and vegetables and are often 
further away from the nearest supermarkets (Black & Macinko 2008, Darmon & Drewnowski 2008, Drewnowski 
2009).   In contrast, energy-dense foods seem to be more accessible in such neighbourhoods as fast-food outlets, 
convenience stores and small local vendors are common.  Healthy food is thus more difficult to find, more 
expensive and possibly of lower quality compared to the large variety available in retail supermarkets (Black & 
Macinko 2008, Darmon & Drewnowski 2008, Drewnowski 2009).  Similar findings have been reported in rural 
areas and townships in South Africa where shops and street vendors only stock full cream milk, high fat meats 
and snacks, fried foods and few fresh fruits and vegetables (Faber & Kruger 2005, Chopra & Puoane 2003).  In 
contrast, more affluent neighbourhoods generally have lower exposure to fast-food restaurants, but higher 
access to fresher produce, large supermarkets and restaurants serving better quality and healthier foods (Black 
& Macinko 2008, Drewnowski 2009).  Furthermore, more opportunities for physical activity are generally found 
in neighbourhoods with high SES whereas people from lower SES neighbourhoods are more likely to be 
sedentary (Black & Macinko 2008, Drewnowski 2009).  These individuals are probably more affected by some 
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aspects of the built environment such as smaller activity spaces, fewer parks and other recreational facilities, 
less “walkable” neighbourhoods and a lack of resources and transportation to afford and access physical activity 
opportunities (Papas et al. 2007, Black & Macinko 2008).  Furthermore, these residents report that crime, 
unattended dogs and less trust of neighbours are additional barriers to physical activity (Black & Macinko 2008). 
As a consequence, low SES individuals were found to watch much more television than those with high SES 
(WHO 2000). 
 
The changing role of women in modern societies has also influenced family eating habits.  With more women 
entering the job market and returning to work soon after childbirth, less time is spent on shopping, preparing 
food and doing other household tasks (WHO 2000).  While women usually still take responsibility for the health 
and well-being of their families, many lack the motivation, skills, energy and time to prepare food for their 
families.  This situation together with the fact that working women now have access to their “own money”, has 
contributed to the creation of a market for time-saving, prepared and convenience foods (WHO 2000, Popkin 
2006, Ulijaszek 2007).  These factors result in an increasing consumption of unhealthy fast foods and other 
convenience foods, contributing to the rise in childhood and adult obesity that has been observed (WHO 2000). 
 
In summary, a lower income, lower education, minority status, and a higher incidence of poverty are linked to 
higher obesity prevalences (Drewnowski 2009).  Furthermore, obesity in women is generally associated with a 
low income and education status while this association is less consistent in men (Drewnowski 2009). 
 
2.1.6 Behavioural and psychological factors 
 
Eating behaviour and the specific components thereof including dietary restraint, disinhibition and hunger have 
been linked to weight gain and obesity development (Bryant et al. 2008).  The Three-factor eating questionnaire 
(TFEQ) is the most widely used instrument measuring the three components of eating behaviour.  Individuals 
with a higher disinhibition score are characterized with having a higher tendency to overeat for instance, when 
food is very palatable, when in the company of someone that overeats, when at social occasions, when having 
an emotional or personal problem or when stressed (Stunkard & Messick 1985, Bryant et al. 2008).  A review by 
Bryant et al. (2008) indicates that these individuals prefer high-fat foods, high-fat and high-salt foods, processed 
meats, sweet fruits and vegetables, and sweet carbonated drinks and have higher intakes of sweets, cookies, ice 
cream, butter, coffee and alcohol.  Higher disinhibition scores have consistently been associated with a higher 
weight, BMI or weight gain over time (Bryant et al. 2008, Chaput et al. 2009, Rideout & Barr 2009, Savage et al. 
2009).  Furthermore, obese individuals have higher disinhibition scores than their normal weight counterparts 
(Bryant et al. 2008).  These associations were found to be independent of SES, dieting status and previous 
weight history (Bryant et al. 2008).   
 
A higher restraint score is associated with employing specific dieting related strategies to consciously limit food 
intake in order to control body weight.  These strategies include the avoidance of fattening foods, eating smaller 
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portions, stop eating before reaching satiation and consistently considering the energy content of food in order 
to control energy intake and to buy low energy containing foods (Bryant et al. 2008).  It has been reported that a 
lower restraint score is associated with a higher body weight (Hainer et al. 2006, Rideout and Barr 2009) and 
that decreases in dietary restraint over time were associated with concurrent weight gain (Savage et al. 2009).  
However, the results of studies investigating these relationships are inconsistent (Bryant et al. 2008, Savage et al. 
2009).  It has been reported that the combined effect of restraint and disinhibition influence body weight.  
Therefore, the effect of disinhibition on weight disappears when a high level of restraint eating is present (Hays 
et al. 2002, Savage et al. 2009). Individuals with the highest weight have high levels of disinhibition together with 
the lowest levels of restraint (Hays et al. 2002, Dykes et al. 2004).  Perceived hunger refers to how often hunger 
feelings are felt and the extent to which these feelings increase food intake.  A higher hunger score has been 
associated with a higher weight (Chaput et al. 2009), and weight gain over a four year period (Hays et al. 2006).  
Obese individuals also have a higher hunger score than normal weight individuals (Harden et al. 2009). 
 
Other behavioural and psychological traits that have been associated with weight gain and obesity development 
include having a lower body image, self-esteem and self-motivation and poor coping or problem-solving skills 
(Byrne 2002).  These associations have also been reported in South African population groups.  In a sample of 
South African university students, mainly Caucasian, a higher BMI was significantly associated with a lower self-
concept, having more body shape concerns and disordered eating patterns (Cilliers et al. 2006).  Senekal et al. 
(2003) have shown that the absence of binging in economically active South African adults decreases the risk of 
developing of obesity (Senekal et al. 2003).  Furthermore, various mental and personality disorders including 
mania, anxiety and depression contribute to the hedonic aspects of overeating and may predict the 
development of obesity in both men and women (Ahlberg et al. 2002, Davis 2009).  Psychological explanations of 
obesity focus on addictive personalities, poor decision-making skills, cortisol-mediated responses to stress, or 
simply on the seeking of comfort in high-fat foods (Drewnowski 2009). 
 
According to Davis (2009), individual differences in the mesocorticolimbic pathway that have previously been 
associated with drug addiction, are now also viewed as a possible cause for obesity development.  Individuals 
with a sluggish reward system (reward deficiency syndrome) use addictive substances such as food, as a type of 
self-medication to increase hedonic capacity.  Lower dopamine levels due to lower receptor density in the brain 
have been associated with reduced mesolimbic brain dopamine signalling and a lower ability to experience 
natural reward.  Consequently, affected individuals compensate by overeating energy-dense foods to increase 
extracellular dopamine levels.  On the other hand, a person with a hypersensitive reward system is also at risk of 
obesity development as they are more vulnerable to overeat due to their better motivation to consume foods 
that are palatable and provides a pleasurable feeling.  These individuals are characterized by emotional eating, 
binging, having food cravings and a preference for high-fat foods (Davis 2009). 
 
A personality trait referred to as impulsivity has also been strongly associated with overeating and weight gain as 
these individuals have a heightened drive for smaller immediate rewards which is not counterbalanced by an 
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appropriate sensitivity to punishment (Davis 2009).  Such individuals usually have poor decision-making skills 
and will therefore engage in highly fun-seeking or risky behaviours to provide an immediate reward without 
considering the consequences.  In the current food environment that promotes the availability of a variety of 
highly palatable foods may prove to be problematic if a person is inclined try all the different food options for 
immediate reward, often resulting in overconsumption and thus very high energy intakes (Davis 2009).     
 
The attention deficit/hyperactivity disorder (ADHD) that is characterized by both impulsivity and reward 
sensitivity has also been associated with obesity.  As is mentioned above, it is claimed that some cases of obesity 
result from a food addiction similar to drug addiction.  According to Davis (2009) these forms of obesity may be 
more pronounced in individuals with ADHD, who regularly binge.  It is suggested that obese individuals should 
be screened for ADHD when seeking weight loss treatment, as methods to treat ADHD may be used successfully 
in conjunction with weight loss interventions to treat obesity in such individuals (Davis 2009). 
   
2.1.7 Biological factors 
 
Many biological factors influence weight management and though mostly genetically determined may also be 
influenced by environmental factors.  These include hormonal and neural factors that provide short and long-
term signals influencing satiety and feeding activities, the number and size of adipocytes, regional distribution of 
body fat, resting metabolic rate and absorption of fat from food in the gastro-intestinal tract (WHO 2000).  
Individuals with a genotype that favours the expression of biological factors in such a way that energy storage is 
promoted are more vulnerable to develop obesity (WHO 2000).  A discussion of all the biological pathways 
contributing to obesity development is beyond the scope of this review.  Relevant biological pathways are 
discussed in the sections on the genes selected for this research (sections 2.3 to 2.8).  
 
2.2 Genetics of obesity  
 
There is no doubt that genotype contributes to the development of the obese phenotype.  Although recent 
research has significantly contributed to the understanding of the link between genes and obesity (Rankinen et 
al. 2006), the specific genes, mutations and physiological mechanisms involved in the development of obesity 
have not yet been fully elucidated (Romao & Roth 2008).   
 
The contribution of genetics to obesity development has been clearly indicated by heritability estimates defined 
as “the fraction of the population variation in a trait (e.g. BMI) that can be explained by genetic transmission” 
(Loos & Bouchard 2003).  Heritability estimates derived from a number of epidemiological studies conducted on 
twins, families and adopted families have indicated that genetic factors are responsible for the variation in 
human adiposity from as low as 5% to as high as 90% (Loos & Bouchard 2003, Romao & Roth 2008).  According 
to Loos and Bouchard (2003) the differences in methodology used by these studies mostly explain this wide 
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range of heritability estimates.  The highest heritability levels, with values around 70%, are reported by studies 
conducted on monozygotic and dizygotic twins (Allison et al. 1996, Maes et al. 1997, Hjelmborg et al. 2008, 
Lajunen et al. 2009, Mustelin et al. 2009, Ortega-Alonso et al. 2009).  The lowest heritability levels with values of 
30% or less were seen in adoption studies (Sorensen et al. 1992a, Sorensen et al. 1992b, Vogler et al. 1995), 
while family studies revealed intermediate levels between twin and adoption studies (Rice et al. 1999, Coady et 
al. 2002, Choy et al. 2009).  The role of genes in obesity development is further supported by studies that report 
that a family history of obesity predisposes an individual to a two- to three-time higher risk of becoming obese.  
A family history of severe or extreme obesity (BMI≥45) respectively results in a three- to six-time or a seven- to 
eight-time higher risk to develop obesity (Loos and Bouchard 2003).   
 
Elucidation of the actual genes involved as well as associated mechanisms has been the focus of research for 
many decades.  As early as 1962, Neel proposed the “thrifty” genotype hypothesis, namely that people who are 
genetically prone to develop type-2 diabetes have a “thrifty” genotype that is responsible for high levels of food 
intake and/or low levels of utilization and the consequent development of obesity.  According to Neel (1962) the 
thrifty genotype evolved during the hunter-gatherer era during which food was scarce.  Hunter-gatherers had to 
engage in very high levels of physical activity to obtain food.  Periods of food abundance after successful hunting 
was alternated with periods of greatly reduced food intake and the risk for famine was always present.  
Consequently, through natural selection, the human biological systems evolved to fight against food shortages, 
with the body storing any excess energy for the possibility of future food deprivation (Loos & Bouchard 2003, 
Rosmond 2004, Romao & Roth 2008).   Neel (1962) linked the development of diabetes in current times to a 
quick insulin trigger protection mechanism that limits renal glucose loss that was beneficial for the hunter-
gatherer who was repeatedly exposed to feast and famine situations.  Bouchard (2007) indicated that “although 
the original 1962 paper did not specifically focus on energy balance and obesity, the “thrifty” genotype 
hypothesis has been mostly cited as the source for the notion that the biological predisposition to obesity 
resides in genetic features that favour thriftiness”.  Because certain concepts on which the thrifty genotype 
hypothesis was based, were not confirmed in later years, Neel (1999) suggested that the original thrifty 
genotype hypothesis needed revision (Neel 1999).   
 
Taking this into account, Bouchard (2007) proposed five new genotype-based hypotheses for obesity 
development.  These were formulated by identifying the genes that are supported by at least five positive 
association studies with an obesity phenotype, as is summarized in the latest obesity gene map (Rankinen et al. 
2006).   The 22 genes that were identified were subsequently classified according to biological or behavioural 
traits that may favour obesity development. These five hypotheses are as follows: 
1) The thrifty genotype: low metabolic rate and insufficient thermogenesis; 
2) The hyperphagic genotype: poor regulation of appetite and satiety and propensity to overfeed; 
3) The sedens genotype: propensity to be a couch potato or physically inactive; 
4) The low lipid oxidation genotype: propensity to be a low lipid oxidizer;  
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5) The adipogenesis genotype: ability to expand the complement of adipocytes and high lipid storage 
capacity. 
 
It must be borne in mind that the phenotypic expression of obesity in most individuals is the result of an 
interaction between genetic factors and the environment (Chung & Leibel 2008, Marti et al. 2008, Romao & Roth 
2008).  This synergistic relationship between genes and environmental factors means that in the presence of 
genetic mutations for obesity the severity of the disease is largely determined by environmental conditions (Loos 
& Rankinen 2005, Chung & Leibel 2008).   
 
Environmental influences on gene expression commence in the uterus during pregnancy.  Fetuses may suffer 
from intra-uterine growth retardation when exposed to prenatal energy deprivation as a result of low maternal 
energy intakes, resulting in low birth weight.  Infants and children exposed to early postnatal undernutrition 
have been found to have a higher risk to develop obesity later in life (Candib 2007).   This phenomenon is also 
referred to as a “thrifty phenotype”, where an undernourished fetus, infant or child responds later in life by 
accumulating excess energy more effectively compared to other individuals when food is available.  It is 
speculated that early energy deprivation causes certain genes to be permanently “switched on” by the fetus, 
favouring energy conservation, causing maximum fat storage when the individual is exposed to an abundant 
food environment later in life (Candib 2007). 
 
After birth, weight gain will most likely occur when individuals who live in a ‘restrictive’ environment (associated 
with high physical activity levels and the intake of a diet rich in whole grains, fruits and vegetables and low in fat) 
migrate to an ‘obesogenic’ environment (see section 2.1).  This has clearly been demonstrated in the Pima 
Indians, who have a high genetic predisposition for obesity and type-2 diabetes.  A lower prevalence of obesity 
and type-2 diabetes is evident in the Pima Indians residing in their traditional restricted environment of the 
remote Mexican Sierra Madre Mountains, than their counterparts who live in the ‘obesogenic’ environment of 
Arizona in the United States of America (Ravussin et al. 1994).  The work on the Pima Indians affirms the notion 
that modern day humans still have the ancient hunter-gatherer genome, which is perfectly suitable in a 
restrictive environment.  The mismatch between the ancient genotypes of humans living in the current-day 
obesogenic environments explains the high prevalence of obesity (Loos & Bouchard 2003, Rosmond 2004, Loos 
& Rankinen 2005).  However, it is also known that not all individuals living in an obesogenic environment will 
gain weight.  In this environment, individuals who have genetic mutations that promote the development of 
obesity will gain more weight and probably develop obesity, while those without genetic predisposition for 
obesity will gain little if any weight (Loos & Bouchard 2003, Loos & Rankinen 2005, Chung & Leibel 2008).  
Therefore when investigating the causes, pathogenesis or possible treatments for obesity it is always important 
to consider the gene-environment relationships involved (Loos & Rankinen 2005, Marti et al. 2008).  The 
influence of the environment in expressing the obese phenotype has also been illustrated in experimental work 
in identical twins.  Bouchard et al. (1990) provided 12 male monozygotic twin pairs with their energy 
requirement for weight maintenance plus a surplus of 4200 kJ/ day for 100 days.  The weight gain of two 
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individuals forming a twin pair was found to be similar.  However weight gain experienced by each of the 12 twin 
pairs was significantly different, indicating a genetic effect.  Similar results were reported in a study during which 
seven pairs of young adult male monozygotic twins completed an exercise regime over 93 days to create a 
negative energy balance (Bouchard et al. 1994).  The two individuals forming a twin pair lost the same amount of 
weight following the exercise regime.  However, when comparing the seven twin pairs, some twin pairs lost 
more weight than other twin pairs.  The amount of weight gained or lost is therefore dependent on a 
predisposition that appears to be largely inherited (Bouchard et al. 1994).   
 
According to Loos and Bouchard (2003) the genetic contribution to obesity can be classified as follows: 
 Genetic obesity:  
Includes monogenic cases of obesity i.e. single-gene obesity and Mendelian obesity (see section 2.2.1).  
These individuals will develop obesity with the environment only playing a permissive role in the 
severity of the phenotypic expression. 
 Strong genetic predisposition:   
Includes polygenic cases of obesity i.e. multiple gene mutations, each having a small effect in causing 
obesity (see section 2.2.2).  These individuals are likely to be overweight in an environment that does 
not favour obesity development, while they become obese or severely obese in an obesogenic 
environment.  
 Slight genetic susceptibility:   
Also includes polygenic cases of obesity (see section 2.2.2).  However, these individuals are likely to be 
normal weight or slightly overweight in a restrictive environment, while they become overweight or 
obese in an obesogenic environment. 
 Genetically resistant to obesity:   
These people remain normal weight in a wide range of obesogenic conditions.    
 
2.2.1 Monogenic forms of obesity 
 
Single-gene disorders 
In rare cases of human obesity the presence of a single genetic mutation in one particular gene results in the 
development of obesity independent of environmental factors (Loos & Bouchard 2003, Farooqi & O’Rahilly 2005, 
Mutch & Clement 2006).  According to the latest version of the Human Obesity Gene Map (Rankinen et al. 2006), 
176 human obesity cases due to single-gene mutations in 11 different genes have been reported (Table 2.4).  It is 
clear that the majority of the monogenic obesity cases are attributed to genetic mutations in the MC4R gene 
(143 different cases) (Rankinen et al. 2006).  The presence of only one of the possible 51 genetic mutations 
reported to date in this gene (see Table 2.4), will cause obesity.  The phenotypic expression of these single-gene 
disorders is usually severe and has an early onset.  For instance, the six cases identified with a mutation in the 
leptin gene were all homozygous for the mutation and suffered from severe hyperphagia, hypogonadotrophic 
hypogonadism and morbid obesity from a young age.  These symptoms also presented in patients homozygous 
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for the leptin receptor gene mutation, however the loss of leptin receptor function results in a more severe 
phenotypic expression than the loss of leptin.  In addition, those with the leptin receptor mutation also 
experience significant growth retardation, hypothalamic hypothyroidism and massive obesity soon after birth.  
The heterozygous relatives of these monogenic obesity cases also had a higher than expected prevalence of 
obesity and a higher percentage of body fat compared with ethnicity-matched controls (summarized in Loos & 
Bouchard 2003).   
 
Table 2.4:  Monogenic forms of obesity in the form of single-gene disorders 
 Gene  Gene name Number of 
defects 
Number of 
individual cases 
1 CRHR1 Corticotropin-releasing hormone receptor 1 1 1 
2 CRHR2 Corticotropin-releasing hormone receptor 2 1 3 
3 GPR24 G-protein-coupled receptor 24 2 3 
4 LEP Leptin  2 6 
5 LEPR Leptin receptor 2 3 
6 MC3R Melanocortin 3 receptor 1 2 
7 MC4R Melanocortin 4 receptor 51 143 
8 NTRK2 Neurotrophic tyrosine kinase receptor type 2 1 3 
9 POMC Proopiomelanocortin 3 8 
10 PCSK1 Proprotein convertase subtilisin/kexin type 1 2 2 
11 SIM1 Single-minded homolog 1 2 2 
Adapted and revised from Rankinen et al. (2006) and Pérusse et al. (2005) 
 
Mendelian disorders 
Mendelian disorders, which are also referred to as syndromic obesity, differ from single-gene disorders because 
obesity is only a clinical manifestation and not the dominant feature of the condition, as is the case in single-
gene disorders (Loos & Bouchard 2003, Mutch & Clement 2006).  According to the latest human obesity gene 
map, 50 loci related to Mendelian syndromes relevant to human obesity have been mapped to a genomic region 
(Rankinen et al. 2006).  Causal genes or strong candidates have been identified for most of these syndromes.  
The Mendelian disorders occur as either autosomal recessive or triallelic/digenic or autosomal dominant or X 
linked (Mutch & Clement 2006, Rankinen et al. 2006).  These disorders include among others the Alstrom 
syndrome, Albright hereditary osteodystrophy, Bardet-Biedl syndrome, Cushing’s syndrome, Familial partial 
lipodystrophy (Dunnigan), Prader-Willi syndrome (PWS), Wilson-Turner syndrome and Insulin resistance 
syndromes (Rankinen et al. 2006).  Of these, the PWS is the best characterized and most common with an 
estimated prevalence of 1 in 25 000.  PWS is characterized by obesity, reduced fetal activity, muscular hypotonia 
at birth, short stature, hypogonadism, mental retardation, small hands and feet and hyperphagia that usually 
emerges between 12 and 18 months. The syndrome is caused in most cases (70%) by a deletion or disruption of 
several genes on the proximal long arm of the paternal chromosome 15 (15q11–q13).  The symptoms of other 
syndromes like the Albright hereditary osteodystrophy include obesity, short stature, brachydactyly, 
subcutaneous calcifications, mental retardation in some cases, hypocalcaemia, elevated serum parathyroid 
hormone (PTH) levels and parathyroid hyperplasia. The Bardet–Biedl syndrome (BBS) is characterized by obesity, 
mental retardation, pigmentary retinopathy, polydactyly and hypogenitalism. The prevalence of BBS is 1 in 
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160 000 according to British studies, 1 in 13 500 in the Middle East due to consanguinity (Loos & Bouchard 2003, 
Mutch & Clement 2006). 
 
According to Schadt and Lum (2006) obesity due to currently known monogenetic defects is not due to a slower 
metabolism, but rather due to impaired satiety, affecting the function of appetite control centres in the brain.  
This affirms that human food intake is controlled by powerful biological signals and is not an entirely voluntarily 
controllable phenomenon.  In monogenic obese cases these basic signalling mechanisms are severely disrupted, 
which makes it impossible for such individuals to overcome the drive to eat (Farooqi & O’Rahilly 2007).  
 
Although the identification of these genes and cases will not help to combat the global problem of obesity due 
to low prevalence, they have contributed significantly to the understanding of physiological regulatory pathways 
of appetite and energy homeostasis (Loos & Bouchard 2003).  Additionally, applying this knowledge of the 
underlying genetic defects in these syndromes contributes to more effective genetic counselling and the 
development of mechanism-directed pharmacotherapy or antagonists for future treatment or prevention of 
obesity in these patients (Loos & Bouchard, 2003, Farooqi & O’Rahilly 2007, Romao & Roth 2008).  The discovery 
and understanding of these genetic disorders have also contributed to destigmatization of human obesity and 
allowed it to be recognized as a biomedical disorder and not simply seen as a moral weakness (Farooqi & 
O’Rahilly 2007).  
 
2.2.2 Polygenic (common) forms of obesity 
 
Mendelian obesity syndromes and single-gene disorders explain only a small fraction of the global obesity 
problem (Farooqi & O’Rahilly 2007).  The magnitude of the current obese population develops obesity due to 
polygenic obesity.  In this more common form of obesity individuals may have a number of mutations in multiple 
genes, with each mutation having a minor effect on obesity development.  For the phenotypic expression of 
obesity a combination of these mutations could lead to pronounced weight gain in the presence of an 
obesogenic environment (Bouchard 2007).   
 
To identify the specific genes involved in polygenic obesity in humans, three approaches can be considered (Loos 
& Bouchard 2003):   
 Candidate gene approach: Research is conducted on candidate genes that are identified based on current 
understanding of the pathophysiology of obesity as well as possible role of specific genes in the functioning 
of biochemical pathways related to energy balance regulation or adipose tissue biology (Farooqi & O’Rahilly 
2007, Loos & Bouchard 2003).   
 Genome-wide linkage scans:  These scans are executed to identify specific regions in the chromosomes 
(referred to as QTLs) and eventually genes in these QTLs that may be linked to the development of obesity 
(Farooqi & O’Rahilly 2007, Loos & Bouchard 2003).   
 Tissue-specific gene expression profiles:  These profiles are compared between lean and obese individuals.   
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According to the latest human obesity gene map, the number of QTLs for obesity-related phenotypes is 253 
generated from 61 genome-wide scans.  A total of 52 of these genomic regions are supported by two or more 
studies.  From candidate gene studies, 426 positive associations with obesity related phenotypes have been 
reported for 127 candidate genes.  Of these, 22 candidate genes have been positively associated with obesity-
related phenotypes in at least five studies as identified by Rankinen et al. (2006).  A further 10 genes have shown 
positive associations with obesity-related phenotypes in at least four studies (Rankinen et al. 2006). 
 
Genes selected for investigation in this study (see Chapter 3, Selection of genes, Section 3.4) include FABP2, 
INSIG2, FTO, ADRB3, ADRB2 and GNB3.  A detailed discussion of these genes is presented in the following 
sections of the literature review of which a large component involves summaries of association studies in which 
the associations between the specific polymorphism in question and BMI, obesity, health and lifestyle indicators 
were investigated.  For each polymorphism the association studies are summarized in a number of Tables.  The 
Tables that focus on BMI and obesity associations provide detail on the study-designs, samples sizes, ethnicity, 
age specification (e.g. children, adolescents, students, specific adult age range) if other than adult (>18 years), 
gender (if gender was investigated specifically) and disease states of subjects if specified.  This information is not 
repeated in the Tables focussing on the association between the polymorphism and body fat distribution and 
content as well as health indicators as it can be derived from the BMI/obesity association tables.   
 
It is evident from the reviewed literature in the following sections that the results of the association studies are 
often conflicting. Heid et al. (2009) indicated between-study heterogeneity of as much as 41% in a recent meta-
analysis that included 34 studies involving obesity risk and the INSIG2 rs7566605 polymorphism.  This measure 
of heterogeneity decreased to 11% when only general population based studies were included in a sub-analysis 
(Heid et al. 2009).  The work by Heid et al. (2009) points to the fact that a wide range of factors should be 
accounted for/considered when interpreting the results of association studies.  For these reasons a brief 
perspective of the factors that need to be considered in the interpretation of association studies and thus the 
information presented in the following sections on the abovementioned genes, is provided below.   
 
A major factor to consider is the different study designs used in association studies, including for example case-
control, population-based, family-based linkage and cohort designs.  Andersson et al. (2009) noted that specific 
study design aspects that need to be considered include sample size, power estimates, population stratification, 
genome wide association vs. candidate/pathway approach, Hardy Weinberg Equilibrium, genotyping success and 
errors, frequency of studied genetic variants, functionality of the genetic variants and replication in independent 
data sets.   
 
It is clear from the information in the sections that follow that sample sizes vary from less than 50 subjects to 
large samples or meta-analyses that included more than 30000 subjects.  It is generally understood that the 
power to detect statistical significance improves considerably with larger sample sizes, which may thus explain 
conflicting results between small and larger studies (Andersson et al. 2009, De Krom et al. 2009). Although the 
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results of meta-analyses are deemed more conclusive of associations, such analyses are not available for all 
associations investigated in this review, or if available, included mixed ethnicities without subgroup analysis 
(Souza et al. 2008).  The selection criteria used in meta-analyses may also result in the exclusion of several 
studies that may affect the association outcome and must thus be considered within that context.   
 
As far as race/ethnic factors are concerned it is recognized that genotype and allele frequencies may vary 
between populations from different ethnicities or geographical regions (Tiwari et al. 2008). Population 
stratification i.e. when the sample consists of subjects with different race/ethnic background and thus different 
allele frequencies, might influence the results of studies (Andersson et al. 2009).  If not taken into account, over- 
or underestimation of associations can occur (Andersson et al. 2009), which might be responsible for the lack of 
replication in many association studies (Lewis 2002). The possibility that this problem may be prevalent is 
supported by the facts that race/ethnic composition of samples are inadequately described and that the 
selection criteria for inclusion are not appropriately explained in many studies (Fullerton et al. 2010).   
 
Genotyping errors can be suspected when frequencies are not in Hardy-Weinberg Equilibrium (HWE).  However, 
deviations from HWE can also indicate that the sample consists of a heterogeneous population or in cases it can 
indicate a true genetic effect or strong association with the disease state.  Therefore, the genotype frequencies 
of control or population-based samples (if selected from large populations where random mating is assumed) 
should be in HWE, whereas samples consisting of only cases may deviate from HWE (Lewis et al. 2002, 
Andersson et al. 2009). 
 
The statistical analyses used in association studies vary considerably and may account for much of the variation 
in reported results.  The different statistical tests and models used often include either one of or a combination 
of the following: 1) t-tests or linear models that provide indication of association; 2) classification tests that are 
used to plot the proportion of positive test results among cases (indication of true positive fraction) and controls 
(indication of false positive fraction) on a receiver operating characteristic (ROC) curve and measuring the area 
under the curve to provide a guarantee of effective discrimination between cases and controls; and 3) logistic 
regression tests that predict the risk of disease (Jakobsdottir et al. 2009).  Furthermore, in these tests different 
genetic models can be used to investigate the association with a polymorphism, including the genotype 
(comparing the three genotypes), additive (numerically coded as 0, 1, 2 minor alleles), recessive (mutant 
homozygous genotype is compared to the carriers of the wild-type allele) or dominant (wild-type homozygous 
genotype is compared to the carriers of the mutant allele) models (Lewis 2002).  It should further be 
acknowledged that multiple comparisons are often used in genetic association studies, which increase the 
likelihood of a significant association occurring once in every 20 tests.  Andersson et al. (2009) summarised three 
approaches from the literature that can be used to discriminate between false positive and true associations.  
The possibility that the significant results generated are true associations may be strengthened by 1) recurrence 
of an association in several case-control sets within a study, 2) the replication of an association in one or two 
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independent studies and 3) when a functional justification of the polymorphism in the disease biology exists or 
evidence that the polymorphism is in LD with the functional polymorphism (Andersson et al. 2009).    
 
Other factors such as gender, age and level of adiposity of subjects included, as well as the inclusion or exclusion 
of specific disease states or metabolic conditions or controlling for these confounding factors may also have a 
profound impact on the results generated (Hainer et al. 2008).  It is known that the risk for chronic diseases 
increases with age due to the longer lifetime exposure to risk factors (Joost et al. 2007).  Therefore, conflicting 
results could be obtained from samples with different age categories.  It is also interesting to note that despite 
the fact that many studies indicate that data were controlled for confounders, the actual factors controlled for 
vary across studies (such as age, gender, smoking status, BMI, alcohol intake, disease state etc.), with the 
reasoning behind controlling for specified factors mostly not mentioned and the uncontrolled data either being 
presented with the controlled data or not presented or mentioned at all.  For instance, associations with the 
FABP2 Ala54Thr polymorphisms were tested in some samples consisting of males and females without 
controlling for gender (Lei et al. 1999, Canani et al. 2005, Takakura et al. 2005, Martinez-Lopez et al. 2007), while 
others adjusted for gender (Stan et al. 2005, Vimaleswaren et al. 2006, De Koning et al. 2008, Tavridou et al. 
2009) or analyzed males and females separately (Duarte et al. 2003, Nakanishi et al. 2004, Pollex et al. 2006).  
This may also contribute to disparity in findings.   
 
It should also be borne in mind when interpreting association studies that for complex, multifactorial, polygenic 
phenotypes such as obesity several gene-gene and gene-environment interactions are involved in the 
development of the disease and secondary complications of the disease (Joost et al. 2007).  The end-products of 
a specific biological pathway and consequent phenotype are governed by a combination of genes as well as 
upstream or downstream effects of the polymorphisms in these genes (De Krom et al. 2009).  Therefore the 
results of studies investigating one polymorphism in such a pathway within a particular context may find 
different results than studies that consider various polymorphisms as well as interactions with various 
environmental factors.  
 
In the sections to follow a summary of the relevant associations is provided in each sub-section.  These 
summaries also reflect disparate outcomes for a number of the associations investigated, which could be 
attributed to any one or combination of the above mentioned factors.  It is very important to consider all these 
factors in reviewing available literature, however it was considered to be beyond the scope of this review to 
provide an in depth analysis and explanation for disparities reported for all these associations.  For instance 
Fullerton et al. (2010) recently reported on the ambiguity in the explanation and generalisation of findings when 
considering only one of the mentioned factors that may influence the results of association studies namely 
population description (race/ethnicity/geographical area) in 80 published studies that investigated the 
association between only one polymorphism, the PPARγ Pro12Ala polymorphism and Type 2 diabetes and 
obesity.  
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2.3 The Fatty acid binding protein 2 (FABP2) gene 
 
2.3.1 The FABP2 gene 
 
A human cDNA probe was used in somatic cell hybrids by Sparkes et al. (1987) to locate the human FABP2 gene 
on chromosome four.  The same probe was then used to assign FABP2 to chromosome position 4q28-q31 using 
fluorescent in situ hybridization analysis (Sparkes et al. 1987).  FABP2 has a total length of 4914 bp and contains 
four exons (103 or 128, 173, 108, and 312 bp) separated by three introns (Sweetser et al. 1987, NCBI 2009).    
 
2.3.2 The FABP2 protein 
 
FABP2 encodes a 131 amino acids protein referred to as the intestinal fatty acid binding protein (I-FABP or 
FABP2) that was first isolated and characterized by Ockner and Manning (1974).  FABP2 is a member of the 
family of fatty acid binding proteins (FABPs) that can be divided in two main groups, namely those related to 
plasma membranes (FABPPM) and the cytoplasmic proteins (FABPC) (Chmurzynska 2006).  The FABPC are all small 
intracellular proteins found in the cytoplasm of many tissues throughout the human body (Ordovas 2007, 
Karsenty et al. 2009).  Nine distinct FABPC members have been identified and named based on the major tissue 
of expression and chronological order of detection (Ordovas 2007, Karsenty et al. 2009).  The nomenclature 
originally used was the first letter of the tissue of expression added to the abbreviation FABP, for example 
intestinal-type (I-), heart-type (H-), brain-type (B-), epidermal-type (E-), liver-type (L-), ileal-type (Il-), myelin-type 
(M-), testis-type (T-) and adipocyte-type (A-FABP).  However, since it has become evident that the expression of 
a particular FABP type is not always restricted to only one tissue, but may actually occur in many different 
tissues, the use of a numerical naming system, based on the order of detection, was found to be more functional 
(Chmurzynska 2006, Ordovas 2007).   
 
In contrast to many of the other FABPC, FABP2 is only expressed in the fully differentiated columnar absorptive 
epithelial cells of the small intestine where it is found in abundance (Sweetser et al. 1987, Cohn et al. 1992; 
Besnard et al. 2002).  It has been indicated that the intestinal expression of FABP2 mRNA is under dietary control 
(Ockner & Manning 1974) and also regulated by hormones and transcription factors, such as the peroxisome 
proliferator-activated receptors (PPARs) (Glatz et al. 1995, Bernlohr et al. 1997).  For example, FABP2 
concentration was found to be greater when fed a high fat diet than a low fat diet, greater in the jejunum 
(primary site for fatty acid absorption) than in the ileum, and greater in the villi than in crypt cells (Ockner and 
Manning 1974).    
 
FABP2 shares a similar tertiary structure with the other FABPC consisting of 10 anti-parallel β-strands that form 
two β-sheet structures that in turn form a β-barrel containing a single ligand binding site (Figure 2.1).  The cavity 
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of the β-barrel is filled with water, lined with hydrophilic and hydrophobic amino acids and closed at the one end 
by two α-helices (Zhang et al. 1997, Weiss et al. 2002).   
 
 
Figure 2.1: The structure of the FABP2 protein.  The photo indicates the 10 β-strands (marked A to J), the two α-
helices and the position of the FABP2 Ala54Thr polymorphism (from Zhang et al. 2003). 
 
 
The amino acid sequences of the nine FABPC vary considerably and are between 17.2% (identity between Il-FABP 
and M-FABP) to 66.7% (identity between H-FABP and B-FABP) identical to each other.  Based on these 
percentages of amino acid homology between the different FABPC, they are divided into three groups: (1) L- and 
Il-FABP, (2) H-, B-, E-, M-, A and T-FABP and (3) FABP2 (I-FABP).  The members within the same group have 
similar specific ligand binding abilities (see next section 2.3.3) (Chmurzynska 2006).   
 
2.3.3 Physiological function of FABP2 
 
FABP2 and all the other FABPC are transport proteins that bind specifically to long chain fatty acids or other 
lipophilic ligands (Chmurzynska 2006, Ordovas 2007, Karsenty et al. 2009).  All proteins in group one (grouping 
introduced in the previous section) bind to ligands such as bile salts, cholesterol and heme, while group two 
proteins additionally bind fatty acids, retinoids and eicosanoids (Chmurzynska 2006).  FABP2 (group three) binds 
to fatty acids (Chmurzynska 2006) and non-fatty acid lipophilic drugs (Velkov et al. 2005).  The unique 
hydrophilic and hydrophobic lining of FABP2’s β-barrel cavity results in a high binding affinity for both saturated 
and unsatured long-chain fatty acids (Baier et al. 1995, Baier et al. 1996, Weiss et al. 2002, Rajabzadeh et al. 
2003).  This fatty acid binding potential of FABP2s together with the fact that they are only expressed in the 
enterocyte of the gastro-intestinal tract have lead to the hypothesis that they are mainly involved in the uptake 
and intracellular transport of dietary fatty acids (Weiss et al. 2002, Cianflone et al. 2008).  After digestion of 
dietary lipids, the digestion products are presented to the brush border membrane of the enterocytes in the 
small intestine for uptake through a passive- or carrier-mediated process (Chmurzynska 2006).  After uptake, the 
hydrophobic fatty acids face an aqueous environment inside the cytoplasm of enterocytes and rely on a 
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transport protein to survive (Weiss et al. 2002).  FABP2 functions inside the enterocytes to bind to these fatty 
acids and transports them from the brush border membrane to the endoplasmic reticulum (ER) (Cianflone et al. 
2008).  The fatty acids are then released at the site of the ER where the majority are reesterified with glycerol-3-
phosphate to form triglycerides and packed into chylomicrons for delivery to peripheral tissues in the circulation 
(Hegele 1998, Tso et al. 2006, Cianflone et al. 2008).   
 
However, the exact physiological functions of FABP2 and the other FABPC are not yet fully elucidated (Helwig et 
al. 2007, Montoudis et al. 2008).  Various functions including the modulation of intracellular lipid metabolism, 
modulation of enzyme activity (e.g. lipoprotein lipase and hepatic lipase) and lipid-mediated signal transduction, 
cell growth and proliferation, indirect regulation of gene expression and control of ligand availability have been 
proposed, investigated and in some cases ascribed to different FABPC (Veerkamp & Maatman 1995, Weiss et al. 
2002, Chmurzynska 2006, Ordovas 2007, Wolfrum 2007).   It has been proposed that the FABPC have the ability 
to increase the speed of intracellular fatty acid uptake by increasing their rate of dissociation from plasma 
membranes and enhancing their aqueous solubility inside cells (Weiss et al. 2002, Chmurzynska 2006).  
Furthermore, FABPC may protect fatty acids against potential detergent-like effects from cellular solutes, but 
also protect the enterocyte from the cytotoxic effects of free fatty acids (Weiss et al. 2002).  FABPs may also 
contribute to the maintenance of membrane integrity by protecting cells from excess free fatty acids (Ordovas 
2007).  Their involvement in the regulation of gene expression entails the intracellular transport and delivery of 
regulatory lipids to the nuclear receptors of the PPAR family situated inside the nucleus of cells and enhancing 
the activation of the PPAR receptors (Weiss et al. 2002, Chmurzynska 2006, Wolfrum 2007).   
 
In vivo and in vitro experiments have supported some of these proposed functions of FABP2.  In vitro 
experiments have shown that Fabp2 transports long-chain saturated fatty acids (SFA) and unsaturated fatty 
acids (UFA) in Caco-2 cells but incubation with palmitic acid (SFA) resulted in a greater lipid transport compared 
to oleic acid (UFA) (Baier et al. 1996).  In one of the more recent in vitro experiments, Karsenty et al. (2009) have 
shown that the addition of a fluorescent fatty acid analogue to transfected Cos-1 cells with the wild-type FABP2 
resulted in complete colocalization of the FAs and FABP2s in cytoplasmic and perinuclear regions and in 
cytoplasmic clusters.  In the cytoplasmic region, it was shown that the target organelles for FABP2 bound to a FA 
are not only the ER but also the mitochondria and Golgi apparatus.  This was not observed in the vector only 
cells or the Cos-1 cells transfected with a variant FABP2 without the α-helical domains.  These results indicate 
that FABP2 binds to long-chain FAs and transports them to specific intracellular organelles and the perinuclear 
area (Karsenty et al. 2009).  A possible explanation for this was provided by Montoudis et al. (2008) who 
transfected normal human intestinal epithelial cells (HIEC-6) with cDNA to overexpress FABP2 and compared this 
with cells treated with an empty vector.  They have found that FABP2 overexpression stimulates a higher FA 
penetration in the mitochondria and higher mitochondrial β-oxidation rates.  Furthermore, FABP2 induce the 
expression and activity of catalytic enzymes necessary for β-oxidation such as the carnitine palmitoyltransferase 
1, a critical enzyme controlling the entry of fatty acid (FA) into mitochondria, and increased activity of 3-
hydroxyacyl-CoA dehydrogenase, a mitochondrial β-oxidation enzyme.  At the same time, it was also indicated 
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that lipogenesis might be reduced due to the lower gene and protein expression of key enzymes, FA synthase 
and acetylcoenzyme A carboxylase 2 (Montoudis et al. 2008).  
 
The importance of FABP2 and FA colocalization in the perinuclear area (Karsenty et al. 2008) was further 
illustrated by its involvement in the modulation of nuclear receptors by increasing the gene expression of PPARα 
and PPARγ (Montoudis et al. 2008).  A possible role in cholesterol metabolism has also been highlighted.  FABP2 
increases mRNA transcripts, protein expression and activity of HMG-CoA reductase, the rate limiting enzyme in 
cholesterol biosynthesis.  Furthermore, FABP2 increases the gene and protein expression of ABCA1 and the 
protein mass of ABCG5, which functions as an efflux pump in exporting cholesterol out of absorptive cells.  In 
summary, these authors suggest a function for FABP2 in intestinal cholesterol transport and FA delivery to the 
mitochondria for β-oxidation. Furthermore, they hypothesized that a deficiency of FABP2 may result in increased 
cholesterol absorption, prevention of FA oxidation and consequently higher blood lipid levels (Montoudis et al. 
2008). 
 
Although extensive accumulation of FABP2 in the perinuclear area (Karsenty et al. 2009) together with its 
involvement in increasing the expression of nuclear receptors (Montoudis et al. 2008) was observed, FABP2 has 
never been found within the nucleus of cells.  Therefore it is still unknown whether the FA actually enters the 
nucleus, bound or unbound to FABP2, to participate in the regulation of gene expression as seen in other FABPC 
(Karsenty et al. 2009).   
 
In vitro studies have shown that FABP2 may not be essential for dietary fat uptake from the small intestine in 
knock-out mice containing no FABP2 (Fabp2-/- mice)  (Vassileva et al. 2000, Agellon et al. 2007).  It is known that 
besides FABP2 expression in the entire intestine, two other FABPC namely the L-FABP and Il-FABP are also 
expressed in the proximal and distal small intestine respectively.  Therefore, it has been hypothesized that in the 
intestine of Fabp2-/- mice, the expression of L- and Il-FABP is consequently increased to ensure a consistent total 
pool of FABPs and therefore no change in fatty acid uptake are observed (Vassileva et al. 2000, Agellon et al. 
2007).  Although, Fabp2 knockout does not produce a detrimental effect on dietary fat absorption, it has been 
shown that in comparison to male wild-type mice, the male Fabp2-/- mice developed hepatomegaly on a high fat 
(Agellon et al. 2007) and a high fat and high cholesterol diet (Vassileva et al. 2000).  Male Fabp2-/- mice also 
gained more body weight and developed insulinemia and elevated TG levels regardless of dietary fat content 
consumed (Vassileva et al. 2000), although Agellon et al. (2007) did not find these effects.  In females no 
difference in weight gain was observed when feeding a low fat diet.  However when fed a high-fat diet, female 
wild-type mice gained more body weight and had higher hepatic fat levels compared to female Fabp2-/- mice 
(Vassileva et al. 2000).  Aged Fabp2-/- female mice showed higher plasma insulin levels and better tolerance to 
glucose challenge than wild-type mice (Agellon et al. 2006).  These results might indicate a gender-specific effect, 
namely that in females FABP2 is important to transport fatty acids and contribute to increased fatty acid uptake 
when consuming a high fat diet resulting in weight gain and insulin resistance.  However in males the findings 
seen in knock-out mice may explain the hypothesis put forward by Montoudis et al. (2008) based on their 
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experimental findings.  In other words, a deficiency in FABP2, as seen in knock-out mice, may result in higher 
cholesterol absorption, higher blood cholesterol and TG levels (Montoudis et al. 2008) and this may contribute 
to the development of hepatomegaly as found in knock-out mice (Vassileva et al. 2000, Agellon et al. 2007).  
Montoudis et al. (2008) highlighted that no in vivo or in vitro function can definitely be ascribed to FABP2 and 
therefore its specific role in the enterocyte is still under investigation.   
 
In summary, although various physiological functions for the FABP2s have been put forward, the specific role 
thereof in the enterocyte is still under investigation.   It is clear that the FABP2s bind to FAs in the cytoplasm of 
enterocytes and transports them to their sites of utilization.  In the mitochondria and nucleus their involvement 
was shown by increased β-oxidation and nuclear receptor expression respectively.  Delivery to the ER might 
indicate an involvement in chylomicron formation and delivery of FAs to the circulation.  They are also involved 
in intestinal cholesterol transport and cholesterol biosynthesis.  A specific gender effect is also possible with 
females gaining weight and being more insulin resistant as a result of FABP2 expression, while lower blood and 
liver lipid levels are found in males possibly due to increased intestinal β-oxidation.  Although the functions of 
the FABP2s are definitely not fully understood it is clear that they play a role in dietary fat assimilation, lipid 
metabolism and blood lipid profile.  These possible functions warrant the consideration of the involvement of 
these proteins in obesity development, insulin resistance and an abnormal blood lipid profile favouring 
cardiovascular diseases. 
 
2.3.4 The FABP2 Ala54Thr polymorphism 
 
A mutation in exon-2 of FABP2 produces a G to A transition at codon 54 resulting in an amino acid substitution 
from alanine (Ala) to threonine (Thr) (Baier et al. 1995).  Amino acids 54 and 55 are situated in a critical tight 
turn of the tertiary structure of FABP2 where a major conformational adjustment takes place between a free 
FABP2 and a FABP2 bound to a long-chain fatty acid.  When a long-chain fatty acid binds to FABP2 an important 
position shift between these two residues takes place (Baier et al. 1995, Zhang et al. 1997).  Therefore a change 
in the specific amino acids at codon 54 or 55 could affect the structure, overall stability or ligand binding 
potential of FABP2 (Baier et al. 1995).   A comparison of the three dimensional structures of an Ala54 containing 
FABP2 and a Thr54 FABP2 reveals that these two proteins are highly homologous (Zhang et al. 2003).  It appears 
that only minor local structural changes within the portal region might affect the ligand binding potential.  These 
changes include the possible formation of one additional hydrogen bond across the portal, between the side 
chains of Thr54 and Asn35, adding stability to the portal.  This bond cannot be formed between the Ala54 and 
Asn35 amino acids.  Furthermore, the Thr amino acid has a larger side chain in comparison with the Ala amino 
acid at residue 54 of FABP2, which may in part block the open end of the portal region.  Therefore, Zhang et al. 
(2003) hypothesized that these changes may cause the bound ligand to remain locked inside the protein for a 
longer period of time.  It was also concluded that the different ligand binding capacities of the two FABP2 
variants do not originate from direct contact of the bound FA to the different amino acids at position 54, but 
rather due to changes described above (Zhang et al. 2003). 
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Several in vivo and in vitro studies have illustrated the functionality of the Ala54Thr polymorphism.  In vitro 
studies show that the Thr54 containing FABP2 has a two-fold greater binding affinity for dietary long-chain fatty 
acids (Baier et al. 1995) and is associated with increased transport of fatty acids into enterocytes (Baier et al. 
1996, Levy et al. 2001).  In contrast, Kim et al. (2001) did not observe any difference in intestinal uptake of FAs 
when comparing the FABP2 Thr54Ala genotypes in humans and concluded that the FABP2 Thr54Ala 
polymorphism does not enhance intestinal uptake of fatty acids.  In vitro studies further show that the Thr54 
containing FABP2 is associated with increased ApoBI and increased lipid synthesis, specifically with increased TG 
and phospholipid esterification and TG secretion (Baier et al. 1996, Levy et al. 2001).  Consequently, elevated 
postprandial chylomicron concentrations were observed in the Thr54 containing protein compared to the Ala54 
containing protein in a cellular enterocyte model with Caco-2 cells (Baier et al. 1996) and in human intestinal 
explants (Levy et al. 2001).  These observations have been confirmed by in vivo studies showing an increased 
lipid profile after ingestion of mixed meals or oral fat tolerance tests (summarized in Section 2.6.9, Table 2.7).  
Furthermore, in humans Thr54 allele carriers have higher fasting lipid oxidation rates (Baier et al. 1995, Kim et al. 
2001) and 60% higher lipid oxidation rate four hours after an OFTT (Weiss et al. 2007).   
 
Although discrepancies in results are evident, available evidence does point to the fact that the presence of the 
mutant Thr54-allele in FABP2 with its greater affinity for long-chain fatty acids, potentially results in an increased 
flux of fatty acids across the intestinal mucosa, allowing a higher absorption rate of fatty acids from ingested 
food and therefore higher plasma lipid levels, greater fat oxidation rates and decreased insulin action (Hegele 
1998, De Luis et al. 2007).  This may support a role for the FABP2 Ala54Thr polymorphism in the etiology of 
metabolic disorders with Thr54-allele carriers potentially exhibiting higher BMIs, cholesterol, LDL, TG, apoB 
levels and insulin resistance. 
 
2.3.5 Genotype and allele frequencies  
 
The frequency of the wild-type FABP2 Ala54Ala homozygous genotype is mostly between 50 and 57% in 
Caucasian populations with European ancestry (Table 2.5).  However, a higher frequency is reported for African-
American populations (60 to 63%) and American Indian tribes (>72%), while a lower frequency is found in 
populations from Asian origin such as the Japanese (mostly <50%).  Although the frequency of the mutant 
Thr54Thr homozygous genotype is less than 10% in most Caucasian and African populations, association studies 
combine them with the Ala54Thr heterozygous genotype to make comparisons between all Thr54-allele carriers 
(Thr54Thr and Ala54Thr referred to as Thr54-allele carriers onwards) and the wild-type Ala54Ala genotype.   
 
The highest frequency of the mutant Thr54 allele is found in the Japanese populations in the range of 34 to 40%, 
while the frequency in the Caucasian and African populations range between 24 to 30% and 19 to 23% 
respectively.   
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Table 2.5: Genotype frequencies of the FABP2 Ala54Thr polymorphism and frequency of the mutant Thr54-allele.  
Population Weight or disease 
status 
n Ala/ 
Ala 
% 
Ala/ 
Thr 
% 
Thr/ 
Thr 
% 
Thr54 
allele 
% 
References 
Caucasian         
USA  714 51 41 8 29 Damcott et al. 2003 
USA ♀  120 57 38 5 24 Lara-Castro et al. 2005 
USA  71 48 45 7 30 Chiu et al. 2001a 
USA  55 44 49 7 32 Chiu et al. 2001b 
USA  DM2 287 52 37 11  Georgopoulos et al. 2000 
USA (ethnicity not indicated)  122 48 48 4 28 Weiss et al. 2007 
Chile: premenopausal ♀ 
 
   
All 
Obese 
Non-obese 
63 
33 
30 
37 
24 
50 
47 
58 
37 
16 
18 
13 
40 Albala et al. 2004 
Chile: aged 65-79 years  223 31 49 20 45 Albala et al. 2007 
French Canadian ♂  217 46 47 7 31 Berthier et al. 2001 
French Canadian children  
& adolescents  
 1742 55 38 7 26 Stan et al. 2005 
Framingham         ♂ 
offspring study:    ♀ 
 907 
1023 
53 
53 
  47 
47 
Galluzzi et al. 2001 
European ♂ students   666 52 41 7 27 Tahvanainen et al. 2000 
Sweden:  DM2 
Obese 
Non-obese  
399 
59 
59 
55 
53 
52 
40 
39 
36 
6 
8 
12 
25 
28 
30 
Carlsson et al. 2000 
Greece   430 51 41 8 29 Tavridou et al. 2009 
Germany: ♂ 45-65 years  700 51 41 8  Helwig et al. 2007 
Finland obese 170 50 45 5 29 Sipiläinen et al. 1997 
Spain  538 52 40 8 27 Morcillo et al. 2007 
Hispanic American        
Argentina  202 52 41 7 28 Gomez et al. 2007 
Brazil       25 Canani et al. 2005 
Mexican  obese 114 39 55 6 26 Martínez-López et al. 2007 
African         
African-American ♀  103 63 36 0 19 Lara-Castro et al. 2005 
African-American  1748 60 35 5 23 Lei et al. 1999 
Native American        
Pima Indians  non-DM2 457 48 45 7 29 Baier et al. 1995 
Aboriginal Chilean : Aymara 
(traditional lifestyle). 
 96 66 31 3 18 Pérez-Bravo et al. 2006 
Aboriginal Chilean: Mapuche 
(urban)  
 111 46 44 10 31 Pérez-Bravo et al. 2006 
Aboriginal Canadians  507 72 27 1 14 Hegele et al. 1996 
Oji-Cree Canada adults   72 26 2 15 Pollex et al. 2006 
Oji-Cree Canada adolescents   74 24 2 14 Pollex et al. 2006 
Tonga  1022 76 23 1 12 Duarte et al. 2003 
Asian         
Japanese ♂  395 43 45 12 34 Yamada et al. 1997 
Japanese ♂ aged 40-65y: 
   
   
   
Hyperglycemic 
Normoglycemic 
Hyperlipidemic 
Normolipidemic 
122 
186 
27 
204 
41 
33 
41 
29 
43 
54 
48 
55 
16 
13 
11 
16 
37 
40 
35 
43 
Ishii et al. 2001 
Japanese ♂ aged 21-39y:  196 42 40 18  Ishii et al. 2001 
Japanese ♀:   
   
Obese (BMI>25) 
Normal (BMI<25) 
80 
146 
41 
44 
40 
47 
19 
9 
39 
33 
Takakura et al. 2005 
Japanese  258 45 41 14 34 Hayakawa et al. 1999 
Japanese-Americans  249 39 44 17  Nakanishi et al. 2004 
Korean ♂ students  96 45 43 12 34 Kim et al. 2001 
Indians   567    57 Leprêtre et al. 1998 
Indians  DM2 
NGT 
773 
899 
48 
51 
42 
42 
10 
7 
30 
28 
Vimaleswaran et al. 2006 
USA = United States of America, DM2 = Type 2 diabetes, NGT = Normal glucose tolerance 
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2.3.6 Association with obesity related phenotypes 
 
Weight, BMI and obesity 
The majority of studies summarized in Table 2.6 (25 out of 30 published studies) did not show an association 
between BMI and the FABP2 Ala54Thr polymorphism. The five studies indicating a positive association between 
the FABP2 Ala54Thr polymorphism and BMI all found a higher BMI in Thr54-allele carriers compared to the 
Ala54Ala homozygous genotype.  These positive associations with BMI were reported in German women (Fisher 
et al. 2006), Mexican obese women (Martínez-López et al. 2007), non-obese Japanese-American women 
(Nakanishi et al. 2004) and Canadian Oji-Cree Indians (Hegele et al. 1996).  In Japanese women, the 
retrospectively reported weight and BMI when they were 20 years old was higher for Thr54-allele carriers 
compared to Ala54Ala homozygotes (Takakura et al. 2005).  
 
Only a few studies have compared the Ala54Thr allele frequency between obese and non-obese subjects.  In 
Caucasians, two of the four published reports found an association between the Thr54-allele and obesity in 
Spaniards (Morcillo et al. 2007) and Greeks (Tavridou et al. 2009).  No association with obesity was found in the 
other two studies conducted on Swedish (Carlsson et al. 2000) and Finnish (Sipiläinen et al. 1997) subjects.  In 
Hispanic Americans, a case-control study reported a higher Thr54-allele frequency in obese compared to non-
obese Chileans (Albala et al. 2004), while a cross-sectional study in Chileans (Albala et al. 2007) and a study in 
Mexicans found no association with obesity.  In other non-Caucasian populations no associations between the 
Thr54-allele and obesity in African-Americans (Lei et al. 1999), Tongans (Duarte et al. 2003), Japanese (Nakanishi 
et al. 2004, Takakura et al. 2005), Asian Indians (Vimaleswaran et al. 2006) or Aboriginal Chileans with Asian and 
Native American ancestry (Pérez-Bravo et al. 2006) have been found.   
 
In summary, the majority of studies reported no association between the FABP2 Ala54Thr polymorphism and 
BMI or obesity.  However, eight studies did report an association between Thr54-allele carriers or the Thr54-
allele and a higher BMI or obesity prevalence in Caucasian, Hispanic American, Native American or Asian 
subjects.   
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Table 2.6: The association between the FABP2 Ala54Thr polymorphism and weight, BMI and obesity.   
Population group Weight or diseases  n Design Association with obesity  Association with BMI Reference 
 status   Yes No Yes No  
Caucasian          
German ♂  700 Cross-sectional  ni ni -  Helwig et al. 2007 
Germany:   DM2 
Control 
192 
384 
Case-control ni ni T54 = ↑ BMI in ♀ - Fisher et al. 2006 
 
USA  714 Cross-sectional  ni ni -  Damcott et al. 2003 
USA  71 Cross-sectional ni ni -  Chiu et al. 2001a 
USA  55 Cross-sectional ni ni -  Chiu et al. 2001b 
USA:  DM2 287  ni ni -  Georgopoulos et al. 2000 
French Canadian ♂  217 Volunteers in City ni ni -  Berthier et al. 2001 
American ♀  120 Cross-sectional  ni ni -  Lara-Castro et al. 2005 
USA (ethnicity unknown)  122  ni ni -  Weiss et al. 2007 
Framingham offspring 
study 
 1930 Cross-sectional  ni ni -  Galluzzi et al. 2001 
European university ♂ 
students: 
   
Cases (fathers had 
premature MI) 
Controls 
330 
 
336 
Case-control 
BMI compared in total sample 
ni ni -  Tahvanainen et al. 2000 
Spain  538 Cross-sectional  Obese = ↑ T54 - ni ni Morcillo et al. 2007 
Greek  430 242 with DM2 vs 188 controls & 
258 non-obese vs 172 obese. 
Obese = ↑ T54 - ni ni Tavridou et al. 2009 
Sweden:    DM2 siblings 
IGT siblings 
Normal BG siblings 
Obese 
Non-obese 
399 
93 
195 
59 
59 
 ni ni 
 
 
 
 
-  
(in siblings) 
Carlsson et al. 2000 
Finland:  CHD 414 Cross sectional ni ni -  Erkkilä et al. 2002 
Finland:  Obese 
Non-obese 
170 
82 
Case-control   -  Sipiläinen et al. 1997 
Hispanic American         
Chilean ♀:  Obese 
Non-obese 
33 
30 
Case-control Obese = ↑ T54 - -  Albala et al. 2004 
Chili  223 Cross sectional -  -  Albala et al. 2007 
Argentina  202 Volunteers  ni ni -  Gomez et al. 2007 
Mexican  Obese 114  -  T54 = ↑ BMI - Martínez-López et al. 2007 
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Table 2.6:  continue 
Population group Weight or diseases  n Design Association with obesity  Association with BMI Reference 
 status   Yes No Yes No  
African          
African-American ♀  103 Cross-sectional  ni ni -  Lara-Castro et al. 2005 
African American:   Controls 
Diabetes 
Severe obesity 
Hyperinsulinemia 
992 
321 
260 
258 
Case-control  -  -  (BMI) 
BMI at 25y ΔBMI 
since age 25 
years 
Lei et al. 1999 
Native American         
Pima-Indians  no BMI reported 137 Subset of population sample 
to exclude related subjects  
ni ni - not with weight 
 
Baier et al. 1995 
Aboriginal Chileans:  
Aymara (rural) 
Mapuche (urban) 
  
96 
111 
 -  -  Pérez-Bravo et al. 2006 
Aboriginal Canadians  507 All subjects in community ni ni T54A = ↑ BMI 
(T54T excluded 
from analysis) 
- Hegele et al. 1996 
Tonga  1022 Random population sample -  -  Duarte et al. 2003 
Asian          
Japanese ♂  395 Cross-sectional ni ni -  Yamada et al. 1997 
Japanese ♂:age=21-39 
                age=40-65  
 196 
186 
 ni ni - 
- 
 
 
Ishii et al. 2001 
Japanese ♀:   Obese (BMI>25) 
Non-obese (BMI<25) 
80 
146 
Case-control  -  T54 = ↑ BMI at 
age 20 years 
 
 
Takakura et al. 2005 
Japanese  285  ni ni -  Hayakawa et al. 1999 
Japanese-Americans  249 Follow-up of 7.8 years -  T54 non-obese 
♀ = ↑ BMI 
in ♂ & the obese 
♀ 
Nakanishi et al. 2004 
Japanese school children  
  
Morbidly obese 
Non-obese 
370 
463 
Case-control -  ni ni Endo et al. 2001 
Korean ♂  96  ni ni -  Kim et al. 2001 
Pondicherian Tamil 
Indians from South 
India:  
49 families with at 
least 2 sibships had 
DM2. 
567 Purposively selected sample, 
Compared 49 DM2 vs 50 
controls for BMI  
ni ni -  Leprêtre et al. 1998 
Asian Indians  773 
899 
Case-control for DM2 vs. NGT 
compared obese vs. non-obese 
-  ni ni Vimaleswaran et al. 2006 
ni = not investigated, BMI = body mass index, DM2 = Type 2 diabetes mellitus, ♀ = female, ♂ = male, CHD = coronary heart disease, NGT = normal glucose tolerance, IGT = impaired glucose 
tolerance, MI = myocardial infarction, BG = blood glucose. 
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Measures of body fat distribution and content 
Only a limited number of published studies included variables measuring body fat distribution and content in 
research focused on the FABP2 Ala54Thr polymorphism (Table 2.7).  Martínez-López et al. (2007) indicated that 
Mexican Thr54-allele carriers had a higher waist circumference (WC) compared to Ala54Ala homozygotes.  
However, all prior studies failed to find any association with either WC or waist-hip ratio in Caucasians 
(Sipiläinen et al. 1997, Carlsson et al. 2000, Tahvanainen et al. 2000, Berthier et al. 2001, Chiu et al. 2001a, Chiu 
et al. 2001b, Erkkilä et al. 2002, Helwig et al. 2007), Hispanic Americans (Albala et al. 2004, Albala et al. 2007), 
Native Americans (Duarte et al. 2003, Pérez-Bravo et al. 2006) or Asians (Leprêtre et al. 1998, Hayakawa et al. 
1999, Kim et al. 2001).  
 
When considering body fat content Hegele et al. (1996) found that Thr54-allele carriers among Canadian Oji-
Cree Indians had a higher percentage body fat while Thr54Thr homozygotes among Japanese men had higher 
levels of visceral adipose tissue as indicated by a higher intra-abdominal fat thickness and intra-abdominal fat/ 
subcutaneous fat ratio (Yamada et al. 1997).  However, no association between the FABP2 Ala54Thr 
polymorphism and percentage body fat was found in Japanese women (Takakura et al. 2005), Pima-Indians 
(Baier et al. 1995) or Tongans (Duarte et al. 2003).  In contrast with this, Caucasian premenopausal women who 
were Thr54-allele carriers had lower levels of total abdominal adipose tissue and abdominal subcutaneous 
adipose tissue compared with Ala54Ala homozygotes (Lara-Castro et al. 2005).  This association was not found 
for African-American women (Lara-Castro et al. 2005).  In other populations from European ancestry, no 
associations were found with percentage body fat (Sipiläinen et al. 1997, Martínez-López et al. 2007, Weiss et al. 
2007), fat mass (Damcott et al. 2003, Lara-Castro et al. 2005), lean mass (Lara-Castro et al. 2005) or visceral 
adipose tissue (Berthier et al. 2001, Lara-Castro et al. 2005).  
 
In summary, in only four of the 23 published studies positive associations were reported.  In three of these 
studies the mutant Thr54-allele was associated with measures indicative of a higher body fat content.  In 
contrast, one study associated the Thr54-allele with a lower total and subcutaneous abdominal tissue.  The bulk 
of evidence at this point in time points to no association between the FABP2 Ala54Thr polymorphism and both 
body fat distribution and content.   
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Table 2.7: The association between the FABP2 Ala54Thr polymorphism and measures of body fat distribution and 
content 
Population Associations No associations Reference 
Caucasian     
German ♂ - WC Helwig et al. 2007 
USA - Fat mass Damcott et al. 2003 
USA - WHR Chiu et al. 2001a 
USA - WHR Chiu et al. 2001b 
French Canadian ♂ - WC, VAT area Berthier et al. 2001 
USA T54 = ↓ TAT, SAAT Fat mass, lean mass, VAT Lara-Castro et al. 2005 
USA  - % body fat Weiss et al. 2007 
European ♂ students - WHR Tahvanainen et al. 2000 
Sweden - WHR Carlsson et al. 2000 
Finnish obese subjects - WC, WHR, body fat %, LBM Sipiläinen et al. 1997 
Finnish subjects with CHD - WC, WHR Erkkilä et al. 2002 
Hispanic American    
Chilean ♀ - WC, WHR Albala et al. 2004 
Chili - WC Albala et al. 2007 
Mexico T54 = ↑ WC body fat %  Martínez-López et al. 2007 
African     
African-American - Fat mass, lean mass, TAT, 
VAT, SAAT 
Lara-Castro et al. 2005 
Native Americans     
Pima-Indians - body fat % Baier et al. 1995 
Tonga - WHR, FFM, % fat Duarte et al. 2003 
Aboriginal Chileans - WHR, WC Pérez-Bravo et al. 2006 
Aboriginal Canadian T54A = ↑ body fat % 
(T54T were excluded) 
 Hegele et al. 1996 
Asian ancestry    
Japanese ♂ T54T = ↑ AFT, ASR SFT Yamada et al. 1997 
Japanese obese ♀ - % body fat Takakura et al. 2005 
Korean ♂ - WHR Kim et al. 2001 
Japanese - WHR Hayakawa et al. 1999 
Indians - WHR Leprêtre et al. 1998 
T54 = Thr54-allele carriers, T54T = Thr54 homozygotes, T54A = heterozygotes, WC = waist circumference, WHR = 
waist-hip-ratio, VAT = visceral abdominal tissue, TAT = total abdominal adipose tissue, SAAT = subcutaneous 
abdominal fat, LBM = lean body mass, FFM = fat free mass, AFT = intra-abdominal fat thickness, SFT = Subcutaneous 
fat thickness, ASR = Intra-abdominal fat/subcutaneous fat ratio. 
 
 
2.3.7 Associations with health indicators  
 
Indicators of glucose and insulin homeostasis 
Several studies have investigated the association between the FABP2 Ala54Thr polymorphism and fasting 
glucose, insulin and post-prandial glucose and insulin levels (Table 2.8).  The Thr54-allele has been found to be 
associated with higher fasting glucose levels in Caucasian (Chiu et al. 2001b, Weiss et al. 2007) and male 
Japanese subjects (Ishii et al. 2001).  Higher fasting insulin levels were found in Thr54-allele carriers from 
Caucasian (Weiss et al. 2007), Hispanic-American (Albala et al. 2004), Pima-Indian (Baier et al. 1995) and Asian 
populations (Yamada et al. 1997, Kim et al. 2001).  However, in the majority of studies across all populations no 
association with fasting glucose or insulin was found. 
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When challenged with a 75g oral glucose tolerance test, Thr54-allele carriers responded with higher post-
prandial glucose levels in Caucasian (Chiu et al. 2001a) and Asian populations (Vimaleswaran et al. 2006) and 
higher post-prandial insulin levels in Caucasians (Chiu et al. 2001a, Helwig et al. 2007), Pima-Indians (Baier et al. 
1995) and Asians (Yamada et al. 1997, Vimaleswaran et al. 2006).  Furthermore, Weiss et al. (2007) indicated 
that fewer Thr54-allele carriers had a normal glucose tolerance compared to Ala54Ala homozygotes in 
Caucasians.  
 
Thr54-allele carriers were reported to have a higher prevalence of MetS in Aboriginal Canadian adolescent girls 
(Pollex et al. 2006) and Asians (Vimaleswaran et al. 2006).  These genotypes were also associated with insulin 
resistance as assessed by the homeostasis model (HOMA-IR) in Caucasians (Helwig et al. 2007) and Japanese 
(Yamada et al. 1997).  Decreased insulin sensitivity and a decreased insulin sensitivity index (ISI) were also 
reported in Thr54-allele carriers in Caucasian populations (Chiu et al. 2001a, Chui et al. 2001b, Weiss et al. 2007).  
Similarly, in Pima Indians the insulin-stimulated glucose uptake rate was lower in Thr54-allele carriers (Baier et al. 
1995).  The Thr54Thr homozygous genotype was also associated with an increased prevalence and incidence of 
type-2 diabetes over a four year period in Chileans (Albala et al. 2007).   However, several studies did not find an 
association between the FABP2 Ala54Thr polymorphism and HOMA-IR in Caucasians (Damcott et al. 2003, De 
Koning et al. 2008), Hispanic Americans (Albala et al. 2004, Albala et al. 2007, Martínez-López et al. 2007) and 
Asians (Hayakawa et al. 1999, Ishii et al. 2001, Nakanishi et al. 2004, Takakura et al. 2005, Vimaleswaran et al. 
2006, De Koning et al. 2008) or with type-2 diabetes in Caucasians (Tavridou et al. 2009), Native Americans 
(Baier et al. 1995, Hegele et al. 1996), African-Americans (Lei et al. 1999) and Asians (Vimaleswaran et al. 2006).  
Two studies indicated increased HbA1C levels in Asian Thr54-allele carriers with a normal glucose tolerance 
(Vimaleswaran et al. 2006) and obese Asians (Takakura et al. 2005) while this association was not found in Asian 
type-2 diabetics (Vimaleswaran et al. 2006), Tongans (Duarte et al. 2003) or other Asians (Leprêtre et al. 1998).   
 
In summary, across all ancestral groups the positive association studies all indicated that the Thr54-allele or 
Thr54-allele carriers were associated with higher fasting glucose and insulin levels, higher post-prandial insulin 
levels, decrease insulin sensitivity and insulin stimulated glucose uptake, increased insulin resistance, a higher 
HbA1C and a higher prevalence of MetS and type-2 diabetes.  
 
Blood lipid profile and blood pressure  
Thr54-allele carriers in Caucasian (Carlsson et al. 2000, Berthier et al. 2001), Hispanic American (Martinez-Lopez 
et al. 2007), Native American (Hegele et al. 1996) and Asian (Nakanishi et al. 2004, Vimaleswaran et al. 2006, De 
Koning et al. 2008) populations have been found to have higher fasting TG levels (Table 2.8).  In a population of 
persons with type 2 diabetes, fasting TG and postprandial TG after fat ingestion increased linearly only in 
homozygotes for the Thr54-allele (Georgopoulos et al. 2000).   
 
Thr54-allele carriers in Caucasian (Carlsson et al. 2000, Galluzzi et al. 2001, Stan et al. 2005), Hispanic-American 
(Martínez-López et al. 2007) and Asian (Nakanishi et al. 2004, Vimaleswaran et al. 2006) populations have also 
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been found to have higher TC, LDL and VLDL levels and lower HDL levels.  However, in Tongans the Thr54-allele 
carriers were found to have lower TC and LDL levels (Duarte et al. 2003).  Some studies have also found 
associations between Thr54-allele carriers and other indicators of lipid metabolism, including higher levels of 
ApoB (Stan et al. 2005, Galluzzi et al. 2001), TNFα (Albala et al. 2004), leptin (Albala et al. 2004) and fasting fat 
oxidation rate (Baier et al. 1995, Kim et al. 2001).  However, many studies found no associations between the 
FABP2 Ala54Thr polymorphism and TC, TG, LDL, HDL, LDL/HDL ratio, TC/HDL ratio, FFA, ApoAI and ApoB.   
 
From the above it may be deduced that Thr54-allele carriers might have an increased risk to develop CHD.  
Research by Carlsson et al. (2000) supports this possibility as they found that the Thr54-allele carriers had a 
higher stroke prevalence and higher prevalence of parents with a stroke history (Carlsson et al. 2000).  The 
Thr54-allele carriers were also associated with a higher MI prevalence in subjects with MetS (Oguri et al. 2009) 
and a higher prevalence of transient ischemic attacks and non-cardioembolic infarction at a younger age (Wanby 
et al. 2004).   However, Galluzzi et al. (2001) and Gomez et al. (2007) found no association between the FABP2 
Ala54Thr polymorphism and CHD or cardiovascular risk.  It is also clear from the studies summarized in Table 2.9 
that the FABP2 Ala54Thr polymorphism does not seem to influence blood pressure (Yamada et al. 1997, 
Leprêtre et al. 1998, Hayakawa et al. 1999, Lei et al. 1999, Carlsson et al. 2000, Chiu et al. 2001a, Chiu et al. 
2001b, Ishii et al. 2001, Kim et al. 2001, Nakanishi et al. 2004, Albala et al. 2007, Gomez et al. 2007).  
 
In summary, although many studies did not find an association between the FABP2 Ala54Thr polymorphism and 
lipid profile and heart disease risk the studies summarized in Table 2.8 point to the possibility that having a 
Thr54-allele may predispose an individual to an unfavourable lipid profile and a higher heart disease risk.   
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Table 2.8: The association between the FABP2 Ala54Thr polymorphism and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure.   
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP)  
 Association No association Association No associations Reference 
Caucasian populations      
German ♂ - Fasting & postprandial 
insulin, glucose, HOMA after 
an OGTT 
- TC, LDL/HDL ratio Helwig et al. 2007 
German  T54T = ↓ risk of T2DM, 
↓ HbA1c in ♀ 
- ni ni Fisher et al. 2006 
USA - HOMA-IR - TC, TG, FFA Damcott et al. 2003 
USA T54 = ↑ glucose & insulin 2h 
after OGTT, ↓ %S, ISIs 
fasting glucose, insulin, 
β cell function 
- BP Chiu et al. 2001a 
USA T54 = ↑ fasting glucose, 
↓ %S 
fasting insulin, 
β cell function 
- TC, TG, LDL, HDL, BP Chiu et al. 2001b 
USA - HbA1c T54 = ↑ TC, TG, non-HDL 
cholesterol 
HDL, LDL Georgopoulos et al. 
2000 
America (ancestry not 
indicated) 
Normal OGTT = ↓ T54 
T54 = ↓ ISI, ↑ fasting glucose, 
insulin AUC, fasting insulin 
2h insulin, 2h glucose, 
glucose AUC 
- fasting TG, fasting FA, fasting 
& 2h lipid oxidation 
Weiss et al. 2007 
French Canadian ♂ - Glucose, insulin - TC, LDL, VLDL, HDL, TG, FFA, 
ApoA1, ApoB 
Berthier et al. 2001 
French Canadian youth - IRS high TG + T54T = 
↑ TC, LDL, apoB 
- Stan et al. 2005 
French Canadian youth 
without IRS 
- Glucose, insulin - TC, LDL, HDL, TG FFA, ApoB, 
ApoAI 
Stan et al. 2005 
French Canadian youth 
with IRS 
- Glucose, insulin T54 = ↑ TC, LDL HDL, TG FFA, ApoB, ApoAI Stan et al. 2005 
Framingham offspring 
study 
  
- 
 
- T54 ♂ = ↑ LDL, ApoB, small 
VLDL, large HDL 
 
T54 ♀ = ↑ TC, LDL 
♂ & ♀ = HDL, TG, ApoAI, 
CHD.  In ♂ = TC 
♀ = ApoB, all lipoprotein 
subclass profiles. 
Galluzzi et al. 2001 
Greek - DM2 ni ni Tavridou et al. 2009 
European ♂ university 
students 
- fasting glucose, insulin, & 
glucose & insulin changes 
after OGTT 
- TC, TG, HDL, LDL, ApoB, 
ApoAI 
Tahvanainen et al. 2000 
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Table 2.8: continue 
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP)  
 Association No association Association No associations Reference 
Caucasian populations      
Sweden - 2-h glucose, insulin, DM T54 siblings = ↑ TG, TC 
T54 offspring = ↑ parental 
stroke Hx.  
Stroke Hx =↑ T54 
fasting NEFA, BP 
 
Carlsson et al. 2000 
Finnish obese subjects - glucose, insulin, fasting 
glucose oxidation. 
- TC, HDL, LDL, VLDL, TG, FFA, 
BMR, fasting lipid oxidation 
Sipiläinen et al. 1997 
Finnish with CHD - MetS, glucose - TC, TG, CHD, BP Erkkilä et al. 2002 
Canada  - HOMA-IR - TG De Koning et al. 2008 
Hispanic American      
Chilean ♀ T54T = ↑ insulin HOMA-IR T54T = ↑ TNFα, Leptin TG Albala et al. 2004 
Chili T54T = ↑ DM2 prevalence, 
↑ DM2 incidence over 4 yrs 
Glucose, insulin, 
HOMA-IR 
- TC, TG, HDL, BP Albala et al. 2007 
Argentina - Glucose - TC, BP, Cardiovascular risk Gomez et al. 2007 
Mexico - Glucose, insulin, 
HOMA-IR 
T54 = ↑ TC, LDL, VLDL, TG HDL, total lipids, ApoAI, ApoB Martínez-López et al. 
2007 
Native American      
Pima-Indians (non-diabetics) T54 = ↑ insulin, ↓ insulin-
stimulated glucose uptake, 
↑ insulin after 75g OGTT. 
glucose, DM2 T54 = ↑ fasting fat oxidation 
rate 
- Baier et al. 1995 
Aboriginal Chileans - HOMA-IR, fasting insulin - TG Pérez-Bravo et al. 2006 
Aboriginal Canadian - DM2, impared glucose 
tolerance, insulin 
T54A = ↑ TG 
(Thr54Thr excluded from 
analysis) 
TC, HDL, LDL Hegele et al. 1996 
Tonga ♂ A54A = ↑ 1h glucose fasting BG, 2h glucose, 
insulin, HbA1c 
T54 = ↓ TC, LDL HDL, TG, total/HDL ratio Duarte et al. 2003 
Tonga ♀ - fasting BG, 1h glucose,  2h 
glucose, insulin, HbA1c 
T54 = ↓ TC, HDL, LDL TG, total/HDL ratio Duarte et al. 2003 
Oji-Cree Canada  T54 = ↑ MetS prevalence in 
adolescent ♀ 
MetS in adults ni ni Pollex et al. 2006 
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Table 2.8: continue 
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP)  
 Association No association Association No associations Reference 
African       
African-American - glucose, insulin, DM2 - HDL, LDL, TG, BP, 
total kJ intake, leisure index 
Lei et al. 1999 
Asian ethnicity      
Japanese ♂ T54T = ↑ insulin, ↑ HOMA-
IR, ↑ insulin levels 120min 
after 75g oral glucose load. 
Fasting glucose, 
75g Glucose tolerance test 
- BP, TC, HDL, TG Yamada et al. 1997 
Japanese ♂ T54 normoglycemic ♂ = ↑ 
glucose 
Insulin, HOMA-IR - TC, TG, HDL, LDL, FFA, Leptin, 
heart rate, BP 
Ishii et al. 2001 
Japanese obese ♀ T54 = ↑ HbA1c Fasting glucose, insulin, 
HOMA-IR 
- TC, TG, LDL, 
free T3, free T4, TSH 
Takakura et al. 2005 
Japanese - Fasting glucose, insulin, 
HOMA-IR 
- TC, TG, HDL, FFA, BP, uric 
acid 
Hayakawa et al. 1999 
Japanese-American obese ♀ - Glucose, HOMA-IR T54 = ↑ TC, LDL TG, HDL, BP Nakanishi et al. 2004 
Japanese-American obese ♂ - Glucose, HOMA-IR - TC, TG, LDL, HDL, BP Nakanishi et al. 2004 
Japanese-American non-
obese  
- Glucose, HOMA-IR T54 = ↑ LDL in ♀ 
T54 = ↑ TG in ♂ 
TC, HDL, BP, TG in ♀ & LDL in 
♂ 
Nakanishi et al. 2004 
Japanese obese children - - T54T = ↓ p-AA, D6D 
(ω6 PUFA pathway) 
- Okada et al. 2006 
Korean ♂ T54 = ↑ insulin Fasting glucose, 
2h glucose, 2h insulin 
T54 = ↑ fat oxidation TC, TG, HDL, LDL, FFA, BP, 
leptin, carbohydrate 
oxidation, BEE, BMR 
Kim et al. 2001 
Chinese Canadians - HOMA-IR - TG De Koning et al. 2008 
South-Asian Canadians  - HOMA-IR Thr54 = ↑ TG - De Koning et al. 2008 
Asian Indians NGT T54= 
↑ 2h glucose, HbA1c, 
2h insulin, 
MetS = ↑ T54 
DM2.   In DM2 & NGT: 
glucose, HOMA-IR, insulin 
In DM2: 2h glucose, 2h 
insulin, HbA1c 
NGT T54 = ↑ TG, LDL, ↓ HDL 
DM2 T54 = ↑ TG 
↑ TG = ↑ T54 vs low TG 
In NGT: TC 
In DM2: TC, HDL, TG, LDL 
Vimaleswaran et al. 
2006 
Pondicherian Tamil Indians - HbA1c - TC, TG, BP Leprêtre et al. 1998 
Ni = not investigated, MetS = Metabolic Syndrome, DM2 = Type 2 Diabetes Mellitus, TG = triglycerides, TC = Total Cholesterol, HOMA-IR = Homeostasis model assessment of insulin resistance, HDL = 
High density lipoprotein, VLDL = Very low-density lipoprotein, LDL = Low density lipoprotein, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, FFA = free fatty acids, CHD = Coronary heart 
disease, Lipoprotein subclass profiles includes small, intermediate & large VLDL, HDL, LDL, OGTT = oral glucose tolerance test, OMTT = oral metabolic tolerance test, PPLT = postprandial lipemia test, 
OFFT = oral fat tolerance test, AUC = area under curve, ISI = insulin sensitivity index, %S = insulin sensitivity, p-AA = plasma arachidonic acid, D6D = delta-6 desaturase. 
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Associations with post prandial lipid levels 
To date nine studies examined the role of the FABP2 Ala54Thr polymorphism on post-prandial responses to oral 
fat tolerance tests (OFTT) (Table 2.9).  As no universally standard OFTT is available, different OFTT protocols 
were used in these studies.  In general subjects fasted overnight and received the OFTT (with different 
compositions as specified in Table 2.9) either in the form of a drink or meal in the morning.  Blood samples were 
collected before and every half hour or hour or two hours for a period of six to eight hours to measure post-
prandial changes.   
 
Four studies showed that Thr54Thr homozygotes had elevated post-prandial levels of chylomicron cholesterol 
(Ågren et al. 1998), total TG (Ågren et al. 1998, Georgopoulos et al. 2000, Helwig et al. 2007), HDL-TG (Berthier 
et al. 2001), chylomicron TG (Ågren et al. 1998, Georgopoulos et al. 2000), VLDL-TG (Ågren et al. 1998), LDL/HDL 
ratio, TG increase over five hours (Helwig et al. 2007) and elevated levels of long-chain fatty acids such as stearic 
and palmitic acids in chylomicrons and VLDLs (Ågren et al. 2001).  However, four studies reported no effect on 
post-prandial TG levels (Pratley et al. 2000, Tahvanainen et al. 2000, Dworatzek et al. 2004, Weiss et al. 2007).  
Weiss et al. (2007) also reported that an OFTT caused increased lipid oxidation rates in Thr54-allele carriers.  This 
was supported by one study showing higher levels of FFA (Pratley et al. 2000) in Thr54Thr homozygotes 
following an OFTT, however four studies did not find this association with FFA levels (Ågren et al. 1998, Berthier 
et al. 2001, Dworatzek et al. 2004, Weiss et al. 2007).  It was further found that a OFTT consisting of 85% fat of 
TE (Pratley et al. 2000) or mixed meals OFTTs consisting of 40% fat and 40% carbohydrates (Baier et al. 1995) or 
51.6% fat and 29.6% carbohydrates (Helwig et al. 2007) might be harmful for Thr54-allele carriers as it decreases 
insulin sensitivity.  Although not significant, Pratley et al. (2000) showed a tendency to higher post-prandial NEFA 
and insulin levels after the ingestion of a mixed meal (40% fat and 40% carbohydrates) in Thr54-allele carriers.  
These differences in outcomes might be explained by the different OFTT protocols used.  However, factors such 
as differences in sample size, ethnicity, age and body fatness of populations investigated as well as differences in 
accounting for confounding factors such as habitual physical activity levels and dietary composition also need to 
be borne in mind (Morcillo et al. 2007, Weiss et al. 2007).  
 
Five studies also examined the association between the FABP2 Ala54Thr polymorphism and the ingestion of 
specific fats on insulin resistance or post-prandial changes (Table 2.10).  It was found that replacing half of the 
C18:1 cis fatty acids in a meal with C18:1 trans fatty acids resulted in greater post-prandial lipogenesis 
(measured with increased TG fractional synthetic rate) and a two-fold greater post-prandial glucose response in 
Thr54-allele carriers (Lefevre et al. 2005).  Thr54-allele carriers may respond more negatively to a high SFA diet 
than non-carriers as a diet containing 38% fat of TE (20% SFA) caused higher FFA levels and lower peripheral 
insulin sensitivity in carriers.  These subjects may respond more positively to a low fat (<30% fat of TE) high 
carbohydrate (57% of TE) diet or a high MUFA (22% MUFA and 38% fat of TE) diet because these diets had no 
negative post-prandial effects in carriers (Marín et al. 2005).  Similar beneficial effects of MUFA use in Thr54-
allele carriers were illustrated by Morcillo et al. (2007).  These researchers found that Thr54-allele carriers who 
use olive oil as the cooking oil in their homes were less insulin resistant while Thr54-allele carriers using 
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sunflower oil were the most insulin resistant according to higher HOMA-IR levels (Morcillo et al. 2007).  A study 
in rats also showed that the Fabp2 protein had a greater affinity for linoleic acid (PUFA) than for oleic acid 
(MUFA) (Richieri et al. 1994).  Thus, Thr54-allele carriers, who have a higher binding affinity for fat (Baier et al. 
1995), may experience above-mentioned negative effects with the consumption of a high linoleic acid diet.  A 
diet high in MUFA may protect Thr54-allele carriers against these effects as indicated by the mentioned studies 
and the fact that FABP2 does not have a high affinity for these fatty acids.  However, contradictory results were 
found by Dworatzek et al. (2004) indicating that an olive oil OFTT was associated with higher chylomicron 
cholesterol in Thr54-allele carriers, but no negative effect was experienced after a safflower oil or butter OFTT.  
Another report also showed that replacing 20g triacylglycerol (TAG) with a 20g diacylglycerol (DAG) test oil may 
positively effect Thr54-allele carriers as indicated by lower VLDL-phospholipids and a lower visceral fat/total 
body fat percentage (VF/TF %) after four weeks of intervention (Yanagisawa et al. 2003).     
 
Not included in Table 2.9 is another study that investigated the effect of the FABP2 Ala54Thr polymorphism and 
dietary soluble and insoluble fibre on blood lipid levels.  In a year long cross-over study with 43 subjects it was 
shown that Thr54-allele carriers benefit more from a high soluble fibre diet than an insoluble fibre diet to 
decrease plasma TC, LDL and apoB levels compared to Ala54Ala homozygous subjects (Hegele et al. 1997).   
 
In summary these results suggest that Thr54-allele carriers may experience higher post-prandial lipid levels and 
decreased insulin sensitivity following an OGTT or diets high in PUFAs, SFAs or trans fatty acids.  However, a high 
intake of MUFAs could counter these effects.  It is known that chronic exposure to postprandial hyperlipidemia 
results in accumulation of intracellular fat in muscle and adipocytes which ultimately impairs insulin action, 
causing glucose intolerance, and increases the risk for the development of Type-2 diabetes (Baier et al. 1995, 
Weiss et al. 2002).  Therefore, these results may indicate that Thr54-allele carriers could benefit from specific 
dietary fat manipulation strategies to decrease their overall risk for the development of CVD and Type-2 
diabetes.   
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Table 2.9: The association between the FABP2 Thr54Ala polymorphism and postprandial lipid and insulin parameters following OFTTs or interventions with different fatty acids. 
Population n Genotype 
(n or %) 
OFTT or dietary intervention with different fatty acids Results: Postprandial associations No 
associations 
Reference 
OFTT       
Finland 
 
15 
 
 
T/T=8 
A/A=7 
OFTT: meal = 0.75g/kg body weight. 
7.6g rice cake + 10g cheese + 5 min later 100ml cream 
mixture + heptadecanoic acid + 20ml fish oil. 
Thr54Thr: 
= ↑ AUC for TG, chylomicron TG, VLDL-TG,  
= ↑ LDL-TG from 6-8 hrs 
= ↑ chylomicron cholesterol 
= Correlation between TG & insulin response 
insulin 
response 
FFA 
 
Ågren et al. 1998 
Finland 
 
15 
 
 
T/T=8 
A/A=7 
OFTT: meal = 52g fat/ 70kg body weight. 
7.6g rice cake + 10g cheese + 5 min later 100ml cream 
mixture + heptadecanoic acid + 20ml fish oil. 
Thr54Thr  
= ↑ increases in most post prandial 14 to 18   
    carbon chain FA in chylomicrons & VLDL 
- Ågren et al. 2001 
Pima Indians 137 
 
T/T=12 
T/A=57 
A/A=68 
Mixed meal: 
30% of weight maintenance kJ,  
20% protein, 40% carbohydrate, 40% fat 
Thr54  
= ↑ postprandial insulin response 
- Baier et al. 1995 
French Canadian ♀ 20 
 
T/A=10 
A/A=10 
OFTT: Meal = 60g lipid/l m2 body surface area; 1800-
2200kcal, 64% fat, 18% carbohydrate, 18% protein. 
Ala54Thr   
= ↑ postprandial HDL-TG at 0 & 4h 
= ↑ AUC for HDL-TG 
= TG in large-TRL correlated with HDL-TG  
BG, FFA, LDL, 
TRL, insulin 
Berthier et al. 2001 
Canadian subjects, 
ethnicity not 
specified 
 
22 
 
 
T54=11 
A/A=11 
Each subject underwent 3 OFTT.  Test 1 = safflower oil, Test 
2 = olive oil, Test 3 = butter.   
All prepared as milk shakes  
Thr54  
= ↓ insulin/C-peptide ratio, AUC for insulin 
= suggest greater hepatic insulin clearance 
= ↑ chylomicron cholesterol after olive oil 
TC, TG, FFA, 
chylomicron, 
BG. 
Dworatzek et al. 
2004 
Caucasian ♂ T2DM  15 
 
 
T/T=6  
A/A=9 
OFTT: shake (egg white, sweet-and-low, fruit flavour, and 
55g corn oil/ M2 of body surface). 
Thr54Thr 
= ↑ postprandial TG, ↑ AUC of TG levels in  
   the chylomicron subfraction  
VLDL-TG Georgopoulos et al. 
2000 
German ♂ 700 
 
A/A=51%  
A/T=41%;  
T/T=8% 
Liquid mixed meal = 4392kJ, 51.6% fat, 29.6% 
carbohydrates, 11.9% protein. 
 
Thr54Thr  
= ↑ postprandial TG, ↑ AUC of TG, ↑ TG   
    increase, ↑ LDL/HDL ratio,  
= ↑ AUC of postprandial insulin levels 
- Helwig et al. 2007 
Pima Indians 
 
 
18 
 
T/T=9 
A/A=9 
Subjects received weight-maintaining diet for 14 days.  Diet 
= individualized kJ, 40% fat, 40% carbohydrate, 20% protein 
After day 5: 
Mixed meal test = 35% of calculated 24h energy needs, 40% 
carbohydrates, 20% protein, 40% fat. 
High fat meal test = 1362 kcal, 85% fat. 
Mixed meal:   
Thr54 tended to have ↑ postprandial NEFA and 
insulin levels.  
 
High fat meal:  
Thr54 = ↑ insulin at 1h, ↑ NEFA at 7h. 
TG, BG, 
Insulin, NEFA 
 
 
TG, BG 
Pratley et al. 2000 
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Table 2.9: continued 
Population n Genotype 
(n or %) 
OFTT or dietary intervention with different fatty acids Results: Postprandial associations No 
associations 
Reference 
OFTT       
European male 
students 
666 
 
 
A/A=52%;  
A/T=41%;  
T/T=7% 
OFTT = liquid consisting of 42g SFA, 22g protein, 56g 
carbohydrate, 6186 kJ. 
 
- TG Tahvanainen et al. 
2000 
USA 
 
36 
 
T/T=2 
A/T=22 
A/A=12 
OFTT = meal with whipping cream, sugar, chocolate syrup 
and nonfat powdered milk.  Size of meal = 386g/ 2m2 body 
surface area. 386g meal = 1362 kcal, 84% fat 
Thr54  
= ↑ lipid oxidation rates at 4h 
TG, FA, 2h 
lipid oxidation 
Weiss et al. 2007 
Fatty acid interventions      
Caucasian: Spain 
 
538 
 
 
A/A=52%;  
A/T=40%;  
T/T=8% 
No intervention. On home visits investigators took sample 
of cooking oil used.  Samples analyzed & categorized in 3 
groups: sunflower oil, olive oil & mixed oil.  
Thr54 + sunflower oil = ↑ HOMA-IR 
Thr54 + olive oil = lowest HOMA-IR values 
- Morcillo et al. 2007 
Caucasian: Spain 
♀ only 
 
 
59 
 
 
A/A=47%  
A/T=46%;  
T/T=7% 
All completed 3 diets, each lasting 28 days.  All started with 
diet 1, then randomly assigned (cross-over design) to follow 
diet 2 and 3.  All meals served in student cafeteria.  
All diets = 10200 kJ, 15% protein, 6% PUFA and: 
Diet 1: ↑ SFA diet=47% carb, 38% fat, 20% SFA, 12% MUFA 
Diet 2: ↓ fat = 57% carb, 28% fat, <10% SFA, 12% MUFA 
Diet 3: ↑ MUFA diet = 47% carb, 38% fat, <10% SFA, 22% 
MUFA 
Thr54 
= ↑SSPG (less peripheral insulin sensitivity) 
   after SFA  diet than MUFA diet,  
= ↑ FFA after consuming SFA diet (not seen 
   after carb or MUFA diets). 
- Marín et al. 2005 
USA (include 18% 
African Americans) 
 
22 
 
 
T54=10 
A/A=12 
Subjects received low fat diet for 16 days (24% fat, 7% SFA, 
7% PUFA, 10% MUFA). 
Days 10 and 16, consumed 1 of 2 OFTT  
Both meals = egg, mushroom and pototo quiche 
 = 40% of energy need, 50% total fat, 15%     
SFA, 15% PUFA and: 
C18:1cis test meal: 20% cis-MUFA 
C18:1trans test meal: 10% cis-MUFA +10% trans-MUFA 
Postprandial, C18:1 trans resulted in: 
Thr54   
= ↑ increments in glucose,  
= ↑ triacylglycerol fractional synthetic rate  
TG, FFA, fat 
oxidation, 
carbohydrate 
oxidation. 
Lefevre et al. 2005 
♀ Japanese 
university students 
majoring in 
Nutritional science 
49 
 
 
A/A=17%  
A/T=56%;  
T/T=27% 
9-day conditioning constant diet. 
Day 10: DAG or TAG for 8 weeks.   
Diets = identical except for either 20g DAG or TAG test 
oils/day. 
Ala54Thr:  
TAG = ↑ VLDL-phospholipids (week 4-8) 
DAG = ↓ VLDL-phospholipids (week 4-8) 
        = ↓ VF/TF %. 
FFA, TC, VLDL- 
cholesterol, 
VLDL-TG 
Yanagisawa et al. 
2003 
SSPG = steady state plasma glucose, SSPI = steady state plasma insulin, NEFA = non-esterified fatty acids, TAG = triacylglycerol, DAG = Diacylglycerol, VF/TF = Visceral fat/ total fat ratio, TRL 
= triglyceride rich lipoprotein, TG = triglycerides, TC = total cholesterol, VLDL = very low density lipoprotein, LDL = low density lipoprotein, HDL = high density lipoprotein, BG = blood glucose, 
AUC = area under the curve, OFTT = oral fat tolerance test, FFA = free fatty acids, SFA = saturated fatty acids, PUFA = poly-unsaturated fatty acids, MUFA = mono-unsaturated fatty acids, TE 
= total energy, HOMA-IR = Homeostasis model assessment of insulin resistance. 
 56
2.3.8 Associations with weight loss outcomes  
 
The association between the FABP2 Ala54Thr polymorphism and weight loss following a weight loss intervention 
has been investigated in Spaniards (De Luis et al. 2006, De Luis et al. 2008a, De Luis et al. 2008b) and Japanese 
(Takakura et al. 2005) (Table 2.10).  In one of these studies the weight loss intervention consisted of bariatric 
surgery with associated lifestyle intervention guidelines performed (De Luis et al 2008b).  In the other three 
studies obese subjects were enrolled in weight loss interventions consisting of dietary, physical activity and 
behavioural components that lasted either two months (De Luis et al. 2008a), three months (De Luis et al. 2006), 
or six months (Takakura et al. 2005).   
 
The results indicated that the BMI of both the Thr54-allele carriers and the Ala54Ala homozygotes decreased 
from baseline to follow-up in three of the four intervention studies (De Luis et al. 2006, De Luis et al. 2008a, De 
Luis et al. 2008b).  As there was no difference between the Thr54-allele carriers and the Ala54Ala homozygotes 
for weight or BMI at baseline or follow-up, it was concluded that the FABP2 Ala54Thr polymorphism did not 
affect weight loss (Takakura et al. 2005, De Luis et al. 2006, De Luis et al. 2008a, De Luis et al. 2008b).  However, 
the fact that actual change in BMI from baseline to follow-up within each genotype group was not compared 
between the genotype groups needs to be borne in mind when considering this conclusion. 
 
When considering change in fat distribution and health variables the FABP2 Ala54Thr polymorphism does seem 
to influence the outcome of weight loss interventions.  For instance, only the Ala54Ala homozygotes achieved a 
lower fat mass after a three-month intervention (De Luis et al. 2006), while Takakura et al. (2005) reported a 
higher WC in Thr54-allele carriers at six-month follow-up.  However, the other interventions led to a decrease in 
WC (De Luis et al. 2006, De Luis et al. 2008a) and fat mass (De Luis et al. 2008a, De Luis et al. 2008b) in both 
Thr54-allele carriers and Ala54Ala homozygotes.  In Ala54Ala homozygotes the three-month intervention also 
effectively decreased LDL and leptin levels (De Luis et al. 2006), while the two-month intervention decreased 
blood pressure, TC, TG, insulin, leptin levels and glucose levels (De Luis et al. 2008a).  The only positive effects 
found in Thr54-allele carriers were decreases in systolic blood pressure and glucose levels (De Luis et al. 2006), 
while a negative effect, namely a lower metabolic rate compared to the Ala54Ala homozygotes was reported at 
six-month follow-up (Takakura et al. 2005).   In contrast to these results, the FABP2 Ala54Thr polymorphism did 
not influence the significant improvements in weight, fat mass, blood pressure, glucose, total cholesterol, LDL, 
HDL, and TG levels at three-, nine- and 12-months following bariatric surgery (De Luis et al. 2008b).   
 
In summary, it seems that the FABP2 Ala54Thr polymorphism does not influence weight loss outcome in terms 
of BMI.  However, the Ala54Ala homozygotes benefit more from weight loss interventions to decrease risk 
factors for obesity related comorbidities. 
 
 57
Table 2.10: The association between the FABP2 Thr54Ala polymorphism and change in weight and other variables following a weight loss intervention. 
Population Sample 
size 
Genotype 
frequencies 
Inclusion 
criteria 
Weight loss intervention Variables measured Results Reference 
Caucasian: 
Spain 
 
 
n=69 
♀= 55 
♂= 14 
 
A54A=54% 
A54T=30% 
T54T=16% 
BMI>30 
 
 
 
3 month intervention: 
Diet = 6384 kJ/ 1520 kCal, 52% 
carbohydrates, 25% fat, 23% 
proteins. 
Exercise: 60 min aerobic 
3×/week  
 
Measured at 0, 3 months:  
BMI, WC, HC, WHR, BW, FM, FFM, 
BP, TC, HDL, LDL, TG, Energy, 
carbohydrate, protein, fat intake, 
RMR, VO2 max, BG, insulin, HOMA-
IR, lipoprotein (a), CRP, 
Adipocytokines: leptin, 
adiponectin, resistin, TNF-α, IL-6. 
No difference in weight loss or changes in any of the 
other variables between the T54 allele carriers and 
the A54A homozygotes. 
 
Change over 3 months within genotype groups: 
T54:   ↓ BMI, WC, SBP, glucose, ↑ VO2. 
A54A:  ↓ BMI, fat mass, WC, LDL, leptin, ↑ VO2. 
De Luis et 
al. (2006) 
Caucasian: 
Spain 
 
 
n = 204 
♀= 154 
♂= 50 
 
A54A=54% 
A54T=40% 
T54T=6% 
BMI>30 
 
 
2 months intervention 
randomly assigned to groups: 
Diet 1: low-fat diet  
1500 kcal/day, 27% fat, 52% 
carbohydrate, 20% protein. 
Diet 2: low carbohydrate diet 
1507 kcal/day, 36% fats, 38% 
carbohydrates, 26% proteins. 
Exercise: 60 min aerobic 
3×/week  
Measured at 0, 2 months: 
All as described above (De Luis et 
al. 2006) 
Change over 2 months within genotype groups: 
Diet 1 & 2 (same effects): 
A54A: ↓ BMI, weight, fat mass, WC, WHR, BP, 
  TC, TG, insulin, leptin 
T54:   ↓ BMI, weight, WC, fat mass  
Differences between genotype  
Diet 1: T54 = ↑ SBP, glucose, leptin (at baseline) 
Diet 1: T54 = ↑ SBP, leptin (at follow-up) 
Diet 2: T54 = ↑ WC, insulin, leptin (at baseline) 
Diet 2: T54 = ↑ WC, leptin (at follow-up) 
De Luis et 
al. (2008a) 
Caucasian: 
Spain 
 
n = 41 
♀= 32 
♂= 9 
 
A54A=56% 
A54T=36% 
T54T=7% 
BMI>40 
 
 
Intervention 
Bariatric surgery: 
biliopancreatic diversion 
Follow-up = 3, 9, 12 months 
after surgery 
 
Measured at 0, 3, 9, 12 months: 
BMI, fat mass (measured with body 
electrical bioimpedance), BP, TC, 
HDL, LDL, TG, Glucose 
Frequency of patients with DM, 
hypertension, hyperlipidemia. 
T54 =  ↑ TG at baseline 
Within genotype group changes: 
In A54A and T54 groups = ↓ BMI, fat mass, SBP, 
glucose, TC, LDL, TG, ↑ HDL (at 1 yr) 
No association between genotype and weight loss 
at 3, 9 and 12 months after bariatric surgery 
De Luis et 
al. (2008b) 
Japanese 
 
 
n = 80 
♀ only 
 
A54A=56% 
A54T=37% 
T54T=7% 
BMI>25 
 
6 months intervention 
Limit energy intake by 1200 
kcal/day 
Protein intake = 70 g/day 
 
Measured at 0 and 6 months: 
BMI, weight & BMI at 20 years of 
age, body fat %, glucose, HbA1c, 
insulin, HOMA-IR, TC, TG, LDL, free 
T3, free T4, TSH, VWAT, SWAT, RMR 
Change over 6 months within genotype groups: 
Thr54 = ↓ adjusted RMR, ↑ WC at 6 months 
 
 
Takakura et 
al. 2005 
A54A = Ala54 homozygotes, A54T = heterozygotes, T54T = Thr54 homozygotes, T54 = Thr54 allele carriers, BMI = body mass index, WC = waist circumference, HC = hip circumference, WHR 
= waist-hip ratio, BW = body water, FM = fat mass, FFM = fat free mass, BP = blood pressure, SBP = systolic blood pressure, TC = total cholesterol, HDL = high density lipoprotein, LDL = low 
density lipoprotein, TG = triglycerides, RMR = resting metabolic rate, BG = blood glucose, VWAT = visceral white adipose tissue, SWAT = subcutaneous white adipose tissue. 
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2.4 The insulin induced gene 2 (INSIG2) 
 
2.4.1 The INSIG2 gene 
 
The insulin induced gene 2 (INSIG2) is located on chromosome 2 at position 2q14.1 (Herbert et al. 2006), has a 
total length of 21548 bp and contains six exons (NCBI 2008).    
 
2.4.2 The INSIG2 protein 
 
The INSIG2 gene encodes a 225 amino acid protein that was identified in a search of an Expressed Sequence 
Tags (EST) database for proteins homologous to the INSIG1 protein (Yabe et al. 2002, NCBI 2008).  The amino 
acid sequences of the INSIG1 and INSIG2 proteins are 59% identical and differ mainly due to a much shorter NH2-
terminal sequence found in INSIG2.  Both proteins contain six membrane spanning helices (Figure 2.3) and are 
expressed in the endoplasmic reticulums (ER) of cells (Yabe et al. 2002). 
 
 
Figure 2.2: The human INSIG2 protein (from Radhakrishnan et al. 2007). 
 
 
The INSIG1 protein is predominantly expressed in the liver of humans.  Relatively low expression levels are also 
found in extrahepatic tissues such as the testes, kidney, brain, lung, intestine, trachea, thymus, muscle, ovaries, 
heart, cervix, oesophagus, placenta, prostate, adipose tissue and colon (Krapivner et al. 2008).   Although INSIG2 
is also highly expressed in the liver, it shows a more ubiquitous expression pattern in humans and is 
predominantly expressed in extrahepatic tissues including the adipose tissue.  In comparison to INSIG1, the 
INSIG2 expression levels are higher in all the mentioned extrahepatic tissues (Krapivner et al. 2008).    
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2.4.3 Physiological function of INSIG2 
 
As the functions of the INSIG1 and INSIG2 proteins overlap and the specific physiological contribution of each 
has not yet been fully elucidated, both INSIG proteins are discussed in this section.  It should be noted that initial 
in vitro and in vivo research investigating the physiological role of these proteins was conducted on INSIG1 
proteins only, as they were discovered in 1997 (Peng et al. 1997), five years before the INSIG2 proteins (Yabe et 
al. 2002). 
 
INSIG1 and INSIG2 are both attractive candidate genes for investigation of potential association with obesity 
development due to the role of their protein products in adipocyte metabolism as well as the regulation of the 
synthesis of cholesterol, triglycerides and other lipids through the sterol regulatory element binding protein 
(SREBP) pathway.  Both INSIG proteins block the proteolytic activation of the SREBPs.  Activated SREBPs are 
necessary to stimulate the transcription of more than 30 genes required for the synthesis and uptake of fatty 
acids, triglycerides, phospholipids, cholesterol, the NADPH cofactor and the low density lipoprotein (LDL)-
receptor (Horton et al. 2002, DeBose-Boyd 2008).     
 
The three SREBP isoforms, namely SREBP1a, SREBP1c and SREBP2 are encoded by two genes as inactive 
precursor proteins attached to the ER of cells (reviewed by Horton et al. 2002, Goldstein et al. 2006).  
Immediately following their synthesis, the ER attached SREBPs bind to the SREBP cleavage-activation protein 
(SCAP).  In sterol depleted cells, SCAP transports SREBPs from the ER to the Golgi apparatus where SREBPs are 
processed by two membrane bound proteases (Figure 2.3).  Consequently, the active SREBP portions are 
released into the cytosol to enter the nucleus and activate transcription by binding to the sterol response 
element (SRE) in the promoter/ enhancer regions of multiple target genes (Brown et al. 2002, Horton et al. 2002, 
Goldstein et al. 2006, DeBose-Boyd 2008).   
 
For example, SREBPs increase cholesterol synthesis through direct activation of the expression of 3-Hydroxy-3-
methylglutaryl (HMG)-CoA reductase, a rate-limiting enzyme required to convert HMG-CoA to mevalonate, an 
important step in the cholesterol biosynthesis pathway (Sul & Storch 2006, DeBose-Boyd 2008).  Reversal of this 
increase in reductase is mediated through feedback control by the end-products of the mevalonate pathway, 
namely cholesterol and cholesterol derivates oxysterols (Radhakrishnan et al. 2007).  Both cholesterol and 
oxysterols induce the binding of SCAP to either the INSIG1 or INSIG2 anchor proteins, but utilize different 
mechanisms to achieve this (Yang et al. 2002, Adams et al. 2004).  Cholesterol binds directly to SCAP and 
consequently initiates the binding of SCAP to an INSIG protein (Adams et al. 2004, Radhakrishnan et al. 2004).  
However, SCAP does not bind directly to the oxysterols because they contain polar groups such as extra hydroxyl 
or keto groups.  INSIG2 protein has high specificity for these hydroxyl groups of oxysterols and facilitates the 
binding of oxysterols to SCAP (Radhakrishnan et al. 2007).  Therefore in sterol abundant cells, the binding of 
sterols and INSIG proteins to SCAP prevents SCAP from escorting SREBPs to the Golgi apparatus and 
consequently block the proteolytic activation of SREBPs (DeBose-Boyd 2008).  The SREBP-SCAP complex now  
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Figure 2.3:  The regulation of the synthesis of cholesterol and other products by the INSIG proteins in the SREBP-SCAP 
pathway.  Scap transports the SREBP from the ER to the Golgi apparatus, where SREBP are processed by two 
proteases, Site-1 protease (S1P) and Site-2 protease (S2P), to release the active bHLH-Zip domain of SREBP.  The 
released domain migrates to the nucleus and binds to a sterol response element (SRE) in the promoter region of 
target genes (such as the gene encoding HMG-CoA reductase), activating their transcription.  Accumulation of sterols 
in ER membranes stimulates the binding of Insig proteins to Scap.  This prevents the translocation of SREBP to the 
Golgi-apparatus and the transcription of reductases is inhibited.  Consequently, the production of cholesterol and 
other sterols are increased (DeBose-Boyd 2008). 
 
remains in the ER and cholesterol and fatty acid syntheses are consequently inhibited, which may result in lower 
plasma cholesterol and triglyceride levels (Yabe et al. 2002, Yang et al. 2002, Sun et al. 2005, Goldstein et al. 
2006).   
 
The regulation of HMG-CoA reductase by the INSIG proteins has been illustrated by in vitro research.  For 
example, in Chinese hamster ovary cells the overexpression of Insig-1 and Insig-2 proteins activates the 
degradation of HMG-CoA reductase (Sever et al. 2003a).  It was further indicated that this degradation of HMG-
CoA reductase is suppressed in human SV-589 fibroblasts when the amounts of either Insig-1 or Insig-2 are 
decreased through RNA interference (Sever et al. 2003b).  However, when both Insig-1 and Insig-2 were 
simultaneously removed with RNA interference, no degradation of HMG-CoA reductase occurs (Sever et al. 
2003b).  These studies and others (Lee et al. 2005a) illustrate that the degradation of HMG-CoA reductase is 
dependent on the presence of the Insig-1 and Insig-2 proteins and is only stopped when both Insig proteins are 
removed.  This might indicate that the two proteins show complementary roles in the regulation of the SREBP 
pathway.  In vivo research by Engelking et al. (2005) have shown that  Insig-1 or Insig-2 knockout mice appear 
normal, however only the combined knockout of both Insig genes was associated with a phenotype related to 
disturbances of  the SREBP pathway.  It also appears that a decrease in concentration of one Insig protein is 
compensated for by an increase in the other Insig protein (Engelking et al. 2005).  However, further research by 
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Krapivner et al. (2008) showed increased mature SREBP1 protein levels and increased expression of all eight 
SREBP target genes under investigation following siRNA gene silencing of the Insig1 but not the Insig2 gene.  
These authors concluded that Insig-1 may play a more profound role than Insig-2 in the expression of SREBP 
protein and its target genes.  More research is necessary to confirm these findings. 
 
A four-fold increase in Insig-1 mRNA that was observed in the fat tissue of normal rats at the onset of diet 
induced obesity pointed to the possibility that Insig proteins might play a role in adipocyte metabolism (Li et al. 
2002).  This observation was confirmed when mice fed a high fat diet for five weeks showed progressively 
increased epididymal fat pad weight, leptin and Insig-1 mRNA levels (Li et al. 2003).  Furthermore, restriction of 
food intake by 50% led to decreased expression of Insig-1 mRNA in mice (Li et al. 2003).  It is known that when 
the diet is high in total energy and fat to induce weight gain and obesity development, adipose tissue expands as 
a result of triglyceride accumulation in adipocytes, with preadipocytes differentiating into mature adipocytes 
(Peters 2006).  In support of a possible role for INSIG proteins in adipocyte metabolism, in vitro experiments 
have shown a rise in Insig-1 and Insig-2 mRNA during maturation of 3T3-L1 preadipocytes (Li et al. 2003, 
Krapivner et al. 2008).  Both studies indicated that the rise in Insig-2 expression was more pronounced than 
Insig-1 expression (Krapivner et al. 2008).  This together with the fact that the INSIG2 protein is the predominant 
isoform expressed in adipose tissue may indicate that the INSIG2 gene may play a more profound role in 
controlling adipocyte metabolism and contribute to BMI changes. It was further illustrated that the transfection 
of the 3T3-L1 preadipocytes with mouse or human Insig-1 cDNA prevents the accumulation of lipids in 
differentiating preadipocytes and inhibits lipogenesis completely (Li et al. 2003).  Further in vivo work confirmed 
that the overexpression of Insig-1 or Insig-2 in the livers of Zucker diabetic fatty rats (ZDF (fa/fa) rat model) 
reduced SREBP activation of target lipogenic enzymes.  This consequently resulted in a reduction in lipogenesis, 
hypertriglyceridemia and hepatic steatosis independent of food intake, body weight and fat weight (Takaishi et 
al. 2004).  It is thus proposed that SREBPs play a role in the promotion of adipogenesis and triglyceride storage 
while the INSIG proteins potentially block these actions of the SREBPs.  Based on these premises it was 
postulated that in individuals with altered INSIG activity the subsequent elevation in plasma triglyceride levels 
and storage in adipose tissue could be a plausible explanation for a possible association with obesity 
development (Yabe et al. 2002, Herbert et al. 2006).   
 
In summary, INSIG2 blocks cholesterol and fatty acid synthesis by binding to the SCAP and preventing 
translocation and activation of SREBP and consequently decreases the transcription of necessary genes for these 
biosynthesis pathways.  In adipocyte metabolism, INSIG2 expression seems to increase following a high fat diet 
and consequently limits adipocyte differentiation and lipogenesis.     
 
2.4.4 The rs7566605 polymorphism near INSIG2 
 
The rs7566605 polymorphism near INSIG2 was the first common obesity associated gene variant to be identified 
through a GWA approach using participants from the Framingham Heart Study (Herbert et al. 2006).  The 
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mutation produces a Guanine (G) to Cytosine (C) transition which is located 10 kb upstream of the transcription 
start site of the INSIG2 gene (Herbert et al. 2006).   
           
Whether this variant itself, or maybe another variant in strong linkage disequilibrium (LD) alters INSIG2 
expression, is still unknown.  It was pointed out that it is unlikely that the INSIG2 rs7566605 polymorphism is 
functional due to its location and that this mutation may rather be a marker for the yet unidentified functional 
variation elsewhere in the INSIG2 gene or another gene at the same locus (Smith et al. 2007).  However, Hotta et 
al. (2008a) argued that the INSIG2 rs7566605 polymorphism may affect the transcriptional activity of INSIG2 and 
may therefore have an impact on its expression levels (Hotta et al. 2008a).  More research is necessary to 
elucidate these findings. 
 
It has been shown that a variant INSIG2 protein lost the ability to bind with SCAP and consequently decreasing 
SREBP activitation and the transcription of biosynthetic enzymes (Gong et al. 2006).  In contrast, others have 
hypothesized that a polymorphism may result in INSIG2 overexpression in presence of excess sterols and 
consequently block cholesterol synthesis through the SREBP pathway to a greater degree (Oki et al. 2009).  
However, these findings still need to be confirmed by functional analyses of the polymorphism and further in 
vivo and in vitro investigations. 
 
2.4.5 Genotype and allele frequencies  
 
The frequency of the wild-type GG genotype of the INSIG2 rs7566605 polymorphism reported for Caucasian 
populations with European ancestry ranges between 43 to 50%, but is much higher in African Americans at 59 to 
62% and American Indians at 62% (Table 2.11).  Consequently, the frequency of the mutant CC genotype ranges 
between 10 and 13% in Caucasians but only between 5.3 to 5.9% in African Americans.   
 
In Caucasian populations the minor allele frequency of the INSIG2 rs7566605 polymorphism ranges from 0.31 to 
0.37.  This range is similar in Japanese and other populations of Eastern origin but lower in African-American and 
Native-American populations.   
 
Table 2.11: Genotype frequencies of the rs7566605 polymorphism near INSIG2 and frequency of the mutant C-allele.  
Population Disease state n GG 
% 
GC 
% 
CC 
% 
C-allele 
% 
References 
Caucasian        
Denmark 
  
Controls 
Overweight 
Obese 
5106 
6973 
4702 
44 
45 
45 
45 
44 
44 
11 
11 
11 
33 
33 
33 
Andreasen et al. 2008 
UK  1372 50 42 8 31 Hall et al. 2006 
UK:  Epic cohort 
 MRC Ely study 
 4916 
1683 
46 
47 
44 
42 
10 
11 
32 
32 
Loos et al. 2007 
FHS offspring  694 - - - 37 Herbert et al. 2006 
UK  2721 48 42 10  Smith et al. 2007 
UK  566   10 33 Smith et al. 2007 
UK: 77% Caucasian DM2 747 45 44 11  Smith et al. 2007 
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Table 2.11: continued 
Population Disease state n GG 
% 
GC 
% 
CC 
% 
C-allele References 
Caucasian        
USA: 56% Caucasian  Overweight 1994 45 44 11  Franks et al. 2008 
USA: >97% Caucasian Morbidly obese 707 43 44 13 35 Chu et al. 2008 
Canada MetS 
Without MetS 
66 
165 
47 
45 
44 
48 
9 
6 
31 
30 
Pollex et al. 2007 
USA & Ireland  752 47 44 9 31 Orkunoglu-Suer et al. 2008 
USA BMI>33 
Controls 
1026 
818 
45 
44 
45 
44 
10 
12 
 Boes et al. 2008 
Austria  1696 43 45 12  Boes et al. 2008 
Germany  4089 46 44 10  Rosskopf et al. 2007 
Germany  Obese children 293 50 43 7  Reinehr et al. 2008 
Germany  Obese children 280 52 41 7  Reinehr et al. 2009 
Germany (KORA)  4084 43 46 11  Lyon et al. 2007 
Scandinavia  913 44 45 11  Lyon et al. 2007 
Iceland  5187 43 45 12  Lyon et al. 2007 
Sweden  634    36 Krapivner et al. 2008 
FHS  8359 46 42 12  Lyon et al. 2007 
Italy  925    24 Ciullo et al. 2008 
Hispanic American         
Hispanic American  Overweight 591 50 41 9.0  Franks et al. 2008 
African         
African American  893 62 32 6  Lyon et al. 2007 
African American  Overweight 713 59 34 5  Franks et al. 2008 
Afro-Caribbean:  69   12 29 Smith et al. 2007 
Native American        
American Indian  Overweight 85 62 33 5  Franks et al. 2008 
Canada: Kivalliq Inuit MetS 
Without MetS 
13 
115 
77 
55 
15 
37 
8 
8 
15 
26 
Pollex et al. 2007 
Canada: Greenland Inuit MetS 
Without MetS 
163 
930 
62 
65 
36 
30 
2 
5 
20 
20 
Pollex et al. 2007 
Canada: Oji-Cree MetS 
Without MetS 
156 
270 
63 
58 
33 
37 
4 
5 
20 
23 
Pollex et al. 2007 
  
Asian        
Japanese  2233 47 43 10 32 Kuzuya et al. 2007 
Japanese 
  
Obese 
Controls 
908 
1495 
46 
46 
40 
44 
14 
9 
34 
31 
Hotta et al. 2008a 
Japanese  1976 43 44 13 35 Tabara et al. 2008 
American Japanese 
Japanese 
 885 
378 
46 
39 
43 
50 
11 
11 
32 
36 
Oki et al. 2009 
Chinese  3125 40 47 12 36 Yang et al. 2008 
Chinese Obese 
Controls 
258 
982 
39 
48 
52 
43 
9 
9 
35 
31 
Zhang et al. 2008 
American from Asia/ Pacific  Overweight 150 40 45 15  Franks et al. 2008 
Chinese Canadian MetS 
Without MetS 
57 
236 
46 
40 
37 
48 
18 
12 
36 
36 
Pollex et al. 2007 
Chinese: school children & 
adolescents 
Normal weight 
Overweight 
Obese 
607 
725 
708 
42 
42 
42 
44 
44 
44 
14 
14 
14 
 Wang et al. 2008 
India:  AIIMS cohort 
 IGV cohort 
CAD (n=255) 610 
1577 
51 
49 
42 
42 
7 
9 
28 
30 
Kumar et al. 2007 
 
UK Indians  103   17 36 Smith et al. 2007 
South Asian Canadian MetS 
Without MetS 
100 
214 
58 
56 
32 
38 
10 
7 
26 
25 
Pollex et al. 2007 
UK: United Kingdom; MRC: Medical Research Council; UDACS: University College London Diabetes and Cardiovascular 
Disease Study; USA: United States of America; FHS: Framingham Heart Study. 
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2.4.6 Associations with obesity related phenotypes 
 
Association with weight, BMI and obesity 
Following the first identification of an association between the INSIG2 rs7566605 polymorphism and BMI using a 
genome wide association (GWA) approach on 694 individuals from the Framingham Heart Study population 
(Herbert et al. 2006), two further independent GWA scans in Caucasian Americans (Liu et al. 2008) and South 
Italians (Ciullo et al. 2008) confirmed these results (Table 2.12). 
 
Herbert et al. (2006) further investigated their GWA results using samples from cohort studies and family based 
studies.  In four of the five studies obesity was associated with a higher frequency of CC homozygotes in 
Caucasian subjects from Germany, Poland and the United States of America as well as with African-Americans.  
The results of these analyses indicate that the recessive model (CC homozygous genotype compared to the GC 
and GG genotypes) is associated with a higher BMI, with individuals who are homozygous for the C-allele having 
a 1 kg/m2 higher BMI compared to G-allele carriers (Herbert et al. 2006).  In the meta-analysis of 9881 
individuals identified from all the case-control samples in the cohort and family based studies, Herbert et al. 
(2006) indicated that individuals homozygous for the mutant C-allele incurred a 1.22-fold increased risk of being 
obese compared with individuals with the G-allele. The association with BMI was further confirmed by Lyon et al. 
(2007) in an analysis comprising nine independent large cohorts studies with nearly 17000 individuals across 
multiple ethnicities, showing positive associations in five of the nine cohorts including Caucasians from the 
United States of America, Iceland, Germany, the Framingham Heart Study and Costa Ricans with an American-
Indian and Spanish ancestry.  Rosskopf et al. (2007) also reported a higher risk for obesity amoung CC 
homozygotes from Germany.  In populations with Eastern ancestry the CC genotype or C-allele carriers was also 
associated with severe obesity in Japanese (Hotta et al. 2008a) and with an increased risk for obesity and a 
higher BMI in Chinese (Yang et al. 2008, Zhang et al. 2008).   
 
To illustrate heritability of these mutations and associations with weight status Herbert et al. (2006) tracked the 
presence of the INSIG2 rs7566605 polymorphism in a Caucasian Western European parent-child trios sample.  
The trios comprised both parents and one obese child or adolescent offspring and assessments involved the 
detection of an allele transmitted from the obese parent to the obese offspring.  The results show that the 
INSIG2 rs7566605 polymorphism was associated with obesity from an early age, which was explained by the 
observed overtransmission of the C-allele to the obese offspring.  However, in a further study by Dina et al. 
(2007a) in French Caucasian trios this association could not be confirmed.    
 
Despite these positive associations, several other independent studies have failed to observe an association 
between the INSIG2 rs7566605 polymorphism and obesity or BMI in Caucasians from the United Kingdom (Hall 
et al. 2006, Loos et al. 2007, Smith et al. 2007), Austria (Boes et al. 2008), France (Dina et al. 2007a), Denmark 
(Andreassen et al. 2008, Vimaleswaran et al. 2009), Italy (Ciullo et al. 2008), Sweden (Krapivner et al. 2008), 
Belgium (Peeters et al. 2009), Scandinavia (Lyon et al. 2007) and the United States of America (Boes et al. 2008, 
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Orkunoglu-Suer et al. 2008).  The lack of association was also evident in other populations such as Afro-
Caribbeans (Smith et al. 2007), Indians (Smith et al. 2007, Kumar et al. 2007), Asians (Feng et al. 2007) the 
Japanese (Tabara et al. 2008, Oki et al. 2009, Kuzuya et al. 2007), Japanese-Americans (Oki et al. 2009), Filipino 
women (Marvelle et al. 2008) and Canadian populations, including the Kivalliq Inuit, Greenland Inuit, Oji-Cree 
and those of South Asian, Chinese and European descent (Pollex et al. 2007).  More specifically, the work by Loos 
et al. (2007) in actual fact points to an association in the opposite direction, namely CC homozygotes appearing 
to be leaner than individuals carrying the G-allele, versus the observation by Herbert et al. (2006) that the leaner 
individuals carried the G-allele.  Kumar et al. (2008) also reported that the CC genotype was more frequent in 
the non-obese when compared to the obese Indian population. 
 
Several authors suggested that the different BMI distributions in the populations under investigation may 
explain the inconsistency in the association of BMI with the INSIG2 rs7566605 polymorphism (Herbert et al. 2006, 
Hall et al. 2006, Lyon et al. 2007, Smith et al. 2007).  These authors have particularly found a lack of association 
when a population had lower overweight and obesity levels and the BMI was distributed more in the normal 
weight range.  Therefore, they suggested that a population with low obesity prevalence may lack sufficient 
power to investigate the association between the INSIG2 rs7566605 polymorphism and obesity.  According to 
Kuzuya et al. (2007) this may be the case in the Japanese where only 0.97% of male and 3.37% women in the 
sample were obese and no association with BMI was reported.  Herbert et al. (2006) have also shown that if the 
upper quartile BMI values are excluded from their analysis in the German population, the evidence for an 
association between the CC genotype of the INSIG2 rs7566605 polymorphism and BMI was eliminated.  
Rosskopf et al. (2007) reported no association between the INSIG2 rs7566605 polymorphism and BMI in a 
population-based sample, however after manipulating their data by excluding all the normal weight BMIs from 
the population-based sample and only including overweight BMIs in the analysis, the CC homozygotes had a 
higher BMI than the G-allele carriers.  These authors therefore conclude that the association between the INSIG2 
rs7566605 polymorphism and obesity is strongest in those who are more obese (Herbert et al. 2006, Rosskopf et 
al. 2007).  Whether this hypothesis is true and the possible physiological explanation thereof still needs to be 
elucidated.   
 
In summary, the majority of studies that did find an association between the INSIG2 rs7566605 polymorphism 
and obesity or BMI support the possibility that being a CC homozygote or having the C-allele predispose an 
individual to a higher BMI and obesity risk. 
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Table 2.12: The association between the rs7566605 polymorphism near INSIG2 and weight, BMI and obesity. 
Population  n Design Association with obesity Association with BMI Reference 
    Yes No Yes No  
Caucasian          
FHS  694 Family based offspring cohort obese = ↑ CC  GWA: CC = ↑ BMI - Herbert et al. 2006 
Germany   3996 Cohort with case-control analysis obese = ↑ CC  CC = ↑ BMI - Herbert et al. 2006 
Germany  4089 Cross-sectional -  -  Rosskopf et al. 2007 
Germany Overweight 2701 Overweight sub-sample of cross-sectional 
sample 
CC = ↑ obesity risk  CC = ↑ BMI - Rosskopf et al. 2007 
Poland and USA  2761 Case-control obese = ↑ CC  - - Herbert et al. 2006 
USA: >95% Caucasian  2726 Nurses health study (lower mean BMI 
compared to other samples) 
- -   
 
Herbert et al. 2006 
Western-Europe  1104 Family: Parents + obese child or 
adolescent 
C-allele = transmitted 
to obese child 
 C-allele = ↑ BMI 
from early age 
 Herbert et al. 2006 
Caucasian + African 
American 
 9881 Meta-analysis of case-control samples obese = ↑ CC - - - Herbert et al. 2006 
Denmark  16781 Population based samples with case-
control analysis 
-  
 
-  
 
Andreasen et al. 
2008 
Denmark   3878 Sub-sample of population based sample - - 
 
-  
 
Andreasen et al. 
2008 
Belgium 
    
obese 
controls 
1078 
323 
Case-control   
 
  
 
Peeters et al. 2009 
Austria  1696 Population sample with case-control 
analysis 
  
 
  
 
Boes et al. 2008 
Canada  231 Population sample - -   Pollex et al. 2007 
USA  BMI>33 
Controls 
1026 
818 
Case-control   
 
  
 
Boes et al. 2008 
USA and Ireland  752 Cohort from populations at 8 centres  - -   
 
Orkunoglu-Suer et al. 
2008 
USA  1000 Population GWA: CC = ↑ obesity - - - Liu et al. 2008 
UK  1372 Family based study with 4-6 members of 
a family with a hypertensive proband 
-  
 
-  
 
Hall et al. 2006 
 
UK 
 
 4916 
1683 
6599 
Cohort: EPIC 5000 
Cohort: MRC Ely 
Combined cohorts 
- - C-allele =↓ BMI  
 
 
Loos et al. 2007 
UK 
  
 3012 
572 
Cohort: ♂  
Cohort: Cross-sectional of DM2 pt.   
  
 
  
 
Smith et al. 2007 
Iceland  5187 Cohort obese = ↑ CC  CC = ↑ BMI  Lyon et al. 2007 
Germany  4084 Cohort: KORA S3      Lyon et al. 2007 
 67
Table 2.12: continued 
Population  n Design Association with obesity Association with BMI Reference 
    Yes No Yes No  
Caucasian          
Essen  1381 Cohort obese = ↑ CC - ni ni Lyon et al. 2007 
France   1531 Case-control: Obese vs. control children -  ni ni Dina et al. 2007a 
France  1138 Children of family study with at least 1 
obese sibling 
- C-allele not 
transmitted 
-  Dina et al. 2007a 
France   7593 
4998 
1572 
1023 
Case-control: meta-analysis from: cohort, 
family (parents of obese child) unrelated 
adult case-control sample 
- 
- 
- 
- 
 
 
 
 
- 
- 
- 
- 
- 
 
- 
- 
Dina et al. 2007a 
USA: >97% Caucasian  707 Intervention: Morbidly obese ni ni -  Chu et al. 2008 
USA: 56% Caucasian Overweight 3533 RCT ni ni -  Franks et al. 2008 
European American  - DB-RCT: schizophrenia pt ni ni -  Skelly et al. 2007 
Danish & Estonian 
children 
 2003 School based cross-sectional study -    Vimaleswaran et al. 
2009 
Scandinavia  512 Family: siblings without DM ni ni -  Lyon et al. 2007 
Scandinavia  913 Cohort -  -  Lyon et al. 2007 
Sweden  634 Cohort of healthy men ni ni -  Krapivner et al. 2008 
USA  1224 Family: (CAMP) children with asthma 
history and their parents 
ni ni CC = ↑ BMI  Lyon et al. 2007 
Italy  925 Populations in Campora & Gioi, remote 
South Italy 
-  
 
-  
 
Ciullo et al. 2008 
FHS exam 1 
FHS exam 2 
FHS exam 3 
FHS exam 4 
FHS exam 5 
FHS exam 6 
 1491 
1267 
1310 
1431 
1431 
1429 
Cohort - 
- 
obese = ↑ CC 
- 
- 
- 
 
 
 
 
 
 
- 
- 
- 
- 
- 
- 
 
 
 
 
 
 
Lyon et al. 2007 
African          
African American  866 Family based sample obese = ↑ CC - ni ni Herbert et al. 2006 
African American  398 Case-control obese = ↑ CC - ni ni Herbert et al. 2006 
African American  893 Cohort -  -  Lyon et al. 2007 
African American   - DB-RCT: schizophrenia pt 
(n=756 with European American) 
ni ni -  Skelly et al. 2007 
UK: Afro-Caribbean   70 Cohort: Cross-sectional of DM2 pt -  -  Smith et al. 2007 
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Table 2.12: continued 
Native American         
Canadian Greenland 
Inuit 
 1093 Population sample ni ni -  Pollex et al. 2007 
Canadian Kivalliq 
Inuit 
 128 Population sample ni ni -  Pollex et al. 2007 
Canadian Oji-Cree  426 Population sample ni ni -  Pollex et al. 2007 
American-Indian + 
Spanish 
 1284 Family: Costa-Rica cohort of children with 
asthma + families 
ni ni CC = ↑ BMI - Lyon et al. 2007 
Asian          
Filippines  1886 Population sample of women ni ni -  Marvelle et al. 2008 
China  2040 School-based study with selected obese, 
overweight, normal weight children and 
adolescents 
-  -  Wang et al. 2008 
China  3125 
1574 
1551 
Combined cross-section sample of: 
Cross-sectional Beijing sample 
Cross-sectional Shanghai sample 
- 
- 
CC = ↑ risk for obese 
or overweight 
 
 
- 
- 
- 
CC = ↑ BMI 
 
 
- 
Yang et al. 2008 
China: Uyghurs  1240 Population sample: Uyghur farmers Obese = ↑ C-allele - C-allele=↑ BMI - Zhang et al. 2008 
India  1577 Population-based cohort with case-
control analysis. 
-  ni ni Kumar et al. 2007 
India  610 
255 
355 
Case-control: all 
CAD cases  
controls 
Obese = ↓ CC 
- 
Obese = ↓ CC 
- 
 
- 
- 
- 
- 
 
 
 
Kumar et al. 2007 
Indian in UK  105 Cohort: Cross-sectional of DM2 pt -  -  Smith et al. 2007 
South Asians in 
Canada 
 314 Population sample ni ni -  Pollex et al. 2007 
Japan 
 
 1976 Population sample - 
- 
 
 
- 
- 
 
 
Tabara et al. 2008 
Japan  2233 Population sample -  -  Kuzuya et al. 2007 
Japanese Americans 
Japan 
 885 
378 
Cross-sectional of an epidemiological 
study 
ni ni - 
- 
 
 
Oki et al. 2009 
 
Chinese Canadians  293 Population sample ni ni -  Pollex et al. 2007 
Japan:  
   
Obese 
Controls 
908 
1495 
Case-control  obese = ↑ CC - - 
- 
 
 
Hotta et al. 2008a 
 
*Recessive model = compares the CC homozygotes with G-allele carriers; Dominant model = compares GG homozygotes with C-allele carriers 
EPIC: European Prospective Investigation of Cancer; MRC: Medical Research Council; NILS-LSA: National Institute for Longevity Sciences – Longitudinal Study of Aging; 
CAMP: Childhood Asthma Management Program;  
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Measures of body fat distribution and content 
Only three studies thus far have reported a positive association between the INSIG2 rs7566605 polymorphism 
and fat distribution (Table 2.13).  In Caucasian populations it was indicated that the C-allele carriers had a higher 
subcutaneous adipose tissue area (Franks et al. 2008) and subcutaneous fat volume (Orkunoglu-Suer et al. 2008) 
than GG homozygotes.  However, in contrast with the general association of the C-allele with a higher BMI, 
Pollex et al. (2007) reported a lower waist circumference in C-allele carriers in non-Caucasian populations. 
 
 
Table 2.13: The association between the rs7566605 polymorphism near INSIG2 and measures of body fat distribution 
and content. 
Population Fat distribution No associations Reference 
Caucasian     
Denmark - WC Andreasen et al. 2008 
UK - WHR, leptin Hall et al. 2006 
USA: 56% Caucasian  C-allele = ↑ SAT WC, VAT Franks et al. 2008 
USA & Ireland C-allele ♀ = ↑ sc fat volume sc fat volume in ♂ Orkunoglu-Suer et al. 2008 
Danish & Estonian children  WC, sum of 4 skinfolds Vimaleswaran et al. 2009 
Belgium  WC, WHR, VFA, SFA, 
TFA 
Peeters et al. 2009 
Austria - WC, WHR, % body fat, 
vc & sc abdominal fat 
Boes et al. 2008 
Canadian - WC Pollex et al. 2007 
Native American     
Canadian: Kivalliq Inuit - WC Pollex et al. 2007 
Canadian: Greenland Inuit - WC Pollex et al. 2007 
Canadian: Oji-Cree ♀ C-allele carriers = ↓ WC - Pollex et al. 2007 
Asian     
Canadian: South Asian  ♀ C-allele carriers = ↓ WC - Pollex et al. 2007 
Filippines  - WC, % body fat Marvelle et al. 2008 
Chinese-Canadian ♂ C-allele carriers = ↓ WC - Pollex et al. 2007 
China - WC Yang et al. 2008 
China - WHR Zhang et al. 2008 
Chinese: children and 
adolescents 
- WC, WHR, % body fat Wang et al. 2008 
Japan - Adiponectin, resistin Tabara et al. 2008 
Japan - WC, HC, WHR, fat mass Kuzuya et al. 2007 
Japanese Americans 
Japan  
- % body fat, WC Oki et al. 2009 
Meta-analysis    
Meta-analysis of Canadian 
populations inkling: Oji-
Cree, Greenland Inuit, 
Kivalliq Inuit, South Asian, 
Chinese and Caucasians 
C-allele carriers = ↓ WC - Pollex et al. 2007 
VFA = visceral abdominal fat area; HC = hip circumference; WC = waist circumference; WHR = waist-hip-ratio; SFA, 
subcutaneous abdominal fat area; TFA = total abdominal fat area; PCOS = polycystic ovary syndrome.  
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2.4.7 Associations with health indicators 
 
Indicators of glucose and insulin homeostasis 
Although nine studies have investigated thus far an association between the INSIG2 rs7566605 polymorphism 
and blood glucose and/or insulin levels in 15 populations, none could find any significant results (Table 2.14).  
There was also no indication of an association with type-2 diabetes prevalence, duration of type-2 diabetes, 
insulin resistance as measured with HOMA-IR and MetS.  However, a meta-analysis of six Canadian populations 
with different ancestries showed that C-allele carriers had a decreased MetS risk, based on the IDF criteria for 
the diagnosis of this syndrome (Pollex et al. 2007).  This finding is not in line with the proposed association of the 
CC genotype or the C-allele with obesity and a higher BMI.   
 
Blood lipid profile and blood pressure 
Only three studies thus far have indicated an association between the INSIG2 rs7566605 polymorphism and 
blood lipid profile (Table 2.14).  It was shown that obese Chinese children and adolescents with the CC genotype 
have higher plasma triglyceride levels than the G-allele carriers (Wang et al. 2008). Canadian Oji-Cree female C-
allele carriers had higher LDL than GG homozygotes (Pollex et al. 2007).  However, eight of the 11 studies 
summarized in Table 2.15 found no association between the INSIG2 rs7566605 polymorphism and plasma levels 
of total cholesterol, triglycerides, LDL, HDL, free fatty acids or blood pressure.  Further conflicting results indicate 
that female Japanese-Americans with the CC genotype have decreased dyslipidemia and hypercholesterolemia 
(Oki et al. 2009).   
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Table 2.14: The association between the rs7566605 polymorphism near INSIG2 and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure.    
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP) Reference 
 Association No association Association No associations  
Caucasian      
Caucasians: Denmark - insulin, glucose after 
OGTT 
- TG, HDL Andreasen et al. 2008 
UK (>77% Caucasian) - DM2, duration of DM2 - CHD Smith et al. 2007 
USA (>97% Caucasian) ni ni - TG, TC, HDL, LDL Chu et al. 2008 
USA ni ni - TC, TG, LDL, HDL, FFA Boes et al. 2008 
Canada - Glucose, MetS - TC, TG, LDL, HDL, BP Pollex et al. 2007 
Austria ni ni - TC, TG, LDL, HDL, FFA Boes et al. 2008 
Danish & Estonian children ni ni - TC, TG, LDL, HDL Vimaleswaran et al. 2009 
Native American      
Canadian Greenland Inuit - Glucose, MetS - TC, TG, LDL, HDL, BP Pollex et al. 2007 
Canadian Kivalliq Inuit - Glucose, MetS - TC, TG, LDL, HDL, BP Pollex et al. 2007 
Canadian Oji-Cree - Glucose, MetS C-allele ♀ = ↑ LDL TC, TG, HDL, BP Pollex et al. 2007 
Asian       
Chinese: children & 
adolescents 
- glucose, insulin obese CC = ↑ TG TC, LDL, HDL, BP Wang et al. 2008 
Chinese - Glucose - TG, TC, BP Zhang et al. 2008 
Chinese Canadian - Glucose, MetS - TC, TG, LDL, HDL, BP Pollex et al. 2007 
Japanese - BG, HOMA-IR - HDL, TG Tabara et al. 2008 
Japanese - DM2, glucose, insulin,  
HbA1C, HOMA-IR 
ni ni Kuzuya et al. 2007 
Japanese - Insulin, HOMA-IR - TG, TC, HDL Oki et al. 2009 
Japanese Americans 
 
- Insulin, 
HOMA-IR 
♀:  CC = ↓ dyslipidaemia 
& hypercholesterolaemia  
TG, TC, HDL Oki et al. 2009 
 
Japanese - glucose, HbA1C - TC, TG, HDL, BP Hotta et al. 2008a 
Canadian South Asian - Glucose, MetS - TC, TG, LDL, HDL, BP Pollex et al. 2007 
Meta-analysis      
Meta-analysis of Canadian 
populations inkling: Oji-
Cree, Greenland Inuit, 
Kivalliq Inuit, South Asian, 
Chinese and Caucasians 
C-allele carriers = ↓ MetS 
risk with IDF criteria 
 
C-allele carriers ♀ = ↓ 
MetS risk with IDF criteria 
MetS with NCEP ATPIII 
criteria 
 
MetS in ♂ with IDF criteria 
ni ni Pollex et al. 2007 
 
 
 
TG = triglycerides, TC = Total Cholesterol, HDL = High density lipoprotein, MetS = Metabolic Syndrome, IDF = International Diabetes Federation, NCEP ATPIII = National Cholesterol 
Education Program Adult Treatment Panel III. 
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2.4.8 Associations with weight loss outcomes  
 
Three studies (Table 2.15) have thus far investigated the association between the INSIG2 rs7566605 
polymorphism and weight loss after a weight loss intervention programme.  Two studies were executed on 
obese children aged six to 16 years in Germany (Reinehr et al. 2008, Reinehr et al. 2009).  In both reports the 
children were enrolled in the one year “Obeldicks” outpatients’ intervention programme comprising of nutrition 
education, physical exercise, behaviour therapy (covered in group sessions) and individualized psychological care 
components.  In both studies the CC homozygotes lost less weight than G-allele carriers after following the one 
year intervention programme (Reinehr et al. 2008, Reinehr et al. 2009).  It was further illustrated that although 
the total sample lost weight after one year, when considering the INSIG2 rs7566605 polymorphism, it was only 
the G-allele carriers who lost weight while the CC homozygotes actually gained weight during this period 
(Reinehr et al. 2009).    However, Franks et al. (2008) reported opposite findings for overweight adults enrolled 
in an ongoing Diabetes Prevention Program in the United States of America.  In this randomized controlled trial, 
adults were assigned to one of four treatment groups and follow-up measurements were reported after one 
year on the programme.  In the overall study the lifestyle intervention component was the most effective 
treatment strategy to induce weight loss compared to the placebo, Metformin and Troglitazone groups.  When 
the INSIG2 rs7566605 polymorphism was considered, the CC homozygotes lost more weight than the G-allele 
carriers after one year lifestyle intervention.   
 
Two further studies that were not weight loss interventions, but investigated the effect of physical activity on 
subcutaneous fat volume and BMI, need to be mentioned.  Orkunoglu-Suer et al. (2008) tested the influence of a 
12 weeks resistant training programme on the change in subcutaneous fat volume of a trained and untrained 
arm of healthy Caucasian subjects.  Subjects received two 45 to 60 minute sessions per week for 12 weeks.  
Sessions consisted of resistant training exercises for the biceps and triceps muscles in the non-dominant arm.  
After the 12 week intervention, the GG homozygotes experienced a decrease in subcutaneous fat levels in their 
non-dominant arm, while C-allele carriers were resistant to such fat losses and actually gained subcutaneous fat 
(Orkunoglu-Suer et al. 2008).  Andreasen et al. (2008) compared the BMI of physically active and passive 
subjects according to the INSIG2 rs7566605 polymorphism.  Physically passive subjects had a higher BMI than 
physically active, which was more pronounced in the CC physically passive homozygotes who had a 1.00 unit 
higher BMI than the physically active CC homozygotes.  In physically passive subjects, the CC homozygotes had a 
0.54 unit higher BMI than the G-allele carriers (Andreasen et al. 2008).    
 
Although the results seem conflicting, two of the three weight loss studies, the one exercise intervention study 
and the one study comparing habitual exercise all indicate that the INSIG2 rs7566605 polymorphism may 
influence weight management.  These studies point to the possibility that CC homozygotes may find it more 
difficult to lose weight on weight loss intervention programmes or with physical activity interventions.  
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Table 2.15: The association between the rs7566605 polymorphism near INSIG2 and change in weight (BMI) and other variables following a weight loss intervention. 
Population Sample 
size 
Genotype 
frequencies 
Inclusion 
criteria 
Weight loss intervention Variables 
measured 
Results Reference 
USA: 
56% white 
20% African-
American 
17% Hispanic 
4% Asian 
3% American 
Indian 
n=3533 GG=49% 
CG=41% 
CC=10% 
Non-DM, 
overweight 
DPP is ongoing RCT, here results of 1 year 
intervention reported, pt received 1 of the 
following 4 interventions:  
1) Placebo, 2) Metformin, 3) Troglitazone  
4) Lifestyle modification programme with   
    aim =150 min PA/wk & 7% weight loss  
Weight, WC, 
abdominal 
adipose tissue 
distribution, 
lipids, insulin, 
glucose, OGTT 
After 1 year 
CC = lost more weight than G-allele carriers in 
lifestyle intervention group  
No significant differences in other groups 
CC = lost more subcutaneous and visceral adipose 
areas 
 
 
Franks et 
al. 2008 
German 
children 
n=293 
♀=161 
♂=132 
 
Follow-
up: 
n=185 
GG=50% 
CG=43% 
CC=7% 
obese 
children  
6-16 yrs 
1 year “Obeldicks” program: 
First 3 months = eating behaviour 
&nutrition course  in 6 group sessions of 
1.5h each for children and 6 parents group 
sessions. 
Months 3-9 = individual psychological family 
therapy 
Months 9-12: individual care if necessary 
Throughout year: 1-2/week exercise 
Diet: 30% fat, 15% protein, 55% 
carbohydrate including 5% sugar 
 
BMI, TG, HDL, 
LDL, glucose, 
insulin, HOMA-
IR, BP. 
n=77 drop-out in motivation phase, n=31 drop-out 
in first 3 months 
 
CC=lost less weight than G-allele carriers 
Reinehr et 
al. 2008 
German 
children 
n=280 
♀=154 
♂=126 
 
Follow-
up: 
n=240 
GG=52% 
CG=41% 
CC=7% 
obese 
children  
6-16 yrs 
as described above BMI n=40 drop-out  
 
After 1 yr on programme: 
Total sample = ↓ BMI by 0.71 kg/m2 & 68% lost 
weight 
CC = ↑ BMI & G-allele carriers = ↓ BMI 
CC=loss less weight than G-allele carriers 
INSIG CC & FTO AA = highest ↑ BMI 
Reinehr et 
al. 2009 
 
Non-DM = non-diabetics, DPP = diabetes prevention programme, RCT = randomized controlled trial, PA/wk = physical activity per week, BMI = body mass index, WC = waist 
circumference, BP = blood pressure, HDL = high density lipoprotein, LDL = low density lipoprotein, TG = triglycerides, HOMA-IR = Homeostasis model assessment of insulin 
resistance, OGTT = oral glucose tolerance test. 
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2.5 The Fat mass and obesity associated (FTO) gene 
 
2.5.1 The FTO gene 
 
Peters et al. (1999) originally cloned the mouse Fto gene from screening a cDNA library of the fused toes (ft) 
mutant mouse whose phenotype was created by insertional mutagenesis (Van der Hoeven et al. 1994).  This 
resulted in a 1.6 Mb deletion of six genes including the Fto gene on the mouse chromosome 8 (Peters et al. 1999, 
Peters et al. 2002).  Following a GWA study, the human FTO gene was assigned to chromosome 16 at position 
16q12.2 (Frayling et al. 2007).  FTO has a total length of 410509 bp and contains nine exons (NCBI 2009). 
 
2.5.2 The FTO protein 
 
It has been proposed that the FTO gene encodes a 505 amino acid protein (Peters et al. 1999).  A recent 
sequence similarity search revealed that the human FTO protein shares sequences homologues with the non-
heme ferrous iron (Fe(II))- and 2-oxoglutarate (OG)-dependent oxygenase (non-heme dioxygenase superfamily) 
proteins of several eukaryotic species (Sanchez-Pulido & Andrade-Navarro 2007).  Conserved amino acids 
involved in the binding of iron, an essential co-factor as well as 2-OG, a co-substrate of these dioxygenases, were 
found on the human FTO protein (Sanchez-Pulido & Andrade-Navarro 2007).  These findings are supported by 
bioinformatic analysis that confirmed that FTO shares sequence motifs with the Fe(II)- and 2-OG dependent 
oxygenases (Gerken et al. 2007).  Although the FTO protein structure is still unknown, these studies have now 
provided evidence that FTO might be a 2-OG dependent nucleic acid demethylase. 
 
The FTO gene is expressed mostly inside the cell nucleus of almost all human tissues (Dina et al. 2007b).  In 
humans the highest FTO expression levels were found in the brain, then muscle, kidneys, adipose tissue, 
pancreas and liver (Frayling et al. 2007).  Dina et al. (2007b) also reported human FTO expression in all these 
aforementioned tissues and additionally in the heart, placenta and lungs.  In the brain the highest expression 
levels were found to be in the cerebral cortex, with high expression levels also reported for the parietal lobe, 
temporal lobe, hippocampus, cerebellum (Frayling et al. 2007), pituitary gland, hypothalamus and adrenal gland 
(Dina et al. 2007b, Frayling et al. 2007).  Furthermore, in subcutaneous adipose tissue FTO expression was found 
to be higher in the adipocytes than in the rest of the adipose tissue (Wahlen et al. 2008).  FTO was also found to 
be expressed in human fetuses with the highest levels in the fetal brain, then kidneys, liver and pancreas 
(Frayling et al. 2007).   
 
Consistent with human data, Fto expression in mice was detected in all tissues tested (Peters et al. 1999, Gerken 
et al. 2007, Stratigopoulos et al. 2008) and found in mouse embryos (Gerken et al. 2007).  In rodents, Fto was 
expressed in all 33 tissues tested including all brain slices encompassing the entire rat brain (Fredriksson et al. 
2008).  These studies also revealed highest Fto mRNA expression in the brain, specifically in the hypothalamus.  
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With in situ hybridization of hypothalamic slices it was shown that Fto mRNA was highly expressed in arcuate, 
paraventricular, dorsomedial and ventromedial nuclei of the mouse (Gerken et al. 2007) and rat hypothalamus 
(Fredriksson et al. 2008).  Furthermore, Fto was found predominately in neurons and not in astrocytes or glia 
cells (Fredriksson et al. 2008). 
 
Studies performed on humans, mice and rodents also indicated that Fto mRNA expression might be nutritionally 
regulated.  In mice, fasting resulted in a 60% decreased Fto expression in the arcuate nucleus of the 
hypothalamus (Gerken et al. 2007).    Similarly, Stratigopoulos et al. (2008) have shown decreased hypothalamic 
Fto expression in fasted obese and lean mice or in lean mice exposed to cold temperatures.  However, 
contradictory to these results, rodents had an increased Fto expression in the hypothalamus following food 
deprivation (Fredriksson et al. 2008).  Furthermore, monogenic obese mice had decreased Fto expression levels 
in mesenteric adipose tissue and several other tissues investigated compared to normal mice (Stratigopoulos et 
al. 2008).  However, in humans FTO mRNA expression levels in subcutaneous adipose tissue of obese women 
(Wahlen et al. 2008) and morbidly obese adults (Zabena et al. 2009) were higher than the non-obese controls.  
Although these human, mice and rodent studies seem contradictory, all results point to the fact that nutritional 
intake, environmental conditions and weight status regulate FTO expression.   
 
2.5.3 Physiological function of FTO 
 
Recent research indicates that FTO probably encodes a 2-OG dependent nucleic acid demethylase.  However, 
the physiological role of this protein in the development of obesity is still unclear (Gerken et al. 2007, Fischer et 
al. 2009).  It is known that 2-OG dependent oxygenases are involved in DNA repair, fatty acid metabolism, and 
posttranslational modifications (Hausinger 2004, Clifton et al. 2006). In vitro experiments have shown that 
murine Fto catalyzes Fe(II) and 2-OG dependent demethylation of 3-methylthymine in single stranded DNA 
(ssDNA) (Gerken et al. 2007).  Similarly, it was shown that mouse and human FTO are capable of repairing 3-
methylthymine in ssDNA and 3-methyluracil in single stranded RNA (ssRNA) and prefer these substrates over 
other base lesions tested (Jia et al. 2008).  However, no or negligible demethylation activities were observed for 
mouse and human FTO in double-stranded DNA and higher demethylation efficiency was also reported for 
ssRNA than ssDNA (Jia et al. 2008).  These studies concluded that the FTO protein might exert gene regulation at 
RNA level in humans (Gerken et al. 2007, Jia et al. 2008).  However, as a 2-OG dependent oxygenase it might also 
play a potential role in adaptation to hypoxia and lipolysis (Gerkin et al. 2007, Sanchez-Pulido & Andrade-
Navarro 2007). 
 
New insights into the functional role of FTO were recently provided by Fischer et al. (2009) who created Fto 
deficient homozygous (Fto-/-) and heterozygous (Fto-/+) mice and compared several measures of adiposity, 
dietary intake and energy expenditure between these mice and normal mice (Fto+/+).  No embryonic growth 
differences were observed between these mice, while the Fto-/- mice were growth retarded from day two after 
birth throughout their entire lifespan.  These mice had a smaller length and after the age of six weeks they had a 
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generally 30 to 40% lower body weight.  Furthermore, only the Fto-/- mice showed overall decreased measures 
of adiposity as they were characterized by a decreased fat mass, lean mass, adipocyte size, serum leptin, 
increased adiponectin and a complete loss of white adipose tissue (WAT) by the age of 15 months.  However, 
both the Fto-/- and Fto-/+ mice were protected from diet-induced obesity as their weight and WAT accumulation 
was lower compared to Fto+/+ mice following a 12 week high fat diet.  The general leanness associated with the 
Fto
-/- mice was not related to a decreased food intake or major alterations of hypothalamic development but 
rather due to increased energy expenditure.  The Fto-/- mice exibited higher day and night energy expenditure as 
measured by increased oxygen consumption, carbon dioxide production and calculated heat generation.  This 
increase in energy expenditure occurred in the presence of lower physical activity levels and increased plasma 
epinephrine and thus increased sympathetic activation compared to the other mice.  Further investigation into 
explanations for the increased energy expenditure in the presence of decreased physical activity indicated no 
involvement of mitochondrial uncoupling or altered thyroid function.  This led the authors to suggest that 
altered futile cycling might possible explain these effects, however this hypothesis still needs to be confirmed.  
Because neuropeptide expressing neurons in the arcuate nucleus of the hypothalamus play an important role in 
the regulation of energy homeostasis, the expression of pro-opiomelanocortin-α (Pomc), agouti related peptide 
(AgRP) and neuropeptide Y (Npy) was measured during the fed and fasted state in the above mentioned mouse 
model.  No differences between the mice were observed for the fed state, however during the fasted state Fto-/- 
mice had decreased Pomc and Npy levels (Fischer et al. 2009).   
 
One study on human adipocytes indicated that increased expression of FTO mRNA is related to increased leptin 
and perilipin but not adiponectin gene expression in subcutaneous adipose tissue, as well as with increased 
perilipin expression in visceral adipose tissue (Zabena et al. 2009).  
 
The fact that high levels of FTO expression are found in the brain, specifically in the arcuate nucleus of the 
hypothalamus, which is known to play a major role in controlling energy homeostasis and eating behaviour, 
together with new insights from recent in vitro studies indicating a possible role in energy expenditure, provides 
support for a role of FTO in the explanation of obesity development. 
 
2.5.4 The FTO rs1421085 and rs17817449 polymorphisms 
 
The first FTO polymorphisms associated with obesity were identified through a genome wide association (GWA) 
study searching for novel genes associated with type-2 diabetes in diabetic cases and population controls from 
the Wellcome Trust Case Control Consortium in the United Kingdom (Frayling et al. 2007).  From scanning 
490032 autosomal polymorphisms in various genes these authors revealed that the strongest association 
between a polymorphism and type-2 diabetes was found for the rs9939609 polymorphism in the FTO gene.  A 
strong association was also found between this FTO polymorphism and BMI and it was subsequently shown that 
the association with diabetes disappears with adjustment for BMI.  Frayling et al. (2007) have also shown strong 
association signals with BMI in a cluster of ten polymorphisms found in the first intron of FTO, of which 
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rs9939609 polymorphism forms part.  These results were soon confirmed with three other GWA studies carried 
out on obese class III French Caucasians (Dina et al. 2007b), obese and lean German children and Sardinians 
(Scuteri et al. 2007).  From these initial GWA studies several FTO polymorphisms were identified and further 
tested in large cohort, case-control and family studies all showing strong and consistent associations with BMI 
and obesity in European Caucasians (Dina et al. 2007b, Frayling et al. 2007, Scuteri et al. 2007).  The 
polymorphisms are all located within a high LD block spanning a 47 kb region and includes not only intron 1 but 
also exon 2 of FTO (Dina et al. 2007b, Frayling et al. 2007, Scuteri et al. 2007).  The polymorphisms showing the 
strongest association with obesity, include the rs9939609 (Frayling et al. 2007), rs9930506 (Scuteri et al. 2007), 
rs1421085, rs17817449 and rs1121980 variants (Dina et al. 2007b).  The mutant alleles of these polymorphisms 
were consistently found to be associated with a higher BMI or with obesity at significant levels unobserved for 
the contribution of genetics to common obesity (Dina et al. 2007b).  These studies indicate that the FTO 
polymorphisms yield a population-attributable risk of 22% (Dina et al. 2007b) and 20% (Frayling et al. 2007) for 
common obesity in Caucasian European populations.  However, thus far no association with obesity for an 
exonic FTO polymorphisms has been found and because of the strong LD between the various intronic 
polymorphisms, the functional polymorphism of FTO has not yet been determined (Dina et al. 2007b).  
 
For the purposes of this study the FTO rs1421085 and rs17817449 polymorphisms were investigated and 
therefore only these two polymorphisms are discussed further.  The FTO rs1421085 polymorphism results in a T 
to C transition, while the FTO rs17817449 polymorphism results in a T to G transition.  Both polymorphisms are 
located within intron 1 of the FTO gene (Dina et al. 2007b).  It is unknown whether these polymorphisms 
influence the expression and regulation of the FTO protein (Fischer et al. 2009).  When considering studies 
investigating other polymorphisms in the same FTO locus it was found that the FTO rs9939609 polymorphism 
had no effect on FTO mRNA expression levels (Wahlen et al. 2008) or on the expression of genes regulating 
lipolysis such as leptin, perilipin and HSL in subcutaneous and visceral adipose tissue (Wahlen et al. 2008, Zabena 
et al. 2009).  However, healthy women who are homozygous for the wild-type FTO rs9939609 genotype seem to 
be protected from obesity development due to their 28% higher in vivo lipolytic activity compared to the mutant 
allele carriers (Wahlen et al. 2008).  Furthermore, these women also had 22% higher in vitro basal lipolysis levels 
as measured by adipocyte glycerol release (Wahlen et al. 2008). 
 
2.5.5 Genotype and allele frequencies 
 
In Caucasian populations with European ancestry the frequency for the wild-type FTO rs1421085 TT genotype 
ranges between 23 to 38% (Table 2.16).  In obese groups, the frequency of the TT genotype was more towards 
the lower end of this range (23 to 27%) compared to frequencies from population-based samples or non-obese 
controls that were more towards the upper range of 34 to 38%.  The frequency of the mutant CC genotype 
ranges between 11 and 39%, with the frequency in the obese more towards the upper end of this range (20 to 
28%) and population-based samples or controls between 11 and 22%.  The genotype frequencies of only one 
Asian population have been published and are similar to those of Hispanic-Americans.  When compared to 
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Caucasian populations the CC genotype frequencies were lower (4 to 5%) and the TT genotype frequencies were 
higher (58 and 67%) in the Asian and Hispanic-American populations.  The C-allele frequency ranges between 
0.37 and 0.59 for Caucasians, which is higher than the frequencies of 0.04 to 0.35 reported for Asian and Oceanic 
populations as well as for Hispanic and African Americans.   
 
Table 2.16: Genotype frequency of the FTO rs1421085 polymorphism and frequency of the mutant C-allele. 
Population Weight or disease 
status 
n TT 
% 
TC 
% 
CC 
% 
C-allele References 
Caucasian        
Romanian ♀ 
  
All PCOS 
Control lean 
PCOS lean 
PCOS obese 
MetS in PCOS 
207 
100 
107 
100 
75 
26 49 25 
16 
22 
28 
39 
52 
46 
46 
52 
59 
Attaoua et al. 2008 
Finnish children  5532 35 48 17 41 Cauchi et al. 2009 
French  4726 34 49 17 42 Cauchi et al. 2009 
French-Canadian  359 38 44 18 41 Do et al. 2008 
French children & adults Obese and non-obese     49 Stutzmann et al. 2009 
French Obese class III 
Non-obese 
867 
2411 
23 
35 
49 
47 
28 
18 
52 
41 
Dina et al. 2007b 
Swiss  Obese class III     51 Stutzmann et al. 2009 
Non-Hispanic Americans 
  
Obese cases 
Obese sisters 
Thin sisters 
Controls 
523 
93 
92 
521 
26 
25 
34 
37 
47 
55 
55 
52 
27 
20 
11 
11 
51 
48 
39 
37 
Price et al. 2008 
Belgian Caucasians 
  
Controls 
Obese cases 
268 
1099 
35 
27 
47 
50 
18 
23 
41 
48 
Peeters et al. 2008 
Hispanic American        
Hispanic Americans  1237 61 34 5 20 Wing et al. 2009 
Africa        
African Americans  581    14 Wing et al. 2009 
Asian        
Japanese  Obese 
Control 
924 
1519 
58 
67 
37 
29 
5 
4 
24 
18 
Hotta et al. 2008b 
Singapore: Chinese  2919    12 Tan et al. 2008 
Singapore: Malay  785    28  
Singapore: Malay  2996    29  
Singapore: Indian  594    35  
Oceanic populations        
 Munda  39    24 Ohashi et al. 2008 
 Paradise  96    11  
 Rawaki  96    4  
 Balopa  39    13  
 Gidra  48    11  
 Tongan  198    17  
 Thai  48    18  
♀ = women, PCOS = poly-cystic ovary syndrome, Obese class III = BMI≥40 kg/m2 
 
For the FTO rs17817449 polymorphism, the GG genotype ranges between 26 and 40% for Caucasians, while the 
TT genotype frequency ranges between 8 and 27% (Table 2.17).  Again the genotype frequencies reported in the 
different studies for obese subjects were similar, but different from frequencies reported for non-obese subjects.  
The genotype frequencies for populations with Asian ancestry were not published by Ohashi et al. (2008) or Tan 
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et al. (2008), but it can be speculated that it may be similar to those of Hispanic Americans as was found for the 
FTO rs1421085 polymorphism.   
 
The G-allele frequency ranges between 0.48 and 0.51 for obese Caucasians and 0.36 to 0.40 for non-obese or 
population samples.  The G-allele frequency for Hispanic, Asian and Oceanic populations is lower and ranges 
between 0.05 and 0.34. 
 
Table 2.17: Genotype frequency of the FTO rs17817449 polymorphism and frequency of the mutant G-allele. 
Population Weight and 
disease status 
n TT 
% 
TG 
% 
GG 
% 
G-allele 
% 
References 
Caucasian        
French Canadian  359 18 42 40 39 Do et al. 2008 
French Obese class III 
Non-obese 
873 
2400 
27 
16 
49 
48 
24 
36 
51 
40 
Dina et al. 2007b 
Non-Hispanic 
Caucasians 
  
Controls 
Obese cases 
Thin sisters 
Obese sisters 
522 
527 
98 
93 
11 
26 
8 
23 
50 
47 
57 
52 
39 
28 
35 
26 
36 
49 
37 
48 
Price et al. 2008 
Hispanic American        
Hispanic Americans  1235 6 35 59 22 Wing et al. 2009 
Africa         
African Americans  581    46 Wing et al. 2009 
Asian        
Singapore: Chinese  2919    12 Tan et al. 2008 
Singapore: Malay  785    28  
Singapore: Malay  2996    30  
Singapore: Indian  594    34  
Oceanic populations        
 Munda  39    30 Ohashi et al. 2008 
 Paradise  96    19  
 Rawaki  96    5  
 Balopa  39    13  
 Gidra  48    10  
 Tongan  198    18  
Thai  48    18  
Obese class III = BMI ≥ 40 kg/m2 
 
 
2.5.6 Associations with obesity related phenotypes 
 
Weight, BMI and obesity 
Consistent evidence from small and large-scale studies shows that the FTO rs1421085 polymorphism is 
associated with obesity and BMI in Caucasian populations with European ancestry (Table 2.18) (Dina et al. 2007b, 
Attaoua et al. 2008, Do et al. 2008, Peeters et al. 2008, Price et al. 2008, Cauchi et al. 2009, Stutzmann et al. 
2009).  Most of these studies compared the BMI of subjects or the genotype frequencies of obese cases with 
controls using the additive model (CC vs. CT vs. TT).  It was evident that the CC homozygotes had significantly 
higher BMIs or frequency in obese cases than the CT heterozygotes, while these measures for the CT 
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heterozygotes were again significantly higher than for the TT homozygotes.  The CC or CT genotypes were 
associated with higher BMIs from birth through childhood, adolescence and adulthood, while it was associated 
with obesity in children from as young as seven years (Cauchi et al. 2009).  The association with obesity in 
children was consistently shown in Finnish (Cauchi et al. 2009), French and German children (Dina et al. 2007b).  
In family based studies using pedigree analysis it was also observed that the C-allele is over-transmitted to obese 
French children (Dina et al. 2007b, Stutzmann et al. 2009) and French and Swedish severely obese adults (Dina et 
al. 2007b).  In patients with polycystic ovary syndrome (PCOS) it was found that the risk for obesity was higher in 
those who had the CC homozygous genotype (Attaoua et al. 2008).  Even in lean PCOS patients, having the CC 
genotype resulted in a significantly higher BMI and therefore these patients have a higher risk of becoming 
obese when compared to TT homozygous PCOS patients (Attaoua et al. 2008).  
 
The two studies thus far that investigated the role of the FTO rs1421085 polymorphism in African-Americans, 
found no association with BMI (Scuteri et al. 2007, Wing et al. 2009). These authors speculate that the lower 
reported C-allele frequency (see Table 2.16) and the lower LD found between the FTO variants in individuals of 
African descent might explain this lack of association with BMI and obesity (Dina et al. 2007b, Scuteri et al. 2007, 
Wing et al. 2009).   The one study conducted on Asian populations indicated that a higher BMI was associated 
with the CC and CT genotypes in Malayan and Chinese subjects living in Singapore.  However, no association was 
found for Indian subjects living in Singapore (Tan et al. 2008).  
 
The FTO rs17817449 polymorphism shows similar associations with BMI and obesity as discussed for the FTO 
rs1421085 polymorphism (Table 2.19).  The GG and GT genotypes or the mutant G-allele of the FTO rs17817449 
polymorphism have consistently been found to be associated with a higher BMI or higher obesity prevalence in 
Caucasians with European ancestry (Dina et al. 2007b, Do et al. 2008, Price et al. 2008).  The G-allele was also 
over-transmitted to French obese children and French and Swedish obese adults (Dina et al. 2007b).  These 
associations were not found for subjects with African ancestry, more specifically for Gambians (Hennig et al. 
2009) and African-Americans (Wing et al. 2009).  In Asian populations a higher BMI was also found to be 
associated with the GG and GT genotypes in Malayan and Chinese subjects living in Singapore, with no 
association found for Indians from Singapore (Tan et al. 2008).  
 
In summary, these findings indicate that the C-allele of the FTO rs1421085 polymorphism and the G-allele of the 
FTO rs17817449 polymorphism are strongly and consistently associated with a higher BMI and with early-onset 
obesity in Caucasians.  This is in agreement with the findings from several other studies reporting significant 
associations between BMI and/ or obesity in Caucasians and the mutant alleles of other polymorphisms in strong 
LD with the FTO rs17817449 and rs1421085 polymorphisms also found in intron 1 of the FTO gene (Cornes et al. 
2009, Frayling et al. 2007, Freathy et al. 2008, Grant et al. 2008, Hunt et al. 2008, Kring et al. 2008, Qi et al. 2008, 
Rampersaud et al. 2008).  However, current evidence points to an absence of such associations with the FTO 
rs1421085 or rs17817449 polymorphisms in populations with African ancestry.  More research is needed to 
draw final conclusions regarding such associations in populations with Asian ancestry.  
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Table 2.18: The association between the FTO rs1421085 polymorphism and weight, BMI and obesity. 
Population Weight or  n Study design Association with Obesity Association with BMI  
 disease status   Yes No  Yes No  Reference 
Caucasian         
Americans:  Controls 
Obese cases 
521 
523 
Case-control Obese = ↑ C-allele - ni ni Price et al. 2008 
Americans:  Thin sisters 
Obese sisters 
92 
93 
Case-control -  ni ni Price et al. 2008 
Americans:  1496 Family based ni ni C-allele = ↑ BMI - Scuteri et al. 2007 
Romania ♂   PCOS obese 
PCOS lean 
Lean controls 
100 
107 
100 
Case-control: unrelated ♂ with 
PCOS and lean controls. PCOS 
divided in obese and lean groups 
Obese = ↑ CC - ni ni Attaoua et al. 2008 
Romania ♂  All with PCOS 207 as above ni ni -  Attaoua et al. 2008 
Romania ♂  Lean PCOS 107 as above ni ni CC = ↑ BMI - Attaoua et al. 2008 
French Canadian  908 Family-based ni ni CC = ↑ BMI 
CC/CT = ↑ BMI 
- Do et al. 2008 
French  4726 Prospective cohort -  CC/CT = ↑ BMI - Cauchi et al. 2009 
Finnish children  
  
 5532 Prospective cohort:  at birth 
   7 years 
   16 years 
- 
Obesity = ↑ CC/CT 
Obesity = ↑ CC/CT 
 
- 
- 
CC/CT = ↑ BMI 
CC/CT = ↑ BMI 
CC/CT = ↑ BMI 
- Cauchi et al. 2009 
French: children 
  
 adults 
Obese  
Non-obese  
Obese  
Non-obese  
1004 
313 
2438 
2009 
Family study with pedigree analysis 
including children, parents and 
grandparents 
C-allele = 
overtransmitted to 
obese subjects 
- C-allele = ↑ BMI z-
score 
- Stutzmann et al. 2009 
French adults:  obese class III 
non-obese 
867 
2411 
Case-control Obese = ↑ CC/CT   - ni ni Dina et al. 2007b 
French: children 
 adults 
obese  
non-obese  
702 
979 
Case-control Obese = ↑ CC/CT   - ni ni Dina et al. 2007b 
French: children 
 adults 
obese  
non-obese  
482 
519 
Case-control Obese = ↑ CC/CT   - ni ni Dina et al. 2007b 
French: children 
 adults 
obese 
obese class III 
 Family-based: obese parents and 
sibs 
C-allele transmitted to 
obese children & adults 
- ni ni Dina et al. 2007b 
Swedish: adults obese class III 154 Family-based: discordant for 
obesity class III 
C-allele transmitted to 
obese 
- ni ni Dina et al. 2007b 
German: children obese  
non-obese 
283 
699 
Case-control Obese = ↑ CC/CT   - ni ni Dina et al. 2007b 
Belgium :  Obese 1099 Case-control Obese = ↑ CC/CT   - CC+CT = ↑ BMI - Peeters et al. 2008 
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Table 2.18: continued 
Population Weight or  n Study design Association with Obesity Association with BMI  
 disease status   Yes No  Yes No  Reference 
Caucasian         
Swiss:  obese class III 
all 
504 
514 
Case-control Obese = ↑ CC/CT   - ni ni Dina et al. 2007b 
Swiss  obese class III 1274 Purpositively selected ni ni -  Stutzmann et al. 2009 
Swiss and French  7038 Case-control Obese = ↑ C-allele - ni ni Stutzmann et al. 2009 
Hispanic American         
Hispanic Americans  839 Family-based ni ni -  Scuteri et al. 2007 
Hispanic Americans  1237 Family-based ni ni CC/CT = ↑ BMI - Wing et al. 2009 
African          
African Americans  1101 Family-based  ni ni -  Scuteri et al. 2007 
African Americans  604 Family-based ni ni -  Wing et al. 2009 
Asian          
Japanese Obese 
Controls 
924 
1519 
Case-control Obese = ↑ CC/CT  
Obese = ↑ CC  
 CC/CT = ↑ BMI 
CC+CT = ↑ BMI 
- Hotta et al. 2008b 
Singapore: Malay  2996 Cross-sectional ni ni CC/CT = ↑ BMI - Tan et al. 2008 
Singapore: Malay  785  ni ni CC/CT = ↑ BMI -  
Singapore: Indian  594  ni ni -   
Singapore: Chinese  2919  ni ni CC/CT = ↑ BMI -  
ni = not investigated, Mutant allele = C-allele, Genotype frequency comparisons: CC+CT = Dominant model (TT vs. CC+CT), CC = recessive model (CC vs. CT+TT), CC/CT = additive 
model (CC vs. CT vs. TT), Allele frequency comparisons: C-allele = compared vs. G-allele 
 
 
Table 2.19: The association between the FTO rs17817449 polymorphism and weight, BMI and obesity. 
Population Weight or disease  n Study design Association with obesity Association with BMI Reference 
 status   Yes No Yes No  
Caucasian          
Americans:  Controls 
Obese cases 
521 
523 
Case-control Obese = ↑ G-allele - ni ni Price et al. 2008 
Americans:  Lean sisters 
Obese sisters 
92 
93 
Case-control Obese = ↑ G-allele - ni ni Price et al. 2008 
French Canadian  908 Family-based ni ni GG = ↑ BMI 
GG/GT = ↑ BMI 
- Do et al. 2008 
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Table 2.19: continued 
Population Weight or disease  n Study design Association with obesity Association with BMI Reference 
 status   Yes No Yes No  
Caucasian          
French adults:  obese class III 
non-obese 
873 
2400 
Case-control Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
French:  children 
  adults 
obese  
non-obese  
693 
990 
Case-control Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
French: children 
  young 
adults 
obese  
non-obese  
485 
525 
Case-control Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
French: children 
 adults 
obese 
obese class III 
685 
111 
Family-based: obese parents and 
sibs 
G-allele transmitted to 
obese children & adults 
- ni ni Dina et al. 2007b 
Swedish: adults obese class III 154 Family-based: discordant for 
obesity class III 
G-allele transmitted to 
obese 
- ni ni Dina et al. 2007b 
German: obese  
non-obese  
281 
691 
Case-control Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
Swiss:  obese class III 
all 
516 
519 
Case-control Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
French, Swiss, 
Germans  
Obese 
non-obese 
2848 
5125 
Meta-analysis of all case-control 
samples 
Obese = ↑ GG/GT - ni ni Dina et al. 2007b 
Hispanic American         
Hispanic Americans  1235 Family-based ni ni GG/GT = ↑ BMI - Wing et al. 2009 
African          
Gambians  2164 All children of moms enrolled in 
antenatal scheme 
ni ni -  Hennig et al. 2009 
African Americans  604 Family-based ni ni -  Wing et al. 2009 
Asian         
Singapore: Malay   2996 Population based (SiMES) ni ni GG/GT = ↑ BMI - Tan et al. 2008 
Singapore: Malay   785 Population based (NHS98) ni ni GG/GT = ↑ BMI -  
Singapore: Indian  594 Population based ni ni -   
Singapore: Chinese  2919 Population based ni ni GG/GT = ↑ BMI -  
ni = not investigated, mutant allele = G-allele, Genotype frequency comparisons: GG+GT = Dominant model (TT vs. GG+GT), GG = recessive model (GG vs. GT+TT), GG/GT = additive 
model (CC vs. CG vs. GG), Allele frequency comparisons: G-allele = compared vs. T-allele, BMI = body mass index, SiMES = Singapore Malay Eye Study, NHS98 = 1998 Singapore 
National Health Survey. 
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Measures of body fat distribution and content 
The mutant C-allele of the FTO rs1421085 polymorphism has been associated with a higher waist circumference, 
hip circumference, waist-hip ratio, body fat percentage, sum of six skinfolds, fat mass, total fat area, 
subcutaneous fat area and subcutaneous adipose tissue in Caucasian populations (Table 2.20).  The CC and CT 
genotypes were also associated with a higher waist circumference in Asian populations, however no association 
was found in African-Americans. 
 
Table 2.20: The association between the FTO rs1421085 polymorphism and measures of body fat distribution and 
content. 
Population Associations No associations Reference 
Caucasian     
Belgian CC+CT = ↑ fat mass, TFA,  SFA VFA, FFM, HC, WC, WHR Peeters et al. 2008 
Romanian ♀ with PCOS - WC Attaoua et al. 2008 
French Canadian CC = ↑ FM, FFM, WC, HC, 
WHR, % body fat, sum of 6 
skinfolds 
- Do et al. 2008 
French  CC/CT = ↑ fat mass - Cauchi et al. 2009 
Hispanic American     
Hispanic American CC/CT = ↑ WC, SAT WHR, VAT, VSR Wing et al. 2009 
African     
African-American - WC, WHR, VAT, SAT, VSR Wing et al. 2009 
Asian     
Singapore: Malay (NHS98) CC/CT = ↑ WC WHR Tan et al. 2008 
Singapore: Indian - WC, WHR  
Singapore: Chinese CC/CT = ↑ WC WHR  
VFA = visceral fat area, SFA = subcutaneous fat area, TFA = total fat area, PCOS = polycystic ovary syndrome, FM = fat 
mass, FFM = fat free mass, HC = hip circumference, WC = waist circumference, WHR = waist-hip-ratio, SAT = 
subcutaneous adipose tissue, VAT = visceral adipose tissue, VSR = visceral to subcutaneous ratio. 
 
Only three studies investigated the association between measures of body fat distribution and fat content with 
the FTO rs17817449 polymorphism (Table 2.21).  The mutant G-allele, either in the form of homozygotes or with 
an additive model was associated with a higher fat mass, waist circumference, hip circumference, waist-hip ratio, 
body fat percentage, sum of six skinfolds and subcutaneous adipose tissue in Caucasian populations.  The GG 
and GT genotypes were also associated with a higher waist circumference in Asian populations, however no 
association was found in African-Americans. 
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Table 2.21: The association between the FTO rs17817449 polymorphism and measures of body fat distribution and 
content. 
Population Associations No associations Reference 
Caucasian     
French Canadian GG = ↑ FM, FFM, WC, HC, WHR, % 
body fat, sum of 6 skinfolds  
- Do et al. 2008 
Hispanic American    
Hispanic Americans GG/GT = ↑ SAT WC, WHR, VAT, VSR Wing et al. 2009 
African     
African-American - WC, WHR, VAT, SAT, VSR Wing et al. 2009 
Asian     
Singapore: Malay (NHS98) GG/GT = ↑ WC  WHR Tan et al. 2008 
Singapore: Indian - WC, WHR  
Singapore: Chinese GG/GT = ↑ WC  WHR  
FM = fat mass, FFM = fat free mass, HC = hip circumference, WC = waist circumference, WHR = waist-hip-ratio, SAT = 
subcutaneous adipose tissue, VAT = visceral adipose tissue, VSR = visceral to subcutaneous ratio. 
 
2.5.7 Associations with health indicators  
 
Indicators of glucose and insulin homeostasis 
In general, the C-allele or the CC and CT genotypes of the FTO rs1421085 polymorphism were associated with 
higher plasma glucose levels as well as measures indicating insulin resistance (Table 2.22).  French CC 
homozygous subjects were more insulin resistant - as indicated by a lower metabolic clearance rate and insulin 
sensitivity index following an oral glucose tolerance test - than T-allele carriers (Do et al. 2008).  The prevalence 
and nine year incidence of Type 2 diabetes was also found to be higher in CC homozygous French subjects.  
However, it is likely that this effect was mediated through BMI as the association disappeared after adjustment 
for BMI (Cauchi et al. 2009).  Romanian CC homozygous women with PCOS had higher fasting glucose, two-hour 
glucose and AUC for glucose as well as a higher prevalence of impaired glucose tolerance (IGT), impaired fasting 
glucose (IFG) and the MetS (NCEP ATP III criteria) (Attaoua et al. 2008).  All components of MetS were more 
prevalent in C-allele carriers, but the most significant was fasting hyperglycemia.  Even lean CC homozygous 
PCOS patients were more insulin resistant according to the HOMA-IR test, had higher fasting glucose levels and a 
higher prevalence for IFG and MetS (Attaoua et al. 2008).  No association was found for African-Americans and 
Hispanic-Americans (Wing et al. 2009).  The one study conducted on Asian populations indicated higher fasting 
glucose levels associated with the C-allele according to the additive model (Tan et al. 2008) 
 
Similar patterns of associations as reported for the FTO rs1421085 polymorphism were found for measures of 
glucose metabolism and insulin resistance and the G-allele according to the additive model or the GG genotype 
of the FTO rs17817449 polymorphism in the different population groups (Table 2.23).  
 
In summary, available research results indicate that the mutant C-allele of the FTO rs1421085 polymorphism and 
G-allele of the FTO rs17817449 polymorphism might be associated with impaired glucose homeostasis, insulin 
resistance and consequently the development of Type-2 diabetes in Caucasians. However, more research is 
necessary to confirm these associations in all ancestral groups.   
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Blood lipid profile and blood pressure 
No studies could be found that investigated the association of the FTO rs1421085 and rs17817449 
polymorphisms and plasma lipid profile in Caucasians or African-Americans (Tables 2.22 and 2.23).  Only Tan et 
al. (2008) reported an association between the mutant alleles of these two polymorphisms and higher plasma 
LDL cholesterol in Chinese living in Singapore.  The C-allele of the FTO rs1421085 polymorphism was also 
associated with higher plasma triglycerides in Malayans living in Singapore included in the 1998 National Health 
Survey (NHS98).  However this association was not found in Malayans participating in the Singapore Malay Eye 
Study (SiMES) (Tan et al. 2008). 
 
In summary, more research is necessary to elucidate the associations between the FTO rs1421085 and 
rs17817449 polymorphisms and plasma lipid profile. 
 
2.5.8 Associations with weight loss outcomes  
 
No reports could be traced regarding weight loss interventions and association with the FTO rs1421085 or 
rs17817449 polymorphisms.  However, two reports that investigated the role of the FTO rs9939609 
polymorphism (also found in intron 1 of the FTO gene and in strong LD with the FTO rs1421085 and rs17817449 
polymorphisms) and weight loss following weight loss interventions, were found.  These studies showed no 
association between the FTO rs9939609 polymorphism and weight loss outcome at 10 to 12 months in obese 
German children (n=207) following the “Obeldicks” intervention programme (Müller et al. 2008) or in 
overweight non-diabetic American adults (n=3533) who were treated with either a placebo, or metformin or 
troglitazone or a lifestyle intervention in the Diabetes Prevention Programme (DPP) (Franks et al. 2008).  The 
“Obeldicks” (Reinehr et al. 2008, Reinehr et al. 2009) and DPP (Franks et al. 2008) intervention programmes are 
summarized in Table 2.15, p70.  
 
The work by Stutzmann et al. (2009) on the association between eating behaviour of children and adults with 
European ancestry and the FTO rs1421085 polymorphism should also be considered in this regard.  In French 
obese and non-obese children no association between the FTO rs1421085 polymorphism and eating large 
quantities of food, frequent snacking or cravings was found.  No association was found with snakcing during 
weekends or eating large quantities of food at meals in 16 year olds who participated in a Finnish Birth cohort.  
Furthermore, in adults no association between the FTO rs1421085 polymorphism and scores on the three factor 
eating questionnaire was found in obese and non-obese French adults, or with snacking and eating large 
quantities of food at meals in Swiss class III obese adults or with snacking and bulimia in French adults from a 
randomly selected population study (Stutzmann et al. 2009).  These cross-sectional analyses of children and 
adults with different weight classifications indicate that no association between the eating behaviour and the 
FTO rs1421085 polymorphism seems to exist.   
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Table 2.22: The association between the FTO rs1421085 polymorphism and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure.    
Population Indicators of glucose and insulin homeostasis Blood lipids  
 Association No association Association No associations Reference 
Caucasian      
French Canadian CC = ↓ MCR-OGTT,   
     ↓ ISI-OGTT 
insulin, insulin AUC, glucose, AUC 
for glucose, HOMA-IR 
CC = ↑ leptin - Do et al. 2008 
French CC = ↑ DM2 prevalence and incidence 
over 9 yrs (not after adjustment for BMI) 
- ni ni Cauchi et al. 2009 
Romanian ♀  All PCOS: CC = ↑ glucose, 2h glucose, 
AUC for glucose, IGT, IFG, MetS 
Lean controls: CC = ↑ IGT 
Lean PCOS: CC = ↑ glucose, IFG, HOMA-
IR, MetS 
PCOS with MetS: CC = ↑ 2h glucose, 2h 
insulin, AUC for glucose, HOMA-IR,  vs. 
obese PCOS 
All parameters were measured in 
all groups, therefore those not 
indicated under association 
column = no association in that 
specific group 
ni ni Attaoua et al. 2008 
Hispanic American      
Hispanic Americans - Glucose, insulin, ISI, AIR, DI ni ni Wing et al. 2009 
African       
African-Americans - Glucose, insulin, ISI, AIR, DI ni ni Wing et al. 2009 
Asian       
Singapore: Malay (SiMES) CC/CT = ↑ glucose IFG/IGT - LDL, HDL, TG, BP Tan et al. 2008 
Singapore: Malay (NHS98) CC/CT = ↑ glucose IFG/IGT CC/CT = ↑ TG LDL, HDL, BP  
Singapore: Indian - glucose, IFG/IGT - LDL, HDL, TG, BP  
Singapore: Chinese CC/CT = ↑ glucose IFG/IGT CC/CT = ↑ LDL HDL, TG, BP  
ni = not investigated, PCOS = polycystic ovary syndrome, AUC = area under the curve, IFG = impaired fasting glucose, IGT = impaired glucose tolerance, HOMA-IR = Homeostasis 
model assessment of insulin resistance, MetS = Metabolic Syndrome, MCR-OGTT: Metabolic Clearance Rate derived from the Oral Glucose Tolerance Test; ISI-OGTT: Insulin 
Sensitivity Index derived from the Oral Glucose Tolerance Test, DM2 = Type 2 diabetes, AIR = acute insulin response, DI = deposition index, TG = triglycerides, TC = Total 
Cholesterol, HDL = High density lipoprotein, LDL = low density lipoprotein, BP = blood pressure.  
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Table 2.23: The association between the FTO rs17817449 polymorphism and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure.    
Population Glucose and insulin homeostasis Blood lipids and blood pressure  
 Association No association Association No associations Reference 
Caucasian      
French Canadian GG = ↑ insulin, insulin AUC, 
↓ MCR-OGTT  
glucose, AUC for glucose, 
HOMA-IR, ISI-OGTT  
GG = ↑ leptin - Do et al. 2008 
Hispanic American      
Hispanic-Americans - Glucose, insulin, ISI, AIR, DI ni ni Wing et al. 2009 
African       
African-Americans - Glucose, insulin, ISI, AIR, DI ni ni Wing et al. 2009 
Asian       
Singapore: Malay (SiMES) GG/GT = ↑ glucose IFG/IGT - LDL, HDL, TG, BP Tan et al. 2008 
Singapore: Malay (NHS98) GG/GT = ↑ glucose IFG/IGT - LDL, HDL, TG, BP  
Singapore: Indian - glucose, IFG/IGT - LDL, HDL, TG, BP  
Singapore: Chinese GG/GT = ↑ glucose IFG/IGT GG/GT = ↑ LDL HDL, TG, BP  
ni = not investigated, AUC = area under the curve, IFG = impaired fasting glucose, IGT = impaired glucose tolerance, HOMA-IR = Homeostasis model assessment of insulin 
resistance, MCR-OGTT = Metabolic Clearance Rate derived from the Oral Glucose Tolerance Test, ISI-OGTT = Insulin Sensitivity Index derived from the Oral Glucose Tolerance Test, 
AIR = acute insulin response, DI = deposition index, TG = triglycerides, TC = Total Cholesterol, HDL = High density lipoprotein, LDL = low density lipoprotein, BP = blood pressure.  
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2.6 The β3-Adrenergic receptor gene (β3-AR and ADRB3; β3-adrenoceptor) 
 
2.6.1 The ADRB3 gene 
 
The human β3-adrenergic receptor gene (ADRB3) was first cloned in 1989 (Emorine et al. 1989) and is located on 
chromosome position 8p12-p11.2 (Wilkie et al. 1993).  The ADRB3 gene consists of 3699 bp and has two exons 
separated by one intron (Rozec & Gauthier 2006, NCBI 2009).   
 
2.6.2 The ADRB3 protein 
 
The ADRB3 gene encodes a 408 amino acids protein, namely the β3-adrenergic receptor.  The first exon of 
ADRB3 encodes for the first 402 amino acids of the receptor and the second exon encodes the last six amino 
acids of the C-terminus tail and the 3′ region not translated from the mRNA (Rozec & Gauthier 2006, NCBI 2009).  
 
The β3-adrenergic receptor is a member of the family of adrenergic receptors (also referred to as adrenoceptors) 
comprising of the α-adrenoceptors and β-adrenoceptors.  The α-adrenoceptors are divided into six subtypes, 
namely the α1A-, α1B-, α1D-, α2A-, α2B-, α2C-adrenoceptors, while the β-adrenoceptors are divided into three 
subtypes namely the β1-adrenoceptors (ADRB1 or β1AR), β2-adrenoceptors (ADRB2 or β2AR) and β3-
adrenoceptors (ADRB3 or β3AR) (Emorine et al. 1989, Small et al. 2003, Robidoux et al. 2004).   
 
All adrenoceptors are members of the Guanine binding protein coupled receptors (GPCRs).  The GPCRs are cell 
surface receptors and thus integral proteins of plasma membranes (Small et al. 2003, Robidoux et al. 2004).  The 
general structure of all GPCRs, including the β-adrenoceptors is characterized by seven transmembrane domains 
of 22–28 amino acids each with three intracellular and three extracellular loops (Figure 2.4).  The amino (NH2) 
terminus of all three β-adrenoceptors is glycosylated and located extracellular, whereas the carboxy (COOH) 
terminus is found intracellular (Small et al. 2003, McGraw & Liggett 2005, Rozec & Gauthier 2006).  A 65 to 70% 
amino acid sequence homology exists between the β1-, β2- and β3-adrenoceptors in humans, mostly in the 
seven transmembrane segments and the membrane-proximal regions of the intracellular loops (Small et al. 2003, 
Johnson 2006, Rozec & Gauthier 2006).  Figure 2.4 also illustrates the position on the GPCRs where important 
single nucleotide polymorphisms with clinical relevance of seven of the nine adrenergic genes have been found 
(Small et al. 2003) 
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Figure 2.4:  General structure of the human adrenoceptors and the approximate location of 
polymorphisms of human adrenergic receptors (from Small et al. 2003). 
 
 
In humans, ADRB3 is mainly expressed in WAT and BAT, especially in the fat and adipocytes lining the 
gastrointestinal tract, thus mainly in visceral fat tissue (Emorine et al. 1989, Krief et al. 1993, Rohrer 1998, Lowell 
& Bachman 2003, Robidoux et al. 2004).  ADRB3 is also expressed in various other human tissues (Small et al. 
2003). 
 
2.6.3 Physiological function of ADRB3 
 
ADRB3 is primarily involved in the regulation of energy metabolism through influencing resting metabolic rate 
(thus energy expenditure), thermogenesis and lipolysis (Emorine et al. 1989, Loktionov 2003, Loos & Bouchard 
2003) on activation of the sympathetic nervous system (Lofantan & Berlan 1993, Small et al. 2003).   Activation 
of ADRB3 in white fat cells results in the mobilization of lipids (lipolysis) and in brown fat cells thermogenesis is 
increased (Loktionov 2003, Small et al. 2003).  In general, the β-adrenoceptors stimulate fat lipolysis while the α-
adrenoceptors inhibit fat lipolysis (Robidoux et al. 2004). 
 
The GPCRs, including ADRB3, represent the largest signalling family in the human genome and transduce signals 
from the outside to the inside of cells from various host systems including sight, smell, hormonal, 
neurotransmitter, autocrine, and paracrine systems (McGraw & Liggett 2005).  GPCR cell signalling occurs 
through coupling with the Guanine nucleotide binding proteins (G-proteins) (Robidoux et al. 2004, McGraw & 
Liggett 2005).  Several G-proteins exist including the Gq, Gi and Gs proteins.  The α-ARs and β-ARs can couple to 
more than one G-protein, however α1-ARs and α2-ARs usually couple with Gq (stimulation of phopholipase C) 
and Gi (inhibition of adenylyl cyclase) respectively while the β-ARs usually couple with Gs (stimulation of adenylyl 
cyclase) (Small et al. 2003).  The Gs-protein is a heterotrimer consisting of an α-, β- and γ-subunit (see section 
2.2.8, p111 for more information) (McGraw & Liggett 2005, Oldham & Hamm 2006). 
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The role of the β-ARs in WAT lipolysis can be described as follows (Figure 2.5): 
In the basal state (Figure 2.5a), when nutrients are abundant (e.g. after consumption of food), adipocytes 
synthesize and also take up non-esterified fatty acids (NEFAs).  In both WAT and brown adipose tissue (BAT) 
these NEFAs are esterified and stored inside the lipid droplets in the form of triacylglycerol (TAG).  The amount 
that is stored reflects the range of positive energy balance over time determined by energy intake minus energy 
expenditure (Peters 2006).  In the WAT, the cyclic adenosine monophosphate (cAMP) dependent protein kinase 
(PKA) is bound to an AKAP anchor protein on the WAT cell membrane.  In the cytosol the nonphosphorylated 
hormone sensitive lipase (HSL) is bound to cytosolic acceptors such as lipotransin.  For HSL to have access to the 
lipid droplet to hydrolyse the stored TGs, it must first be phosphorylated and then be translocated to the surface 
of the droplet. Furthermore, nonphosphorylated perilipin is tightly bound to the surface of the lipid droplet, 
protecting the stored TG against lipolysis (Robidoux et al. 2004).     
 
Lipolysis (Figure 2.5b) is triggered by a drop in blood glucose levels which occurs either a few hours after 
ingestion of food or during an overnight fast or when a negative energy balance exists (in response to decreased 
food intake, fasting, or sustained increased physical activity).  This decrease in blood glucose levels triggers the 
sympathetic nervous system to release the catecholamines epinephrine and norepinephrine (Robidoux et al. 
2004).  The release of catecholamines is also stimulated by exercise, with the stimulation increasing markedly as 
the intensity of the exercise increases to 50% maximal exertion and above (Snyder et al. 2008).  The released 
catecholamines interact with the β-ARs on the cell membranes of WAT, which then couple to Gs and Gi proteins.  
Gs coupling leads to stimulation of adenylyl cyclase and PKA, which is consequently released from the AKAP 
anchor protein into the cytosol.  PKA then phosphorylates two serine residues (Ser-659 and Ser-660) of HSL and 
six serine residues (Ser-81, Ser-222, Ser-276, Ser-433, Ser-494, and Ser-517) of perilipin A.  The phosphorylated 
HSL can now translocate to the surface of the lipid droplet.  On the surface of the lipid droplet the tight 
association of Perilipin A is lost when it becomes phosphorylated.  Consequently, HSL can access the inside of 
the droplet and stimulate lipolysis (Snyder et al. 2008, Robidoux et al. 2004).  Furthermore, elevated 
glucocorticoids stimulate the transcription of a TAG lipase named denustrin/ATGL. The stored TAG in the lipid 
droplet will firstly be hydrolyzed to diacylglycerol (DAG) and a fatty acid by denustrin/ATGL.  DAG is then 
hydrolyzed by HSL to monoacylglycerol (MAG) and a second fatty acid. MAG is lastly hydrolyzed by MAG-lipase 
to glycerol and a third fatty acid (Ahmadian et al. 2010).  Gi activation also leads to EGF receptor transactivation 
and activation of the ERK pathway including the ERK1/2 MAP kinase and p38 MAP kinase.  Activation of p38 
MAPK increases cAMP levels and PKA activity.  Therefore the ERK pathway can also lead to the phosphorylation 
of a different serine residue on HSL (Ser-600) and probably phosphorylation of perilipin as well.  However, 
lipolysis through the ERK pathway appears to account for only 15-25% of total lipolysis, with the Gs coupled 
pathway accounting for most (Robidoux et al. 2004).    
 
It is clear that catecholamines are important regulators of lipolysis in WAT and act by stimulating the β-ARs to 
induce lipolysis (Robidoux et al. 2004).  The β-AR genes are therefore important candidate genes to consider for 
obesity development as a variation in these genes might affect the functionality of the receptor that may alter 
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adipocytes lipolysis.  It has been shown that mice without β-ARs displayed reduced metabolic rate and were 
slightly obese on a normal chow diet.  However, on a high fat diet, these mice developed massive obesity 
compared to wild-type mice (Bachman et al. 2002).  Furthermore, a decreased ADRB3 mRNA expression that has 
been reported in all models of congenital obese mice and rats including the leptin-deficient ob/ob mice, db/db, 
tubby, fat and the Zucker fatty rat is responsible for the inability to mobilize stored fat in response to a β-agonist 
(reviewed by Robidoux et al. 2004).   
 
 
Figure 2.5: Mechanism of WAT lipolysis stimulation by ADRB3 in two stages namely the basal state (Figure 
2.5a) and lipolysis stage (Figure 2.5b) (from Robidoux et al. 2004). 
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2.6.4 The ADRB3 Trp64Arg polymorphism 
 
In 1995, three groups independently reported a missense mutation in the first transmembrane domain or the 
most proximal residue of the first intracellular loop (Figure 2.4) of the human β3-adrenergic receptor.  The 
mutation produces a Thymine (T) to Cytosine (C) transition at nucleotide position 190, causing the replacement 
of tryptophan (Trp) by arginine (Arg) at amino acid position 64 (Trp64Arg) (Clément et al. 1995, Walston et al. 
1995, Widén et al. 1995).   
 
Although the exact functional effect of the Trp64Arg polymorphism on the expression and activity of the ADBR3 
gene is still unclear, in vitro research indicates that the Trp64Arg polymorphism might cause an expression of a 
β3-adrenergic variant receptor (Kurokawa et al. 2008, Small et al. 2003).  This has been demonstrated in murine 
pre-adipocytes (Kimura et al. 2000), Chinese hamster ovary cells and human embryonic kidney cells (Pie´tri-
Rouxel et al. 1997).   Stimulation of rodent and human cell lines with the Arg64-allele results in a reduced 
amount of cAMP released after catecholamine stimulation, a reduced ability to stimulate adenyl cyclase activity 
(Kimura et al. 2000, Pie´tri-Rouxel et al. 1997) and a reduction in lipolysis (Umekawa et al. 1999).  It appears that 
the fact that the Arg64 and Trp64 variants of ADBR3 prefer different G-proteins to couple with (Small et al. 2003), 
could explain these findings. When compared to the wild-type Thr64 ADRB3, the mutant Arg64 receptor couples 
less efficiently with the Gs protein after catecholamine stimulation which results in the release of less cAMP 
(Pie´tri-Rouxel et al. 1997).  PKA is dependent on cAMP for activation and therefore decreased phosphorilation 
of HSL and perilipin occurs with decrease cAMP levels, resulting in the decrease in lipolysis seen in Arg64 
adipocytes (Pie´tri-Rouxel et al. 1997, Umekawa et al. 1999).  However, although these in vitro findings have 
been published by some (Pie´tri-Rouxel et al. 1997, Umekawa et al. 1999, Kimura et al. 2000), others have failed 
to observe any in vitro functional effects (Candelore et al. 1996, Li et al. 1996).  Furthermore, it has been shown 
that the Arg64 variant has a decreased sensitivity to ADRB3 agonists and this may also result in lower signal 
transduction accompanied by decreased lipolysis (Hoffstedt et al. 1999).   
 
2.6.5 Genotype and allele frequencies 
 
The frequency of the wild-type Trp64Trp genotype is higher in Caucasian populations ranging between 82 and 
90%, lower in Asian populations ranging between 65 and 70%, intermediate in African-Americans (75%) and 
Jamaicans (81%), while the lowest frequencies were observed in South African Blacks and Pima Indians at 48% 
and 46% respectively (Table 2.24).  The Arg64Arg genotype is virtually absent in Caucasian populations while 
between one and 7% of African or Asian populations have this genotype, with the highest frequency (9%) 
reported for Pima Indians.  The frequency of the mutant Arg64-allele is therefore lower in Caucasians, 
intermediate in Asians and high in South African Blacks and Pima Indians. 
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Table 2.24: Genotype frequencies of the ADRB3 Trp64Arg polymorphism and frequency of the mutant Arg64-allele. 
Population Weight and 
diseases status 
n Trp/ 
Trp 
% 
Arg/ 
Trp 
% 
Arg/ 
Arg 
% 
Arg64-
allele 
% 
References 
Caucasian        
Finnish Obese 170 81 19 0  Valve et al. 1998 
Finnish DM2 
Non-DM2 
119 
185 
87 
84 
13 
16 
0 
0 
8 
7 
Pulkkinen et al. 1999 
Spanish  1063 90 10 0 5 Corella et al. 2001 
Spanish With OSAS 
Without OSAS 
387 
137 
82 
85 
17 
15 
1 
0 
10 
8 
Pierola et al. 2007 
Spanish ♀ 
  ♂ 
 172 
160 
90 
87 
10 
13 
0 
0 
5 
7 
Ramis et al. 2004 
Austrian ♀  179 83 17 0 9 Festa et al. 1999 
Dutch ♀  1519 88 12 0 6 Zafarmand et al. 2008 
German  988 82 17 1 9 Stangl et al. 2001 
European  4854 86 13 1  Kurokawa et al. 2008 
French Canadian  743 85 15 0 8 Ukkola et al. 2000 
USA  156 84 15 1  Lima et al. 2007 
African         
South African Black Insulin resistant 102 48 47 5 28 Van Rooyen et al. 2008 
Jamaicans  586 81 18 1 11 McFarlane-Anderson et al. 1998 
African-American  72 75 21 4  Lima et al. 2007 
Native American        
Pima Indian  642 46 45 9 31 Walston et al. 1995 
Asian        
Chinese  695 69 28 3 17 Hao et al. 2004 
Japanese  287 65 32 3 19 Tsuzaki et al. 2007 
Japanese   261 68 28 4 18 Shima et al. 1998 
Japanese   191 67 28 5 19 Kadowaki et al. 1995 
Japanese  106 70 24 6  Kahara et al. 2002 
Japanese  120 71 23 6 20 Murata et al. 2003 
USA = United States of America, DM2 = Type 2 diabetes, OSAS = obstructive sleep apnoea syndrome 
 
2.6.6 Associations with obesity related phenotypes. 
 
Weight, BMI, obesity and measures of body fat distribution and content 
According to the latest Human Obesity Gene Map (Rankinen et al. 2006), numerous human studies have 
reported positive associations between the ADRB3 mutant Arg64-allele and obesity, early onset obesity, higher 
weight, BMI, abdominal subcutaneous fat, abdominal visceral fat, hip circumference, fat mass, waist 
circumference, body fat percentage and waist-to-hip ratio (Rankinen et al. 2006, Pierola et al. 2007).  Three 
independent studies also indicated an association between the Arg64-allele and a higher body weight increase 
over 5 years (Matsuoka et al. 2004), 20 (Clement et al. 1995) and 25 years (Nagase et al. 1997).  Many other 
studies have however failed to find any associations with the above-mentioned obesity related phenotypes and 
the Arg64-allele (Rankinen et al. 2006).   
 
Four meta-analyses have been published regarding the association between the ADRB3 Trp64Arg polymorphism 
and BMI (Table 2.25).  The first meta-analysis showed no association between this polymorphism and BMI in 
7399 individuals from different ethnicities reported in 23 studies published before June 1997 (Allison et al. 1998).  
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Subsequent meta-analyses (Fujisawa et al. 1998, Kurokawa et al. 2001, Kurokawa et al. 2008) indicated that 
Arg64-allele carriers have a significantly higher BMI in comparison with wild-type Trp64Trp homozygotes.  The 
most recent meta-analysis including 97 studies and 44833 individuals indicated that the Arg64-carriers had a 
0.24kg/m2 higher BMI compared to the Trp64Trp homozygotes (Kurokawa et al. 2008).  Although the meta-
analysis by Fujisawa et al. (1998) showed that the association between the Arg64-allele and a higher BMI was 
applicable to all ethnicities included, the last two meta-analyses point towards associations being present only in 
Asian populations.   
 
Table 2.25: Meta-analyses of the association between the ADRB3 Trp64Arg polymorphism and BMI. 
Nr of 
studies  
Date studies 
were published 
Nr of 
subjects 
Ethnicity Results Author 
23 Before June 
1997 
7399 
 
different 
ethnicities 
No significant association. 
No effect of heterogeneity by ethnicity. 
Allison et 
al. 1998 
 
31 Before January 
1998 
9236 
 
different 
ethnicities 
Arg64 allele carriers had a higher BMI (0.30kg/m2) 
compared with Trp64 homozygotes. 
No effect of heterogeneity by ethnicity. 
 
Fujisawa 
et al. 1998 
27 Before January 
2001 
6582 
 
Japanese 
only 
Arg64 allele carriers had a higher BMI (0.26kg/m2) 
compared with Trp64 homozygotes. 
 
Kurokawa 
et al. 2001 
97 Before May 
2007 
44833 
 
Caucasian 
=European 
 
East Asian 
=Japanese 
Arg64 allele carriers had a higher BMI (0.24kg/m2) 
compared with Trp64 homozygotes. 
Heterogeneity effects: significant difference 
(0.31kg/m2) in the East Asian subgroup but not in the 
European descendents subgroup.  No difference 
between Asian and European subgroups.  
Kurokawa 
et al. 2008 
 
 
2.6.7 Associations with health indicators 
 
Indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure 
A meta-analysis on the associations between the ADRB3 Trp64Arg polymorphism and obesity related co-
morbidities that was published in 2005 by Zhan and Ho, found that the Arg64-allele was associated with higher 
fasting insulin levels in Asians but not Caucasians (Zhan & Ho 2005).  In the most recent meta-analysis published 
on this topic (Zafarmand et al. 2008) no association with acute myocardial infarction or coronary heart disease 
risk and the ADRB3 Trp64Arg polymorphism was found.  The Arg64-allele has also been associated with early 
onset type-2 diabetes (Walston et al. 1995), diabetic retinopathy and nephropathy (Sakane et al. 1997a, Sakane 
 96
et al. 1998).  Although inconclusive, some studies also reported on associations with hypertension, while others 
do not support such associations (summarized by Rozec & Gauthier 2006).   
 
2.6.8 Associations with weight loss outcomes 
 
The association between the ADRB3 Trp64Arg polymorphism and weight loss outcome has been investigated in 
13 weight loss interventions of which four were performed in Caucasians, seven in Japanese, one in Koreans and 
one in Chinese children (Table 2.26).  In the Caucasian populations, two 12-month interventions and one three-
month weight loss intervention showed that the Trp64Trp homozygotes and Arg64-allele carriers experienced 
similar weight reductions (Tchernof et al. 2000, Rawson et al. 2002, De Luis et al. 2007).  The authors did 
however argue that the wild-type Trp64Trp homozygotes benefited more from these interventions as they 
experienced greater decreases in visceral adipose tissue, total cholesterol-to-HDL ratio (Tchernof et al. 2000) and 
greater decreases in glucose, insulin resistance (De Luis et al. 2007).  The fourth weight loss intervention 
involving a Caucasian population consisted of a 12-month programme.  With this programme, Finnish obese 
subjects attended weekly group sessions with a nutritionist and followed a weight loss diet for 12 weeks 
followed by a weight maintenance period of 40 weeks.  These authors indicated that subjects who were carriers 
of the mutant ADRB3 Arg64 allele and the mutant UCP1 A/G allele were not able to maintain their weight loss 
during the 40-week weight maintenance phase (Fogelholm et al. 1998).  Therefore, such subjects may benefit 
from more intensive interventions to induce long-term weight loss maintenance. 
 
Four of the seven weight loss interventions carried out in Japanese showed that wild-type Trp64Trp 
homozygotes experienced greater weight losses after following low energy diets and exercise recommendations 
(Kogure et al. 1998, Yoshida et al. 1995, Sakane et al. 1997b) or the medication Mazindol (Shimizu et al. 2007) 
for three months.  Although the other three interventions indicated that the ADRB3 Trp64Arg polymorphism did 
not influence weight loss outcome, it was also proposed that wild-type Trp64Trp homozygotes might benefit 
more from a conservative weight loss programme to decrease not only their weight but also other variables such 
as visceral fat area and visceral-to-subcutaneous fat ratio (Nakamura et al. 2000).  A similar argument was 
applicable to the Koreans after following a three months weight loss intervention.  Although the BMI of both 
genotype groups decreased similarly, the Trp64Trp homozygotes experienced better decreases in total, visceral 
and subcutaneous fat areas and improvements in blood lipid levels and glucose metabolism (Kim et al. 2003).  
Finally, Trp64Trp homozygous Chinese obese children benefited more from a three-month intervention aiming 
at decreasing their fat and cholesterol intake to limit weight gain (Xinli et al. 2001).   
 
It is thus evident that subjects with Caucasian or Asian ancestry who are ADRB3 Trp64Trp homozygotes may 
either have more successful weight loss or weight maintenance following a weight loss intervention or may 
experience additional improvements in associated health variables.  However, the mutant Arg64-allele carriers 
may find it more difficult to lose weight or successfully maintain weight loss and may need more intensive 
interventions to secure sustained health effects.    
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Table 2.26: The association between the ADRB3 Trp64Arg polymorphism and change in weight (BMI) and other variables following a weight loss intervention. 
Population Sample 
size 
Genotype 
frequencies 
Inclusion 
criteria 
Weight loss intervention Variables measured W64W = 
↑ weight 
loss 
Results Reference 
Finland n=85 ♀ W64W=84% 
R64=16% 
BMI>29 12 months intervention: 
 Weight loss phase (12 weeks) 
- Week 1 & 10-12 = 4200 - 
4600 kJ/ day 
- Weeks 2-9 = VLCD (40% of 
REE) 2700 kJ/ day 
 Maintenance phase (40 weeks) 
 Weekly small group sessions 
with nutritionist all 12 months 
 
Measured at 0, 3 & 12 months:  
 BMI, FM,  
 REE, adjusted REE, VO2 max, 
insulin. 
Yes Combined effect of ADRB3 W64R and UCP1 
A/G 
Compared 4 groups: 1) subjects with no 
mutations for both genes, 2) with R64; 3) UCP1 
mutation, 3) both mutations. 
Between group differences: 
 No baseline differences 
 No difference after 3 months weight loss 
phase 
 During 9 months weight maintenance phase: 
- ↑ BMI  in both mutations group vs. ↓ 
BMI in no mutations group (p<0.05) 
- Over whole 12 months: Both mutations 
group loss less weight than no mutations 
group 
Fogelholm 
et al. 1998 
USA ♀ 
Caucasian 
n=24  R64R=4%; 
W64R=42% 
W64W=54% 
BMI≥27 
post-
meno-
pausal 
♀ 
 
13.5 months intervention: 
 First 1.5 months = weight stable 
period  
 Next 12 months: 5000 kJ / day 
AHA step 2 diet.  
 Dietitian visits.   
 Encouraged not to change 
physical activity habits. 
 With or without modified 
fasting supplements 
Measured at 0 and 13.5 months:  
 DEXA: FM, FFM   
 CT scanner: VAT SAT,  
 TC, TG, HDL, LDL,  
 Hyperinsulinemic-euglycemic 
clamp: glucose disposal, clamp 
insulin levels, EGP 
No After intervention both genotype groups 
(W64W and R64 carriers) experienced: 
 ↓ BMI, FM, FFM, VAT, SAT, TC:HDL ratio, 
clamp insulin, basal glucose, clamp glucose 
and improved glucose disposal rates. 
 
R64 carriers: 
 Lower ↓ in visceral adipose tissue  
 Lower ↓ TC:HDL ratio 
 
Tchernof et 
al. 2000 
USA ♀: 
ethnicity 
unknown 
 
 
n=34 
 
Drop-
out = 35 
 
W64W=56% 
 
R64R+ 
R64W=44% 
BMI≥27 
post-
meno-
pausal 
♀ 
 
 
13.5 months intervention: 
 First 1.5 months = weight stable 
period  
 Next 12 months: 5000 kJ / day 
AHA step 2 diet.  
 Dietitian visits.   
 With or without modified 
fasting supplements 
Measured at 0 and 13.5 months:  
 BMI.  
 Indirect calorimetry: TEF, RMR, 
RQ 
 Doubly labelled water dose: 
after 10 days = determine 
TEE, % body fat, FFM, FM, 
PAEE. 
No  No difference in SNP between drop-outs and 
subjects completed the study. 
 
 After intervention total sample experienced: 
    ↓ BMI, % body fat, FFM, FM, RMR 
 
 After intervention no significant differences 
between W64W and R64 carriers. 
Rawson et 
al. 2002 
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Table 2.26: continued 
Population Sample 
size 
Genotype 
frequenies 
Inclusion 
criteria 
Weight loss intervention Variables measured W64W = 
↑ weight 
loss 
Results Reference 
Spain n=65 
 
♀= 47 
♂= 18 
W64W=85% 
W64R=15% 
BMI≥30 
 
3 month intervention: 
 Diet = 6384 kJ/ 1520 kCal, 52% 
carbohydrates, 25% fat, 23% 
proteins. 
 Exercise: 60 min aerobic 
3×/week  
 
Measured at 0, 3 months:  
 BMI, WC, WHR, FM, FFM. 
 Energy, carbohydrate, protein, 
fat intake. 
 BP, TC, HDL, LDL, TG, BG, 
insulin, HOMA-IR, lipoprotein 
(a), CRP, Adipocytokines: 
leptin, adiponectin, resistin. 
 RMR, VO2 max. 
No % of responders (those who lost weight) was 
similar in W64W (89%) and W64R (80%) groups 
Difference between groups at 0 & 3 months: 
 W64R = ↑ CRP 
Change over 3 months within genotype 
groups: 
 W64W = ↓ BMI, FM, WC, SBP, glucose, 
HOMA-IR, leptin and ↑ RMR, RMR/FM ratio, 
exercise, VO2 
 W64R = ↓ BMI, FM, WC, SBP, leptin and ↑ 
RMR, RMR/FM ratio, VO2 
De Luis et 
al. 2007 
Japanese n=24 
 
♀= 17 
♂= 7 
W64W=67% 
W64R=33% 
 
BMI≥35 
 
3 months intervention: 
Previously unsuccessful pt in 3 
month low kJ diet & 60min PA/d 
received treatment with Mazindol 
for 3 months  
 
Measured at 0 & 3 months 
 Weight, % fat, BP 
Yes W64W = greater ↓ in weight & BP. Shimizu et 
al. 2007 
Japanese  n=88 ♀ W64W=60% 
R64W=34% 
R64R=6% 
BMI≥30 
 
3 months intervention: 
Low energy diet and exercise 
regime 
 
Measured at 0, 3 months:  
 weight, height, BMI 
Yes W64W = greater weight loss Yoshida et 
al. 1995 
Japanese ♀ 
 
n=61 W64W=61% 
W64R=34% 
R64R=5% 
 
BMI≥30 
♀ with 
DM2 
3 months intervention 
 Low calorie diet and exercise  
 
 
 BMI, WHR. 
 Adjusted resting metabolic 
rate. 
 Fasting blood glucose, insulin, 
insulin resistance index, 
HbA1C,  
 % body fat (skinfold 
measurements) 
Yes Baseline differences between groups 
 R64 carriers =  ↑ body fat %, WHR, glucose, 
insulin, HOMA-IR, HbA1c  
 
Change within groups over 12 weeks:  
 W64W = ↓ BMI, WHR, glucose, HOMA-IR, 
HbA1c 
 R64 carriers = ↓ BMI, WHR, glucose 
 
Difference between groups for change in 
variables: 
 R64 carrriers = smaller ↓ in BMI, WHR, 
glucose, HbA1c compared to W64W 
 
Sakane et 
al. 1997b 
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Table 2.26: continued 
Population Sample 
size 
Genotype 
frequenies 
Inclusion 
criteria 
Weight loss intervention Variables measured W64W = 
↑ weight 
loss 
Results Reference 
Japanese n=90 ♀ W64W=56% 
R64W=39% 
R64R=5% 
BMI≥26.4 
 
3 months intervention: 
 Diet = 5880 kJ/d, 1.5 g/kg 
protein, 30g fat, 20g fibre. 
 Exercise = walking 60min 3-7× 
/week 
 Individualized dietary advice by 
dietitian.  
Measured at 0 & 3 months 
 BMI, weight, % fat, FM, 
MRI:TFA, VFA, SFA, V/S 
 Glucose, insulin, TC, HDL, TG 
No Baseline differences between W64W & R64 
carriers 
Post-menopausal women:  
 W64W = ↓ BMI, weigh, FM, TFA, SFA. 
 
Difference between W64W and R64 carriers 
for change in variables over 3 months: 
 Premenopausal ♀: W64W = greater ↓ in V/S 
ratio and HDL 
 No difference in post-menopausal ♀ 
 All ♀: W64W = greater ↓ in VFA and V/S 
ratio 
 
Nakamura 
et al. 2000 
Japanese ♀ n=76 
 
W64W=64% 
W64R=32% 
R64R=4% 
BMI>21 3 month intervention  
Behavioural weight-loss 
programme:  
 Diet  
 Exercise: counting step/day 
with pedometer 
 Supportive group therapy 
 Health check to recognize risks 
 Intensive individual sessions 
with professional to address 
unhealthy lifestyle, weekly 
weigh-ins 
 
 Body fat, WC, HC, triceps skin 
fold. 
 Indirect calorimetry: REE,  
 Blood pressure, TC, TG, 
phospoholipid, NEFA, glucose, 
insulin, leptin, HOMA-IR 
 FFQ, PA questionnaire,  
 bio-electrical impedance, 
No Change over 3 months within genotype 
groups: 
 W64W: ↓ kJ, prot, fat /day, BMI, WC, HC, 
BP, LDL:HDL ratio, phospholipid and ↑ in 
body fat %, HDL, nr of steps/day.   
 Correlation between weight change & 
change in kJ intake & change in nr of steps 
(PA) 
 R64 carriers: ↓ kJ, fat / day, HC, LDL, 
LDL:HDL ratio, phospholipid and ↑ in body 
fat %, HDL (No correlations) 
No significant differences for change in these 
variables between W64W and R64 carriers. 
Shiwaku et 
al. 2003 
Japanese n=37 W64W=67% 
R64W=30% 
R64R=67% 
BMI≥23 
 
6 months intervention: 
 Trained nutritionists & nurses 
taught 7-10 diet, exercise and 
behaviour modification lessons 
on individualized basis to each 
pt  
 Health check to recognize risks. 
 
Measured at 0 & 6 months 
 Weight, BMI, VFA, SFA,  
 Glucose, 2h glucose, HbA1c, 
insulin, HOMA-IR. 
 TC, LDL, TG. 
No Change over 6 months within genotype 
groups: 
 W64W = ↓ weight, BMI, SFA, HbA1c. 
 R64 carriers = ↓ weight, BMI, glucose, 
HbA1c. 
 No difference between genotype groups for 
change in variables over 6 months  
Kuriyama et 
al. 2008 
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Table 2.26: continued 
Population Sample 
size 
Genotype 
frequenies 
Inclusion 
criteria 
Weight loss intervention Variables measured W64W = 
↑ weight 
loss 
Results Reference 
Japanese n=113 
♀ 
W64W=66% 
R64W=30% 
R64R=4% 
BMI≥30 
 
3 months intervention: 
 Low kilojoules diet and exercise 
regime 
 
Measured at 0, 3 months:  
weight, height, BMI 
Yes Combined effect of ADRB3 T64A and UCP1 
A/G: A64 carriers + mutant UCP1 = lost less 
weight 
Kogure et 
al. 1998 
Korean n=70 ♂ W64W=71% 
R64W=29% 
R64R=0% 
BMI≥25 / 
WHR>0.9/ 
% body 
fat>24% 
and CAD 
3 months intervention: 
 Goal = 5% weight loss 
 Diet = 300 kCal/d less than 
usual 
 60% carbohydrate, 20% 
protein, 20% fat. 
 Weekly individual sessions with 
dietitian 
 3-day dietary records & daily 
activities records for 3 months.  
Measured at 0, 3 months:  
 BMI, WHR, BP, Newly onset 
DM %, HT%, smoking. 
 TE, protein, fat carbohydrate,  
 Basal & 2h glucose, FFA, 
Insulin, C-peptide.  
 TG, TC, HDL, LDL, athrogenic 
index, TC/HDL, LDL/HDL, 
ApoAI, ApoB.  
 At L1 & L4: TFA, VFA, SFA V/S 
ratio, Calf fat & muscle area, 
Mid-thigh fat & muscle area 
No  Similar weight loss in both genotype groups 
 
Change over 3 months within genotype 
groups: 
T64T =  ↓ BMI, SBP, energy intake,  
  ↓ TFA, VFA, SFA at L1, L4 
  ↓ insulin, 2h glucose, FFA, C-peptid 
  ↓TG, TC, LDL, athrogenic index,  
  TC/HDL, LDL/HDL, ApoB 
T64A =  ↓ BMI, SBP, energy intake, mid thigh 
fat 
  
Kim et al. 
2003 
Chinese 
children 
n=47 
♀= 16 
♂= 31 
 
n=36: 
obese 
interven
tion 
group 
 
n=11: 
obese 
controls 
In school 
sample 
n=311: 
 
W64W=67% 
W64R=31% 
R64R=2% 
obese 
children 
3 months intervention: 
 Parents & children receive 
lecture on nutrition & health. 
 Parents received: nutrient 
information, examples of diets 
and menus for children. 
 Diet aims to decrease fat and 
cholesterol intake 
 Diet = based on USA NCEP Step 
I diet 
 Individualized instruction from 
nutritionist with: 
 - Family visits 1/months  
 - Telephone calls 1/week 
 Control group received none of 
the above. 
Measured at 0, 3 months:  
 weight, height, BMI, sum of 3 
skinfolds (subscapular, biceps, 
triceps), BP. 
 From 3 day food diaries: 
    TE, fat%, cholesterol 
Yes  Intervention group had a ↓ TE, fat %, 
cholesterol intake 
 
 Difference between W64W and R64 carriers 
in intervention and all controls for change in 
variables over 3 months: 
 W64W = lower increase in weight & BMI vs. 
R64 carriers and controls who had similar 
changes in these variables. 
Xinli et al. 
2001 
R54R = Arg64 homozygotes, R64W = heterozygotes, W64W = Trp64 homozygotes, W64 = Trp64 allele carriers, BMI = body mass index, WC = waist circumference, HC = hip circumference, 
WHR = waist-hip ratio, BW = body water, FM = fat mass, FFM = fat free mass, BP = blood pressure, SBP = systolic blood pressure, TC = total cholesterol, HDL = high density lipoprotein, LDL = 
low density lipoprotein, TG = triglycerides, RMR = resting metabolic rate, BG = blood glucose, VWAT = visceral white adipose tissue, SWAT = subcutaneous white adipose tissue, TFA = total 
fat area, VFA = visceral fat area 
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2.7 β2 Adrenergic receptor (β2-AR and ADRB2; β2-adrenoceptor) gene 
 
2.7.1 The ADRB2 gene  
 
The human β2-adrenergic receptor gene (ADRB2) was first cloned in 1987, assigned to the long arm of 
chromosome five and localized to position 5q31-32 using somatic cell hybrids and in situ hybridization 
respectively (Kobilka et al. 1987a).  The intronless ADRB2 gene consists of 1242 bp and has only one exon 
(Kobilka et al. 1987a, Kobilka et al. 1987b).  ADRB2 also contains a short open reading frame located 102 bp 
upstream of the receptor coding block referred to as the 5’ leader cistron (Parola & Kobilka 1994). 
 
2.7.2 The ADRB2 protein  
 
The ADRB2 gene encodes a 413 amino acid β2-Adrenergic receptor and a 19 amino acid leader cistron peptide, 
which regulates the amount of ADRB2 expressed in a cell by obstructing its mRNA translation (Parola & Kobilka 
1994, Liggett 2000).  The structure of the β2-Adrenergic receptor is similar to that of the other GPCRs as depicted 
in Figure 2.4, p87. 
 
The ADRB2 protein is abundant in human WAT and BAT (Robidoux et al. 2004).  It is also expressed in the human 
heart including the atria, ventricles and sinoatrial node as well as throughout the lungs from the trachea to the 
alveoli including the airway smooth muscle, lung epithelial and endothelial cells, type II cells and mast cells 
(Johnson 2006, Snyder et al. 2008).  
 
2.7.3 Physiological function of ADRB2 
 
The β2-adrenoceptors are primarily stimulated by epinephrine to increase lipolysis (as described in section 2.6.3, 
p87), bronchodilation, vasodilation and ventricular function (Snyder et al. 2008).  The specific involvement 
thereof in the lungs and heart to increase bronchodilation, vasodilation and ventricular function is not discussed 
as it is beyond the scope of this review, but is reviewed in several articles (McGraw & Liggett 2005, Johnson 2006, 
Snyder et al. 2008). 
 
2.7.4 The ADRB2 Arg16Gly polymorphism 
 
The mutation in ADRB2 produces an Adenine (A) to Guanine (G) transition at nucleotide position 46, causing the 
replacement of arginine (Arg) by glycine (Gly) at amino acid position 16 (Arg16Gly) (Green et al. 1994, Green et 
al. 1995, Large et al. 1997).  This polymorphism is found in the extracellular amino terminus of the ADRB2 
protein (see Figure 2.4, p87). 
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In vitro studies have indicated that the Arg16Gly polymorphism can alter the ADRB2 function and consequently 
influence lipolysis regulation in subcutaneous fat cells (Green et al. 1994, Green et al. 1995, Large et al. 1997, 
Hoffstedt et al. 2001).  In vitro experiments on abdominal subcutaneous adipocytes obtained from 140 
Caucasian women illustrated a five-fold increase in agonist sensitivity in Gly16 carriers without any change in 
ADRB2 expression or maximum lipolytic action (Large et al. 1997).  In contrast, a 10-fold decrease in ADRB2 
agonist sensitivity was observed in subcutaneous adipocytes of subjects carrying the mutant alleles, Gly16-
Glu27- and Ile164, of three ADRB2 polymorphisms (Hoffstedt et al. 2001). 
 
The Arg16Gly polymorphism has been associated with altered agonist-promoted downregulation of ADRB2 
expression, causing altered cellular trafficking and desensitization of the receptor (Green et al. 1994, Green et al. 
1995, Moore et al. 2000).  The ADRB2 Gly16-allele has been associated with a higher decrease in ADRB2 
expression in adipose tissue due to enhanced down-regulation after prolonged agonist stimulation (Green et al. 
1994, Green et al. 1995).  This may consequently result in reduced receptor function and lower efficiency of 
lipolysis stimulation, leading to excess fat accumulation over time (Ellsworth et al. 2002).  Consequently, 
individuals carrying the Gly16-allele (especially homozygotes) may be more likely to become obese (McGraw et 
al. 1998, Ellsworth et al. 2002).   It is also apparent that the Gly16-allele may inhibit lipolysis to a greater degree 
in abdominal adipose tissue than in gluteal-femoral tissue.  Ellsworth et al. (2002) proposed that males carrying 
the Gly16-allele might be unable to compensate effectively to increase lipolysis due to higher abdominal α2-AR 
efficiency, which also inhibits lipolysis.   
 
Jocken et al. (2007) measured the effect of stepwise infusion of increasing doses of the non-selective β-agonist 
isoprenaline (ISO) on in vivo lipolysis and fat oxidation in 65 male and 43 female overweight and obese subjects.  
During ADRB2 stimulation with ISO, Gly16Gly women experienced a higher increase in circulating free fatty acids 
and glycerol compared to Arg16-allele carriers.  This enhanced lipolytic response was accompanied by increased 
fat oxidation after ISO stimulation in Gly16Gly homozygous women compared to a decrease in fat oxidation in 
Arg16-allele carriers (Jocken et al. 2007).  These effects were not as pronounced in male overweight subjects.  In 
the latter subjects the Gly16Gly genotype was only associated with increased circulating free fatty acids and not 
with glycerol or fat oxidation levels (Jocken et al. 2007).  Similarly, Gly16 female allele carriers had higher fasting 
free fatty acid levels and higher increases in free fatty acids following an oral glucose tolerance test (Meirhaeghe 
et al. 2001). 
 
2.7.5 Genotype and allele frequencies  
 
The frequency of the ADRB2 wild-type Arg16Arg genotype ranges between 10 and 29% in Caucasians, while that 
of the mutant Gly16Gly genotype ranges between 32 and 53% (Table 2.27).  Lower ranges for the Gly16Gly 
genotype are found in subjects with African (26 to 31%) or Asian ancestry (9 to 33%).  This Gly16Gly genotype 
frequency range does not include frequencies for subjects with Asian ancestry of 59%, 49% and 57% reported 
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respectively for overweight subjects who had blood pressure or weight increases over a five year follow-up 
period (Kawaguchi et al. 2006) or normal weight subjects with high norepinephrine levels (Masuo et al. 2007).   
 
Although the Gly16-allele is the mutant variant of the ADRB2 gene, it is actually not found as the minor allele 
frequency in most populations.   The Gly16-allele was found at a frequency of 0.55 to 0.66 in Caucasians, 0.36 to 
0.55 in subjects with African ancestry and 0.35 to 0.57 in subjects with Asian ancestry. 
 
 
Table 2.27: Genotype frequencies of the ADRB2 Arg16Gly polymorphism and frequency of the mutant Gly16-allele. 
Population Weight and disease 
status 
n Arg/ 
Arg  
% 
Arg/ 
Gly  
% 
Gly/ 
Gly  
% 
Gly16 
allele 
References 
Caucasian         
Scandinavian ♀ BMI>25  141 19 45 36  Eriksson et al. 2004 
Danish   2904 14 47 39 0.62 Gjesing et al. 2007 
Sweden ♂ non-obese  180 19 44 37 0.59 Ehrenborg et al. 2000 
Sweden  267 29 31 39 0.55 Rosmond et al. 2000 
Sweden Obese 
Non-obese 
82 
58 
17 
22 
38 
24 
45 
53 
0.64 
0.66 
Large et al. 1997 
Austrian ♀ Obese 
Non-obese 
183 
216 
20 
17 
45 
47 
35 
36 
0.57 
0.60 
Oberkofler et al. 2000 
Caucasian         
French-Canadian  334 17 39 44 64 Ukkola et al. 2000 
France  836 14 48 38 63 Meirhaeghe et al. 2000 
France ♂  567 13 50 37  Dallongeville et al. 2003 
France ♀  562 15 46 39  Dallongeville et al. 2003 
Netherlands:  ♂ 
   
  ♀ 
  
weight gain over 7 yrs 
weight stable over 7 yrs 
weight gain over 7 yrs 
weight stable over 7 yrs 
134 
138 
152 
158 
16 
10 
12 
10 
40 
55 
53 
44 
44 
36 
35 
46 
 Van Rossum et al. 2002 
Italians  Random population 
DM2 
305 
342 
16 
20 
41 
44 
43 
36 
 Pinelli et al. 2006 
German children Obese 
Lean 
296 
134 
18 
17 
46 
44 
40 
39 
59 
61 
Tafel et al. 2004 
UK  604 12 44 44 65 Meirhaeghe et al. 2001 
American  816 12 47 41 64 Ellsworth et al. 2002 
American  161 21 37 42  Lima et al. 2007 
American ♀  538    58 Terra et al. 2005 
European Brazilians  334 19 49 32 56 Mattevi et al. 2006 
Hispanic American        
Hispanic-American 
 rural area 
 urban area 
  
272 
448 
    
36 
45 
Lange et al. 2005 
Mixed ancestry from 
Brazil: 51% Mulatto 
35% Caucasian. 
 1576 21 47 32 56 Pereira et al. 2003 
African         
African-American  335 23 51 26 52 Ellsworth et al. 2002 
African-American  272    55 Lange et al. 2005 
African-American  74 16 53 31  Lima et al. 2007 
African-American ♀  105    44 Terra et al. 2005 
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Table 2.27: continued 
Population Weight and disease 
status 
n Arg/ 
Arg  
% 
Arg/ 
Gly  
% 
Gly/ 
Gly 
 % 
Gly16 
allele 
% 
References 
Asian         
Japanese 
  
obese 
non-obese 
124 
450 
28 
25 
50 
50 
22 
25 
47 
50 
Yamada et al. 1999 
Japanese 
  
obese 
non-obese 
108 
400 
28 
25 
52 
50 
20 
25 
46 
50 
Ishiyama-Shigemoto et al. 
1999 
Japanese ♂ BMI>25 55 18 49 33 57 Kawaguchi et al. 2006 
Japanese ♂  
  
BMI>25 & 
BP ↑ over 5 yrs 
No BP ↑ over 5 yrs 
 
27 
28 
 
0 
36 
 
41 
57 
 
59 
7 
 Kawaguchi et al. 2006 
Japanese ♂  
  
BMI>25 & 
weight gain over 5 yrs 
weight stable over 5 yrs 
 
33 
22 
 
9 
32 
 
42 
59 
 
49 
9 
 Kawaguchi et al. 2006 
Japanese ♂  All subjects BMI<25 + 
normal NE 
high NE 
219 
182 
37 
31 
34 
13 
47 
51 
30 
22 
15 
57 
46 
40 
72 
Masuo et al. 2007 
Taiwanese DM2 
Non-DM2 
130 
130 
37 
24 
43 
58 
20 
18 
42 
47 
Chang et al. 2002 
Korean Non-DM2 & non-obese 
Non-DM2 & obese 
43 
46 
40 
39 
51 
50 
9 
11 
35 
36 
Kim et al. 2002 
Korean DM2 & non-obese 
DM2 & obese 
44 
62 
34 
42 
39 
47 
27 
11 
40 
35 
Kim et al. 2002 
BMI = body mass index, DM2 = Type 2 diabetes, BP = blood pressure, NE = norepinephrine. 
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2.7.6 Associations with obesity related phenotypes 
 
Weight, BMI and obesity 
The majority of studies summarized in Table 2.28 (10 out of 12 published studies) did not show an association 
between obesity and the ADRB2 Arg16Gly polymorphism in Caucasians (six studies) and in subjects with African 
(two studies) and Asian (two studies) ancestry.  A meta-analysis of 13 case-control studies including populations 
from different ethnicities revealed no association between obesity and the ADRB2 Arg16Gly polymorphisms 
(Gjesing et al. 2007).  Two studies have shown that obesity is associated with a lower frequency of the Gly16Gly 
homozygous genotype in Japanese obese women (Ishiyama-Shigemoto et al. 1999) and a lower frequency of 
Gly16-allele carriers in French Canadian men with a BMI more than 35 compared to controls (Ukkola et al. 2000).  
In line with these results, a lower BMI was found for Gly16Gly homozygotes in Caucasian females (Meirhaeghe et 
al. 2001) and a Brazilian cross-sectional sample consisting of mixed ethnicities (Perreira et al. 2003).  However, in 
contrast to these findings other studies have reported an association between the Gly16Gly homozygous 
genotype or Gly16-allele carriers and a higher BMI in Caucasian (Ehrenborg et al. 2000) and Brazilian males 
(Mattevi et al. 2006) and with weight gain in males over a period of seven years (Van Rossum et al. 2002).  
Furthermore, in a longitudinal follow-up of different cohorts with subjects from birth to their late 30s an 
association between Gly16-allele carriers and a higher BMI was observed in Caucasian males and African-
Americans (Ellsworth et al. 2002).  This difference in BMI between the Arg16Gly genotypes became more 
pronounced with age and was not seen in females.  It was found that the BMI of males who are Gly16-allele 
carriers increased at a greater rate over time than the Arg16Arg homozygotes.  The association that was not 
significant when subjects were in childhood and adolescent years, tended to reach significance by 21 years of 
age, and reached significance at the age of 35 years (Ellsworth et al. 2002).  This relates to a 4% higher BMI 
found in Gly16-allele carriers at age 26 and an 8% higher BMI at age 32 (Ellsworth et al. 2002).  In contrast with 
males, females (when they were ages 12 and 21 years) who are Gly16 allele carriers had lower BMIs than 
Arg16Arg homozygotes (Ellsworth et al. 2002).  
 
In non-Caucasian populations two studies reported an association between the Arg16Gly genotype and BMI.  
The Gly16Gly homozygous genotype was associated with a lower BMI in Koreans with type 2 diabetes (Kim et al. 
2002).  However, in Japanese Gly16-allele carriers had a significant increase in weight over a follow-up period of 
five years (Kawaguchi et al. 2006).  Furthermore, three studies in subjects with African ancestry (Lange et al. 
2005, Terra et al. 2005, Lima et al. 2007) and two on Japanese (Ishiyama-Shigemoto et al. 1999, Masuo et al. 
2007) did not find any association.   
 
In summary, at this stage most studies indicate no association between the ADRB2 Arg16Gly polymorphism and 
BMI or obesity.   Furthermore, the results of the positive association studies were equivocal with some linking 
the Gly16-allele carriers or Gly16Gly homozygotes with a higher BMI or with weight gain while others linked 
these genotypes with a lower BMI or obesity prevalence.   
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Table 2.28: The association between the ADRB2 Arg16Gly polymorphism and weight, BMI and obesity. 
Population  Weight and disease  n Study design Association with obesity Association with BMI Reference 
 status   Yes No Yes No  
Caucasian          
Austrian ♀ Obese 
Non-obese 
183 
216 
Case-control -  -  Oberkofler et al. 2000 
Danish  7808 Meta-analysis -  -  Gjesing et al. 2007 
Sweden healthy ♂ Non-obese 180 Population based ni ni ♂ Gly16Gly = ↑ BMI - Ehrenborg et al. 2000 
Sweden ♂  284 Cross-sectional -  -  Rosmond et al. 2000 
Sweden ♀ Obese 
Non-obese 
82 
58 
Cohort sample with case-
control analysis 
-  -  Large et al. 1997 
Netherlands Over 7 yrs: 
Weight gain 
Stable weight 
 
286 
296 
Cohort: follow-up of 7 
years 
ni ni ♂ with 7 yr weight gain =  ↑ 
Gly16Gly vs stable weight 
subjects 
In ♀ Van Rossum et al. 2002 
German children Obese 
Lean 
296 
134 
Case-control -  ni ni Tafel et al. 2004 
UK  604 Population based cohort ni ni ♀ Arg16 = ↑ BMI In ♂ Meirhaeghe et al. 2001 
France  836 Population based  -  -  Meirhaeghe et al. 2000 
French-Canadian  743 Family-based  BMI≥35 ♂ = ↓ 
Gly16-allele 
- ni ni Ukkola et al. 2000 
American  161 Population based ni ni -  Lima et al. 2007 
American ♀ >18 yrs referred for 
coronary angiogram 
for suspected CHD 
538 Case-control -  -  Terra et al. 2005 
Mixed ancestry: 
African American & 
Caucasian American 
 1151 Longitudinal: 3 cohorts 
newborn-, childhood- & 
teenage each followed 
for 20 yrs 
ni ni Childhood cohort, Gly16 ♂: 
 0.2% BMI ↑ pa 
 = 4% ↑ BMI at age 26 
Teenage cohort, Gly16 ♂: 
 0.4% BMI ↑ pa 
 = 8% ↑ BMI at 32 yrs 
in newborn 
/childhood 
cohorts 
In all ♀ 
Ellsworth et al. 2002 
Hispanic American         
Brazilians  334 Population based ni ni ♂ Gly16 = ↑ BMI In ♀ Mattevi et al. 2006 
Mixed ancestry: 
African American & 
Hispanic American:  
 992 
 
Cross-sectional -  -  Lange et al. 2005 
Mixed ancestry from 
Brazil: 51% Mulatto 
35% Caucasian. 
 1576 Cross-sectional ni ni Gly16Gly = ↓ BMI - Pereira et al. 2003 
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Table 2.28: continued 
Population  Weight and disease  n Study design Association with obesity Association with BMI Reference 
 status   Yes No Yes No  
African         
African American ♀ >18 yrs referred for 
coronary angiogram 
for suspected CHD 
105 Case-control -  -  Terra et al. 2005 
African American  74 Population-based ni ni -  Lima et al. 2007 
Asian          
Japanese 
   
Obese  
Non-obese 
108 
400 
Case-control obese ♀ = ↓ 
Gly16Gly 
in ♂ -  Ishiyama-Shigemoto et 
al. 1999 
Japanese 
  
Obese 
Non-obese 
124 
450 
Case-control -  ni ni Yamada et al. 1999 
Japanese ♂ Obese + weight gain 
Obese + stable 
weight  
33 
22 
Cohort: Follow-up for 5 
years 
ni ni Weight gain over 5 year 
= ↑ Gly16Gly% 
Gly16 allele = BMI ↑ over 5 
years (NS for Arg16Arg) 
- Kawaguchi et al. 2006 
Japanese ♂ Non-obese 219 Company-based sample: 
baseline and change 
over 5 years 
ni ni -  Masuo et al. 2007 
Korean Obese & Non-obese 
DM2 & non-DM2 
195 Cohort -  DM2: Gly16Gly = ↓ BMI - Kim et al. 2002 
*Recessive model = compares the CC homozygotes with G-allele carriers; Dominant model = compares GG homozygotes with C-allele carriers, childhood and adolescent years the 
Gly16 allele carriers generally gained 0.2% and 0.4% more per year respectively, which relates to a 4% higher BMI at age 26 and a 8% higher BMI at age 32 
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Measures of body fat distribution and content 
In Caucasians, the majority of studies have reported no association between the ADRB2 Arg16Gly polymorphism 
and body fat distribution or content (Table 2.29).  The studies that did report a positive association indicated 
that the mutant Gly16-allele carriers had a higher waist circumference than subjects with the Arg16Arg genotype 
(Mattevi et al. 2006).  In a mixed ethnicity sample consisting of African American and Caucasian males the Gly16-
allele carriers experienced a 0.5% and 2% increase in subscapular skinfolds per annum in a childhood and 
teenage cohort respectively.  Consequently, the Gly16-allele carriers had a 20% and 27% higher subscapular 
skinfold measurement in their 20s (Ellsworth et al. 2002).  However, contradictory results were reported in a 
French population with Gly16-allele carriers having a lower waist circumference, hip circumference and waist-to-
hip ratio (Meirhaeghe et al. 2000).   
 
No positive associations were found by the studies that included subjects with Hispanic or African ancestry.  In 
Japanese men, Gly16-allele carriers had a higher body fat mass, waist-hip-ratio, leptin, norepinephrine and 
higher five-year increases in body fat mass, waist-hip-ratio and leptin (Kawaguchi et al. 2006, Masuo et al. 2007).  
As only a limited number of studies measured these associations in populations with Hispanic, African and Asian 
ancestry, more research is necessary to confirm these findings. 
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Table 2.29: The association between the ADRB2 Arg16Gly polymorphism and measures of body fat distribution and 
content. 
Population Associations No associations Reference 
Caucasian    
French Gly16 = ↓ WC, HC, WHR - Meirhaeghe et al. 2000 
UK - WHR Meirhaeghe et al. 2001 
Danish  WC, HC, WHR Gjesing et al. 2007 
Sweden ♂ - WHR, abdominal sagittal 
diameter 
Rosmond et al. 2000 
Sweden ♀ - WHR, body FM, fat cell 
volume. 
Large et al. 1997 
American ♀ - WHR, WC Terra et al. 2005 
American - body fat % Lima et al. 2007 
Mixed ancestry African-
Americans and Caucasian-
Americans 
Childhood cohort, Gly16 ♂: 
 0.5% SS ↑ pa 
 = 20% ↑ SS at 20 yrs 
Teenage cohort, Gly16 ♂: 
 2% SS ↑ pa 
 = 27% ↑ SS at 22 yrs 
 ↑ SS, TS 
in newborn cohort or in ♀ Ellsworth et al. 2002 
European Brazilians ♂ Gly16 = ↑ WC WC in ♀ Mattevi et al. 2006 
Hispanic American    
Mixed ancestry:  
African-American & 
Hispanic-American 
- 
 
WHR, VAT, SAT, VSR Lange et al. 2005 
Mixed ancestry from 
Brazil: 51% Mulatto 35% 
Caucasian. 
- WHR, WC Pereira et al. 2003 
African     
African-American - body fat % Lima et al. 2007 
African-American ♀ - WHR, WC Terra et al. 2005 
Asian     
Japanese ♂ with BMI>25 Gly16 = ↑ body FM, WHR, 
leptin, ↑ in body FM, leptin 
over 5 yrs (NS for Arg16Arg) 
NE Kawaguchi et al. 2006 
Japanese ♂ with BMI<25 ↑ Gly16 = high p-NE 
Gly16 = ↑ baseline and 5 yrs 
body fat, WHR, p-NE 
Gly16=higher ↑ in body fat & 
WHR over 5 yrs 
- Masuo et al. 2007 
Korean - WHR, body fat % Kim et al. 2002 
HC = hip circumference, WC = waist circumference, WHR = waist-hip-ratio, SS = subscapular skinfolds, TS = triceps 
skinfolds, NE= norepinephrine, NS = non-significant, SAT = subcutaneous adipose tissue, VAT = visceral adipose tissue, 
VSR = visceral to subcutaneous ratio. 
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2.7.7 Associations with health indicators 
 
Indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure 
The studies showing a positive association between the ADRB2 Arg16Gly polymorphism and glucose and insulin 
homeostasis points to the possibility that Gly16Gly homozygotes or Gly16-allele carriers with Caucasian (Gjesing 
et al. 2007, Meirhaeghe et al. 2000, Dallongeville et al. 2003, Meirhaeghe et al. 2001) or Asian (Chang et al. 2002) 
ancestry are protected from the development of MetS or type 2 diabetes (Table 2.30).  In contrast, Caucasians 
with these genotypes had higher total cholesterol and LDL cholesterol levels (Ukkola et al. 2000, Meirhaeghe et 
al. 2001).   
 
The blood pressure results summarized in Table 2.30 are equivocal.  Recent reviews also concluded that the 
results from a large number of studies in various ethnic groups have shown that the association between the 
ADRB2 Arg16Gly polymorphism and blood pressure are controversial and probably not important in 
hypertension development (Hahntow et al. 2006, Brodde et al. 2008).  In the 32 studies summarized by Hahntow 
et al. (2006), hypertension was associated with the Arg16-allele in five studies and with the Gly16-allele in seven 
studies, while 20 studies found no association.  Controversial results were also obtained from studies 
investigating the association between this ADRB2 polymorphism and heart failure (Brodde et al. 2008).  Brodde 
et al. (2008) concluded that the ADRB2 Arg16Gln27 haplotype might predict poor outcome of heart failure, but 
that large prospective studies need to substantiate these findings.   
 
 In summary, Gly16-allele carriers seem to have a lower risk to develop Type-2 diabetes.  However, results for 
the association between the ARDB2 Arg16Gly polymorphism and blood lipid profile or blood pressure are 
equivocal and no final conclusions can be drawn. 
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Table 2.30: The association between the ADRB2 Arg16Gly polymorphism and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure.   
Population Indicators of glucose and insulin homeostasis Blood lipids and blood pressure (BP)  
 Associations No associations Associations No associations Reference 
Caucasian       
Sweden: non-obese healthy ♂ - glucose - TG, VLDL, TC, LDL, HDL, BP Ehrenborg et al. 2000 
Sweden ♂ - glucose, insulin Arg16Gly = ↑ SBP vs. 
Arg16Arg 
TG, TC, HDL, LDL, DBP Rosmond et al. 2000 
Sweden ♀ - glucose, insulin ni ni Large et al. 1997 
Danish DM2 = ↓ Gly16Gly Glucose, insulin, 2h glucose, 
insulin after OGTT 
Gly16Gly = ↓ SBP - Gjesing et al. 2007 
French Gly16 ♂ = ↓ insulin insulin in ♀, glucose - TG, TC Meirhaeghe et al. 2000 
French Gly16Gly ♂ = ↓ MetS, 
high glucose prevalence 
(NCEP ATPIII criteria) 
- Gly16Gly ♂ = ↓ prevalence 
of low HDL (NCEP ATPIII 
criteria) 
High TG, BP 
(NCEP ATP III) 
Dallongeville et al. 2003 
French-Canadian  ni ni Gly16Gly = ↑ TC,  
Gly16Gly ♂ = ↑ TC, LDL 
HDL, TG Ukkola et al. 2000 
UK Gly16Gly ♀ =  ↓ 30 min 
insulin increment 
Fasting insulin, glucose 
In ♂: 30 min insulin 
increment 
Gly16 ♀ = ↑ fasting NEFA, at 
30min, NEFA AUC 
Gly16Gly ♀ = ↓ TG  
TC, HDL, LDL. 
In ♂: TG, NEFA (fasting, 30 min, 
AUC)  
Meirhaeghe et al. 2001 
Italians - DM2 ni ni Pinelli et al. 2006 
American - glucose, insulin, HbA1c, 
HOMA-IR 
ni ni Lima et al. 2007 
Hispanic American      
Mixed ethnicity from Brazil:  
51% Mulatto, 35% Caucasian  
- glucose Gly16Gly = ↑ SBP TC, TG, LDL Pereira et al. 2003 
African       
African-American - glucose, insulin, HbA1c, 
HOMA-IR 
ni ni Lima et al. 2007 
Asian       
Japanese - glucose tolerance 
DM2 
- TC, TG 
BP 
Ishiyama-Shigemoto et al. 
1999 
Japanese ♂ with BMI>25 - - BP ↑ over 5 yrs = ↑ Gly16% - Kawaguchi et al. 2006 
Japanese ♂ with BMI<25 - HOMA-IR - BP Masuo et al. 2007 
Taiwanese Gly16 = ↓ DM2 
later onset of DM2 
- ni ni Chang et al. 2002 
Korean  Glucose, insulin, DM2 - LDL, HDL, TG, FFA, BP Kim et al. 2002 
ni = not investigated, MetS = Metabolic Syndrome, DM2 = Type 2 Diabetes Mellitus, TG = triglycerides, TC = Total Cholesterol, HOMA-IR = , HDL = High density lipoprotein, VLDL = Very low-
density lipoprotein, LDL = Low density lipoprotein, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, IDF = International Diabetes Federation, NCEP ATPIII = National Cholesterol 
Education Program Adult Treatment Panel III, NEFA = non-esterified fatty acids, OGTT = oral glucose tolerance test, AUC = area under curve. 
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2.7.8 Associations with weight loss outcomes  
 
Only one weight loss intervention that investigated the role of the Arg16Gly polymorphism and weight outcome 
was found (Table 2.31).  Japanese men (n=154) were enrolled in a two year weight loss intervention consisting of 
individual one hour teaching and counselling sessions every week in the first month and then biweekly for the 
rest of the 24 months (Masuo et al. 2005).  The main findings indicate that the mutant Gly16-allele carriers were 
resistant to weight loss or had a slower weight loss compared to the wild-type Arg16Arg homozygotes.  Although 
significant decreases were reported in all genotype groups from baseline to 24-month follow-up, the Gly16-allele 
carriers had higher BMIs at 24 months and a higher body fat mass, waist-hip-ratio, norepinephrine and leptin 
levels at baseline and throughout the study period.  This study points to the possibility that a weight loss 
intervention consisting of a high carbohydrate and low fat diet, exercise and nutrition education and counselling 
sessions is effective to reduce weight in Arg16Arg homozygotes (Masuo et al. 2005).   
 
The effect of the ADRB2 Arg16Gly polymorphism on changes in body fat content was measured in two 
independent studies (Garenc et al. 2003, Ukkola et al. 2003) using similar exercise programmes consisting of 
cycling sessions on ergometers three times a week for 20 weeks with an increasing intensity and duration 
protocol based on each subjects’ heart rate.  Ukkola et al. (2003) showed that Black subjects (n=205) who were 
Arg16-allele carriers experienced greater decreases in fat mass and abdominal total fat area.  Similarly, white 
Arg16Arg homozygous women experienced greater reductions in BMI, fat mass and body fat percentage 
following the 20-week exercise programme (Garenc et al. 2003). In contrast, Garenc et al. (2003) found no 
association in Black subjects between the Arg16Gly polymorphism and changes in BMI, fat mass, body fat 
percentage, sum of eight skinfolds, abdominal visceral or subcutaneous or total abdominal fat following the 
exercise intervention.  Furthermore, Ukkola et al. (2003) showed no association between the Arg16Gly 
polymorphism and body fat changes for white subjects (n=415), but they did notice a similar trend in Caucasians 
similar to that reported for Blacks (Ukkola et al. 2003) and Caucasian women (Garenc et al. 2003).  
 
The results point to the possibility that mutant Gly16-allele carriers are resistant to weight loss or decreases in 
body fat content when following a 24-month weight loss intervention or an exercise regime.  So far it has been 
shown that Japanese men with the wild-type Arg16Arg genotype benefit from following a 24-month weight loss 
intervention, while Black Arg16-allele carriers and White Arg16Arg women benefit from following an exercise 
regime.  Whether these results are applicable to all Caucasian, African and Asian populations still needs to be 
investigated.   
   
 113 
Table 2.31: The association between the ADRB2 Arg16Gly polymorphism and change in weight (BMI) and other variables following a weight loss intervention. 
Population Sample 
size 
Genotype 
frequencies 
Inclusion 
criteria 
Weight loss intervention Variables measured Results Reference 
Japanese ♂ 154 Arg16Arg=27% 
Arg16Gly=49% 
Gly16Gly=23% 
 
Gln27Gln=81% 
Gln27Glu=19% 
Glu27Glu=0% 
BMI≥25 
and 
BMI<30 
24 months intervention 
Private teaching & counselling 
sessions: 
 Month 1 = 1 session/ week  
 Next 23 months: 1 session 
biweekly. 
 
Diet =1600kcal/d, 15% fat, 55% 
carbohydrate, 30% protein. 
 
Exercise = >1h / day (recorded 
with step counters) 
BMI, total body FM, 
WHR, BP, heart rate, 
NE, Leptin, HOMA-IR 
Subjects divided in 4 groups: 1) weight loss maintenance 
group, 2) rebound weight loss group, 3) slow weight loss 
group, 4) weight loss resistance group 
 
Weight loss group = ↓ Gly16-allele frequency 
Weight loss group & rebound group = ↓ Glu27 
frequency 
 
Compared Arg16Arg vs. Gly16 allele carriers at baseline, 
6 and 12 months.  From baseline to 24 months both 
groups had significant ↓ in BMI, total body FM, WHR, 
DBP, NE, Leptin HOMA-IR.  However, Gly16 allele carriers 
had: 
 ↑ BMI at 24 months. 
 ↑ total body FM at baseline, 6 and 24 months 
 ↑ WHR at baseline and 24 months. 
 ↑ NE at baseline, 6 and 12 months 
 ↑ Leptin at baseline, 6 and 12 months 
 ↑ HOMA-IR at baseline. 
 
Compared Gln27Gln vs. Glu27 allele carriers at baseline, 
6 and 12 months.  From baseline to 24 months both 
groups had significant ↓ in BMI, total body FM, WHR, 
DBP, NE, Leptin.  However, Glu27 allele carriers had: 
 ↑ total body FM at baseline, 6 and 24 months. 
 ↑ NE at baseline, 6 and 12 months 
 ↑ Leptin at baseline, 6 and 12 months 
Masuo et 
al. 2005 
 
BMI = body mass index, WHR = waist-hip ratio, FM = fat mass, BP = blood pressure, NE = norepinephrine  
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2.8 G-protein β3 subunit gene (GNB3) 
 
2.8.1 The GNB3 gene 
 
The human GNB3 gene was first cloned in 1990 (Levine et al. 1990) and located to the short arm of chromosome 
12 (12p13) using somatic cell hybrids and in situ hybridization (NCBI, 2009; Modi et al. 1989, Levine et al. 1990).  
The GNB3 gene consists of 7183 bp and 11 exons (NCBI, 2009).   
 
2.8.2 The GNB3 protein 
 
The GNB3 gene encodes a β-subunit of the guanine nucleotide binding proteins (G-proteins) comprising of 340 
amino acids.   The G-proteins are heterotrimers consisting of three subunits namely the Gα-, Gβ-, and Gγ-
subunits.  In humans 21 Gα-subunits encoded by 17 genes, six Gβ-subunits encoded by five genes (including the 
β3-subunit or GNB3) and 12 Gγ subunits have been identified (Milligan & Kostenis 2006, Oldham & Hamm 2006).   
 
The amino acid sequences of the six Gβ-subunits share a 50 to 90% homology (Oldham & Hamm 2006).  The 
structure of the Gβ-subunits consist of seven bladed β-propellers (Figure 2.6) that are protein folds formed from 
a common structural motif, the WD 40 (tryptophan-aspartic acid) repeat domains on the genes encoding the Gβ-
proteins (Li & Roberts 2001, Milligan & Kostenis 2006, Oldham & Hamm 2006).  Each blade has four antiparallel 
β-strands with the WD 40 sequence forming the last three strands of a blade and the first strand of the next 
blade.  The final blade requires the first few sequences of the N-terminus to close the ring structure, while the 
remaining sequences on the N-terminus forms a α-helical coil that is essential for binding to the Gγ-subunits.   
 
 
Figure 2.6: The seven bladed β-propeller structure of the 
G-proteins (from Oldham & Hamm 2006). 
 
The Gβ- and Gγ-subunits cannot be expressed independently and exist as a functional dimer that is only 
dissociated from each other by denaturation (Jones et al. 2004, Oldham & Hamm 2006).  Most of the six Gβ-
subunits can interact with most of the 12 Gγ-subunits.  However not all 60 possible combinations of dimers form 
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and selectivity between specific Gβ- and Gγ-subunits has been identified (Oldham & Hamm 2006).  The Gβγ-
dimer binds to the Gα-subunit with high affinity to form the heterotrimeric αβγ G-protein and dissociates from 
the Gα-subunit upon activation. The conformation of the Gβγ-dimers remains constant whether it is in the 
heterotrimeric complex or in the free active dimer state (Cabrera-Vera et al. 2003).  However, distinct 
conformational changes are prevalent in the Gα-subunit when it is bound to the Gβγ-dimer as an inactive 
heterotrimer or when it exists as an activated Gα-subunit (Jones et al. 2004, Milligan & Kostenis 2006).  The G-
proteins are principally localized to the inner side of plasma membranes and expressed in all cells of the human 
body (Siffert 2005).  
 
2.8.3 Physiological function of GNB3 
 
The G-proteins are the most commonly used signal transducers in eukaryotic cells, allowing extracellular stimuli 
to induce signals across cell membranes and translating these into a cellular response, affecting 
neurotransmission, growth, differentiation or cell death (Siffert 2005, Koelle 2006). An interaction between the 
G-proteins and a guanine nucleotide exchange factor (GEF), of which the most common are the members of the 
GPCRs on cell membranes, is necessary for activation of the G-proteins and consequent signal transduction 
(Jones et al. 2004, Milligan & Kostenis 2006). 
 
In the basal state, the Gα-subunit is attached to GDP while the Gβγ-dimer is anchored to the inner side of the 
plasma membrane and associated to the GDP-bound Gα-subunit to form an inactive αβγ heterotrimer (Jones et 
al. 2004, Penn & Benovic 2008).  The binding of ligands such as hormones, neurotransmitters, chemokines, light 
and odorants to GPCRs facilitates coupling with the G-proteins.  All three subunits of the G-proteins are required 
for successful coupling to GPCRs that result in conformational changes in GPCRs, increasing the affinity thereof 
for the ligand.  The activated GPCRs act as a GEF and consequently induce a structural change to the Gα-subunit, 
resulting in the release of GDP and the binding of GTP to the Gα-subunit.  This binding destabilizes the 
heterotrimer, followed by the dissociation of the activated G-protein from GPCRs and the formation of a Gα-
subunit-GTP complex and a Gβγ complex.  Both these complexes can then activate or inhibit several 
downstream effector proteins such as adenylyl cyclases, phospholipase Cb (PLCb), tyrosine kinases, 
phosphodiesterases, phosphoinositide 3-kinase, GPCR kinases, ion channels, and molecules of the mitogen-
activated protein kinase pathway, resulting in the initiation of signal transduction cascades and a variety of 
cellular functions.  To terminate these effector activation cellular processes, the intrinsic GTPase activity of the 
Gα-subunit hydrolyses GTP to GDP.  The αβγ subunits will then re-associate to form the inactive GDP bound 
Gαβγ heterotrimer to complete the cycle of signal transductions.  The intrinsic GTPase activity of the Gα-subunit 
can be accelerated by RGS (regulators of G-protein signalling) proteins, which consequently modulate the 
duration of signalling events (Cabrera-Vera et al. 2003, Jones et al. 2004, Milligan & Kostenis 2006, Oldham & 
Hamm 2006, Bagos et al. 2007, Penn & Benovic 2008, Vogler et al. 2008).   
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Figure 2.7: The activation of G-proteins through the binding of a ligand to GPCRs (from 
Cabrera-Vera et al. 2003). 
 
The G-proteins are typically divided into four different subfamilies based on sequence homology, with each 
subfamily activating or inhibiting specific downstream effector proteins (Riobo & Manning 2005, Oldham & 
Hamm 2006, Penn & Benovic 2008): 
 Gs-proteins (including Gs and Golf ) activate adenylyl cyclase,  
 Gi/o-proteins (including Gi1, Gi2, Gi3, Go1, Go2, Gz, Gt1, Gt2, and Ggust) inhibit adenylyl cyclase, 
 Gq/11-proteins (including Gq, G11, G14, and G15/16) activate phospholipase C (PLC), 
 G12/13-protein (including G12 and G13) activate Rho guanine nucleotide exchange factors (RhoGEFs), Na
+ H+ 
exchangers, and PLC-ε. 
 
The G-proteins are also located on the cell membranes of WAT where they interact with GPCRs and the 
adrenergic receptor, transducing signals that affect lipolysis in the adipocytes as described in Section 2.6.3, p87. 
 
2.8.4 The GNB3 C825T polymorphism 
 
A synonoumous polymorphism in exon 10 of the GNB3 gene results in a C to T transition at nucleotide position 
825 without causing a change in Serine amino acid at codon 275 (Ser275Ser) of this gene (Siffert et al. 1998).  
Although this polymorphism does not affect the amino acid sequence, the mutant 825T allele causes the 
generation of GNB3 splice variants (Siffert 2005).  Siffert et al. (1998) identified a truncated GNB3 splice variant 
(GNB3s) in which nucleotides 498 to 620 of exon 9 are deleted due to alternative splicing. This in-frame deletion 
is associated with the 825T allele and results in a variant GNB3 protein lacking 41 amino acids and one of its 
seven WD repeat domains (Siffert et al. 1998).  Another GNB3 splice variant, designated GNB3s-2, is formed 
when alternative splicing causes the deletion of 129 bp in the coding sequence of the wild-type GNB3 protein.  
The expression of GNB3s-2 mRNA in the heart, blood cells and tumor tissue correlates with the 825T allele 
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(Rosskopf et al. 2003a).  Both these truncated GNB3 splice variants result in the expression of a protein that now 
consists of a six-bladed β-propeller structure instead of the seven-bladed wild-type GNB3 protein (Siffert et al. 
1998, Rosskopf et al. 2003a).  A third splice variant, GNB3v, is generated when alternative splicing of intron 9 
causes the formation of a new exon 10a and consequently the GNB3v protein is expressed with four WD repeat 
domains and a novel C terminus (Rosskopf et al. 2003b). However, GNB3v was not found to be associated with 
an allele of the GNB3 C825T polymorphism, and therefore it was suggested that GNB3v does not contribute to 
the phenotypes observed in association with the 825T-allele (Rosskopf et al. 2003b). 
 
The GNB3 splice variants have been associated with enhanced activation of the G-proteins, which ultimately 
increases G-protein signalling (Siffert et al. 1998, Rosskopf et al. 2003a, Rosskopf et al. 2003b).  This was 
observed in COS-7 cells and Sf9 insect cells in which the over-expression of the GNB3s variant resulted in 
enhanced GTPγS binding (Siffert et al. 1998) and increased chemotaxis (Virchow et al. 1999) respectively.   It was 
also shown that the GNB3s variant could form dimers with various other Gγ-subunits than the wild-type GNB3 
(Rosskopf et al. 2003a).  Furthermore, ex vivo studies showed that humans who are 825T-allele carriers exibited 
enhanced features of signal transduction such as enhanced chemokine-stimulated chemotaxis and proliferation 
in neutrophils and lymphocytes (Virchow et al. 1998, Lindemann et al. 2001) and enhanced epinephrine-induced 
platelet aggregation (Naber et al. 2000).  It was further indicated that the 825T-allele is associated with altered 
modulation of acetylcholin-activated K+ channels in atrial myocytes (Dobrev et al. 2000).  Siffert (2005) concludes 
that sufficient studies support the fact that the 825T-allele is a valid genetic marker associated with increased G-
protein signal transduction. 
 
The exact physiological role of the GNB3 825T variant in the development of obesity is not fully understood.  It 
has been suggested that the predisposition to obesity may result from the observed decreased catecholamine 
induced lipolysis in adipose tissue of the 825T variant GNB3 (Hauner et al. 2002, Rydén et al. 2002).  Rydén et al. 
(2002) investigated the influence of the GNB3 C825T polymorphism on lipolysis in isolated subcutaneous fat cells 
from 114 obese subjects.  These authors showed that TT homozygous subjects had lower circulating free fatty 
acids and glycerol and decreased β-adrenoceptor agonist-stimulated lipolysis.  More specifically, it was found 
that norepinephrine induced lipolysis was reduced in adipocytes of GNB3 TT homozygotes (Rydén et al. 2002).  
This finding was supported by Hauner et al. (2002) who showed decreased catecholamine induced lipolysis in 
the adipose tissue collected from ten women who are T-allele carriers compared to ten CC homozygotes.  The 
C825T polymorphism was not associated with adipocyte differentiation in the adipose tissue collected from a 
larger sample of 65 women (Hauner et al. 2002).  Although these findings are not in line with increased signal 
transduction associated with the GNB3 splice variants that would be expected to result in increased lipolysis, 
Ruiz-Velasco and Ikedal (2003) hypothesized that obesity and other resultant phenotypes may be due to a lack 
of the functional wild-type GNB3 protein rather than increased activation of the mutated GNB3 protein.  This is 
supported by the finding of Rydén et al. (2002) that the GNB3 protein content in adipocytes of TT homozygous 
subjects was markedly reduced.  However, more research is required to elucidate the physiological function of 
the GNB3 splice variants and how this contributes to the development of obesity (Vogler et al. 2008). 
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2.8.5 Genotype and allele frequencies 
 
The wild-type CC genotype is almost absent in populations from African descent, but found at a frequency in the 
range of 22 to 29 % in Asian populations (Table 2.32).  In most Caucasian populations the CC and CT frequencies 
are found in similar ranges around 45%.  The lowest frequency of the mutant TT genotype is found in Caucasian 
populations (around 10%), while populations with African ancestry show the highest frequency (around 60%), 
with Asian populations having an intermediate frequency (around 20%).  Consequently, the lowest 825T-allele 
frequency is found in Caucasians, while an intermediate frequency is reported for Asians and the highest 
frequency are found in African descendants. 
 
Table 2.32: Genotype frequencies of the GNB3 C825T polymorphism and the frequency of the mutant T-allele.  
Population Weight or disease status n CC 
% 
CT 
% 
TT 
% 
T- 
allele 
References 
Caucasian         
Caucasians*  3289 45 44 11 33 Siffert et al. 1999a 
Belgium  1512 47 44 9 31 Brand et al. 2003 
Italy  1359 45 43 12 33 Casiglia et al. 2008 
  794 49 42 9  Gutersohn et al. 2000 
German HT  
Lean HT sub-sample 
Overweight HT sub-sample 
Obese HT sub-sample 
197 49 
60 
45 
40 
41 
32 
46 
40 
10 
8 
8 
20 
31 
24 
31 
10 
Siffert et al. 1999b 
German:  mothers 
     babies 
 181 
113 
41 
45 
49 
41 
10 
14 
 Hocher et al. 2000 
German ♂  277 46 44 10 32 Siffert et al. 1999a 
German  774 45 45 10 32 Stefan et al. 2004 
German Controls 
CAD pt all 
CAD with MI 
733 
2583 
1370 
49 
50 
48 
41 
41 
42 
10 
9 
10 
 Renner et al. 2007 
Spain Essential hypertensive 130 45 47 8  Poch et al. 2002 
Spain Essential hypertensive 
Normotensive 
76 
78 
33 
37 
55 
46 
12 
17 
 Martín et al. 2005 
Austrian  932 47 45 8 31 Wascher et al. 2003 
Scandinavian obese 114 54 39 7  Rydén et al. 2002 
Danes Glucose-tolerant 4723 49 41 10 30 Andersen et al. 2006 
Danes DM2  1358 46 46 9 32 Andersen et al. 2006 
Danes  Normotensive 4193 48 42 10 31 Andersen et al. 2006 
Danes Hypertensive 3139 49 41 10 30 Andersen et al. 2006 
Italian Grade I HT 461 48 44 8  Sartori et al. 2003 
Brazilian Caucasian  548 42 44 14 36 Danoviz et al. 2006 
Australian Obese 
Non-obese 
92 
189 
52 
53 
40 
43 
8 
3 
28 
0.25 
Benjafield et al. 2001 
Australian  BMI>25 & normotensive 
BMI≤25 & normotensive  
84 
105 
56 
50 
42 
45 
2 
5 
27 
23 
Benjafield et al. 2001 
Australian BMI>25 & HT 
BMI≤25 & HT 
55 
56 
16 
30 
69 
63 
15 
7 
49 
38 
Benjafield et al. 2001 
Americans  10988 48 43 9 31 Grove et al. 2007 
Americans ♀ Suspected CHD 485 54 40 6 27 Terra et al. 2005 
Hispanic American        
Mexican HT 180 41 46 13 36 Kopf et al. 2008 
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Table 2.32: continued 
Population Weight or disease status n CC 
% 
CT 
% 
TT 
% 
T- 
allele 
References 
Native American        
Canadian Nunavut 
Inuit 
 213 22 54 24 50 Hegele et al. 1999 
Brazilian Mulatto  795 26 51 23 51 Danoviz et al. 2006 
Canadian Oji-Cree  447 21 58 21 50 Hegele et al. 1998 
Amerindians*  245 53 40 7 26 Siffert et al. 1999a 
African         
Black Africans*  1015 4 34 62 79 Siffert et al. 1999a 
African-Americans  175 6 38 56  Poston et al. 2002 
African-Americans  3728 7 38 54 73 Grove et al. 2007 
African-Americans ♀ Suspected CHD 94 7 29 64 79 Terra et al. 2005 
South African Black ♂  254 2 28 70  Siffert et al. 1999a 
Namibian Bushmen  97 9 47 41 66 Siffert et al. 1999a 
Zimbabwean Black ♂  459 3 30 67  Siffert et al. 1999a 
West Africans & 
Caribbean’s 
 428 4 34 62 79 Dong et al. 1999 
West Africans  158 3 30 67  Dong et al. 1999 
Caribbean’s  270 5 35 60  Dong et al. 1999 
Brazilian Africans  122 14 47 39 37 Danoviz et al. 2006 
Asian         
Japanese  806 29 45 27 49 Yamamoto et al. 2004 
Japanese DM2  
Random healthy sample 
427 
368 
29 
23 
46 
49 
25 
28 
48 
47 
Hayakawa et al. 2007 
Japanese Extremely obese (BMI>30) 
Controls 
208 
150 
28 
25 
48 
49 
24 
26 
48 
51 
Ohshiro et al. 2001 
Japanese ♂ Normal weight  
Overweight 
1131 
322 
25 
25 
52 
50 
23 
25 
49 
50 
Suwazono et al. 2004 
Japanese ♀ Normal weight  
Overweight 
989 
183 
25 
28 
55 
50 
20 
22 
48 
47 
Suwazono et al. 2004 
Chinese HT 
Controls 
585 
580 
23 
22 
50 
52 
27 
26 
52 
52 
Huang et al. 2003 
Korean ♂ Obese (BMI>25) 
Non-obese (BMI≤25) 
152 
130 
26 
25 
57 
52 
17 
23 
45 
49 
Lee et al. 2005b 
Chinese EH 
NT 
290 
244 
22 
24 
50 
49 
28 
27 
47 
48 
Wang et al. 2005 
Chinese ♂  960 27 51 22 48 Siffert et al. 1999a 
Asian*  520 28 53 19 46 Siffert et al. 1999a 
*Includes populations from various countries, HT = hypertension, CAD = coronary artery disease, MI = myocardial 
infarction, DM2 = Type 2 diabetes mellitus, CHD = coronary heart disease, EH = essential hypertension, NT = 
normotension, BMI = body mass index.  
 
 
2.8.6 Associations with obesity related phenotypes 
 
Weight, BMI and obesity 
Studies that have found a positive association between the GNB3 C825T polymorphism and weight status (Table 
2.33) indicated that the 825T-allele or TT genotype are associated with post-pregnancy weight retention 
(Gutersohn et al. 2000) and a higher obesity prevalence or risk for obesity development in Caucasians (Siffert et 
al. 1999a, Siffert et al. 1999b, Brand et al. 2003).  Various studies have also reported a higher BMI for the TT 
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homozygous genotype or T-allele carriers (Siffert et al. 1999a, Siffert et al. 1999b, Benjafield et al. 2001, Poch et 
al. 2002, Stefan et al. 2004, Casiglia et al. 2008).  However, eight of the 17 studies performed in Caucasians could 
not replicate these associations.  A recent meta-analysis including 18903 subjects from 18 studies (of which 12 
studies were performed in Caucasians, three in Asians, one in Africans and two in subjects with mixed ancestry) 
published from 1999 to 2007, found a non-significant trend (p=0.053) towards a higher BMI in TT homozygotes 
(Souza et al. 2008).   
 
Only one of the six studies in populations with African ancestry summarized in Table 2.34 found an association 
between the 825T allele and a higher overweight (BMI≥25) and obesity (defined as BMI>27) prevalence in a 
South African Black population (Siffert et al. 1999a). These authors also proposed that the risk of obesity in 
Blacks is only increased when an obesogenic environment and the mutant 825T allele of GNB3 co-exist.  By 
comparing the BMIs of rural Black Zimbabweans and urban Black Zimbabweans and South Africans, Siffert et al. 
(1999a) found that the frequencies of the 825T allele were similar in the rural and urban Blacks.  However the 
overweight and obesity prevalence was lower in the rural Blacks who follow a traditional low fat, high maize 
meal and vegetable diet and have high physical activity levels.   
 
For Asian populations the majority of studies (seven out of eight) found no association between the GNB3 C825T 
polymorphism and obesity or BMI. 
 
In summary, the mutant 825T-allele may predispose Caucasian populations to weight gain and obesity.  However, 
the GNB3 C825T polymorphism does not seem to influence the weight of individuals with African or Asian 
ancestry.   
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Table 2.33: The association between the GNB3 C825T polymorphism and weight, BMI and obesity.   
Population  Weight or disease  n Study design Associations with obesity Associations with BMI Reference 
 status   Yes No Yes No  
Caucasian          
Belgium  1512 Population based T-allele ♂= ↑ 
obesity 
TT ♂= ↑ obesity 
- ni ni Brand et al. 2003 
Italian  fertile ♀ 173 Population based ni ni TT = ↑ BMI - Casiglia et al. 2008 
Italian  menopausal ♀ 575 Population based ni ni -  Casiglia et al. 2008 
Italian  fertile vs. menopausal 
♀ 
748 Population based ni ni CC menopausal ♀ = 
↑ BMI vs. CC fertile 
♀ 
between TT or TC ♀ Casiglia et al. 2008 
 Nulliparous and 
primiparous ♀ 
794 Cross-sectional Primiparous TT = 
↑ overweight 
  
in 
nulliparous  
Primiparous TT + low 
PA = ↑ BMI  
in nulliparous with 
low/ high PA 
in primiparous with 
high PA 
Gutersohn et al. 2000 
Austrian  932 Population-based -  -  Wascher et al. 2003 
German   774 Population based ni ni TT+TC = ↑ BMI - Stefan et al. 2004 
German ♂  277 Population based obesity = ↑ TT & 
T-allele 
- TT = ↑ BMI 
TT+TC = ↑ BMI 
- Siffert et al. 1999a 
German  HT pt 197  TT = ↑ obesity - TT = ↑ BMI - Siffert et al. 1999b 
German  controls 
CAD pt 
733 
2583 
Cross-sectional ni ni -  Renner et al. 2007 
German:  mothers 
    babies 
 181 
113 
 ni ni TC moms had babies 
with ↓ birthweight 
- Hocher et al. 2000 
Danes  glucose-tolerant 4387 Population based -  -  Andersen et al. 2006 
Spain  130  ni ni TT+TC = ↑ BMI - Poch et al. 2002 
Spain  HT 76 Hypertensive pt ni ni -  Martín et al. 2005 
Scandinavian obese 113  ni ni -  Rydén et al. 2002 
American ♀  485 Suspected CHD -  -  Terra et al. 2005 
Americans  10988 Population-based -  ni ni Grove et al. 2007 
Australian:   obese 
non-obese 
92 
189 
Case-control -  T carriers = ↑ BMI - Benjafield et al. 2001 
Australian:   normotensive BMI>25 
normotensive BMI≤25 
84 
105 
Case-control -  -  Benjafield et al. 2001 
Australian:  hypertensive BMI>25 
hypertensive BMI≤25 
55 
56 
Case-control -  -  Benjafield et al. 2001 
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Table 2.33: continued 
Population  Weight or disease  n Study design Associations with obesity Associations with BMI Reference 
 status   Yes No Yes No  
Hispanic American          
Mixed Brazilian 
population: African, 
Caucasian, Mulatto  
 1568 Cross-sectional -  -  Danoviz et al. 2006 
African          
West-Africans + 
Carribeans 
 428 Population based ni ni -  Dong et al. 1999 
RSA Blacks  254 Population based T allele = ↑ %  
BMI>25 
- ni ni Siffert et al. 1999a 
Zimbabwean Blacks  459 Population based -  ni ni Siffert et al. 1999a 
African-American ♀  94 Suspected CHD -  -  Terra et al. 2005 
African-Americans  3728 Population based -  ni ni Grove et al. 2007 
African-Americans  175 Randomly 
selected 
ni ni -  Poston et al. 2002 
Native American         
Nunavut Inuit  213 Cross-sectional - - TT = ↑ BMI - Hegele et al. 1999 
Canadian Oji-Cree  447 Population-based ni ni -  Hegele et al. 1998 
Asian          
Japanese  806 Cross-sectional? -  -  Yamamoto et al. 2004 
Japanese  DM 427  ni ni -  Hayakawa et al. 2007 
Japanese  368  ni ni -  Hayakawa et al. 2007 
Japanese:  overweight & normal 2625 Case-control -  ni ni Suwazono et al. 2004 
Japanese:  obese & non-obese 358 Case-control -  -  Ohshiro et al. 2001 
Chinese   HT & controls 1165 Case-control ni ni -  Huang et al. 2003 
Korean:  obese & non-obese 282 Case-control -  -  Lee et al. 2005b 
China:   534 Case-control ni ni -  Wang et al. 2005 
Chinese   960 Population based T allele = ↑ %  
BMI>25 
- ni ni Siffert et al. 1999a 
BMI = body mass index, DM2 = Type 2 diabetes mellitus, ♀ = female, ♂ = male, CHD = coronary heart disease, NGT = normal glucose tolerance, HT = hypertension 
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Measures of body fat distribution and content 
Studies investigating the association between the GNB3 C825T polymorphism and body fat distribution or body 
fat content were mostly performed on Caucasians (Table 2.34).  The TT homozygous genotype was found to be 
associated with higher triceps skinfolds in Belgian males (Brand et al. 2003) and Italians and a higher body fat 
percentage in Germans (Stefan et al. 2004).  Furthermore, pre-menopausal Italian TT homozygous females had 
higher triceps, supra-iliac and subscapular skinfolds and mean skinfold thickness compared to C-allele carriers.  
However, no differences in skinfold measurements were found between the genotype groups of menopausal 
females (Casiglia et al. 2008).  When the skinfold measurements and genotypes of pre-menopausal Italian and 
menopausal women were compared, the only differences were observed between the CC homozygous group, 
while all women in the other genotype groups had similar measurements.  The CC menopausal women showed a 
higher prevalence of truncal obesity and higher skinfold thickness compared to CC pre-menopausal women 
(Casiglia et al. 2008).  Therefore, although the CC homozygous women seem to be protected from a higher body 
fat content when younger, they might be at risk for gaining body fat after menopause, explaining the 
disappearance of the difference in fat content between genotype groups.  However, TT homozygous women are 
at risk for higher fat content already during their pre-menopausal years, which remains high in the TT 
menopausal women.  It might therefore be important to target TT homozygous women for weight management 
interventions during their younger years. 
 
A number of studies have not found any relationship between the GNB3 C825T polymorphism and waist 
circumference or weight-to-hip ratio in Caucasians (Stefan et al. 2003, Wascher et al. 2003, Terra et al. 2005, 
Andersen et al. 2006, Danoviz et al. 2006, Kopf et al. 2008), African-Americans (Terra et al. 2005), Japanese with 
Type 2 diabetes (Hayakawa et al. 2007) and Koreans (Lee et al. 2005b).    
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Table 2.34: The association between the GNB3 C825T polymorphism and measures of body fat distribution and 
content. 
Population Associations No associations Reference 
Caucasian     
Belgium TT ♂ = ↑ Triceps SF In ♀ Brand et al. 2003 
Italians TT = ↑ triceps SF, MST subscapular, suprailiac SF Casiglia et al. 2008 
Italian fertile ♀ TT = ↑ MST, triceps suprailiac, 
subscapular SF 
- Casiglia et al. 2008 
Italian menopausal ♀ - MST, subscapular, triceps, 
suprailiac SF 
Casiglia et al. 2008 
Italian fertile vs. 
menopausal ♀ 
CC menopausal ♀ = ↑ truncal 
obesity %, MST, subscapular, 
triceps, suprailiac SF 
- Casiglia et al. 2008 
Austrian - WHR Wascher et al. 2003 
German  T carriers = ↑ body fat % WHR Stefan et al. 2004 
Danes glucose tolerant - WHR Andersen et al. 2006 
American ♀ - WHR, WC Terra et al. 2005 
Hispanic American     
Mixed Brazilian‡  - WHR Danoviz et al. 2006 
Mexicans - WHR Kopf et al. 2008 
African     
African-American - WHR, WC Terra et al. 2005 
Native American    
Canadian Nunavut Inuit TT = ↑ WC, HC, triceps, 
subscapular SF 
WHR Hegele et al. 1999 
Asian     
Japanese DM2 pt - WC, VFA, SFA Hayakawa et al. 2007 
Koreans - Body fat %, WC, WHR Lee et al. 2005b 
‡ Consisting of Caucasian, African and Mulatto ancestry, WC = waist circumference, WHR = waist-to-hip ratio, MST = 
mean skinfold thickness, SF = skinfold. 
 
 
2.8.7 Associations with health indicators  
 
Indicators of glucose and insulin homeostasis 
Associations were reported between the TT homozygous genotype and higher fasting glucose and insulin levels, 
HbA1c, insulin resistance and Type 2 diabetes prevalence in Caucasian populations (Poch et al. 2002, Brand et al. 
2003, Wascher et al. 2003, Andersen et al. 2006).  However, in contrast one report indicated an association in 
the opposite direction with TT homozygous Mexicans having a better glucose homeostasis profile (Kopf et al. 
2008).  In Asians, the GNB3 C825T polymorphism does not seem to influence glucose homeostasis (Table 2.35). 
 
Blood lipid profile and blood pressure 
The role of the GNB3 C825T polymorphism on hypertension pathogenesis and its association with hypertension 
prevalence and blood pressure measurements have been investigated intensively over the years (Bagos et al. 
2007).  Although Table 2.35 does not provide a complete summary of all the association studies published, it 
does point to the fact that discrepancy in results exists.  Siffert (2005) pointed to study design limitations that 
contribute to the controversy in the literature.  The latter review concluded that the majority of studies 
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confirmed a positive association between the 825T-allele carriers and an increased risk for hypertension in 
Caucasians, but that results for Asian populations were still controversial (Siffert 2005).  This view was supported 
by a meta-analysis of 34 papers published before the end of February 2006 on the association between the 
GNB3 gene and hypertension, including 14094 hypertensive cases and 17760 controls (Bagos et al. 2007).  These 
authors confirmed that the TT homozygous genotype is associated with a higher risk for hypertension in 
Caucasians but not in Asian populations (Bagos et al. 2007). 
 
From Table 2.35 it is clear that the GNB3 C825T polymorphism may not influence blood lipid profile as no 
positive associations were reported.  According to the review by Siffert (2005) a few studies did report positive 
associations between the GNB3 C825T polymorphism and atherosclerosis as well as its main consequences, 
namely stroke and myocardial infarction.  It was found that the 825T allele carriers had increased cardiac stroke 
volume, arterial stiffness, radial artery hypertrophy, carotid artery plaque causing atherosclerosis, stroke risk, 
unstable angina, severity of coronary artery disease, risk for three-vessel disease and the constriction of 
coronary arteries in response to pharmacological stimulation (Siffert 2005).  Although some have indicated an 
association with increased MI, other studies did not repeat these findings (Siffert 2005). 
 
In summary, the GNB3 C825T polymorphism does not seem to influence blood lipid profile, but possibly CVD risk.  
However, the TT homozygous Caucasians have a higher risk for hypertension, secondary to obesity, while these 
associations are still contradictory in Asian populations.  
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Table 2.35: The association between the GNB3 C825T polymorphism and indicators of glucose and insulin homeostasis, blood lipid profile and blood pressure. 
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP) Reference 
 Associations No associations Associations No associations  
Caucasian populations      
Belgium ♂ TT  = ↑ insulin, HOMA-IR glucose TT  = ↑ BP - Brand et al. 2003 
Belgium ♀ - glucose, insulin, HOMA-IR - BP Brand et al. 2003 
Italian ♀ - DM2 - HT Casiglia et al. 2008 
Italian fertile ♀ - glucose, DM2, insulin, 
HOMA-IR 
TT = ↑ SBP TC, HDL, TG, DBP Casiglia et al. 2008 
Italian menopausal ♀ - glucose, DM2, insulin, 
HOMA-IR 
- TC, HDL, TG, BP Casiglia et al. 2008 
Spain HT pt - glucose - BP, TG, TC Martín et al. 2005 
Spain: hypertensive TT+TC =↑ insulin, 2h glucose, 
HbA1c and ↓ ISI 
glucose - TC, TG, LDL, HDL Poch et al. 2002 
Austrian T carriers: 
all = ↑ glucose, insulin 
♂ & WHR>0.9 = ↓ insulin 
sensitivity (not in ♀) 
DM2 - TC, TG, HDL, LDL, BP, HT Wascher et al. 2003 
German CAD pt & controls ni ni - BP, CAD, MI, HT,  Renner et al. 2007 
German HT pt  ni ni - MI, stroke, all CVE Siffert et al. 1999b 
German TT = ↑ FFA glucose, insulin, FFA, ISI. 
OGTT: 2h glucose, insulin.  
ni ni  
Danes glucose tolerant DM2 = ↑ % T carriers vs. 
glucose-tolerant subjects 
glucose, insulin, OGTT: 30min 
& 2h & AUC for glucose & 
insulin, HOMA 
TT = ↓ SBP, DBP TC, TG, HDL, LDL, HT Andersen et al. 2006 
Italian HT pt - glucose - TC, TG, HDL, BP Sartori et al. 2003 
Americans ni ni - HT Grove et al. 2007 
Hispanic American      
Mixed Brazilians‡ - DM % Obese T carriers = ↑ SBP vs. 
obese CC 
BP, HT, TC, LDL, HDL, VLDL, 
TG 
Danoviz et al. 2006 
Mexicans TT = ↓ glucose, ↑ insulin 
sensitivity 
- - BP, TC, TG HDL, LDL Kopf et al. 2008 
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Table 2.35: continued 
Population Glucose and insulin homeostasis Blood lipids and blood pressure (BP) Reference 
 Associations No associations Associations No associations  
Native American      
Canadian Nunavut Inuit ni ni - BP, HT Hegele et al. 1999 
Canadian Oji-Cree ni ni TT = ↓ SBP  Hegele et al. 1998 
African       
African-American ni ni - HT Grove et al. 2007 
Asian       
Japanese - glucose, DM2 TT = ↑ SBP 
TT = ↓ % with no disorders 
(including obesity, HT, DM2, 
hypertriglyceridemia) 
TC, TG, HT,  Yamamoto et al. 2004 
Japanese DM2 pt - glucose, HbA1c, duration of 
DM, DM complications 
- HT Hayakawa et al. 2007 
Japanese - glucose, HOMA-IR, FFA TT = ↓ DBP TC, TG, HDL, SBP Hayakawa et al. 2007 
Chinese HT or cases - glucose - TC, TG, LDL, HDL, BP Huang et al. 2003 
Korean BMI>25 ni ni TT = ↑ SBP, ↓ VO2max DBP Lee et al. 2005b 
Korean BMI≤25 ni ni - BP, VO2max Lee et al. 2005b 
Chinese EH & NT - glucose - TG, TC, BP, HT Wang et al. 2005 
‡ Consisting of Caucasian, African and Mulatto ancestry, DM2 = Type 2 Diabetes Mellitus, TG = triglycerides, TC = Total Cholesterol, HOMA-IR = Homeostasis model assessment of insulin 
resistance, HDL = High density lipoprotein, VLDL = Very low-density lipoprotein, LDL = Low density lipoprotein, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, FFA = free fatty 
acids, CAD = Coronary artery disease, OGTT = oral glucose tolerance test, AUC = area under curve, ISI = insulin sensitivity index, MI = myocardial infarction. 
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2.8.8 Associations with weight loss outcomes  
 
Two weight loss interventions investigating the association between the GNB3 C825T polymorphism and weight 
loss outcome were traced (Table 2.36).  Both studies were performed on Caucasian populations using different 
weight loss interventions, including bariatric surgery (Potoczna et al. 2004) and Sibutramine treatment (Hauner 
et al. 2003).  Both studies involved long-term follow-up of these patients.  The patients undergoing bariatric 
surgery were prospectively followed for three years following the surgery and received the same initial and 
follow-up weight management information from a multidisciplinary health team.  After three years, all patients, 
irrespective of the GNB C825T polymorphism, experienced the same weight loss and therefore this study 
concluded that this variant does not influence weight loss outcome (Potoczna et al. 2004).  Although it was also 
mentioned that patients who experienced insufficient weight loss after the bariatric surgery were in addition 
treated with Sibutramine, Orlistat or a re-operation to improve weight loss, the number of patients receiving 
these additional treatment interventions did not differ between the genotype groups (Potoczna et al. 2004).  In 
contrast, Hauner et al. (2003) reported an association between the GNB3 C825T polymorphism and weight loss 
outcome in patients who were randomly assigned to a Sibutramine or placebo treatment intervention for 54 
weeks.  Both groups received individualized counselling sessions from a dietitian, a weight loss diet, 16 physical 
activity group sessions and four educational sessions on healthy eating, behaviour modification and motivation 
(Hauner et al. 2003).  Long-term follow-up measurements were taken two years after the termination of the 54-
week intervention.  It was found that patients with the TT or TC genotype benefited from the conservative 
weight loss intervention without pharmacological intervention, while CC homozygous patients only benefited 
from Sibutramine therapy to lose weight (Hauner et al. 2003).  
 
Several studies investigated the associations between the GNB3 C825T polymorphism and the effects of exercise 
on obesity development.  Grove et al. (2007) pointed out that TT homozygous African-Americans may especially 
benefit from physical activity to decrease their risk for obesity development.  Using the Baecke physical activity 
questionnaire, these authors found that in African-Americans with low physical activity levels, each 825T allele 
contributes to a 23% higher obesity prevalence and therefore the TT homozygous subjects had the highest risk 
for obesity compared to the CC and CT subjects.  However, in the high physical activity group the TT homozygous 
subjects had the lowest risk for obesity with each 825T allele being associated with a 20% lower obesity 
prevalence.  In contrast, the CC subjects with high or low physical activity levels had the same relative risk for 
obesity development (Grove et al. 2007).  In this research it was also shown that TT homozygous African-
Americans may also benefit from being active and lean to decrease their risk for hypertension.  The TT 
homozygotes who were either obese or inactive or both had a higher relative risk for hypertension, while TT 
homozygotes who were active and non-obese had a decreased hypertension risk (Grove et al. 2007).  Rankinen 
et al. (2002) found that a 20-week endurance exercise programme was associated with greater decreases in fat 
mass and percentage body fat in TT homozygous African-Americans compared to C-allele carriers.   Poston et al. 
(2002) reported that TT homozygous subjects with African ancestry were more obese than C-allele carriers 
regardless of their physical activity levels.  Inconclusive results were also reported for Caucasian populations 
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with no associations between physical activity, obesity, body fat content or hypertension found in large samples 
including 10988 (Grove et al. 2007) and 473 (Rankinen et al. 2002) Caucasian-Americans.  In contrast, Gutersohn 
et al. (2000) reported that high physical activity levels counteracted the susceptibility to a higher BMI after 
pregnancy in Caucasian TT homozygous women.  However, when TT homozygous women were physically 
inactive, they suffered from a significantly higher post-pregnancy BMI as well as weight retention (Gutersohn et 
al. 2000).  These findings are in line with those reported by Hauner et al. (2003) that TT homozygous Caucasian 
subjects benefit from a conservative weight loss intervention (that includes physical activity) to lose weight.  In 
populations with Asian ancestry, no association was found between the GNB3 C825T polymorphism, exercise 
duration, obesity and hypertension prevalence in Korean obese and non-obese men.  However, it was shown 
that obese TT homozygous men and non-obese 825T carriers had a lower VO2 max than the other genotype 
groups (Lee et al. 2005b). 
 
In summary, in Caucasians one study found that the GNB3 C825T polymorphism had no effect on weight loss 
outcome.  The other study suggests that patients with the TT or TC genotype lose weight with a conservative 
weight loss intervention while CC homozygotes need in addition to this also Sibutramine to lose weight.  Exercise 
interventions in Caucasian and African Americans also point in the direction that TT homozygous individuals may 
benefit from exercise to prevent obesity development or to decrease fat mass and percentage body fat.  More 
research is needed to confirm these results and to investigate these associations in other populations.   
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Table 2.36: The association between the GNB3 C825T polymorphism and change in weight (BMI) and other variables following a weight loss intervention. 
Population Sample 
size 
Genotype 
frequencies 
Inclusion 
criteria 
Weight loss intervention Variables measured Results Reference 
Caucasian: 
Switzerland 
 
 
N=304 
 
♀= 246 
♂= 58 
 
TT=13% 
CC=47% 
TC=40% 
 
BMI≥35 
 
 
 
 Gastric banding surgery pt followed 
prospectively for 3 years. 
 Pt was assessed by physician, bariatric 
surgeon, dietician, psychologist before 
operation. 
 Office visits & weighing (no indication 
how often) 
 No further description. 
 Bariatric surgery: gastric banding and 
pt with insufficient weight loss (defined 
in article) was also treated with 
Sibutramine (n=37; 12.2% of pt) for 
8.3±1.0 months or Orlistat (n=72; 
23.7% of pt) for 14.9±1.9 months or 
reoperation (n=74). 
Measured at 0 & 36 months:  
Weight loss (kg), change in 
BP, change in HT %, nr of 
reoperations, nr treated with 
sibrutamine, nr treated with 
orlistat 
No significant association between the CC, TC, 
and TT genotype groups for these variables. 
 
Weight loss = 32.4 kg (CC), 30.8 kg (CT), 31.2 kg 
(TT)  
Potoczna et 
al. 2004 
Caucasian: 
Germany 
 
 
Sibutra
mine 
n = 52 
 
Placebo: 
n=59  
 
TT=14% 
CC=43% 
TC=43% 
 
BMI≥30 
 
 
54 week intervention 
 Pt randomly assigned to receive 
Sibutramine or placebo for 54 weeks. 
 All pt: individualized counselling by 
dietitian 
 Diet = 500-1000 kCal less than 
estimated requirements 
 First 4 weeks: 4 educational sessions 
on healthy eating, PA, behaviour 
modification, motivation. 
 PA = 16 groups sessions 
 Follow-up 2 years after termination of 
intervention.  
Measured at 0, 54 weeks & 2 
years thereafter: 
Baseline weight, BMI. 
After 54 weeks: weight loss, 
≥5% and <5% weight loss, 
≥10% and <10% weight loss. 
2 year follow-up: ≥5% and 
<5% weight loss. 
Weight loss over 54 weeks intervention 
 Sibutramine group lost 5.0 kg more than 
placebo  
 Weight loss in placebo group: TT or TC lost 
4.3 kg more than CC 
 TT or TC do not benefit from Sibutramine  
 CC + Sibutramine = 7.2 kg loss vs. 4.1 kg in T 
carriers. 
 
2 years follow-up after intervention 
termination 
 Sibutramine no benefit over placebo 
 Placebo: TT or TC = ↑ OR of ≥ 5% weight 
loss after 2y 
 Sibutramine: CC = ↑ OR of ≥ 5% weight loss 
after 2y, while no benefit for TT or TC 
Hauner et 
al. 2003 
 
A54A = Ala54 homozygotes, A54T = heterozygotes, T54T = Thr54 homozygotes, T54 = Thr54 allele carriers, BMI = body mass index, WC = waist circumference, HC = hip circumference, WHR 
= waist-hip ratio, BW = body water, FM = fat mass, FFM = fat free mass, BP = blood pressure, SBP = systolic blood pressure, TC = total cholesterol, HDL = high density lipoprotein, LDL = low 
density lipoprotein, TG = triglycerides, RMR = resting metabolic rate, BG = blood glucose, VWAT = visceral white adipose tissue, SWAT = subcutaneous white adipose tissue. 
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Chapter 3 
 
 
Methodology and 
Experimental procedures  
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3.1 Study design 
 
A cross-sectional study design was used to investigate the association between genotype and BMI, health and 
lifestyle indicators in overweight/obese Caucasian adults.  For these purposes a cross-sectional sample of 
overweight/obese subjects who showed interest in participating in a weight loss programme was recruited and 
assessed.  To investigate the association between genotype and weight loss outcomes after exposure to the 
treatment, a quasi experimental study design (time-series) was used.  Subjects from the cross-sectional sample 
who volunteered to participate in the weight loss programme were exposed to the treatment (Figure 3.1).   
 
The treatment consisted of a conservative weight loss programme that spanned 24 weeks, 16 weeks of active 
intervention (biweekly group sessions) followed by eight weeks of self-management (Figure 3.1).  The subjects 
were expected to follow the weight loss recommendations during both phases until their goal weight has been 
reached.  The assessments conducted on the cross-sectional sample (Table 3.1) also served as baseline 
assessments for the intervention sample.  The cross-sectional data were collected prior to the commencement 
of the weight loss programme and during the first group session, which also served to explain the intervention to 
the volunteers.  The cross-sectional sample included 133 subjects of whom 88 volunteered to participate in the 
intervention leg of the study.  Follow-up data for the intervention sample were collected at the 16-week group 
session and the final weight measurement was taken at the 24-week group session.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1:  Time-line of the conservative weight loss intervention programme that spanned 24 weeks. 
Abbreviations: G = group session therefore G1 = group session 1; F = final group session. 
 
A summary of the cross-sectional and follow-up assessments is presented in Table 3.1 
  2 weeks 8 weeks 4 weeks 
24 weeks/ 6 months 
  2 weeks 2 weeks 2 weeks 2 weeks 2 weeks 2 weeks   2 weeks 
Recruitment G1 G2 G5 G4 G3 G8 G7 G6 G9 F 
16 weeks 
interactive group sessions 
8 weeks 
self-management 
Cross-sectional 
assessments 
Table 3.1 
Follow-up 
assessments 
Table 3.1 
Final weight 
assessment 
Table 3.1 
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Table 3.1:  Summary of the cross-sectional and follow-up assessments. 
Measuring tool/ technique Cross-sectional variables Follow-up variables 
 0 weeks 16 weeks 24 weeks 
Blood samples: DNA extraction 
and genotype analyses 
Genotype of 7 polymorphisms: FABP2 Ala54Thr, INSIG2 rs7566605, 
FTO rs17817449, FTO rs1421085, ADRB3 Trp64Arg, ADRB2 Arg16Gly, 
GNB3 C825T. 
  
Anthropometric measurements Weight and height 
BMI 
Weight 
BMI 
Weight  
BMI 
Questionnaire developed for this 
research 
Socio-demographic:  
Age, gender, marital status, home language, highest education levels, 
living alone or with friends/family. 
- - 
 Perceived weight history:  
Perception of weight during childhood, adolescence and young 
adulthood. 
Perception of parents’ current weight and weight history. 
 
- 
 
- 
Non-quantified food frequency 
questionnaire 
Dietary intake of indicator food groups prior to intervention - - 
Baecke questionnaire Physical activity: Work index, sport index, leisure-time index Physical activity: Work index, sport 
index, leisure-time index 
- 
3-Factor Eating Questionnaire Eating behaviour: Dietary restraint, disinhibition and perceived hunger Eating behaviour: Dietary restraint, 
disinhibition and perceived hunger 
- 
Beck Depression Inventory Depression Depression - 
Rosenberg Self-Esteem Scale  Self-esteem Self-esteem - 
General Health questionnaire General psychological well-being General psychological well-being - 
Anthropometric measurements Waist circumference - - 
Blood pressure Blood pressure - - 
Blood samples Fasting HDL-cholesterol, triglycerides and glucose (for metabolic 
syndrome diagnosis). 
- - 
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3.2 Study population 
 
The study population consisted of Caucasian South African overweight and obese subjects residing in Cape Town 
and surrounding areas. In this study “Caucasian” South Africans refers to individuals of European descent, mainly 
Dutch, French, German and British origin.  
 
3.2.1 Inclusion and exclusion criteria 
 
A brief screening questionnaire (Addendum A) was used to screen potential subjects for inclusion in the study.  
 
Subjects had to have a BMI ≥27 kg/m2 and be between the ages of 25 and 40 years old to be included in the 
study.  Subjects older than 40 years were excluded because weight gain patterns in this age group might be 
different compared to younger people (Korkeila et al. 1995).   
 
The exclusion criteria included the following: pregnancy or currently breastfeeding, a history of major eating 
disorders, serious psychiatric illness, a history of drug or alcohol abuse, treatment with any drugs for weight loss 
in the preceding four weeks, presence of comorbidities of obesity such as diabetes and Cushing’s syndrome and 
inability to exercise. 
 
3.2.2 Subject recruitment 
 
Subjects were recruited by means of advertisements placed in local newspapers, the e-mail bulletins of the 
Universities of Stellenbosch and Cape Town and by word of mouth.  Targeted newspapers included “Die Burger” 
(an Afrikaans newspaper circulating in Cape Town and other towns in the Western Cape), “Cape Times” (an 
English newspaper circulating in Cape Town and other towns in the Western Cape), “District Post” (a regional 
newspaper circulating in the Helderberg region including Somerset-West, Strand, Gordons Bay and Stellenbosch) 
and “Eikestadnuus” (a regional newspaper circulated mainly in Stellenbosch, but also available in the Helderberg 
region).   
 
The newspaper advertisements indicated that individuals should phone or e-mail the primary researcher for 
more information on the study.  On contact the study was briefly explained to the individual and the screening 
questionnaire was administered either telephonically or via e-mail.  This procedure served to exclude individuals 
who clearly did not meet the inclusion/exclusion criterions e.g. if a person did not meet the age requirement.  
Appointments for individual recruitment interviews were made with all potential subjects who seemed to meet 
the inclusion criteria.  At the recruitment interview potential subjects received detailed information regarding 
the project, the consent form (Addendum B) was explained to them and they had the opportunity to ask 
questions for clarification.  After subjects signed the consent form, their weight and height were taken.  If their 
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BMI was ≥27 kg/m2 and the other inclusion criteria were met, the subject was included in the cross-sectional 
sample.  The necessary assessments (Table 3.1) were completed during the recruitment interview and at group 
session one.  An appointment was also made for the collection of a fasting blood sample.  The recruitment 
period stretched over a period of approximately one month before a particular intervention leg started (see 
section 3.3.3 for explanation).  Subjects were phoned to confirm the date, time and place of the first group 
session.  Over and above the completion of some of relevant assessments during the first group session, a 
detailed explanation of the actual intervention was provided to subjects, after which they could finally choose to 
continue with the weight loss intervention or to withdraw from the study.  The final sample of overweight and 
obese individuals who responded to the advertisements and who completed all cross-sectional assessments is 
133.  Of these, 88 chose to continue with the weight loss intervention.   
 
3.3 Treatment 
 
3.3.1 Programme content 
 
All subjects received the same conservative weight-loss treatment that included a balanced weight-loss diet, 
physical activity recommendations as well as behavioural and cognitive strategies to facilitate behaviour change.  
These topics as well as the effective application thereof were discussed in biweekly group sessions that 
stretched over a period of four months (nine group sessions in total) (see Figure 3.1 and Table 3.2).  At the first 
group session the subjects received general weight loss guidelines regarding dietary intake, physical activity and 
behavioural strategies that they needed to follow for the 24-weeks intervention period.  Each subject received 
the self-help weight management manual by Senekal (2005) and they were advised to work through the manual 
in their own time before the next session to identify their personal weight management needs, goals and 
relevant actions as is indicated in the manual. 
 
3.3.2 Individualisation of energy and dietary recommendations 
 
The energy requirement for weight loss for each subject was calculated by subjects themselves using the 
equation recommended by Senekal (2005) that considers current weight, physical activity level and gender.  
Based on the outcome of this calculation and following review by a registered dietitian, the participant was 
advised to follow a 4200, 5000, 5800, 6600 or 7400 kilojoules diet with a macronutrient distribution of 50% 
carbohydrates, 20% protein and 30% fat.  The meal plans for each diet as described in the manual by Senekal 
(2005) were used.  The meal plan for each energy level specifies the number of daily servings from the six food 
groups (starch, protein, fruit, vegetables, milk and fat/extras).  An example of a menu plan for one day for each 
energy level as well as portion sizes for a single serving of common foods and a graphic guide for portion size 
estimation are provided in the manual (Senekal 2005).  During the first group session subjects were guided by 
the dietitian to select an appropriate eating plan to meet their calculated energy intake goal, plan a menu and 
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use the portion size estimation guidelines.  Subjects were also provided with menu examples for one week, after 
which they were expected to compile their own menus using a template that covered a week.  
 
Table 3.2:   Topics and activities covered during group sessions in the weight loss programme.  
Session Topics  Main activities  
1 Diet 
Healthy eating  
Reasonable weight goal  
Subjects: 
 Complete baseline questionnaires. 
 Receive weight management manual (WMM): Love my body, love 
myself (Senekal 2005) 
 Calculate energy goals (each subject) 
 Complete questions in WMM to determine a reasonable weight 
goal.  
Group leader: 
 Explains diet, food groups, portion sizes, meal plans, menu 
planning and basic healthy eating tips.  
 Provide general guidelines for dietary intake, physical activity and 
behavioural strategies necessary for weight loss. 
2 Glycemic index of foods  
Fibre content of foods 
Eating behaviour & healthy 
eating habits  
Group leader: 
 Explains the effect of different food on blood glucose. 
 Discusses hand-out with GI food lists. 
 Discusses fibre recommendation and amount and type of food that 
needs to be consumed to reach this goal. 
 Compares fibre content of different breakfast cereals and 
porridges, fruit, vegetables and starches. 
 Facilitates discussion on unhealthy eating behaviours  
Subjects: 
 Identify unhealthy eating behaviours from checklist in WMM 
3 Physical activity   Exercise educationalist demonstrates activities/ exercises and 
motivates group to increase their activity levels. 
4 Visualisation, self-concept, body 
image, assertiveness, stress 
management, communications 
skills, writing goals,  
self-motivation 
manage environmental cues 
Subjects: 
 Work through exercises covering concepts related to behavioural 
and psychological components influencing weight loss. 
Group leader: 
Facilitates discussion of these concepts and problem areas identified 
by subjects. 
5 Reading labels 
Take-away foods 
Group leader: 
 Compares the energy and macronutrient content of different take-
away foods (e.g. McDonalds, Steers, Nando’s, King Pie etc.) with 
macronutrient composition of their food groups. 
6 Weight loss methods Group leader:  
 Facilitates discussion on over-the-counter drugs for weight loss and 
“famous” weight loss diets. 
7 Cooking demonstration 
Recipe adaptations 
Group leader: 
 Executes a cooking demonstration 
 Facilitates discussion on how to include more legumes and soy in 
meals. 
 Facilitates discussion on how to make recipes healthier. 
Subjects: 
 Work through two recipes and suggest healthy adaptations. 
8 kJ content of drinks Group leader: 
 Compares the energy content of different alcoholic beverages, soft 
drinks, juices, yoghurts, and milk drinks 
9 Quick dinners from frozen meals Group leader: 
 Compares the nutritional content of several frozen meals. 
Subjects: 
 Complete follow-up questionnaires. 
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3.3.3 Procedures and physical arrangements 
 
During the years 2006 and 2007 group sessions were conducted at four different venues starting at 15 different 
time-points. All group sessions were facilitated by registered dietitians (three in total).  The venues for group 
sessions were located in Stellenbosch (three weight loss groups during 2006 and five weight loss groups during 
2007), Strand (two weight loss groups), Cape Town (two weight loss groups), and Tygerberg (three weight loss 
groups).   A dietitian was allocated to a particular group for the duration of the intervention to ensure continuity 
and the development of trust and a treatment relationship between the dietitian and subjects.  Dietitians were 
responsible for phoning subjects before each group session to remind and motivate them to attend the 
upcoming session.  Subjects were allowed to contact respective dietitians at any stage during the 24 week 
intervention via telephone or e-mail regarding any weight management related queries.  Trained fieldworkers 
assisted with the collection of baseline and follow-up assessments, the running of the group sessions as well as 
monitoring of completion and hand in of perceived compliance forms.   
 
3.4 Selection of genes 
 
The genes investigated in this study, which forms part of a larger investigation of in both Caucasian and Zulu 
subjects, were selected based on 1) the criteria for selecting genes and polymorphisms for this type of research 
proposed by Day (2004) and 2) personal communications with experts in the field namely Drs. L Perusse (Division 
of Kinesiology, Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Quebec, 
Canada), A Peeters (Center for Medical Genetics, Department of Biomedical Sciences, University of Antwerp, 
Antwerp, Belgium) and MJ Kotze (Department of Pathology, Faculty of Health Sciences, University of 
Stellenbosch, Tygerberg, South Africa).  Application of the criteria formulated by Day (2004) as well as input from 
the panel of experts in the selection of the candidate genes for this study can be summarized as follows: 
 
Criterion 1: The gene product plays an important role in physiological pathways that might contribute to weight 
gain and obesity development (Day 2004).    
 Gene products involved in fat absorption (FABP2), the regulation of fat storage and fat oxidation (lipid 
turnover) in adipose tissue (ADRB3, ADRB2 and GNB3) and adipogenesis (INSIG2) were deemed relevant 
for inclusion in this research.  
 
Criterion 2: Evidence from in vivo experiments has shown that under- (knockout) or over- (transgenic) 
expression of the gene in animals influences obesity development (Day 2004)  
 The required evidence is available for all the above selected genes (see physiological function sections 
of each of the relevant genes in Chapter 2). 
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Criterion 3: Evidence exists for a gene-diet interaction, either from cross-sectional studies or, more importantly, 
from intervention studies (Expert panel).   
 A list of genes associated with weight loss as a result of a weight loss intervention was compiled from 
available literature.  From this list it was evident that the associations between weight loss outcome and 
polymorphisms in the ADRB3, GNB3 and FABP2 genes have been previously investigated.  
 Relevant evidence in this regard is presented in Chapter 2 for each of these genes.  
 
Criterion 4: Priority must be given to genes with the most consistent evidence of an association with obesity 
(Expert panel).   
 A list of genes that showed positive associations with an obesity related phenotype indicator by more 
than five studies was compiled from the 2006 Obesity gene map (Rankinen et al. 2006)  (Table 2.3 in 
Chapter 2).  From this list it was evident that the associations between ADRB3, ADRB2 and GNB3 and 
obesity phenotype indicators were consistent. 
 It was recommended by the expert panel that the FABP2 gene should also be included in the study as a 
novel gene. At that point in time (2007) the association between obesity phenotype indicators and the 
FABP2 gene was supported by four studies. However, further supportive evidence has since been 
published (Section 2.3.6 in Chapter 2). 
 
Criterion 5: Genome-wide linkage studies have mapped the gene to a chromosomal region associated with 
obesity development (Day 2004). 
 This is true for ADRB3, ADRB2, GNB3 and FABP2, as is evident from the 2006 Obesity gene map 
(Rankinen et al. 2006).   
 
Criterion 6: Promising novel genes identified through Genome-wide association studies should be investigated in 
lieu of the promotion of basic research (Expert panel) 
 The expert panel recommended the inclusion of FTO and INSIG2 genes. 
 
When selecting candidate genes for a particular research study it must be borne in mind that more than one 
polymorphism in a particular gene may be associated with obesity phenotype indicators (Day 2004).  For the 
purposes of this research priority was given to functional polymorphisms with a higher reported frequency in 
Caucasian and/or African (i.e. Zulu) populations that showed the strongest evidence for an association with an 
obesity related phenotype.  Novel polymorphisms of the FTO and INSIG2 genes were also selected although their 
functionality is still under investigation.   
 
3.5 Collection of whole blood samples 
 
Blood was drawn from each subject following a ten hour overnight fast by trained phlebotomists. Blood samples 
were collected in three BD (Becton, Dickinson and Company) vacutainers, namely an ethylene diamine tetra-
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acetic acid (EDTA) tube for DNA analysis, a tube containing succinylsulfathiazole (SST) and gel for testing HDL 
cholesterol and triglyceride levels and a tube containing sodium fluoride for testing blood glucose levels.  
Blood analyses for glucose, HDL-cholesterol and triglyceride levels were conducted by a pathology laboratory, 
Dietrich, Street, Loftus & Partners (Pathcare laboratories) on the day the samples were collected.  
 
3.6 Genotype analysis
3
 
 
3.6.1 DNA extraction from whole blood 
 
The protocol of Miller et al. (1988) was modified to extract DNA from the whole blood samples collected in this 
study.   
 
Each 10 ml whole blood sample was transferred from the EDTA tube into a 50 ml polypropylene Falcon tube 
(Greiner Bio-One, Cellstar) and 30 ml ice cold lysis buffer [155 mM ammonium chloride (NH4Cl), 10 mM 
potassium hydrogen carbonate (KHCO3), 0.1 mM EDTA, pH 7.4] was added.  Each Falcon tube with the solution 
was inverted and then placed on ice for 30 minutes, with inversion every 10 minutes to ensure complete lysis of 
the red blood cells.  The tubes were then centrifuged at 1750 × g for 10 minutes.  After discarding the 
supernatant, the pellet was washed with 10 ml phosphate buffered saline (PBS) solution and centrifuged at 1750 
× g (1500 rpm) for 10 minutes.  The supernatant was discarded and the pellet dissolved by adding 3 ml nuclear 
lysis buffer [10 mM Tris hydrochloride (Tris-HCl), 400 mM sodium chloride (NaCl), 2 mM EDTA, pH8.2], 10mg/ml 
Proteinase K (Roche Diagnostics) and 1% (w/v) sodium dodecyl sulphate (SDS).  The solution was incubated at 
55oC in a water bath overnight. 
 
Following incubation, 1ml saturated 6 M NaCl was added to each Falcon tube.  The tubes were shaken vigorously 
for one minute and then centrifuged at 3250 × g for 30 minutes.  The supernatant was transferred into a new 
Falcon tube and the remaining foam and pellet were discarded.   The Falcon tube was shaken for 15 seconds and 
then centrifuged at 2250 × g for 15 minutes.  The supernatant was transferred into another new Falcon tube and 
the remaining foam and pellet were discarded.  Two volumes ice-cold ±99.9% (v/v) ethanol (EtOH) were added 
to the supernatant to precipitate the DNA.  The spool of DNA formed was scooped out of the tube and placed 
into a new 1.5 ml Eppendorf tube with 70% (v/v) EtOH.  This was centrifuged at 20800 × g for 10 minutes at 4 oC 
for removal of excess salt.  After discarding the ethanol, the pellet was allowed to air-dry before dissolving it in 
250 µl SABAX water.  To completely dissolve the DNA the suspension was shaken overnight at room 
temperature.  The DNA concentration of each suspension was measured with a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies).  Subsequently, the DNA was diluted with SABAX water to a 
concentration of 50 ng/µl and stored at 4 oC.   
 
                                                 
3 The candidate performed all the DNA extractions and the genotyping of the FABP2 Ala54Thr and ADRB3 Trp64Arg polymorphisms 
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3.6.2 Polymerase chain reaction (PCR) amplification 
 
A summary of the oligonucleotide primers used for PCR amplification is shown in Table 3.3.  All primer sets were 
manufactured by Integrated DNA Technologies (IDT) and the melting temperature (TM) for each primer was 
calculated using the equation [TM = 2(nA + nT) +4(nG + nC)] described by Thein and Wallace (1986).   
 
PCR amplification was performed using a GeneAmp® 2700 PCR System (Applied Biosystems).   Each PCR reaction 
was performed in a volume of 25 µl consisting of 50 ng DNA, 0.2 mM of each dNTP (dATP, dCTP, dGTP, dTTP) 
(Fermentas), 10 pmol of each primer, magnesium chloride (MgCl2) and Taq polymerase (as indicated in Table 3.3) 
and 1×Taq buffer (Fermentas or Bioline).  The various amplicons under investigation were amplified using one of 
the following PCR cycles (referred to as cycle A or B): 
 Cycle A consisted of an initial denaturation at 95oC for five minutes, followed by 35 cycles of denaturation at 
95oC for 30 seconds, annealing at 55 oC for 45 seconds and elongation at 72oC for 30 seconds.  The final 
extension step occurred at 72oC for ten minutes. 
 Cycle B consisted of an initial denaturation at 95oC for two minutes, followed by 35 cycles of denaturation at 
95oC for 30 seconds, annealing at 60oC for 30 seconds and elongation at 72oC for 30 seconds.  The final 
extension step occurred at 72oC for ten minutes. 
 
3.6.3 Agarose gel electrophoresis  
 
To investigate whether PCR amplification was successful, 5µl of each PCR product was mixed with 5µl cresol red 
loading buffer (2 mg/ml cresol red and 35% (w/v) sucrose).  The solution was loaded onto a 1% (w/v) horizontal 
agarose gel [2g agarose in 200 ml 1×TBE (90mM Tris-HCl, 90 mM boric acid (H3BO3) and 0.1 mM EDTA, pH 8.0) 
and 0.01% ethidium bromide (EtBr)].  A 100 bp ladder (Fermentas) was also loaded onto the gel to confirm PCR 
amplification of the correct fragment size. Electrophoresis was performed at 120 V for one hour in 1×TBE buffer 
solution and then visualised by ultraviolet light transillumination (GeneSnap MultiGenius Bio Imaging System, 
Syngene). 
 
3.6.4 Restriction fragment length polymorphism (RFLP) analysis 
 
To identify the specified genotypes for the genes under investigation, RFLP analysis was performed.  Digestion of 
the respective PCR products was performed in a 20 µl reaction containing 10 µl PCR product, units of the 
relevant enzyme as shown in Table 3.4 and 1×buffer.  This was placed in a water bath at the temperature and 
time as shown in Table 3.4.  The digested PCR products were loaded onto an agarose gel (gel concentrations 
shown in Table 3.4) and visualized by ultraviolet light transillumination (GeneSnap MultiGenius Bio Imaging 
System, Syngene). Digestion results for all three genotypes (wild-type, heterozygous, mutant) of each of the seven 
polymorphisms were confirmed by Inqaba Biotechnical Industries (Pty) Ltd using sequencing analysis. 
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Table 3.3:  Specific oligonucleotide primers used and PCR conditions implemented.   
Genes: 
Polymorphism 
Primer sequences 
(5′ – 3′) 
Reference(s) TM (
o
C) Amplicon 
size (bp) 
PCR cycle MgCl2 
(mM) 
Taq 
polymerase 
Success
§
 
n(%) 
 
FABP2: Ala54Thr 
 
(F)  ACAGGTGTTAATATAGTGAAAAG  
(R)  TACCCTGAGTTCAGTTCCGTC 
 
 
Baier et al. 1995 
Kim et al. 2001 
 
48 
56 
 
180 
 
A 
 
1 
 
Bioline 
 
112(84.2) 
INSIG2:  rs7566605  (F)  CCTACCTCCCTCCAATACCC 
(R)  TGAGAGTCAGTGCGATGTCC 
 
Feng et al. 2007 56 
57 
164 A 2.5 Fermentas 115(86.5) 
FTO: rs1421085  (F)  TAGTAGCAGTTCAGGTCCTAAGGCGTG* 
(R)  CAGATTAAGGTGATGGGTTG 
 
This study† 61 
51 
240 A 2 Fermentas 101(75.9) 
FTO: rs17817449  (F)  AGGACCTCCTATTTGGGACA  
(R)  AGCTTCCATGGCTAGCATTA 
 
Do et al. 2008 55 
54 
828 A 2 Fermentas 105(79.0) 
ADRB3: Trp64Arg (F)  CAATACCGCCAACACCAGTGGG  
(R)  GGTCATGGTCTGGAGTCTCG 
 
Gagnon et al. 1996 
Hao et al. 2004 
61 
57 
151 B 2 Fermentas 93(69.9) 
ADRB2: Arg16Gly  
 
(F)  CTTCTTGCTGGCACGCAAT* 
(R)  CCAGTGAAGTGATGAAGTAGTTGG 
 
Large et al. 1997 
Ukkola et al. 2000 
57 
55 
200 A 1.5 Fermentas 106(79.7) 
GNB3: C825T  (F)  TGACCCACTTGCCACCCGTGC 
(R)  GCAGCAGCCAGGGCTGGC 
 
Siffert et al. 1998 
Buchmayer et al. 2000 
65 
66 
268 A 2 Fermentas 107(80.5) 
PCR = polymerase chain reaction, (F) = forward primer, (R) = reverse primer, TM = melting temperature, bp = base pairs, MgCl2 = magnesium chloride.  
*Mutagenic primers; † The mutagenic primer was designed using In Silico. 
§Indicates the number of samples for which genotyping was successful 
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Table 3.4:  Specific restriction enzymes and conditions used for RFLP analysis  
Gene: polymorphism 
(amino acid change) 
Units and enzyme 
(Manufacturer) 
 
Recognition site Fragments Water bath:  
Incubation time & 
temperature  
Agarose gel: Concentration, 
voltage & electrophoresis 
time 
FABP2: Ala54Thr 2U HhaI (NEB) 5'-GCG↓C-3' 
 
GG (Ala/Ala) = 99, 81bp 
AA (Thr/Thr) = 180bp 
GA (Ala/Thr) = 180, 99, 81bp 
2 hours at 37oC  4% gel 
80V for 2 hours 
INSIG2:  rs7566605  5U DpnII (NEB)  5'-↓GATC-3' 
 
CC = 88, 76bp 
CG = 164, 88, 76bp 
GG = 164bp 
Overnight at 37oC  3%  
120V for 1 hour 
FTO: rs1421085  1U MaeIII (Roche)  5′-↓GTNAC-3′ TT = 240bp 
CC = 216, 24bp 
TC = 220bp, 216bp, 24bp 
Overnight at 55oC 3% 
120V for 1 hour 
FTO: rs17817449  2U AlwNI (Fermentas)  5'-CAGNNN↓CTG-3' GG = 240bp 
TT = 216, 24bp 
GT = 220, 216, 24bp 
Overnight at 37oC  1.5% 
120V for 50 min 
ADRB3: Trp64Arg 2U MspI (NEB) 
 
5′-C↓CGG-3' TT (Trp/Trp) = 97, 54bp 
CC (Arg/Arg) = 70, 54, 27bp 
TC (Trp/Arg) = 97, 70, 54, 27bp 
Overnight at 37oC 3% gel 
120V for 1 hour 
ADRB2: Arg16Gly  2U BsrDI (NEB)  5'-GCAATGNN↓-3' 
 
AA (Arg/Arg) = 131, 56, 14bp 
AG (Arg/Gly) = 131, 108, 56, 22, 14bp 
GG (Gly/Gly) = 108, 56, 22, 14bp 
Overnight at 65oC  3%  
120V for 1 hour 
GNB3: 825C→T  2U BseDI (Fermentas)  5'-C↓CNNGG-3' 
 
TT = 268bp 
CC = 152, 116bp 
CT = 268, 152, 116bp 
Overnight at 55oC  3%  
120V for 1 hour 
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3.7 Anthropometric assessments 
 
Weight, height and waist circumference of subjects were measured by trained and standardized fieldworkers.  
Weight was measured in light clothing without shoes to the nearest 0.1 kg using a calibrated electronic scale 
with a 250 kg capacity (Physician scale, Scales 2000).  Height without shoes was measured to the nearest 0.1 cm 
with a stadiometer.  The participants stood with their feet together and heels, buttocks, scapulae and back of 
the head touching the vertical surface of the stadiometer, if possible.  Any hair obstructions were removed and 
the head was placed in the Frankfort horizontal plane.  The body mass index (BMI) was computed as weight (kg)/ 
height (m)2 (Bastow 1982).  The BMI was categorized according to the World Health Organization guidelines, 
namely BMI ≥27 and <30 kg/m2 = overweight; BMI≥30 and <35 kg/m2 = obese class I; BMI≥35 and <40 kg/m2 = 
obese class II and BMI≥40 kg/m2 = obese class III (WHO 2000).    
 
Waist circumference was measured to the nearest 0.1 cm using a non-stretchable measuring tape.  The waist 
circumference was taken at the level of the narrowest point between the lower rib border and the iliac crest 
after normal expiration.  When there was no obvious narrowing point, the measurement was taken at the mid-
point between the two landmarks (Norton et al. 1996).  The subject stood relaxed with feet together, while the 
fieldworker ensured that the measuring tape was horizontal when the measurement was taken.  
 
3.8 Diagnosis of the Metabolic syndrome (MetS) 
 
At the time of data collection several definitions to diagnose MetS were available (reviewed by Stolar 2007).  The 
most commonly used definitions included those set by the National Cholesterol Education Programme Adult 
Treatment Panel III (NCEP ATP III), International Diabetes Foundation (IDF) and World Health Organization 
(WHO).  Metabolic syndrome traits included in the definitions of the NCEP ATP III, IDF and WHO are waist 
circumference, blood pressure, fasting triglycerides, HDL-cholesterol and glucose.  In addition to this the WHO 
include obesity, waist-hip-ratio, urinary albumin and albumin-creatinine ratio in their definition.  Diagnostic cut-
offs for each trait are specified by each organization, which vary for most traits, with the exception of cut-offs for 
triglyceride levels.  For diagnosis of the metabolic syndrome the IDF criteria specify the presence of obesity and 
the WHO criteria specify the presence of insulin resistance together with two of the other traits.  The NCEP ATP 
III criteria require any combination of three or more of the mentioned traits for diagnosis (ATP III 2001).  For this 
reason it was decided to use the NCEP ATP III criteria (Table 3.5) to diagnose subjects with the metabolic 
syndrome in our research.  This choice is also supported by the fact that the newly proposed harmonized 
criteria4 cover the same traits as the NCEP ATP III criteria and also require any combination of three or more of 
these traits for diagnosis (Alberti et al. 2009). 
                                                 
4 Joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of 
Obesity. 
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Table 3.5: NCEP ATP III criteria for the diagnosis of the metabolic syndrome (ATP III 2001). 
Indicators of: Measurement Cut-offs for diagnosis 
Central obesity Waist circumference Men: >102 cm; Women: >88 cm  
Impaired glucose tolerance Fasting glucose ≥6.1 mmol/L 
Hypertriglyceridaemia Fasting plasma triglycerides ≥1.69 mmol/L 
 HDL cholesterol Men: <1.04 mmol/L 
Women: <1.24 mmol/L 
Hypertension Blood pressure ≥130/85 mmHg or currently treated with 
hypertension medication 
NCEP ATP III = Adult Treatment Panel third report of the National Cholesterol Education Programme 
 
All measures for MetS diagnosis were only obtained from a sub-sample (n=88) of subjects.  The n for MetS 
variables further vary due to no results received from Pathcare laboratories for HDL-cholesterol for four subjects 
as well as waist circumference and blood pressure measures not obtained from four subjects. 
 
3.9 Physical activity  
 
The Baecke Questionnaire of Habitual Physical Activity was developed by Baecke et al. (1982) to measure three 
components of physical activity, namely physical activity at work, sport during leisure time and physical activity 
during leisure time, excluding sport.  The questionnaire was developed, calibrated and tested for reliability using 
men and women between the ages of 20 to 32 years from a white population in the Netherlands (Baecke et al. 
1982). The test-retest reliability of the work, sport and leisure-time indices were 0.88, 0.81 and 0.74 respectively 
(Baecke et al. 1982).  Other reliability studies showed similar or better test-retest results in male and female 
Caucasian university staff and students ages 20 to 59 years (Jacobs et al. 1993) and Dutch men and women aged 
20 to 70 years (Pols et al. 1995).  Validation studies also showed significant relationships between the Baecke 
physical activity indices and other physical activity questionnaires (Cauley et al. 1987, Albanes et al. 1990, Miller 
et al. 1994), energy intake (Albanes et al. 1990, Miller et al. 1994), VO2max, % body fat, Caltrac readings and 
activity diaries (Richardson et al. 1995, Jacobs et al. 1993, Pols et al. 1995).   
 
The Baecke Questionnaire is self-administered and consists of 16 questions. A score is computed for each of the 
three mentioned sections and referred to as the work index, sport index and leisure-time index.  The score for 
the work index is calculated from the first eight items, for the sport index from items nine to 12 and for the 
leisure-time index from items 13 to 16 in the questionnaire.  All items except items one and nine are answered 
by choosing one of five options, namely ‘never’, ‘seldom’, ‘sometimes’, ‘often’, or ‘always/very often’. These 
responses are scored using a 5-point Likert scale.  In item nine respondents are asked to report on the type of 
sport the subject practises most frequently as well as the number of hours per week and months per year the 
subject practises this sport (Baecke et al. 1982).  Scoring of this item is based on the description supplied by 
Baecke et al. (1982).  As the long-term pattern of habitual physical activity is measured by the questionnaire, the 
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mean scores of each index can be compared between follow-up measurements to reflect changes over time 
(Baecke et al. 1982).   
 
3.10 Dietary intake  
 
The aim of the dietary assessment was to characterize food choices at baseline to 1) direct dietary 
recommendations for the intervention and 2) to compare frequency of intake of energy-dense foods groups 
between genotype groups of subjects in the cross-sectional sample.  For these purposes a non-quantified food 
frequency questionnaire (FFQ), including 67 items allocated to nine food groups, was developed (Addendum C).  
The nine groups included starches (nine items); vegetables (three items); fruit (four items); milk, yoghurt and 
cheese (five items); meat, fish, chicken (13 items); fats (four items); fast foods and take-away foods (five items); 
“other foods” (e.g. vetkoek, samoosas, koeksisters, doughnuts; muffin, scones, cake, tart; rusks; cookies; chips; 
chocolate; ice cream; sweets; energy bars, health bars and breakfast bars; nuts and peanuts; white, cheese and 
meat sauces; tomato sauce, chutney and other sauces; chocolate spread; peanut butter; jam, syrup and honey) 
(15 items); and drinks (alcoholic and non-alcoholic) (nine items).  Food items included were selected to cover all 
the food groups, with emphasis on food items that have been shown to be associated with obesity development 
(Bray et al. 2004a, Rosmond et al. 2004, Black & Macinko 2008, Malik et al. 2006, Gibson 2008, Wolf & Dansinger 
2008).     
 
Frequency of intake of specific food items could be indicated as <1/month, 1-3 times/months, 1/week, 2-4/week, 
5-6/week, 1/day, 2-3/day, 4-5/day, 6+/day.  As it was a non-quantified FFQ, portion size estimation was not 
included.  The daily frequency of intake of each item on the food list in the FFQ was calculated as shown in Table 
3.6.   
 
Table 3.6: Formulas for the calculation of daily frequency of food intake from the non-quantified FFQ 
Intake  Calculation 
Daily  using daily intake as is  
 
- if 1/day was selected daily intake = 1, 
- if 2-3/day = 2.5,  
- if 4-5/day = 4.5,  
- if 6+/day = 6.  
Weekly  dividing weekly intake by seven: 
 
- if 5-6/week was selected daily intake = 5.5/7,  
- if 2-4/week = 3/7  
- if 1/week = 1/7,  
Monthly  dividing monthly intake by 28: - if 1-3/month was selected daily intake = 2/28 
Never or <1/month  use 0.   - 0 
 
 
Energy-dense food items were grouped (Table 3.7) to calculate a daily intake of 1) high fat foods, 2) energy-
dense snacks and 3) non-alcoholic drinks.  Although take-away foods were included in the high fat food group, 
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these foods were also included as a separate fourth food group in statistical analyses.  For data-analysis the daily 
mean±SD frequency of intake of each indicator food group was calculated. 
 
 
Table 3.7: Allocation of food items to the three energy-dense food groups created for the purposes of this study. 
New food 
groups 
Original food groups on non-
quantified FFQ 
Single or groups of food items on non-quantified FFQ 
included in new food groups 
High fat foods  Starches - Potato cooked, baked, mashed with fat added or 
potato salad. 
  Milk, cheese, yoghurt group 
 
- Full cream milk, yogurt, sour milk;  
- Coffee creamer;  
- Cheese (gouda, cheddar, brie etc.)  
  Meat, fish, chicken - Schnitzels, cordon bleu;  
- Red meat e.g. beef, mutton, pork (eat visible fat);  
- Chicken/turkey with skin;  
- Fried fish;  
- Sausages e.g. Vienna’s, Russians, frankfurter;  
- Bacon and cold meat e.g. salami, polony;  
- Eggs e.g. scrambled, baked, omelettes. 
  Fats - Soft margarine;  
- Butter or hard margarine; s 
- Salad dressing/ mayonnaise e.g. normal fat. 
  Take-away foods  - Pizza 
- Pies and sausage rolls;  
- Potato chips;  
- Kentucky;  
- Hamburgers e.g. McDonalds, Steers, Wimpy, Spur etc. 
  Other - Cheese sauce, white sauce, meat sauce;  
- Chocolate spread;  
Energy-dense 
snacks  
(= high fat and 
carbohydrate 
snacks) 
 Other  
 
- Vetkoek, samoosas, koeksister, doughnuts; 
- Muffin, scones, cake, tart;  
- Cookies;  
- Chips;  
- Energy bars, health bars, breakfast bars; 
- Chocolate;  
- Ice cream;  
- Sweets.  
Energy-dense 
drinks (=non-
alcoholic drinks) 
 Drinks  - Juice 
- Fizzy soft drinks;  
- Energy drinks;  
- Milk shake. 
 
 
3.11 Eating behaviour  
 
The Three-Factor Eating Questionnaire (TFEQ) or Eating Inventory, was developed by Stunkard and Messick 
(1985) to measure three dimensions of human eating behaviour, namely dietary restraint (Factor I), disinhibition 
(Factor II) and perceived hunger (Factor III) (Stunkard & Messick 1985).  The questionnaire can be used to study 
individuals and to detect group differences in eating behaviour. The questionnaire was developed and tested for 
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reliability using non-obese and obese men and women who were either very restrained or unrestrained eaters 
(Stunkard & Messick 1985).  Internal reliability (Cronbach’s α) of the TFEQ was 0.93 for Factor I, 0.91 for Factor II 
and 0.85 for Factor III (Stunkard & Messick 1985).  The questionnaire has been validated in large cohorts 
consisting of non-obese and obese men and women (Laessle et al. 1989, Provencher et al. 2003). 
The TFEQ is a self-report questionnaire that consists of 51 questions.  Part I of the questionnaire consists of 36 
true or false questions and Part II (question 37 to 51) consists of questions with four possible answers (with the 
exception of question 50 that has six possible answers).  Respondents must choose one option for each question.  
Responses to all questions are scored as 0 or 1 and summed as explained by Stunkard and Messick (1985).  
Twenty one of the questions comprise Factor I (score ranging from 0 to 21) that measures dietary restraint 
(TFEQ-R) and reflects the extent to which food intake is cognitively restricted (by thought and will power) in 
order to control body shape and weight.  Sixteen questions comprise Factor II (score ranging from 0 to 16) that 
measures disinhibition (TFEQ-D) and reflects the extent of inability to control food intake in response to the 
presence of palatable food which may result in the over-consumption of food.  Other disinhibiting stimuli such as 
emotional stress or social eating cues may also contribute to the inability to resist food intake when not hungry.  
Fourteen questions comprise Factor III (score ranging from 0 to 14) that measures perceived hunger (TFEQ-H) 
and reflects the extent of food intake in response to susceptibility to general subjective feelings and perceptions 
of hunger and the behavioural consequences thereof (Stunkard & Messick 1985).   
 
Specific subscales of these three general eating behaviours have been proposed (Westenhoefer et al. 1999, 
Bond et al. 2001).  The TFEQ-R scale can be subdivided into five subscales, namely rigid control, flexible control, 
attitude to self-regulation, strategic dieting behaviour and avoidance of fattening foods.  The flexible control 
subscale (TFEQ-FC) and rigid control subscale (TFEQ-RC) consist of seven questions each (scores ranging from 0 
to 7) (Westenhoefer et al. 1999).  Flexible control (also referred to as consistent restraint) reflects a more 
gradual approach towards eating and dieting.  Foods like sweets and treats or fattening foods are eaten but in 
smaller quantities, without feelings of guilt.  Rigid control (or inconsistent restraint) is characterized by a 
dichotomous (all-or-nothing) approach towards eating and dieting (Westenhoefer et al. 1999).  TFEQ-FC has 
been associated with the ability to control body weight whereas TFEQ-RC has been associated with a lack of 
control over body weight, bulimia diagnosis, weight fluctuations and body dissatisfaction (Shearin et al. 1994).  
The strategic dieting behaviour subscale consists of four questions (score ranging from 0 to 4) reflecting specific 
behaviours employed to control weight (e.g. “deliberately taking small helpings”).  The attitude to self-regulation 
(of eating) subscale consists of five questions (score ranging from 0 to 5) which indicate the subjects’ general 
view on dietary intake and weight control. The avoidance of fattening foods subscale consists of four questions 
(score ranging from 0 to 4), which are concerned with deliberate efforts to decrease fat content in the diet (e.g. 
`How likely are you to shop for low calorie foods?').  Higher scores for the latter three subscales reflect higher 
levels of restraint (Bond et al. 2001). 
 
The TFEQ-D scale can be divided into three subscales (Bond et al. 2001).  Habitual susceptibility to disinhibition 
consists of five questions (score ranging from 0 to 5) and reflects behaviours occurring when circumstances 
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could predispose to recurrent disinhibition.  Emotional susceptibility to disinhibition consists of three questions 
(score ranging from 0 to 3) and reflects disinhibition associated with negative affective states.  Situational 
susceptibility to disinhibition consists of five questions (score ranging from 0 to 5) and is initiated by specific 
environmental cues (Bond et al. 2001).   
 
Lastly, the TFEQ-H scale can be divided into two subscales (internal and external locus for hunger) with six 
questions (score ranging from 0 to 6) in each subscale (Bond et al. 2001).  Internal locus for hunger reflects the 
type of hunger that is interpreted and regulated internally while external locus for hunger is triggered by 
external cues (Bond et al. 2001). 
 
The scores computed for all scales are continuous variables ranging from a minimum to a maximum, with higher 
scores for each Factor respectively denoting higher levels of restrained eating, disinhibited eating and 
predisposition to hunger (Bas & Donmez 2008).   
 
3.12 Psychological health  
 
3.12.1 Beck Depression Inventory (BDI) 
 
The Beck Depression Inventory (BDI) was developed by Beck et al. (1961) to measure the presence and severity 
of depressive symptoms in adults and adolescents older than 13 years.  For the purposes of this study the 
revised BDI-second edition (BDI-II) that was developed from the original BDI and BDI-IA versions to assess 
depressive symptoms corresponding to the criteria listed in the Diagnostic and Statistical Manual of Mental 
Disorders – Fourth Edition (DSM-IV) (Beck et al. 1996), was used.  The BDI-II can be used in a community and 
clinical settings to measure the severity of depression in diagnosed patients or to detect possible depression in 
normal populations (Beck et al. 1996).  A good test-retest correlation of 0.93 was reported in an out-patient 
sample that completed the questionnaire one week apart.  Two review articles have reported high internal 
reliability of the BDI-II in both clinical and non-clinical populations with coefficient alpha’s greater than 0.80 
(Beck et al. 1988, Steer et al. 1986). Concurrent and construct validation studies also showed significant 
correlations between the BDI-II and the BDI-IA version and several other psychological tests, including the Beck 
Hopelessness Scale, Scale for Suicide Ideation, Beck Anxiety Inventory, Revised Hamilton Psychiatric Rating Scale 
for Depression and the Revised Hamilton Anxiety Rating Scale (Beck & Steer 1987, Beck et al. 1996).  
 
The BDI-II is a self-report questionnaire that consists of 21 questions.  For each item on the questionnaire 
subjects can choose one of four possible statements that best describes their feelings over the past two weeks.  
A 4-point Likert scale is used to score the responses ranging from zero for the absence of depressive symptom or 
least depressive statement to three for the most depressive statement. Scores of all 21 items are summed to 
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obtain a total score between zero and 63.  Higher scores reflect more severe depressive symptoms (Beck et al. 
1996).   
 
3.12.2 General Health Questionnaire (GHQ) 
 
The General Health Questionnaire (GHQ) was developed by Goldberg (1972) to be used as a screening 
instrument for the diagnoses of possible cases of non-psychotic psychiatric disorders among patients attending 
medical consultation settings (Goldberg 1972).  It is a self-administered questionnaire that differentiates 
between psychiatric patients as a general class from those who consider themselves to be well. For the purposes 
of this study the 30-item GHQ (Goldberg et al. 1976) that was derived from the original 60-item version, was 
selected. The questionnaire was originally calibrated on British populations and thus constructed for Caucasian 
population groups (Goldberg et al. 1976).  The main shortcoming of the GHQ is its tendency to miss patients with 
long-standing psychiatric disorders (Goldberg et al. 1976).  Subjects with a psychiatric illness for ‘several years’ 
can obtain a low score on the GHQ because of the nature of the response scale i.e. patients may select the ‘same 
as usual’ option for most questions and therefore not obtain a high score, despite having a psychiatric disorder 
(Goldberg et al. 1976).  This was not considered a limitation for this study, as potential participants with a self-
reported psychiatric disorder were excluded from the study.   
 
For each of the 30 items on the GHQ the respondent is asked to compare his/her recent state with his/her usual 
state by choosing one of four possible answers: ‘not at all’ (score=0), ‘same as usual’ (score=0), ’rather more 
than usual’ (score=1) and ‘much more than usual’ (score=1).  A total score between zero and 30 can be obtained. 
A high score is indicative of poorer mental health.  A higher score is also associated with a greater inability to 
carry out one’s normal ‘healthy’ functions (Goldberg 1972).   
 
3.12.3 Rosenberg Self-Esteem Scale (RSES) 
 
The Rosenberg Self-Esteem Scale (RSES) was developed by Rosenberg (1965) to measure global feelings of self-
worth or self-acceptance.  The RSES has good reliability with test-retest correlations of 0.82 after a 1-week 
interval (Fleming & Courtney 1984), 0.85 after a 2-week interval (Silber & Tippett 1965), and coefficient alpha’s 
ranging from 0.75 (Dobson et al. 1979) to 0.88 (Fleming & Courtney 1984).  Validation studies also showed 
significant positive correlations between the RSES and measures of confidence and popularity (Lorr & 
Wunderlich 1986), academic self-concept (Reynolds 1988), general self-regard, social confidence, and school 
abilities and negative correlations with measures of anxiety and depression (Fleming & Courtney 1984).   
 
The RSES is a self-report questionnaire that consists of 10 items.  For each item on the questionnaire the subject 
can choose one of four possible answers that best describes their present and recent feelings.  A 4-point Likert 
scale is used to score the questions as follows: Strongly disagree (score=1), agree (score=2), disagree (score=3) 
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and strongly disagree (score=4).  A total score between 10 and 40 can be obtained.   Higher scores reflect a 
higher self-esteem (Rosenberg 1965).  
 
3.13 Monitoring of perceived compliance 
 
For the purposes of this study three questions (Figure 3.5) were developed to measure perceived compliance to 
the three components of the intervention programme (diet, physical activity and behavioural/psychological 
components) throughout the 16 weeks of the interactive part of the programme. 
 
 
 
       Please draw a vertical line at the point along the scale that reflects your feeling. 
1) To what extent do you feel you have followed the dietary guidelines over the past 2 weeks? 
 
Not at all 100% 
 
2) To what extent do you feel you have increased your physical activity over the past 2 weeks? 
 
 
Not at all 100% 
 
3) To what extent do you feel you have worked on behavioural and psychological aspects of the 
programme over the past 2 weeks? 
 
Not at all 100% 
 
 
Figure 3.2: Tool for assessment of perceived compliance with dietary, physical activity and behavioural 
components of the programme 
 
According to Weiten (2001) perceived compliance is a feeling or an attitude and for that reason it would be most 
appropriately measured using a graduated scale that can be translated into a numerical score. This method is 
used extensively in psychological research and was deemed appropriate for the purposes of this study (Weiten 
2001). It is important to bear in mind that compliance with a weight loss programme leads to weight loss, and 
that perceived compliance should thus be assessed before weight is measured at a session to ensure that this 
measure is not influenced by the outcome of the weighing session (Saelens & McGrath, 2003). 
 
Perceived compliance in this study was assessed every two weeks before weight was measured. For these 
purposes subjects marked their perceived compliance to each of the three components of the programme on a 
continuous rating scale of 10 cm (Figure 3.2). Perceived compliance was quantified by measuring the point 
where the mark was made on the scale and assigning a score out of 10 for each subject.  The scores collected 
every two weeks were added and the average score out of 10 for perceived compliance to each component of 
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the programme was calculated.  These three scores were then added to calculate a total perceived compliance 
score out of 10.  
 
3.14 Additional questions 
 
A self-administered questionnaire (Addendum C) developed for the purposes of the cross-sectional study, was 
used to obtain information on socio-demographic variables such as age, gender, marital status, home language, 
highest education levels and number of people with living with.  The questionnaire also contained questions on 
medication use, personal and family weight history, including perception of weight during childhood, 
adolescence and young adulthood as well as perception of previous and current weight of parents. For the 
development of this questionnaire a theoretical framework was constructed after which the core concepts to be 
covered in the questionnaire were finalized.  Subsequently the questions were developed and a draft 
questionnaire was compiled, which was reviewed by a panel of experts and pilot tested on a group of 
overweight/obese subjects.  These steps were followed to ensure construct, content and face validity of the final 
questionnaire.  
 
3.15 Statistical analyses 
 
Data were entered in Microsoft Excel spreadsheets, transferred to Statistica and cleaned.  The different 
questionnaire scores and BMI indices were computed and values for of MetS traits were categorized according 
to the indicated diagnostic cut-offs.  Data were then analyzed using Statistica computer software (Statistica 
version 9, Statsoft 2009).  The candidate performed all descriptive statistics, Chi-square tests, Independent 
samples t-tests, One-way ANOVAs and linear models involving the genotype, recessive and dominant genetic 
models using Statistica.  All other statistical analyses involving linear models (with main and interaction effects) 
for the genotype and additive allelic variables were executed by Prof Lize van der Merwe, Biostatistician at the 
Medical Research Council of South Africa, on the statistical programme R (from www.r-project.org).  
 
3.15.1 Cross-sectional data (Chapter 4)  
 
Hypotheses 
The following primary and secondary hypotheses were formulated for the statistical analyses of the cross-
sectional data based on either a physiological explanation for the association or previously reported associations: 
 
Primary null hypothesis:  
There is no association between genotype5 and BMI. 
                                                 
5
 genotype refers to the genotype of the following seven polymorphisms: FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, FTO rs17817449, 
ADRB3 Trp64Arg, ADRB2 Arg16Gly and GNB3 C825T. 
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Secondary null hypotheses: 
 There is no association between BMI and health indicators (perceived weight history, MetS prevalence, 
MetS traits and psychological health). 
 There is no association between BMI and lifestyle indicators (physical activity, dietary intake and eating 
behaviour). 
 There is no association between genotype and perceived weight history. 
 There is no association between genotype and MetS traits or MetS prevalence. 
 The interaction between genotype and BMI has no effect on MetS traits or MetS prevalence. 
 There is no association between dietary intake and genotype. 
 The interaction between dietary intake and genotype has no effect on BMI. 
 There is no association between physical activity and genotype. 
 The interaction between physical activity and genotype has no effect on BMI. 
 There is no association between eating behaviour and the FTO rs1421085, FTO rs17817449 and GNB3 C825T 
polymorphisms. 
 The interaction between eating behaviour and the FTO rs1421085, FTO rs17817449 and GNB3 C825T 
polymorphisms has no effect on BMI. 
 There is no association between psychological health and the GNB3 C825T polymorphism. 
 The interaction between psychological health and the GNB3 C825T polymorphism has no effect on BMI. 
 
To investigate the association between genotype, lifestyle, psychological health and BMI that have not been 
reported on before or for which a physiological explanation is not known, the following exploratory hypotheses 
were formulated: 
 
Exploratory null hypotheses: 
 There is no association between eating behaviour and the FABP2 Ala54Thr, INSIG2 rs7566605, ADRB3 
Trp64Arg and ADRB2 Arg16Gly polymorphisms. 
 The interaction between eating behaviour and the FABP2 Ala54Thr, INSIG2 rs7566605, ADRB3 Trp64Arg and 
ADRB2 Arg16Gly polymorphisms has no effect on BMI. 
 There is no association between psychological health and the FABP2 Ala54Thr, INSIG2 rs7566605, FTO 
rs1421085, FTO rs17817449, ADRB3 Trp64Arg and ADRB2 Arg16Gly polymorphisms. 
 The interaction between psychological health and the FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, 
FTO rs17817449, ADRB3 Trp64Arg and ADRB2 Arg16Gly polymorphisms has no effect on BMI. 
 
Statistical analyses 
For descriptive purposes, means and standard deviations (Mean±SD) were calculated for continuous variables 
and frequencies for categorical variables.  To determine the difference in the mean BMI between the response 
categories for socio-demographic, perceived weight and MetS variables, the Independent Sample t-test was 
used in the case of two response categories and the One-way ANOVA test followed by the Tukey post hoc test in 
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the case of three or more response categories.  Independent Sample t-tests were also used to determine the 
difference in the means of all other continuous variables between male and females.  BMI did not differ 
significantly between females and males.  However, as significant differences were detected in a number of 
other variables, all cross-sectional data was consequently adjusted for gender.    
 
To investigate the association between each MetS trait, lifestyle (Baecke physical activity questionnaire indices, 
energy-dense food groups and TFEQ scales and subscales) and psychological health (GHQ, BDI and RSES) 
variables and BMI, linear models were constructed and the main effect sizes were calculated. The main effect 
size can be interpreted as the average change in BMI corresponding to a one-unit increase in the score of a 
lifestyle or psychological health variable.  For the MetS traits the inverse of the main effect sizes were 
interpreted as the average change in the MetS trait corresponding to a one-unit increase in BMI (1 kg/m2).  
 
Genotype distributions were tested for Hardy Weinberg equilibrium using the exact test.  Linear models were 
used to compare the mean BMI between the genotype groups (categorised as the homozygous wild-type, 
heterozygous and homozygous mutant genotypes) and the additive allelic variable (numerical coded as 0, 1 and 
2 minor alleles) for each polymorphism.   
 
To determine the differences between the genotype groups for responses to categories of perceived weight 
history as well as diagnoses with MetS or MetS traits (Yes/No), cross-tabulations were constructed with 
genotype category as classification variable.  The Pearson’s Chi Square statistic was used to test for significant 
differences in group profiles.   
 
The mean values for MetS trait and scores for lifestyle and psychological health variables were compared 
between the three genotype groups as well as the dominant (homozygous wild-type genotype vs. mutant allele 
carriers) and recessive genotype models (wild-type allele carriers vs. homozygous mutant genotype) of each 
polymorphism using unadjusted and gender-adjusted linear models.   For these analyses only the significant 
differences are reported in the tables in the results section.  When both unadjusted and gender-adjusted linear 
models for an association were significant, only the gender-adjusted results are reported.  However, in cases of a 
discrepancy between unadjusted and gender-adjusted results (i.e. one is significant and the other non-
significant), both p-values are reported in the tables in the results section. 
 
Gender-adjusted linear models were also used to determine the effect of the interaction between each MetS, 
lifestyle and psychological health variable and 1) the genotype groups (categorized as wild-type, heterozygous 
and mutant genotypes) on BMI; and 2) the additive allelic variable (numerically coded as 0, 1 and 2 minor alleles) 
on BMI.  In all cases where significant p-values for the effect of the interaction between genotype groups with a  
specific variable on BMI was found, a significant effect for the additive allelic variable interaction with the 
variable was also found.  Therefore, the interaction effect size for the interaction between genotype and the 
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mentioned variables on BMI is not presented in the results section as it can be derived from the interaction 
effect size for the additive allelic variable interaction that is presented in the results section.   
 
To visualize significant results, a plot depicting each of the significant additive allelic interactions with a specified 
variable (x-axes) on BMI (y-axes) was drawn.  As gender was not significant when included in the models 
showing significant interactions, separate plots for males and females were not drawn, but rather the plots 
representing the total sample and thus unadjusted values.  This means that the results were averaged over the 
genders with the exception of one of the interaction results that were only significant when data were adjusted 
for gender and the plot (Figure 4.4) depicting this result was thus drawn for a woman.  On all plots the symbols 
represent individual observed values and the regression lines show the expected relationships for each genotype 
of the polymorphism under investigation.  The following symbols were used to identify each genotype group: 
wild-type ( ), heterozygous ( ) and mutant genotype ( ).  The plots reflect the modelled rate of 
change in a specified variable in response to a change in BMI for each genotype group. A significant additive 
allelic interaction means that the slopes (e.g. increase in BMI corresponding to a one-unit increase/decrease in 
the MetS, lifestyle and psychological health variable) of the regression lines of each genotype group differ 
significantly from each other.  A positive interaction effect size indicates that the slope of the regression line for 
the heterozygotes is larger than for subjects with no minor alleles and the slope for the subjects with two minor 
alleles is even larger.  As the minor allele was not always the mutant allele for the investigated polymorphisms, 
the minor allele is indicated below each plot in the results section.  A positive additive allelic interaction effect 
size of for example 4 would mean that the addition of one minor allele (thus heterozygote) would result in a 4-
unit increase in the slope of BMI for each one-unit increase in a MetS, lifestyle and psychological health variable 
when compared to subjects with no minor alleles.  Therefore, two minor alleles would result in an 8-unit (2X4=8) 
increase in the slope of BMI for each one-unit increase in a specified variable compared to subjects with no 
minor alleles.  A negative interaction effect size indicates that the slope of the line for the heterozygotes is 
smaller than for subjects with no minor alleles and the slope for the subjects with two minor alleles is even 
smaller. A negative additive allelic interaction effect size of -4 would mean that the addition of one minor allele 
(thus heterozygote) would result in a 4-unit decrease in the slope of BMI for each one-unit increase in a 
specified variable when compared to subjects with no minor alleles.  It is thus important to note that the positive 
or negative designation of the interaction effect sizes is only an indication of whether the slopes increase or 
decrease with the number of minor alleles.  Therefore, to interpret the association between BMI and a specified 
variable for a genotype group (thus whether this association is in a positive or negative direction) the plot (and 
not the designation of the interaction effect size) must be used. The interpretation of the plots in the results 
section focuses on the genotype group that depicts the typically expected association between BMI and the 
specified variable (thus when genotype groups are not considered) and for which the most pronounced 
regression line slope was found.   
 
Gender-adjusted linear models were also used to test for the interaction between the FTO haplotype and each 
MetS, lifestyle and psychological health variable on BMI. 
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3.15.2 Intervention data (Chapter 5)  
 
Hypotheses 
Primary null hypothesis:  
 There is no association between genotype6 and weight loss outcomes in overweight/obese subjects after 
following a conservative weight loss programme for four, eight, 12, 16 and 24 weeks. 
 
Secondary null hypotheses: 
 There is no change in the weight of overweight/obese subject after following the conservative weight loss 
programme for a period of 24 weeks. 
 There are no changes in selected psychological health and lifestyle indicators that were the focus of 
strategies included in the weight loss programme from baseline to 16 week follow-up. 
 The interaction between genotype and change in physical activity levels has no effect on change in BMI over 
the 24 week intervention period. 
 The interaction between the FTO rs1421085, FTO rs17817449 and GNB3 C825T polymorphisms and change 
in eating behaviours has no effect on change in BMI over the 24 week intervention period. 
 The interaction between the GNB3 C825T polymorphism and change in psychological health has no effect on 
change in BMI over the 24 week intervention period. 
 
Exploratory null hypotheses: 
 The interaction between the FABP2 Ala54Thr, INSIG2 rs7566605, ADRB3 Trp64Arg and ADRB2 Arg16Gly 
polymorphisms and change in eating behaviours has no effect on change in BMI over the 24 week 
intervention period. 
 The interaction between the FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, FTO rs17817449, ADRB3 
Trp64Arg and ADRB2 Arg16Gly polymorphisms and change in psychological health has no effect on change 
in BMI over the 24 week intervention period. 
 
Statistical analyses  
For descriptive purposes, Mean±SD were calculated for continuous variables and frequencies for categorical 
variables.  To determine the difference in the mean BMI between the response categories for each socio-
demographic variable the Independent Sample t-test was used in the case of two response categories and the 
One-way ANOVA test in the case of three or more response categories.  To determine the difference in the mean 
weight, BMI, age or scores of all lifestyle and psychological health variables between subjects who volunteered 
to participate in the weight loss programme and those who only completed the cross-sectional assessments, the 
Independent Samples t-test was used.  To test for associations between age or compliance and baseline 
weight/BMI and weight/BMI change over the six month period a Pearson’s correlation matrix was constructed.  
                                                 
6
 genotype refers to the genotype of the following seven polymorphisms: FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, FTO rs17817449, 
ADRB3 Trp64Arg, ADRB2 Arg16Gly and GNB3 C825T. 
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Differences in mean baseline weight/BMI and weight/BMI change over the six month period between males and 
females were determined with an Independent samples t-test.  
 
Linear models were used to determine the mean (SE) difference between baseline and 24-week follow-up 
weight and BMI.  Linear mixed-effects models with weeks as fixed effect and individual as random effect were 
constructed to determine the difference in weight and BMI from baseline to each follow-up point (every two 
weeks on the programme).  For these purposes longitudinal time-trajectories that make it possible to 
incorporate the correlation between observations on the same individual at different time-points, were used.  
Linear models with the 16-week follow-up variable as a function of the baseline variable were constructed to 
determine the mean difference and standard error (SE) of this difference between baseline and 16-weeks 
follow-up scores for lifestyle and psychological health variables.   
 
As females lost significantly more weight than males and total compliance was significantly associated with BMI 
and weight loss (see Chapter 5, Table 5.3), the linear models that were constructed to investigate the effect of 
genotype alone or in combination with other variables on weight or BMI change over the six month intervention 
period (∆ BMI), were adjusted for gender and compliance.  Linear mixed-effects models of genotype on ∆ BMI as 
fixed effect and individual as random effect (to adjust for correlations between observations on the same 
individual) were constructed to determine the genotype and additive allelic effects on time trajectories (change 
in weight and BMI) for different time-periods from the start of the intervention.  Significant genotype or additive 
allelic effects were depicted in plots with modelled weight against time (in weeks) on the weight loss 
programme.  Linear models were also used to investigate the effect of the interaction between genotype and 
change in lifestyle or psychological health variables over the four month period (∆ variable) on ∆ BMI.  Only the 
signficant additive allelic interaction effects are illustrated in plots in the results section.  These modelled graphs 
were constructed for a female with an average compliance of 4.9.  In these graphs, ∆ BMI refers to baseline 
minus follow-up BMI, thus a positive difference on the y-axes should be interpreted as a BMI loss (i.e. baseline 
BMI is more than follow-up BMI).  The ∆ variable also reflects the baseline minus follow-up scores of the specific 
questionnaire depicted on the x-axes.  Therefore, a positive value on the x-axes reflects a decrease in the specific 
questionnaire score from baseline to follow-up.  
 
Linear models were also used to investigate the effect of all gene-gene combinations on BMI change over the 24 
week intervention period.  
 
In all statistical analyses a p-value of <0.05 was designated to be statistically significant.  However, it must be 
borne in mind that with multiple comparisons as performed in this thesis, a false significant p-value (of <0.05) 
can be expected to occur once in every 20 tests.  To overcome this problem Bonferroni adjustments and 
stringent p-values can be used.  However, Perneger (1998) argued that such adjustments have limited value in 
medical research.  This author points to the fact that the significant result of a test (for example a positive 
association between BMI and cholesterol) will be considered true if it was performed together with a small 
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number of other tests (<20).  However, the same result will be obtained when it is performed along with 50 
other tests, which does not justify the exclusion of the result just because the number of tests has increased.  
Perneger (1998) therefore recommends that the results from all tests are important to consider and that each 
significant p-value should rather be interpreted with caution, taking into account the plausibility of the finding.  
This approach was followed in this thesis. 
 
 
3.16 Ethical issues 
 
Ethical permission for this research was obtained from the Health Research Ethics Committee of Stellenbosch 
University and the Human Research Ethics Committee of the Faculty of Health Sciences at the University of Cape 
Town.  The research was conducted according to international and locally accepted ethical guidelines for 
research, namely the Declaration of Helsinki, Guidelines on Ethics for Medical and Genetic Research of the 
Medical Research Council of South Africa.  After being thoroughly informed, each volunteer signed a consent 
form (Addendum B).  Subjects were assured that data would be handled confidentially and only published within 
group context.    
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Chapter 4 
 
 
Cross-sectional study 
Results, discussion and conclusions  
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4.1 Results 
 
Socio-demographic and weight profile of the cross-sectional sample 
 
The subjects had a mean±SD age of 32.9±4.4 years, weight of 99.9±20.1 kg, height of 1.68±0.08 m and BMI 
of 35.2±6.6 kg/m2.  In this sample 21.8% of subjects were overweight (BMI of 27-29.9 kg/m2), 33.1% were 
obese class I (BMI of 30-34.9 kg/m2), 24.1% were obese class II (BMI of 35-39.9 kg/m2) and 21.0% were 
obese class III (BMI ≥ 40 kg/m2).  Most were female, married, Afrikaans speaking, had a tertiary qualification 
and lived with their partners and children (Table 4.1).  There were no significant differences in mean BMI 
between the response categories of the socio-demographic variables.  Two subjects out of 133 (0.02%) 
used medication for hypertension, three subjects (0.02%) used statins for high LDL-cholesterol, seven 
subjects (0.05%) were on oral contraceptives while 11 (0.08%) used anti-depressants.   
 
Table 4.1: Socio-demographic profile of overweight/ obese subjects (n=133) 
 n % BMI (kg/m
2
) 
mean±SD 
p-value 
Gender 
 Female 
 Male 
 
112 
21 
 
84.2 
15.8 
 
35.3±6.9 
34.9±4.5 
 
0.818† 
 
Marital status  
 Married / living together 
 Unmarried (including separated/ divorced) 
 
 
86 
47 
 
 
64.7 
35.3 
 
 
35.1±6.3 
35.5±7.1 
 
 
0.703† 
 
Home language 
 Afrikaans 
 English 
 
 
120 
13 
 
 
90.2 
9.8 
 
 
35.2±6.5 
35.8±7.2 
 
 
0.729† 
 
Level of education  
 Completed Grade 10 or Matric 
 Tertiary qualification 
 
 
43 
90 
 
 
32.3 
67.7 
 
 
35.1±7.3 
35.3±6.2 
 
 
0.887† 
 
Living 
 alone 
 with friends/ parents 
 with a partner 
 with a partner and child(ren) 
 
 
22 
20 
30 
61 
 
 
16.5 
15.0 
22.6 
45.9 
 
 
37.4±8.0 
33.7±6.0 
33.8±5.6 
35.7±6.5 
 
 
0.156§ 
† Independent Samples t-test 
§ One-way ANOVA 
    
 
Genotype and allele frequencies 
 
The genotype and allele frequencies for the polymorphisms investigated in the study sample are presented 
in Table 4.2.   
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Table 4.2: Genotype and allele frequencies of overweight/obese Caucasian subjects and association with BMI.  
Gene Genotype frequencies Association with BMI Allele 
frequencies 
HWE 
polymorphism Base   BMI genotype
†
 additive
§
  
 pair
‡
 n* % mean±SD p-value p-value  % p-valueГ 
 
FABP2 Ala54Thr 
 
GG 
GA 
AA 
 
 
52 
43 
17 
 
46.4 
38.4 
15.2 
 
35.4±6.6 
35.8±7.1 
33.5±6.7 
 
0.4937 
 
0.4421 
 
G-allele 
A-allele 
 
65.6 
34.4 
 
0.1410 
 
INSIG2 rs7566605 GG 
GC 
CC 
 
51 
55 
9 
44.4 
47.8 
7.8 
35.0±6.6 
35.5±6.9 
36.2±6.6 
0.8382 0.5530 G-allele 
C-allele 
68.3 
31.7 
0.3880 
 
FTO rs1421085 TT 
TC 
CC 
 
21 
55 
25 
20.8 
54.5 
24.7 
34.5±7.3 
36.6±7.0 
33.6±5.4 
0.1715 0.6764 T-allele 
C-allele 
48.0 
52.0 
0.4284 
 
FTO rs17817449 TT 
TG 
GG 
 
31 
32 
42 
29.5 
30.5 
40.0 
35.9±7.0 
34.9±6.8 
36.0±7.2 
0.8642 0.8931 T-allele 
G-allele 
44.8 
55.2 
0.0001 
 
ADRB3 Trp64Arg TT 
TC 
CC 
 
84 
9 
0 
90.3 
9.7 
0 
35.8±7.0 
33.3±3.5 
- 
0.2410 0.2410 T-allele 
C-allele 
95.2 
4.8 
1.0000 
 
ADRB2 Arg16Gly 
 
AA 
AG 
GG 
 
19 
51 
36 
17.9 
48.1 
34.0 
35.5±6.8 
35.1±7.1 
36.1±6.1 
0.8129 0.6703 A-allele 
G-allele 
42.0 
58.0 
1.0000 
 
GNB3 C825T CC 
CT 
TT 
 
52 
36 
19 
48.6 
33.6 
17.8 
36.1±7.6 
34.8±5.8 
34.9±5.6 
0.6332 0.4004 C-allele 
T-allele 
65.4 
34.6 
0.0098 
 
*n varies due to missing values 
‡Ascending order: wild-type then heterozygous and mutant genotypes. 
†Gender-adjusted linear model testing the association between BMI and the genotype groups (categorised as the 
homozygous wild-type, heterozygous and homozygous mutant genotypes). 
§Gender-adjusted linear model testing the association between BMI and the additive allelic variable (numerically 
coded as 0, 1 and 2 minor alleles). 
ГExact test; HWE = Hardy-Weinberg equilibrium 
 
 
The frequency of the homozygous mutant (GG) genotype of the FTO rs17817449 polymorphism was higher 
than that of the homozygous wild-type or heterozygous genotypes.  The frequency of the heterozygous 
genotype was higher than the homozygous wild-type or homozygous mutant genotypes of the INSIG2 
rs7566605, ADRB2 Arg16Gly and FTO rs1421085 polymorphisms.  No homozygous mutant (CC) genotype 
was found in this sample for the ADRB3 Trp64Arg polymorphism.  The frequencies of the mutant alleles 
were higher than the wild-type alleles of the ADRB2 Arg16Gly, FTO rs1421085 and rs17817449 
polymorphisms. Although the genotype frequencies of the GNB3 C825T and FTO rs17817449 
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polymorphisms were not in HWE, it must be borne in mind that all subjects were overweight/obese and not 
representative of a random population.  This could provide an explanation for the deviations from HWE.   
 
It is evident from Table 4.2 that no associations between BMI and genotype or additive allelic groups were 
found.   
 
 Weight related perceptions 
 
Only two thirds (62.1%) of subjects perceived their weight as normal during their childhood years while a 
third already perceived themselves as overweight (Table 4.3).  Prevalence of “perceiving weight as normal” 
decreased during adolescence (50.8%) and almost two thirds perceived themselves as overweight or obese 
(65.9%) during young adulthood (ages 20 to 25 years).  The mean current BMI of subjects who perceived 
their weight as either overweight/obese during childhood, adolescence and young adulthood was 
significantly higher than those who perceived their weight as normal during these life cycle phases (Table 
4.3).   
 
Most subjects felt that their mothers were overweight or obese during their (the subjects’) adolescence 
and that their fathers’ weight was normal.  However, when subjects started with this study most thought 
that their parents were either overweight or obese.  There were no significant differences between the 
different response categories for perception of parents’ current or previous weight and the subjects’ mean 
current BMI (Table 4.3). 
 
Subjects with the homozygous wild-type Arg16Arg genotype of the ADRB2 Arg16Gly polymorphism were 
significantly more likely to perceive themselves as overweight during their childhood years, while those 
with the heterozygous or homozygous mutant genotypes mostly thought they had a normal weight (Table 
4.4).  Subjects with the homozygous wild-type or mutant genotypes of the GNB3 C825T polymorphism 
were significantly more likely to perceive their weight as normal during their childhood years than the 
heterozygotes.  During their adolescent years, only those with the homozygous mutant GNB3 genotype 
were significantly more likely to perceive their weight as normal while those with the homozygous wild-
type and heterozygous genotypes mostly thought they were overweight at the time.  However, these 
associations between perceived weight and the GNB3 C825T polymorphism disappeared in young 
adulthood.  Subjects with the homozygous mutant CC genotype of the FTO rs1421085 polymorphism were 
significantly more likely to perceive their weight as normal in adolescence, while the TT and TC genotypes 
mostly thought they were overweight.  There were no significant associations between the subjects’ 
genotypes for all polymorphisms tested and perception of parents’ current or previous weight (results not 
presented in a Table). 
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Table 4.3: Weight related perceptions and association with mean±SD BMI.   
Perceived weight categories n % Collapsed perceived 
weight categories* 
% Current BMI 
mean±SD 
p-value
§
 
Perceived weight during childhood       
 Underweight 3 2.3     
 Normal weight 82 62.1 Normal 62.4 33.8±5.5 0.0003 
 Overweight 44 33.3 Overweight 35.6 38.0±7.5  
 Obese 
 
3 2.3     
Perceived weight during adolescence 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 
 
1 
66 
61 
4 
 
0.8 
50.0 
46.2 
3.0 
 
 
Normal weight 
Overweight 
 
 
50.8 
49.2 
 
 
34.1±6.4 
36.5±6.6 
 
 
0.0322 
Perceived weight when 20 to 25 years 
old 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 
 
 
1 
44 
70 
17 
 
 
0.8 
33.3 
53.0 
12.9 
 
 
 
Normal weight 
Overweight 
Obese 
 
 
 
34.1 
53.0 
12.9 
 
 
 
32.6±5.7a 
35.8±6.5b 
40.3±5.8c 
 
 
 
<0.0001 
Perception of mother’s weight when 
subject was an adolescent 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 
 
 
2 
60 
62 
8 
 
 
1.5 
45.4 
47.0 
6.1 
 
 
 
Normal weight 
Overweight 
 
 
 
46.9 
53.1 
 
 
 
 
35.6±7.5 
34.7±5.7 
 
 
 
0.4400 
Perception of father’s weight when 
subject was an adolescent 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 Diseased/ did not know him 
 
 
 
1 
80 
42 
7 
2 
 
 
0.8 
60.6 
31.8 
5.3 
1.5 
 
 
 
Normal weight 
Overweight 
 
 
 
62.3 
37.7 
 
 
 
 
35.4±6.7 
35.2±6.5 
 
 
 
0.9130 
Perception of mother’s current weight 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 Diseased/ did not know her 
 
 
5 
47 
58 
14 
8 
 
3.8 
35.6 
43.9 
10.6 
6.1 
 
 
Normal weight 
Overweight 
 
 
41.9 
58.1 
 
 
 
35.6±7.6 
35.0±5.9 
 
 
0.6430 
 
Perception of father’s current weight 
 Underweight 
 Normal weight 
 Overweight 
 Obese 
 Diseased/ did not know him  
 
 
1 
49 
47 
11 
24 
 
0.8 
37.1 
35.6 
8.3 
18.2 
 
 
Normal weight 
Overweight 
 
 
46.3 
53.7 
 
 
34.8±6.6 
35.5±7.0 
 
 
0.6340 
 
*Underweight and normal weight categories were collapsed as “normal weight”, while overweight and obese 
categories were collapsed as “overweight” except for “perceived weight when 20 to 25 years old”, where only 
underweight and normal weight categories were combined. 
§ Gender-adjusted linear models; in the case of 3 categories the means with the same letter do not differ significantly 
using the Tukey post-hoc test. 
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Table 4.4: Association between weight related perceptions and genotypes. 
Life cycle stages Polymorphisms Perception of Column % of genotypes × perception  
  weight Wild-type Heterozygous Mutant p-value* 
       
Perception of  ADRB2 Arg16Gly Normal 42.1 74.0 61.1 0.0442 
own childhood   Overweight 57.9 26.0 38.9  
weight       
 GNB3 C825T Normal 76.9 48.6 73.7 0.0177 
  Overweight 23.1 51.4 26.3  
       
Perception of  FTO rs1421085 Normal 33.3 47.3 76.0 0.0102 
own adolescent  Overweight 66.7 52.7 24.0  
weight       
       
*Pearson Chi  square test  
Non-significant differences not included in table 
 
 
Metabolic Syndrome (MetS) 
 
MetS was diagnosed in 46.8% of subjects using the ATP NCEP III criteria (Table 4.5).  The most prevalent 
trait contributing to the diagnoses of MetS was a large waist circumference, followed by a low HDL and high 
blood pressure. The mean waist circumference, HDL and blood pressure were in the ranges set for the 
diagnosis of MetS, while the mean glucose and triglycerides were below these cut-offs.  Subjects who were 
diagnosed with MetS as well as those who met the respective diagnostic cut-offs for waist circumference, 
HDL and blood pressure had a significantly higher mean BMI than subjects who were not diagnosed with 
MetS or who did not meet the respective cut-off values (Table 4.5).  Only 4% of the subjects met none of 
the diagnostic cut-offs set for each MetS trait, while 22.7% met one, 26.7% met two, 34.7% met three, 
10.7% met four and 1.3% met all the cut-off values.  This was also reflected in the fact that the subjects met 
the diagnostic cut-offs for a mean±SD of 2.3±1.1 MetS traits (data not presented in a Table).   
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Table 4.5:  Mean±SD for MetS traits (ATP NCEP III criteria), % subjects who met the relevant diagnostic cut-offs as well 
as association with BMI. 
MetS traits   Cut-offs for MetS  MetS diagnosed BMI 
 n
§
 Mean±SD NCEP ATP III criteria Yes/No % mean±SD p-value† 
        
Triglycerides 
(mmol/L) 
88 1.17±0.60 ≥1.69 mmol/L Yes 
No 
19.3 
80.7 
 
36.2±5.8 
35.6±7.0 
0.7830 
Waist                       All     
circumference        ♀    
(cm)                          ♂ 
                                         
84 
72 
12 
108.1±14.2 
106.6±13.9 
117.6±12.0 
 
Women: >88 cm 
Men: >102 cm 
 
Yes 
No 
92.9 
7.1 
 
36.4±6.7 
28.2±1.3 
0.0044 
Blood pressure 
(mmHg) 
84   Yes 
No 
41.7 
58.3 
38.2±6.7 
34.0±6.4 
0.0048 
 Systolic  84 132.4±17.1 ≥130/85 mmHg or      
 Diastolic  84 88.0±13.8 currently treated with 
hypertension medication 
  
 
 
  
Glucose 
(mmol/L) 
88 5.06±0.55 ≥6.1 mmol/L Yes 
No 
6.8 
93.2 
 
37.9±9.9 
35.6±6.5 
0.4067 
HDL                  All                
(mmol/L)                         
                               ♀ 
                                  ♂ 
                        
84 
 
72 
12 
0.97±0.19 
 
1.14±0.31 
1.11±0.30 
 
 
Women: <1.24 mmol/L 
Men: <1.04 mmol/L 
 
Yes 
No 
67.9 
32.1 
 
36.7±6.7 
33.2±6.2 
0.0235 
MetS diagnosed 77 - 3 or more of above traits Yes 
No 
46.8 
53.2 
37.8±6.4 
33.3±6.6 
 
0.0032 
† Gender-adjusted linear model 
§n varies due to missing values 
MetS = metabolic syndrome; ♀ = women; ♂ = men 
 
 
Significant associations between mean values for different MetS traits and the GNB3 C825T and INSIG2 
rs7566605 polymorphisms were found (Table 4.6).  Subjects with the mutant TT genotype of the GNB3 
C825T polymorphism had significantly higher mean glucose and triglyceride levels, while those with the 
mutant CC genotype of the INSIG2 rs7566605 polymorphism had significantly lower HDL levels.  Subjects 
with the latter two mutant genotypes were also significantly more inclined to meet the criteria of a higher 
number of traits for the diagnosis of MetS.  Furthermore, subjects with the mutant TT genotype of the 
GNB3 C825T polymorphism were more likely (p=0.0322) to be diagnosed with MetS compared to those 
with wild-type and heterozygous genotypes of this polymorphism (Figure 4.1).  No significant associations 
were found between the polymorphisms investigated in this study and the percentage subjects who met 
the diagnostic cut-offs for each of the five MetS traits individually (results not presented in a Table).   
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Table 4.6: Significant associations between MetS traits and genotype.   
MetS trait Polymorphisms Genotypes n* mean±SD p-value§ 
      
Triglycerides (mmol/L) GNB3 C825T C-allele carriers 62 1.1±0.6 0.0447 
  TT 10 1.5±0.6  
      
Glucose (mmol/L) GNB3 C825T CC 34 5.0±0.5a 0.0322 
  CT 29 5.0±0.6a,b  
  TT 9 5.5±0.8b  
      
 GNB3 C825T C-allele carriers 63 5.0±0.5 0.0090 
  TT 9 5.5±0.8  
      
HDL (mmol/L) INSIG2 rs7566605 GG 33 1.1±0.3a,b 0.0343 
  CG 34 1.2±0.3a  
  CC 7 0.9±0.2b  
      
 INSIG2 rs7566605 G-allele carriers 67 1.2±0.3 0.0164 
  CC 7 0.9±0.2  
      
Number of MetS GNB3 C825T C-allele carriers 55 2.2±1.0 0.0417 
traits  TT 9 3.0±1.0  
      
 INSIG2 rs7566605 G-allele carriers 60 2.2±1.1 0.0327 
  CC 6 3.2±1.0  
*n vary due to missing values; § Gender-adjusted linear models, in the case of 3 categories the means with the same 
letter do not differ significantly using the Tukey post-hoc test. 
Non-significant differences not included in table; MetS = metabolic syndrome 
 
 
Figure 4.1:  Prevalence of MetS in overweight/ obese subjects in the total sample and according to genotypes.   
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The main effect sizes of the average change in BMI corresponding to a one-unit increase in each MetS trait 
are presented in Table 4.7.  For instance, a one-unit (1 cm) increase in waist circumference was significantly 
associated with a 0.41 kg/m2 increase in BMI.  Interpreting the inverse of the main effect sizes that would 
correspond to a one-unit change in BMI, revealed that a one-unit (1 kg/m2) increase in BMI was significantly 
associated with a 2.44 cm increase in waist circumference, 4.55 mmHg increase in systolic and 5.56 mmHg 
increase in diastolic blood pressure and a 0.20 mmol/L decrease in HDL.  Furthermore, each 2.4 kg/m2 
increase in BMI was significantly associated with the diagnosis of an additional MetS trait (Table 4.7).   
 
The rate of change in a MetS trait in response to a change in BMI differed significantly between the 
genotype groups of the FABP2 Ala54Thr, FTO rs1421085 and rs17817449 polymorphisms (Table 4.7).  The 
most pronounced increase in triglycerides in response to an increase in BMI was observed for the wild-type 
homozygotes of FABP2 Ala54Thr (Figure 4.2).  The most pronounced increase in HDL in response to a 
decrease in BMI was observed for the homozygous mutant genotypes of the FTO rs1421085 (Figure 4.3) 
and FTO rs17817449 (Figure 4.4) polymorphisms.  Similarly, the most pronounced increase in HDL in 
response to an decrease in BMI was observed for the mutant (C-G) FTO haplotype compared to the wild-
type T-T haplotype of these two FTO polymorphisms (effect size = 13.6, p=0.0135, results not included in a 
Table or Figure). No significant differences were found between the other haplotype combinations. 
 
 
Table 4.7: The main effect size (the average change in BMI in response to a one-unit increase in each MetS trait) and 
corresponding p-values, as well as the interaction effect size and corresponding p-values of the interaction between 
MetS traits and polymorphisms on BMI.   
MetS traits Effect of MetS traits on 
BMI 
Effect of MetS trait × polymorphism on BMI 
 Genes and Genotype Minor allele Additive 
 
Main 
effect size 
p-value* 
polymorphisms 
p-value
†
 
Interaction 
effect size 
p-value
§
 
Triglyceride 1.11 0.3701 FABP2 Ala54Thr 0.0018 -6.20 0.0021 
(mmol/L)   INSIG2 rs7566605 0.7193 -1.53 0.3909 
   FTO rs1421085 0.4602 1.85 0.3810 
   FTO rs17817449 0.1594 -1.33 0.4438 
   ADRB3 Trp64Arg 0.4433 -11.17 0.4433 
   ADRB2 Arg16Gly 0.8564 -0.87 0.6444 
   GNB3 C825T 0.7095 -0.48 0.8062 
       
Waist 0.41 <0.0001 FABP2 Ala54Thr 0.9499 0.00 0.9639 
circumference   INSIG2 rs7566605 0.4873 -0.01 0.9136 
(cm)   FTO rs1421085 0.6364 -0.04 0.5155 
   FTO rs17817449 0.9560 0.01 0.8098 
   ADRB3 Trp64Arg 0.7426 -0.09 0.7426 
   ADRB2 Arg16Gly 0.4933 0.03 0.5360 
   GNB3 C825T 0.6257 0.00 0.9560 
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Table 4.7: (continued) 
MetS traits Effect of MetS traits on 
BMI 
Effect of MetS trait × polymorphism on BMI 
 Genes and Genotype Minor allele Additive 
 
Main 
effect size 
p-value* 
polymorphisms 
p-value
†
 
Interaction 
effect size 
p-value
§
 
Systolic 0.22 <0.0001 FABP2 Ala54Thr 0.7649 0.03 0.6316 
blood pressure   INSIG2 rs7566605 0.7972 0.05 0.5258 
(mmHg)   FTO rs1421085 0.1959 -0.06 0.2523 
   FTO rs17817449 0.6580 -0.01 0.8596 
   ADRB3 Trp64Arg 0.7184 0.16 0.7184 
   ADRB2 Arg16Gly 0.2847 0.03 0.6026 
   GNB3 C825T 0.4807 -0.02 0.7345 
       
Diastolic  0.18 0.0010 FABP2 Ala54Thr 0.3518 0.12 0.2230 
blood pressure   INSIG2 rs7566605 0.8432 -0.04 0.6902 
(mmHg)   FTO rs1421085 0.7457 0.05 0.5716 
   FTO rs17817449 0.5055 -0.03 0.6609 
   ADRB3 Trp64Arg 0.5494 0.60 0.5494 
   ADRB2 Arg16Gly 0.2986 0.02 0.8181 
   GNB3 C825T 0.5784 0.04 0.6435 
       
Glucose  0.11 0.9319 FABP2 Ala54Thr 0.5060 -2.87 0.2654 
(mmol/L)   INSIG2 rs7566605 0.1561 0.89 0.6901 
   FTO rs1421085 0.8425 -0.87 0.7049 
   FTO rs17817449 0.1343 2.99 0.0626 
   ADRB3 Trp64Arg 0.3815 -6.50 0.3815 
   ADRB2 Arg16Gly 0.7124 -0.58 0.8043 
   GNB3 C825T 0.9986 0.29 0.8748 
       
HDL -5.42 0.0334 FABP2 Ala54Thr 0.3485 2.60 0.5663 
(mmol/L)   INSIG2 rs7566605 0.8745 0.22 0.9630 
   FTO rs1421085 0.0587 -10.09 0.0270 
   FTO rs17817449 0.0800 6.84 0.0454 
   ADRB3 Trp64Arg 0.7872 2.99 0.7872 
   ADRB2 Arg16Gly 0.1022 -3.95 0.3686 
   GNB3 C825T 0.9863 0.67 0.8789 
       
Number of  2.40 0.0008 FABP2 Ala54Thr 0.3986 -1.85 0.1711 
MetS    INSIG2 rs7566605 0.2665 -1.10 0.3663 
traits   FTO rs1421085 0.4793 1.55 0.2351 
   FTO rs17817449 0.4026 0.37 0.7221 
   ADRB3 Trp64Arg 0.7810 1.40 0.7810 
   ADRB2 Arg16Gly 0.4273 -0.67 0.5525 
   GNB3 C825T 0.8654 -0.61 0.6273 
All statistical models were adjusted for gender. 
*Linear model of the main effect of specific MetS traits on BMI. 
†Linear model of the interaction between each MetS trait and genotype groups (categorised as wild-type, 
heterozygous and mutant genotypes) on BMI. 
§Linear model of the interaction between each MetS trait and the additive allelic variable (numerically coded as 0, 1 
and 2 minor alleles) on BMI. 
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Figure 4.2:  Plot of BMI against triglycerides.  Symbols represent individual observed values and regression lines show 
the expected relationships for each genotype of the FABP2 Ala54Thr polymorphism (minor allele = A). 
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Figure 4.3:  Plot of BMI against HDL.  Symbols represent individual observed values and regression lines show the 
expected relationships for each genotype of the FTO rs1421085 polymorphism (minor allele = T). 
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Figure 4.4:  Plot of BMI against HDL.  Symbols represent individual observed values and regression lines show the 
expected relationships for a woman for each genotype of the FTO rs17817449 polymorphism (minor allele = T). 
 
 
Physical activity 
 
The mean±SD scores of the work, sport and leisure-time indices are presented in Table 4.8.   A one-point 
increase in the sport index or leisure-time index score was significantly associated with a 2.01 kg/m2 and 
2.43 kg/m2 decrease in BMI respectively (Table 4.8).   
 
The only significant association found between genotype groups and mean±SD scores for the work, sport 
and leisure-time indices was for the INSIG2 rs7566605 polymorphism.  The mutant C-allele carriers had a 
higher mean±SD score of 2.2±0.6 compared to the score (1.9±0.4) of the wild-type GG homozygotes (p= 
0.0470) (not presented in a Table).    
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The rate of change in BMI in response to a change in the leisure-time index score differed significantly 
between the genotype groups of the GNB3 C825T and INSIG2 rs7566605 polymorphisms.  There was a 
more pronounced decrease in BMI in response to an increase in the leisure-time index score for the wild-
type homozygotes (CC and GG respectively) of the GNB3 C825T (Figure 4.5) and INSIG2 rs7566605 
polymorphisms (Figure 4.6) that was not observed for the mutant homozygotes. 
 
Haplotype analysis of the two FTO polymorphisms revealed that the most pronounced decrease in BMI in 
response to an increase in the sport index score was observed for the wild-type T-T haplotype compared to 
the T-G haplotype (effect size = -0.655, p=0.0469) (results not presented in a Table).  No significant 
differences were found between the other haplotype combinations. 
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Table 4.8:   Mean±SD scores of the three physical activity indices, the main effect size (the average change in BMI in 
response to a one-unit unit increase in each physical activity index score) and corresponding p-values, as well as the 
interaction effect size and corresponding p-values of the interaction between physical activity indices and 
polymorphisms on BMI.   
Physical  PA index  Effect of PA indices on 
BMI 
Effect of PA index × polymorphism on BMI 
activity (PA) score Genes and  Genotype Minor allele Additive 
index Mean±SD Main 
effect size 
p-value* polymorphisms p-value
†
 
Interaction 
effect size 
p-value
§
 
Work index 2.4±0.6 1.08 0.3044 FABP2 Ala54Thr 0.2958 0.56 0.7542 
    INSIG2 rs7566605 0.9315 -0.67 0.7460 
    FTO rs1421085 0.1716 0.82 0.6785 
    FTO rs17817449 0.8756 -0.48 0.7762 
    ADRB3 Trp64Arg 0.4121 -5.16 0.4121 
    ADRB2.Arg16Gly 0.8871 0.74 0.6845 
    GNB3 C825T 0.1569 2.39 0.1266 
        
Sport index 2.0±0.7 -2.10 0.0194 FABP2 Ala54Thr 0.7049 0.20 0.9029 
    INSIG2 rs7566605 0.8508 -0.61 0.7218 
    FTO rs1421085 0.1424 1.50 0.2896 
    FTO rs17817449 0.2774 -1.06 0.3949 
    ADRB3 Trp64Arg 0.7812 1.14 0.7812 
    ADRB2.Arg16Gly 0.2041 -2.47 0.0903 
    GNB3 C825T 0.1688 1.19 0.3705 
        
Leisure-time  2.1±0.5 -2.43 0.0233 FABP2 Ala54Thr 0.8880 -0.32 0.8428 
index    INSIG2 rs7566605 0.0797 4.33 0.0243 
    FTO rs1421085 0.0930 2.00 0.2688 
    FTO rs17817449 0.4718 -1.83 0.2169 
    ADRB3 Trp64Arg 0.5333 -3.65 0.5333 
    ADRB2.Arg16Gly 0.4918 -1.95 0.2470 
    GNB3 C825T 0.0388 3.24 0.0447 
        
All statistical models were adjusted for gender 
*Linear model of main effects of the work, sport and leisure-time index scores on BMI. 
†Linear model of the interaction between each physical activity index and genotype groups (categorised as wild-type, 
heterozygous and mutant genotypes) on BMI. 
§Linear model of the interaction between each physical activity index and the additive allelic variable (numerically 
coded as 0, 1 and 2 minor alleles) on BMI. 
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Figure 4.5:  Plot of BMI against the leisure-time index score of the Baecke physical activity questionnaire.  Symbols 
represent individual observed values and regression lines show the expected relationships for each genotype of the 
GNB3 C825T polymorphism (minor allele = T). 
 
 
Figure 4.6:  Plot of BMI against the leisure-time index score of the Baecke physical activity questionnaire.  Symbols 
represent individual observed values and regression lines show the expected relationships for each genotype of the 
INSIG2 rs7566605 polymorphism (minor allele = C). 
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Dietary intake of indicator food groups 
 
The mean±SD frequency of daily intakes of high fat foods (including take-away food), energy-dense snacks, 
take-away foods (as an independent fourth group) and energy-dense drinks are presented in Table 4.9.  A 
one-unit increase in the daily intake of energy-dense drinks was significantly associated with a 1.70 kg/m2 
increase in BMI.  Similar significant associations were found between a one-unit increase in the intake of 
high fat foods, energy-dense snacks and take-away food and a 0.40, 1.61 or 1.96 kg/m2 increase in BMI 
respectively (Table 4.9).   
 
The significant differences in mean intake of indicator food groups between genotype groups are presented 
in Table 4.10.  Subjects with the wild-type CC homozygous genotype of the GNB3 C825T polymorphism had 
higher intakes of energy-dense drinks and high-fat foods.  Subjects with the homozygous mutant GG 
genotype of the FTO rs17817449 polymorphism had higher intake of high-fat foods. The mutant AA 
homozygotes of the FABP2 Ala54Thr polymorphism and the wild-type TT homozygotes of the FTO 
rs1421085 polymorphism had higher intakes of take-away foods (Table 4.10).   
 
The rate of change in BMI in response to a change in the intake of energy-dense snacks differed 
significantly between the genotype groups of the GNB3 C825T polymorphism (Table 4.9).  The most 
pronounced increase in BMI in response to an increase in the intake of energy-dense snacks was observed 
for the wild-type CC homozygotes (Figure 4.7).   
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Table 4.9: Mean±SD intake/day of indicator food groups, the main effect size (the average change in BMI in response 
to a one-unit unit increase in intake of energy-dense food groups) and corresponding p-values, as well as the 
interaction effect size and corresponding p-values of the interaction between energy-dense food groups and 
polymorphisms on BMI.   
Energy-dense 
food groups 
Frequency 
of intake  
Effect of energy-dense 
food groups on BMI 
Interaction between energy-dense food group × 
polymorphism on BMI 
 per day Genes and Genotype Minor allele Additive 
 Mean±SD Main  
effect size 
p-value* Polymorphisms p-value
†
 Interaction 
effect size 
p-value
§
 
Energy-dense 1.0±1.3 1.70 0.0001 FABP2 Ala54Thr 0.9774 -0.15 0.7910 
drinks    INSIG2 rs7566605 0.2018 -1.53 0.0788 
    FTO rs1421085 0.3551 0.06 0.9373 
    FTO rs17817449 0.5730 -0.56 0.3484 
    ADRB3 Trp64Arg 0.8581 1.29 0.8581 
    ADRB2 Arg16Gly 0.2529 1.25 0.1605 
    GNB3 C825T 0.9389 0.08 0.9327 
        
High fat foods 5.3±4.0 0.40 0.0071 FABP2 Ala54Thr 0.7181 -0.01 0.9704 
    INSIG2 rs7566605 0.7821 -0.08 0.8123 
    FTO rs1421085 0.7006 0.27 0.3109 
    FTO rs17817449 0.2983 0.08 0.7103 
    ADRB3 Trp64Arg 0.7701 0.47 0.7701 
    ADRB2 Arg16Gly 0.1406 0.47 0.1133 
    GNB3 C825T 0.5321 0.06 0.8295 
        
Energy-dense  1.4±1.4 1.61 0.0001 FABP2 Ala54Thr 0.3410 -0.06 0.9082 
snacks    INSIG2 rs7566605 0.4686 -1.05 0.1930 
    FTO rs1421085 0.3802 -0.09 0.8831 
    FTO rs17817449 0.1379 -0.71 0.1717 
    ADRB3 Trp64Arg 0.8973 0.63 0.8973 
    ADRB2 Arg16Gly 0.7699 -0.56 0.5024 
    GNB3 C825T 0.0950 -1.25 0.0312 
        
Take-away 0.6±0.8 1.96 0.0069 FABP2 Ala54Thr 0.3917 -1.18 0.3660 
foods    INSIG2 rs7566605 0.4133 -1.37 0.3631 
    FTO rs1421085 0.6505 1.96 0.2809 
    FTO rs17817449 0.1431 -2.27 0.1026 
    ADRB3 Trp64Arg 0.6080 1.65 0.6080 
    ADRB2 Arg16Gly 0.8654 -0.52 0.7208 
    GNB3 C825T 0.3607 -0.20 0.8878 
        
All statistical models were adjusted for gender  
*Linear model of main effects of daily intake of energy-dense food groups on BMI. 
†Linear model of the interaction between each energy-dense food group and genotype groups (categorised as wild-
type, heterozygous and mutant genotypes) on BMI. 
§ Linear model of the interaction between each energy-dense food group and the additive allelic variable (numerically 
coded as 0, 1 and 2 minor alleles) on BMI. 
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Table 4.10: Significant differences in intake of energy-dense food groups between genotype groups.   
Energy-dense 
food groups 
Polymorphisms Genotypes n* Frequency of intake/day 
mean±SD 
p-value
§
 
      
Energy-dense  GNB3 C825T CC 47 1.6±1.8a 0.0003 
drinks  CT 35 0.4±0.4b  
  TT 18 0.8±0.8a,b  
      
 GNB3 C825T CC 47 1.6±1.8 <0.0001 
  T-allele carriers 53 0.5±0.6  
      
Take-away foods FABP2 Ala54Thr G-allele carriers 89 0.4±0.4 0.0337 
  AA (mutant) 14 0.8±1.5  
      
 FTO rs1421085 TT (wild-type) 21 1.0±1.8 0.0207 
  C-allele carriers 73 0.4±0.4  
    
 
 
High fat foods FTO rs17817449 T-allele carriers 59 4.9±3.6 0.0502† 
  GG 38 6.6±4.9 0.0494 
      
 GNB3 C825T CC 47 6.5±5.0 0.0420 
  T-allele carriers 53 4.8±3.1  
      
*n vary due to missing values  
§ Gender-adjusted linear model, in the case of 3 categories the means with the same letter do not differ significantly 
using the Tukey post-hoc test 
† Unadjusted linear model  
Non-significant differences not included in table 
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Figure 4.7:  Plot of BMI against the intake of energy-dense snacks (high fat and carbohydrate extras).  Symbols 
represent individual observed values and regression lines show the expected relationships for each genotype of the 
GNB3 C825T polymorphism (minor allele = T). 
Energy-dense snacks 
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Eating behaviour 
 
The mean±SD scores derived from the TFEQ are presented in Table 4.11.  A one-unit increase in the dietary 
restraint score was significantly associated with a 0.28 kg/m2 decrease in BMI.   A one-unit increase in the 
disinhibition, emotional disinhibition and habitual disinhibition scores was significantly associated with a 
0.33, 1.46 and 1.25 kg/m2 increase in BMI respectively (Table 4.11).   
 
The significant differences in mean TFEQ scores between genotype groups are presented in Table 4.12.  The 
mutant GG homozygotes of the FTO rs17817449 polymorphism had significantly higher rigid control and 
habitual disinhibition scores when using unadjusted linear models.  However, after adjustment for gender 
these associations became non-significant.  The mutant CC homozygotes of the FTO rs1421085 
polymorphism had significantly higher hunger and specifically internal locus for hunger scores.  The mutant 
C-allele carriers also had higher emotional disinhibition and flexible control scores that were dependent on 
gender, as these associations were non-significant in unadjusted models.  The mutant CC homozygotes of 
the INSIG2 rs7566605 polymorphism had a significantly lower attitude to self-regulation score of the 
dietary restraint subscale.   
 
The rate of change in BMI in response to a change in rigid control and self regulation subscale scores 
differed significantly between the genotype groups of the FTO rs1421085 polymorphism (Table 4.11).  The 
most pronounced increase in BMI in response to an increase in rigid control was observed for the mutant 
CC homozygotes (Figure 4.8).  The most pronounced decrease in BMI in response to an increase in self 
regulation subscale scores was observed for the wild-type TT homozygotes (Figure 4.9).  Furthermore, the 
most pronounced decrease in BMI in response to an increase in flexible control score was observed for the 
wild-type Arg16Arg homozygotes of the ADRB2 Arg16Gly polymorphism (Figure 4.10).  For the INSIG2 
rs7566605 polymorphism, the most pronounced increase in BMI in response to an increase in situational 
disinhibition score was observed for the mutant CC homozygotes (Figure 4.11).  
 
Haplotype analysis revealed that the most pronounced increase in BMI in response to a decrease in the 
attitude to self-regulation subscale score (dietary restraint) was observed for the T-G haplotype compared 
to the C-T haplotype of the two FTO polymorphisms (effect size = 2.15, p=0.0393) results not presented in a 
Table).  No significant differences were found between the other haplotype combinations.  
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Table 4.11: Mean±SD score of each scale/subscale of the TFEQ, the main effect size (the average change in BMI in 
response to a one-unit increase in TFEQ scores) and corresponding p-values, as well as the interaction effect size and 
corresponding p-values of the interaction between TFEQ scores and polymorphisms on BMI.   
TFEQ scales and  Score Effect of TFEQ on 
BMI 
Interaction between score × polymorphisms on BMI 
subscales  Polymorphism Genotype Minor allele Additive 
 Mean±SD Main 
effect size 
p-value* 
 p-value
†
 Interaction 
effect size 
p-value
§
 
        
Factor I: 7.9±4.1 -0.28 0.0439 FABP2 Ala54Thr 0.8882 0.14 0.5183 
Restraint    INSIG2 rs7566605 0.1138 0.19 0.4175 
    FTO rs1421085 0.3531 0.37 0.1612 
    FTO rs17817449 0.2386 0.30 0.1743 
    ADRB3 Trp64Arg 0.6936 0.22 0.6936 
    ADRB2 Arg16Gly 0.6670 -0.20 0.3603 
    GNB3 C825T 0.3691 0.23 0.2734 
        
Restraint: 2.4±1.5 -0.46 0.2364 FABP2 Ala54Thr 0.8690 0.15 0.7995 
Rigid control    INSIG2 rs7566605 0.1374 0.39 0.5943 
    FTO rs1421085 0.1334 1.67 0.0290 
    FTO rs17817449 0.7153 0.01 0.9847 
    ADRB3 Trp64Arg 0.7090 0.56 0.7090 
    ADRB2 Arg16Gly 0.9357 0.20 0.7536 
    GNB3 C825T 0.7205 0.28 0.6310 
        
Restraint: 2.3±1.6 -0.46 0.1944 FABP2 Ala54Thr 0.7711 0.16 0.7859 
Flexible control    INSIG2 rs7566605 0.2866 0.71 0.2185 
    FTO rs1421085 0.9609 -0.08 0.9002 
    FTO rs17817449 0.4023 0.66 0.2117 
    ADRB3 Trp64Arg 0.8624 0.31 0.8624 
    ADRB2 Arg16Gly 0.0438 -1.50 0.0161 
    GNB3 C825T 0.0666 1.08 0.0610 
        
Restraint 1.0±1.1 -0.96 0.0707 FABP2 Ala54Thr 0.4489 0.90 0.3167 
Strategic dieting    INSIG2 rs7566605 0.5852 0.55 0.5537 
    FTO rs1421085 0.5599 0.35 0.7079 
    FTO rs17817449 0.1782 1.33 0.0744 
    ADRB3 Trp64Arg 0.8722 0.35 0.8722 
    ADRB2 Arg16Gly 0.6441 -0.64 0.4722 
    GNB3 C825T 0.5649 0.87 0.2751 
        
Restraint: 2.1±1.2 -0.60 0.2109 FABP2 Ala54Thr 0.9231 0.45 0.5521 
Self-regulation    INSIG2 rs7566605 0.6286 0.59 0.4740 
    FTO rs1421085 0.0362 2.29 0.0095 
    FTO rs17817449 0.1374 1.09 0.1491 
    ADRB3 Trp64Arg 0.8957 -0.33 0.8957 
    ADRB2 Arg16Gly 0.7528 -0.02 0.9777 
    GNB3 C825T 0.7204 0.55 0.4278 
        
Restraint: 2.0±1.4 -0.59 0.1554 FABP2 Ala54Thr 0.7567 0.52 0.4289 
Avoidance of    INSIG2 rs7566605 0.2314 0.17 0.8312 
fatty foods    FTO rs1421085 0.9734 0.20 0.7966 
    FTO rs17817449 0.2409 0.48 0.4472 
    ADRB3 Trp64Arg 0.5405 0.99 0.5405 
    ADRB2 Arg16Gly 0.2643 -0.98 0.1428 
    GNB3 C825T 0.0534 0.13 0.8341 
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Table 4.11: (continued) 
TFEQ scales and  Score Effect of TFEQ on 
BMI 
Interaction between score × polymorphisms on BMI 
subscales  Polymorphism Genotype Minor allele Additive 
 Mean±SD Main 
effect size 
p-value* 
 p-value
†
 Interaction 
effect size 
p-value
§
 
        
Factor II 10.5±3.7 0.33 0.0309 FABP2 Ala54Thr 0.8497 -0.03 0.9202 
Disinhibition    INSIG2 rs7566605 0.4700 0.12 0.6599 
    FTO rs1421085 0.6270 -0.23 0.3794 
    FTO rs17817449 0.3942 0.24 0.3396 
    ADRB3 Trp64Arg 0.9969 0.00 0.9969 
    ADRB2 Arg16Gly 0.5776 0.26 0.3177 
    GNB3 C825T 0.4428 0.18 0.4950 
        
Emotional 2.2±1.2 1.46 0.0056 FABP2 Ala54Thr 0.7107 -0.49 0.5324 
disinhibition    INSIG2 rs7566605 0.4333 -0.51 0.5975 
    FTO rs1421085 0.3429 -1.34 0.1298 
    FTO rs17817449 0.9805 -0.07 0.9292 
    ADRB3 Trp64Arg 0.6907 -0.95 0.6907 
    ADRB2 Arg16Gly 0.9364 0.30 0.7199 
    GNB3 C825T 0.3075 0.09 0.9022 
        
Situational 3.4±1.4 0.02 0.9556 FABP2 Ala54Thr 0.5981 -0.19 0.7877 
disinhibition    INSIG2 rs7566605 0.0839 1.76 0.0280 
    FTO rs1421085 0.7466 -0.20 0.7844 
    FTO rs17817449 0.4629 0.48 0.4651 
    ADRB3 Trp64Arg 0.5711 1.42 0.5711 
    ADRB2 Arg16Gly 0.7210 0.21 0.7688 
    GNB3 C825T 0.5123 0.72 0.3187 
        
Habitual  2.8±1.5 1.25 0.0011 FABP2 Ala54Thr 0.9565 -0.15 0.7837 
disinhibition    INSIG2 rs7566605 0.8538 -0.18 0.7713 
    FTO rs1421085 0.4815 -0.70 0.2524 
    FTO rs17817449 0.6520 0.41 0.4466 
    ADRB3 Trp64Arg 0.7422 -0.54 0.7422 
    ADRB2 Arg16Gly 0.2037 1.11 0.0757 
    GNB3 C825T 0.3701 0.05 0.9311 
        
Factor III: 7.2±3.5 0.15 0.3593 FABP2 Ala54Thr 0.2395 -0.42 0.1137 
Perceived    INSIG2 rs7566605 0.1707 0.39 0.2018 
Hunger    FTO rs1421085 0.1942 -0.15 0.5869 
    FTO rs17817449 0.2168 -0.27 0.3071 
    ADRB3 Trp64Arg 0.8467 0.16 0.8467 
    ADRB2 Arg16Gly 0.3478 0.37 0.1746 
    GNB3 C825T 0.9877 -0.01 0.9778 
        
Hunger: 2.9±1.9 0.10 0.7573 FABP2 Ala54Thr 0.2537 -0.74 0.1338 
Internal locus    INSIG2 rs7566605 0.3523 0.14 0.8061 
of control    FTO rs1421085 0.1865 -0.09 0.8756 
    FTO rs17817449 0.2603 -0.45 0.3326 
    ADRB3 Trp64Arg 0.9705 0.05 0.9705 
    ADRB2 Arg16Gly 0.1984 0.95 0.0705 
    GNB3 C825T 0.4284 0.18 0.7150 
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Table 4.11: (continued) 
TFEQ scales and  Score Effect of TFEQ on 
BMI 
Interaction between score × polymorphisms on BMI 
subscales  Polymorphism Genotype Minor allele Additive 
 Mean±SD Main 
effect size 
p-value* 
 p-value
†
 Interaction 
effect size 
p-value
§
 
        
Hunger: 3.2±1.7 0.29 0.4035 FABP2 Ala54Thr 0.3590 -0.72 0.1834 
External locus    INSIG2 rs7566605 0.2272 0.96 0.1150 
of control    FTO rs1421085 0.2481 -0.28 0.6354 
    FTO rs17817449 0.5111 -0.23 0.6733 
    ADRB3 Trp64Arg 0.6801 0.79 0.6801 
    ADRB2 Arg16Gly 0.8055 0.35 0.5243 
    GNB3 C825T 0.7217 -0.27 0.6292 
        
TFEQ = three factor eating questionnaire 
All statistical models were adjusted for gender 
*Linear model of main effects of each TFEQ scale or subscale score on BMI. 
†Linear model of the interaction between each TFEQ scale or subscale score and genotype groups (categorised as 
wild-type, heterozygous and mutant genotypes) on BMI. 
§Linear model of the interaction between each TFEQ scale or subscale score and the additive allelic variable 
(numerically coded as 0, 1 and 2 minor alleles) on BMI. 
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Table 4.12: Significant differences in mean scores of the total and subscale scores of the TFEQ by genotype groups of 
selected polymorphisms.   
Questionnaire Gene  Genotypes n* Score of 
questionnaire 
mean±SD 
p-value 
      
Restraint scale: FTO rs17817449 T-allele carriers 60 2.1±1.6 0.0341† 
Rigid control  GG 40 2.7±1.2 0.0513§ 
      
Restraint scale: FTO rs1421085 TT 20 1.7±1.6 0.0669† 
Flexible control  C-allele carriers 77 2.5±1.7 0.0392§ 
      
Restraint scale: INSIG rs7566605 G-allele carriers 102 2.2±1.1 0.0424§ 
self-regulation  CC 8 1.4±1.4  
      
Habitual  FTO rs17817449 T-allele carriers 60 2.6±1.6 0.0479† 
disinhibition  GG 40 3.2±1.5 0.0771§ 
      
Emotional  FTO rs1421085 TT 20 2.0±1.3 0.2160† 
disinhibition  C-allele carriers 77 2.4±1.1 0.0281§ 
      
      
Hunger FTO rs1421085 TT 20 5.9±3.4a 0.0276§ 
  TC 54 7.3±3.0a,b  
  CC 23 8.8±3.9b  
      
 FTO rs1421085 TT 20 5.9±3.4 0.0373§ 
  C-allele carriers 77 7.8±3.4  
      
 FTO rs1421085 T-allele carrires  74 6.9±3.2 0.0316§ 
  CC 23 8.8±3.9  
      
Hunger: FTO rs1421085 TT 20 2.2±1.7a 0.0135§ 
Internal locus  TC 54 2.8±1.8b  
of control  CC 23 3.9±2.0c  
      
BDI = Beck depression inventory, RSES = Rosenberg self-esteem scale 
*n vary due to missing values 
† Unadjusted linear model 
§ Gender-adjusted linear model, in the case of 3 categories the means with the same letter do not differ significantly 
using the Tukey post-hoc test 
Non-significant differences not included in table 
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Figure 4.8:  Plot of BMI against rigid control score (a subscale of the dietary restraint score of the TFEQ).  Symbols 
represent individual observed values and regression lines show the expected relationships for each genotype of the 
FTO rs1421085 polymorphism (minor allele = T). 
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Figure 4.9:  Plot of BMI against attitude to self-regulation score (a subscale of the dietary restraint score of the TFEQ).  
Symbols represent individual observed values and regression lines show the expected relationships for each genotype 
of the FTO rs1421085 polymorphism (minor allele = T). 
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Figure 4.10:  Plot of BMI against flexible control score (a subscale of the dietary restraint score of the TFEQ).  Symbols 
represent individual observed values and regression lines show the expected relationships for each genotype of the 
ADRB2 Arg16Gly polymorphism (minor allele = A). 
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Figure 4.11:  Plot of BMI against situational disinhibition score (a subscale of the disinhibition score of the TFEQ).  
Symbols represent individual observed values and regression lines show the expected relationships for each genotype 
of the INSIG2 rs7566605 polymorphism (minor allele = C). 
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Psychological health 
 
The mean±SD scores of the BDI, GHQ and RSES are presented in Table 4.13.  A one-unit increase in the BDI 
score was associated with a 0.15 kg/m2 increase in BMI.  There were no associations between the scores of 
the GHQ or RSES and BMI (Table 4.13). 
 
The significant differences in mean BDI and RSES scores between genotype groups are presented in Table 
4.14.  Significantly higher BDI scores were found in subjects with the wild-type CC homozygous genotype of 
the GNB3 C825T polymorphism and in the mutant GG homozygotes of the FTO rs17817449 polymorphism 
(Table 4.14).  The mutant TT homozygotes of the GNB3 C825T polymorphism had a better self-esteem than 
wild-type allele carriers (Table 4.14).  The mutant Thr54-allele carriers also had a better self-esteem than 
the wild-type Ala54Ala genotype, but this association was dependent on gender. No differences were 
observed between GHQ scores and the genotypes of the subjects (not presented in a Table).   
 
The rate of change in BMI in response to a change in the GHQ score differed significantly between the 
genotype groups of the FTO rs1421085 polymorphism (Table 4.13).  The most pronounced increase in BMI 
in response to an increase in GHQ score was observed for the wild-type TT homozygotes (Figure 4.12).  No 
significant effect of the interaction between BDI or RSES scores and genotypes on BMI was found (Table 
4.13).  
 
Haplotype analysis revealed that the most pronounced increase in BMI in response to an increase in GHQ 
was observed for the T-G haplotype compared to the T-C haplotype of the two FTO polymorphisms (effect 
size = -0.655, p=0.469, results not presented in a Table). No significant differences were found between the 
other haplotype combinations. 
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 Table 4.13: The main effect size (the average change in BMI in response to a one-unit unit increase in each 
psychological questionnaire score) and corresponding p-values, as well as the interaction effect size and 
corresponding p-values of the interaction between psychological questionnaire scores and polymorphisms on BMI.   
Psychological Score Effect of BDI, GHQ & 
RSES scores on BMI 
Interaction between score and polymorphism on BMI 
questionnaire  Polymorphism Genotype Minor alele Additive 
 
Mean±SD Main  
effect size 
p-value*  
p-value
†
 Interaction 
effect size 
p-value
§
 
        
BDI 14.0±9.9 0.15 0.0094 FABP2 Ala54Thr 0.6750 0.10 0.3294 
    INSIG2 rs7566605 0.9818 -0.01 0.9072 
    FTO rs1421085 0.2868 -0.12 0.2710 
    FTO rs17817449 0.9353 0.01 0.8992 
    ADRB3 Trp64Arg 0.9193 -0.02 0.9193 
    ADRB2 Arg16Gly 0.4002 -0.09 0.4284 
    GNB3 C825T 0.2132 -0.04 0.6878 
        
GHQ 15.6±5.8 0.06 0.5299 FABP2 Ala54Thr 0.2121 0.23 0.1785 
    INSIG2 rs7566605 0.4031 -0.18 0.2875 
    FTO rs1421085 0.0264 -0.53 0.0085 
    FTO rs17817449 0.5763 -0.15 0.3233 
    ADRB3 Trp64Arg 0.2528 0.41 0.2528 
    ADRB2 Arg16Gly 0.1631 -0.27 0.0882 
    GNB3 C825T 0.9817 -0.03 0.8705 
        
RSES 19.1±5.2 -0.21 0.0634 FABP2 Ala54Thr 0.8811 0.09 0.6592 
    INSIG2 rs7566605 0.4121 0.19 0.3354 
    FTO rs1421085 0.2213 0.33 0.0969 
    FTO rs17817449 0.4353 0.12 0.4221 
    ADRB3 Trp64Arg 0.6105 -0.20 0.6105 
    ADRB2 Arg16Gly 0.6507 -0.03 0.8848 
    GNB3 C825T 0.0377 0.22 0.2119 
        
BDI = Beck depression inventory, GHQ = General health questionnaire, RSES = Rosenberg self-esteem scale. 
All statistical models were adjusted for gender 
*Linear model of main effect of each psychological questionnaire score on BMI. 
†Linear model of the interaction between each psychological questionnaire score and genotype groups (categorised 
as wild-type, heterozygous and mutant genotypes) on BMI. 
§Linear model of the interaction between each psychological questionnaire score and the additive allelic variable 
(numerically coded as 0, 1 and 2 minor alleles) on BMI. 
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Table 4.14: Significant differences in mean scores of the BDI and RSES between genotype groups.   
Psychological 
questionnaire 
Gene  Genotypes n* Score of 
questionnaire 
mean±SD 
p-value 
      
BDI GNB3 C825T CC 49 16.2±10.1 0.0570† 
  CT 36 13.4±11.0 0.0470§ 
  TT 19 9.8±7.1  
      
 GNB3 C825T C-allele carriers 85 15.0±10.5 0.0363§ 
  TT 19 9.8±7.1  
      
 GNB3 C825T CC 49 16.2±10.1 0.0354§ 
  T-allele carriers 55 12.1±9.9  
      
 FTO rs17817449 TT 29 13.7±10.4a,b 0.0454† 
  TG 40 11.7±8.5a 0.0736§ 
  GG 32 17.6±10.7b  
      
 FTO rs17817449 T-allele carriers 61 12.7±9.4 0.0256§ 
  GG 40 17.6±10.7  
      
RSES FABP2 Ala54Thr GG (Ala54Ala) 57 17.8±5.0 0.0581† 
  A-allele carriers 50 19.7±5.1 0.0377§ 
      
 GNB3 C825T C-allele carriers 85 18.5±5.5 0.0182§ 
  TT 19 21.5±4.4  
      
BDI = Beck depression inventory, RSES = Rosenberg self-esteem scale 
*n vary due to missing values 
† Unadjusted linear model 
§ Gender-adjusted linear model, in the case of 3 categories the means with the same letter do not differ significantly 
using the Tukey post-hoc test 
Non-significant differences not included in table 
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Figure 4.12:  Plot of BMI against GHQ score.  Symbols represent individual observed and regression lines show the 
expected relationships for each genotype of the FTO rs1421085 polymorphism (minor allele = T). 
 
 
4.2 Discussion 
 
This discussion firstly sets out to explore physical health of the study sample as reflected by the prevalence 
of the MetS and each MetS trait as well as the association thereof with BMI in overweight/obese 
Caucasians.  Secondly, the associations between BMI and perceived weight history (as a proxy for actual 
weight status) as well as selected lifestyle (physical activity, dietary intake, eating behaviour) and 
psychological health variables are explored.  The main focus of this chapter, namely the associations 
between genotype and BMI, health and lifestyle indicators as well as the effect of the interaction between 
genotype and these indicators on BMI, are explored in depth. 
 
Metabolic syndrome and associations with BMI  
Of the five MetS traits investigated in this study it was evident that abdominal obesity (a large waist 
circumference) was the most prevalent trait diagnosed in 93% of subjects according to the NCEP ATP III cut-
offs.  Compared to other studies using the same diagnostic criteria this prevalence was higher than those 
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reported for Caucasian South African samples, namely 40% in corporate executives that included 
individuals from all BMI categories (Ker et al. 2007) and 80% for women and 55% for men with type 2 
diabetes (Kalk & Joffe 2008).  It was also higher than the prevalence reported for Caucasians from 
Venezuela namely 34% for men and 53% for women (Florez et al. 2005) as well as the 48% reported for 
overweight/obese Italians (Bo et al. 2007) and 35% in Southern European populations (Bellia et al. 2009).    
 
The expected positive association between BMI and waist circumference (Mikkola et al. 2007, Esteghamati 
et al. 2008) was found in this sample.  Subjects who were classified with abdominal obesity according the 
ATP III criteria had a higher mean BMI than those who fell in the normal range for this trait.  The association 
between waist circumference and BMI in our study is also reflected in the finding that a modelled 1 kg/m2 
increase in BMI is associated with a 2.44 cm increase in waist circumference.  These associations between 
BMI and waist circumference explain the lower prevalence for abdominal obesity found in the 
abovementioned population samples when compared to our sample.  It also explains the higher mean 
waist circumferences for men (118 cm) and women (107 cm) found in our overweight/obese sample 
compared to the waist circumferences reported for the Caucasian South African population (men = 91 cm; 
women = 80 cm) in the 2003 South African Demographic and Health Survey (SADHS) (DoH 2007).  The fact 
that the mean waist circumferences in our sample were well above the cut-offs of 88 cm for women and 
102 cm for men (ATP III criteria) and that the majority of the sample were diagnosed with abdominal 
obesity is concerning, as an increase in waist circumference is known to be associated with increased 
visceral fat that has also been related to hypertension, dyslipidemia, hyperglycemia and insulin resistance 
(Stolar 2007).   
 
Dyslipidemia reflected by low HDL levels was the second most prevalent MetS trait in our sample (68%).  
This prevalence was higher than the prevalence reported for other Caucasian South African samples namely 
38% for corporate executives (Ker et al. 2007) and 65% for women or 38% for men with type 2 diabetes 
(Kalk & Joffe 2008).  In other Caucasian samples the prevalence was 8% for overweight/obese Italians (Bo et 
al. 2007), 57% (Bellia et al. 2009) and 62% (Florez et al. 2005) for population samples.  
 
Subjects who were classified with a low HDL according the ATP III criteria had a higher mean BMI than 
those who fell in the normal range for this trait.  The significant association that was found between a 
higher BMI and lower HDL levels was also evident in the fact that a modelled 1 kg/m2 increase in BMI was 
associated with a 0.18 mmol/L decrease in HDL.  This can also be interpreted as indicating that weight loss 
will help overweight/obese subjects to increase their HDL levels.  This is in line with findings that indicate a 
positive effect of weight loss on increasing HDL levels (Williams et al. 1994, Abete et al. 2010, Asztalos et al. 
2010).  However, according to a review by Abete et al. (2010) evidence regarding the effect of weight loss 
on HDL levels is equivocal, with many studies indicating decreases in HDL levels, while some indicate no 
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changes or an increase in HDL levels.  Differences in the macronutrient composition of the weight loss diets 
used in the studies review by Abete et al. (2010) may explain the contradictory results to some extent.  
Conventional weight loss diets (fat = 30%, protein = 15% and carbohydrate = 55% of TE) have mostly been 
found to decrease HDL levels; while low fat (20-30% of TE), high protein (20-30% of TE) diets have mostly 
been found to increase HDL levels.  Furthermore, weight loss diets emphasizing a higher MUFA or omega-3 
PUFA content have also been found to increase HDL levels (Abete et al. 2010).   
 
Hypertension was the third most prevalent MetS trait in this sample of overweight/obese Caucasians.  The 
hypertension prevalence of 42% was higher than the 29% reported for the corporate executives (Ker et al. 
2007), but lower than the 72% reported for individuals with type 2 diabetes (Kalk & Joffe 2008).  It was in 
line with the 37% (Florez et al. 2005) and 43% (Bellia et al. 2009) reported for other Caucasian population 
samples but lower than the 71% reported for overweight/obese Italians (Bo et al. 2007).  The fact that our 
sample consisted of overweight/obese subjects can explain the higher prevalence of hypertension when 
compared to the corporate executive sample that included individuals from all BMI categories (Ker et al. 
2007), as it is known that a positive association between BMI and BP exists (Misra & Khurana 2008).  
Similarly, when compared to the 2003 SADHS our hypertension prevalence was also higher than the 
prevalence reported for Caucasian women (15%) and men (36%) (DoH 2007).  It must be borne in mind that 
the hypertension cut-off values set according to the ATP III criteria (135/85) differ from the cut-offs (140/90) 
used in the SADHS.  Nonetheless our mean SBP/DBP of 132/88 was also higher than the 131/80 or 120/75 
reported for South African Caucasian men and women respectively (DoH 2007).   
 
Subjects who were classified with hypertension according to the ATP III criteria had a higher mean BMI than 
those who fell in the normal range for this trait.  Furthermore, the significant association that was found 
between a higher BMI and a higher systolic or diastolic blood pressure in this sample of overweight/obese 
subjects was also reflected in the finding that a modelled 1 kg/m2 increase in BMI was associated with a 
4.55 mmHg increase in SBP and 5.56 mmHg increase in DBP.  It is known that an increase in weight is a 
major risk factor for increased BP (Romero et al. 2007, Da Silva et al. 2009) and that small weight losses 
may decrease BP and the risk to develop MetS (Neter et al. 2008, Aucott et al. 2009).  The association 
found between BMI and BP can also be interpreted inversely namely that a 1 kg/m2 decrease in BMI may 
result in a 4.55 mmHg or 5.56 mmHg decrease in SBP and DBP respectively.  These findings are in line with 
results from review articles and meta-analyses that typically suggest that a 5 kg weight loss (which is 
typically equal to a 1-2 kg/m2 BMI reduction depending on initial weight and height), results in an average 
of 5.6 mmHg decrease in SBP (Aucott et al. 2009) whereas a 1 kg weight loss results in a 1 mmHg reduction 
in both DBP and SBP (Neter et al. 2008).  Such changes in BP are beneficial as a Cochrane article of cohort 
studies indicated that the estimated effect of a 5 mmHg reduction in DBP is a 21% reduction in coronary 
heart disease and a 34% reduction in stroke (Brunner et al. 2007). 
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Abnormal triglyceride and glucose levels were the least prevalent MetS traits in this sample.  Elevated 
triglycerides were diagnosed in 19% of the sample, which is lower than the prevalence of 81% reported in 
corporate executives (Ker et al. 2007) or 67% for women and 65% for men with type 2 diabetes (Kalk & 
Joffe 2008).  The prevalence in other Caucasian samples was higher ranging from 30% (Bellia et al. 2009), 
31% (Florez et al. 2005) to 36% (Bo et al. 2007).  The prevalence of abnormal glucose levels (7%) in our 
sample was lower than the 12% reported for corporate executives (Ker et al. 2007), in line with the 8% 
reported for Caucasians from Venezuela (Florez et al. 2005) but lower than the 18% for overweight/obese 
Italians (Bo et al. 2007) or 20% for Southern European Caucasians (Bellia et al. 2009).   
 
No associations were found between BMI and triglyceride or glucose levels in this study.  This is in contrast 
with the general expected association between a higher BMI or obesity status and increased triglyceride or 
glucose levels (Stipanuk 2006).  However, it must be borne in mind that an association between BMI and all 
MetS traits is not reported in all studies (Dixon & O’Brien 2001, Lemieux et al. 2006, Mikkola et al. 2007).  
This, together with the differences that were observed in the comparisons of the prevalence of MetS traits 
between our sample and the other Caucasian samples, may indicate that specific MetS traits as well as the 
association thereof with BMI may be population specific.  It also needs to be considered that the variation 
in triglyceride and glucose levels in our overweight/obese sample was small, which may explain the lack of 
association with BMI.  The fact that individuals with type 2 diabetes were excluded from the study may 
explain the low variation found in glucose values to some extent.  The review by Abete et al. (2010) on the 
effect of weight loss programmes on MetS outcomes supports the fact that the expected association 
between glucose and triglycerides and BMI are not consistently found.  Although the weight loss achieved 
by overweight/obese participants in the reviewed weight loss interventions mostly resulted in reductions in 
triglyceride and glucose levels, a number of studies also reported no effect on triglyceride or glucose levels, 
while some reported an increase in triglyceride levels.  These differences may have resulted from specific 
dietary components or the differences in macronutrient composition of the diets (Abete et al. 2010). 
 
MetS as such was diagnosed in almost half (47%) of the subjects using the NCEP ATP III criteria.  This is the 
first South African research that specifically focussed on MetS in Caucasian overweight/obese adults.  
When considering other studies using the same diagnostic criteria, but including Caucasian South Africans 
from all BMI categories, a lower prevalence of 31% was found in corporate executives (Ker et al. 2007) and 
26% in urban women (Greyling et al. 2007).  These other South African figures are in line with the 
prevalence reported for other Caucasian samples namely 30% in Southern European populations (Bellia et 
al. 2009) and 37% in Caucasians from Venezuela (Florez et al. 2005).  However, a higher MetS prevalence 
was reported for Caucasian South African men (74%) and women (84%) with type 2 diabetes (Kalk & Joffe 
2008).  Bo et al. (2007) reported a higher MetS prevalence in overweight/obese Caucasian Italians (27%) 
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compared to their normal weight counterparts (5%) (Bo et al. 2007).  Our prevalence is in line with obese 
Caucasian American men (60%) and women (50%) (Park et al. 2003) 
 
Although normal weight individuals are not exempt from developing MetS, a higher prevalence is generally 
expected in obese individuals (Park et al. 2003, Alberti et al. 2010).  This may explain the higher prevalence 
found in our overweight/obese sample compared to the cross-sectional samples consisting of individuals 
with lower mean BMIs.  When considering the association between BMI and diagnoses of MetS in our 
sample, it was evident that overweight/obese subjects who were diagnosed with MetS had a higher BMI, 
with each modelled 2.4 kg/m2 increase in BMI being significantly associated with the diagnosis of an 
additional MetS trait.   
 
In summary, it can be said that the physical health of the Caucasian overweight/obese subjects in this 
research was compromised as almost half were diagnosed with MetS mainly because of a large waist 
circumference, low HDL levels and hypertension.  The results also indicate that those with a higher BMI 
may have an increased MetS risk.  This stems from the fact that a higher BMI was associated with a larger 
waist circumference, a lower HDL and a higher systolic and diastolic blood pressure in this sample.  
Furthermore, subjects who were classified with having abdominal obesity, dyslipidemia (low HDL) and 
hypertension according to the ATP III cut-offs had a higher mean BMI than subjects who fell in the normal 
ranges for these traits.  From the modelled associations it can be concluded that weight loss may help 
overweight/obese subjects to achieve a smaller waist circumference, higher HDL levels, a lower BP and 
having less MetS traits that met the diagnostic cut-offs. 
 
Association between BMI and perceived weight history, lifestyle and psychological health variables 
When exploring the weight history of a sample of adults, it is often not possible to access actual weight 
records and researchers resort to proxy indicators.  In this study, perceived weight during childhood, 
adolescence and young adulthood were used as a proxy for the actual weight history of subjects.  
Retrospective follow-up of cohorts have indicated that women’s perceived weight status during childhood, 
adolescence and adulthood accurately reflects their actual measured BMIs during those life-cycle stages 
(Munoz et al. 1996, Koprowski et al. 2001, Must et al. 2002).  It has also been indicated that perceived 
weight accurately reflects actual weight in overweight adults, although normal weight women may be more 
likely to perceive themselves as overweight (Paeratakul et al. 2002; Linder et al. 2010).  Paeratakul et al. 
(2002) reported that the best agreement between actual and perceived weight was found for overweight 
Caucasian women and individuals with a higher educational status and income level.  Because the sample 
in this study included only overweight/obese adults who were mostly women with a tertiary level 
educational status and moderate to high income level, the assumption can be made that perceived weight 
history reflects actual weight status during each life-cycle stage.   
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The prevalence of subjects perceiving themselves as overweight/obese increased from childhood to 
adolescence and then to young adulthood.  It was evident that a third of the subjects perceived their 
weight as overweight/obese during childhood, which increased to half of the sample during adolescence 
and to two-thirds during young adulthood.  The subjects who thought that they were overweight/obese 
during a particular life-cycle phase also had a higher actual mean BMI (which was classified in the obese 
class II category of ≥35 kg/m2) at the time of this study.  Furthermore, subjects who thought that they were 
already obese in their young adulthood years, had a morbidly obese BMI of ≥40 kg/m2 at the time of the 
study.  If it is argued that perceived weight during a life-cycle phase is a proxy for actual weight during that 
life cycle phase, these results could firstly indicate that individuals between the ages of 25 to 40 years with 
a BMI≥35 kg/m2 are very likely to have been overweight since childhood.   It also supports the notion that 
obesity develops gradually over time (Williamson et al. 1990, Rothacker & Blackburn 2000, Rzehak & 
Heinrich 2006) and will manifest earlier in adult life depending on the age of onset of weight problems.  
These results are in line with cohort studies that found that childhood or adolescent weight or overweight 
status predicts adult weight or obesity status (Guo et al. 2002, Janssen et al. 2005, Must et al. 2005, 
Mamun et al. 2009).  Adult overweight/ obesity status may therefore implicate life-long incorrect lifestyle 
choices such as an unhealthy diet and/or decreased physical activity levels that promote weight gain.  
However, it must also be borne in mind that some individuals may be normal weight during all the early 
life-cycle stages and only start gaining weight during young adulthood, thus only becoming 
overweight/obese during the investigated age group (25-40 years).  This was reflected in the fact that a 
third of the subjects in our research indicated that they thought their weight was still normal when they 
were 20 to 25 years old.  This possibility is supported by information provided by large prospective cohort 
studies, namely that unwanted weight gain commonly occurs between the ages of 18 to 34 years in both 
men and women (Braddon et al. 1986, Burke et al. 1996, Rothacker & Blackburn 2000, Williamson et al. 
1990).  Furthermore, it has also been shown that weight gain is particularly experienced after school when 
studying at a tertiary educational institution (Anderson et al. 2003, Graham & Jones 2002, Hodge et al. 
1993).   
 
Physical activity is one of the most important lifestyle behaviours contributing to effective weight 
management during all life-cycle phases.  Physical activity does not only increase energy expenditure, but 
also contributes to the suppression of hunger, improvement in psychological well-being and the increased 
ability to oxidize fat instead of carbohydrates for a fuel (summarized by WHO 2000).  In this sample of 
overweight/obese adults a lower BMI was associated with higher physical activity levels as measured by the 
sport index and leisure-time index scores of the Baecke physical activity questionnaire.  The results indicate 
that a modelled one-point increase in the sport index or leisure-time index scores was respectively 
associated with a 2.01 kg/m2 and 2.43 kg/m2 decrease in BMI.  In practical terms, a one-point increase in 
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the sport index score of a physically inactive subject could be brought about by practicing a low-level 
activity such as walking for 1-2 hours per week.  Subjects who already walk 1-2 hours per week should 
increase this to 3-4 hours per week and additionally practice a medium level activity such as swimming, 
jogging, aerobics or cycling for at least one hour per week.  Instead of increasing walking time they can also 
just practice the medium level activity for 3-4 hours per week to achieve a one-point increase in their sport 
index score (all recommendations were calculated using the equations for calculating the sport index score 
by Baecke et al. 1982).  Similarly, to achieve an increase in the leisure-time activity score, subjects must 
watch less television and do more activities such as walking or cycling during leisure-time (Baecke et al. 
1982).  These proposed changes in terms of physical activity levels that need to be implemented to achieve 
a lower BMI are realistic and achievable.  It is also in line with the current South African recommendations 
of ‘accumulating 30 minutes or more of moderate-intensity physical activity on most, preferably all, days of 
the week’ (Lambert et al. 2001).  It is known that the benefits of physical activity are not limited to weight 
maintenance or weight loss but also involve improvement of many other health indicators.  In a review by 
Ross and Janiszewski (2008) it was indicated that the benefits of physical activity to decrease cardiovascular 
disease risk may also be exerted independent of whether weight loss is achieved.  It has been shown that 
physical activity has favourable effects on several risk factors for chronic diseases of lifestyle (CDLs) such as 
to decrease triglyceride levels, blood pressure, insulin resistance and to increase HDL levels (Blair & Morris 
2009, Yung et al. 2009).  The risk of developing MetS and other CDLs can thus be lowered by lifestyle 
changes including physical activity and a healthy dietary intake (Stolar 2007, Abete et al. 2010).   
 
The focus of the dietary intake assessment in this study was on frequency of intake of energy-dense foods 
that may increase total energy intake and have been associated with weight gain and the development of 
obesity (Bray et al. 2004a, Rosmond et al. 2004, Black & Macinko 2008, Malik et al. 2006, Gibson 2008, 
Wolff & Dansinger 2008).  The energy-dense indicator food groups investigated included high fat foods 
(including take-away foods), take-away foods as an independent group, energy-dense snacks, and energy-
dense drinks.  The total daily frequency of intake from these energy-dense food groups was found to be 7.7 
times per day.  The food based dietary guidelines (FBDG) for South African adults recommend that high fat 
foods such as full cream milk, red meat with fat, fried fish, sausages, take-away foods (hamburgers, chips, 
pies, etc.), margarine/butter, eggs prepared with fat, normal mayonnaise etc. should be eaten sparingly 
and substituted for leaner or low fat options on a daily basis in order to maintain weight and prevent the 
development of CDLs (Wolmarans & Oosthuizen 2001).  However, with a mean frequency of intake of 5.3 
times per day from the high fat foods indicator food group, it can be speculated that the overweight/obese 
subjects in this sample are not following these guidelines.  It can also be speculated that this may probably 
have contributed to the development/maintenance of their current overweight/obese weight status.  
Although there are no specific South African FBDG for the intake of energy-dense snacks and drinks, the 
intake of foods from the latter two indicator food groups, which are typically high in fat and/or added 
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sugar/refined carbohydrates such as crisps, chocolate, sweets, cake etc. (energy-dense snacks) and 
carbonated soft drinks, energy drinks, juice etc. (energy-dense drinks), should be limited to avoid excessive 
energy intake.  However, the subjects in this sample had a mean frequency of intake from these indicator 
food groups of 2.4 times per day, which does not reflect an occasional intake but rather a frequent daily 
intake.    
 
It was indeed evident that in this sample of overweight/obese subjects, those with a higher BMI had a 
higher intake of each of the energy-dense indicator food groups.  More specifically, a modelled increase in 
the frequency of intake of high fat foods, take-away foods, energy-dense snacks and drinks by one time per 
day was significantly associated with a 0.40, 1.96, 1.61 or 1.70 kg/m2 increase in BMI respectively.  From 
these main effect sizes it was evident that a more frequent intake of take-away foods was associated with 
the highest modelled increase in BMI.  This is in line with research that has consistently show that a higher 
intake of take-away foods is associated with a higher BMI, greater long-term increases in weight and a 
higher risk of being obese (Duffey et al. 2007, Larson et al. 2009).  This can be explained by the fact that the 
consumption of take-away foods has been associated with having higher total energy intakes (Bowman & 
Vinyard 2004, Schröder et al. 2007, Stender et al. 2007, Black & Macinko 2008, Rosenheck 2008).   
 
A higher frequency of intake of these energy-dense indicator food groups may be reflected in/be the result 
of poorer eating behaviours.  This possibility is supported by the fact that a higher BMI in our subjects was 
associated with having poorer eating behaviours, more specifically with lower dietary restraint, higher 
disinhibition, higher emotional disinhibition and higher habitual disinhibition scores.  This is in line with 
previous work that showed that disinhibition scores are consistently associated with a higher weight, BMI 
or with weight gain over time (Bryant et al. 2008, Chaput et al. 2009, Rideout & Barr 2009, Savage et al. 
2009).  From the current research it was evident that a modelled one-unit increase in the disinhibition, 
emotional disinhibition and habitual disinhibition scores was significantly associated with a 0.33, 1.46 and 
1.25 kg/m2 increase in BMI respectively.  It is known that individuals with a higher disinhibition score are 
more likely to overeat when food is very palatable, when in the company of someone who overeats, when 
at social occasions, when having an emotional or personal problem or when stressed (Stunkard & Messick 
1985, Bryant et al. 2008).  A review by Bryant et al. (2008) indicated that individuals with higher 
disinhibition scores prefer high fat foods, high-fat and high-salt foods, processed meats, sweet fruits and 
vegetables and sweet carbonated drinks and have higher intakes of sweets, cookies, ice cream, butter, 
coffee and alcohol.  Our results also confirm previous reports that indicate that a lower restraint score is 
associated with a higher body weight (Hainer et al. 2006, Rideout & Barr 2009).  It is also known that a 
decrease in dietary restraint over time is associated with weight gain (Savage et al. 2009), emphasizing the 
need for strategies that focus on improving dietary restraint as part of weight management interventions.  
Our results support this view as a modelled one-unit increase in the dietary restraint score was significantly 
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associated with a 0.28 kg/m2 decrease in BMI.  A higher restraint score is associated with being able to 
employ specific eating related strategies to consciously limit food intake in order to control body weight.  
These strategies include the avoidance of fattening foods, eating smaller portions, stopping/discontinuing 
eating before reaching satiation and consistently considering the energy content of food in order to control 
energy intake, as well as to buying low energy containing foods (Bryant et al. 2008).  It has also been 
reported that the combined effect of dietary restraint and disinhibition influences body weight.  The effect 
of disinhibition on body weight disappears when a high level of restraint eating is present (Hays et al. 2002, 
Savage et al. 2009).  Therefore, individuals with the highest weight usually have the highest levels of 
disinhibition together with the lowest levels of restraint (Hays et al. 2002, Dykes et al. 2004), which is in line 
with our results.   
 
In terms of psychological health we found that a higher BMI was significantly associated with having more 
depressive symptoms (BDI), with a modelled one-unit increase in BDI score being associated with a 0.15 
kg/m2 increase in BMI.  Similar relationships between increased BMI and psychological health as well as 
several behavioural and psychological traits have been reported by others, including a lower body image, 
self-esteem, self-motivation and poor coping or problem-solving skills (Byrne 2002) as well as being 
depressed (Ahlberg et al. 2002, Davis 2009).  Results from large cohort studies also indicate a higher 
prevalence of psychiatric disorders (including current depression, life-long depression and anxiety) in 
overweight or obese women or men compared to normal weight adults (Petry et al. 2008, Zhao et al. 2009).  
Although normal weight persons also suffer from depression, Murphy et al. (2009) compared obese and 
non-obese persons who had experienced a major depressive episode and found that the obese 
experienced longer episodes of depression, a larger number of episodes and they were five times more 
likely than the non-obese to overeat, which led to weight gain during a period of depression (Murphy et al. 
2009).  It is known that the intake of energy-dense foods such as sweet or fatty foods improves mood and 
alleviates effects of stress through opioid and dopamine neurotransmission or the serotonergic system.  In 
a number of psychological conditions including depression, changes in these physiological pathways play a 
role in the development of obesity as there is a tendency to choose and overeat energy-dense foods when 
stressed or feeling depressed (reviewed by Gibson 2006).  These studies together with our results 
emphasize the importance of improving the psychological health of subjects in weight management 
programmes in order for them to achieve success.  
 
In summary, overweight/ obese subjects in the current sample who perceived themselves as overweight 
during their childhood, adolescence and young adulthood years had a higher mean BMI than those who 
perceived themselves as being normal weight during these life-cycle phases.  Those who perceived 
themselves as obese during their young adulthood years were morbidly obese at the time of this study. The 
significant associations between BMI and lifestyle as well as psychological health variables provide 
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perspectives that could guide the development of weight management programmes aimed at 
overweight/obese Caucasian subjects.  Based on the results of the modelled associations between BMI and 
specified variables it can be said that a reduction in BMI can be achieved by increasing sport and leisure-
time physical activity; decreasing the intake of high-fat foods, energy-dense snacks, take-away foods and 
energy-dense drinks; improving dietary restraint and disinhibition and decreasing the presence of 
depressive symptoms.    
 
Genotype and allele frequencies 
Most of the genotype and allele frequencies of the polymorphisms tested were in line with those previously 
reported for other Caucasian samples, although some differences were evident.  The wild-type Ala54Ala 
genotype frequency (46%) of the FABP2 Ala54Thr polymorphism was within the range (44-55%) generally 
reported for obese and randomly selected Caucasian samples.  However, the mutant Thr54Thr genotype 
frequency of 15% is double the reported range of 4-8%, while the mutant allele frequency was within the 
wide range of frequencies (25-47%) previously reported for Caucasian samples (Berthier et al. 2001, 
Damcott et al. 2003, Lara-Castro et al. 2005, Stan et al. 2005, Helwig et al. 2007, Morcillo et al. 2007, 
Tavridou et al. 2009).   
 
For the INSIG2 rs7566605 polymorphism the heterozygous genotype frequency was the highest at 48% 
shortly followed by the wild-type genotype frequency of 44%.  This is in line with previously reported 
frequencies ranging between 41-48% for the heterozygous genotype and 43-52% for the wild-type 
genotype in other Caucasian samples.  Similarly, our mutant CC genotype frequency of 8% and mutant C-
allele frequency of 32% also fall within the respective ranges of 7-12% and 30-35% as previously reported 
for Caucasian samples (Loos et al. 2007, Lyon et al. 2007, Pollex et al. 2007, Rosskopf et al. 2007, Smith et al. 
2007, Andreasen et al. 2008, Boes et al. 2008, Chu et al. 2008, Orkunoglu-Suer et al. 2008).   
 
The genotype and allele frequencies of the FTO rs1421085 polymorphism were in line with those previously 
reported for obese Caucasian populations.  In the latter obese samples, the mutant CC genotype frequency 
ranges between 20-28% (Dina et al. 2007b, Attaoua et al. 2008, Peeters et al. 2008, Price et al. 2008, 
Stutzmann et al. 2009) as was found in this study (25%), while a lower range of 11-18% has been reported 
in non-obese samples (Dina et al. 2007b, Attaoua et al. 2008, Do et al. 2008, Peeters et al. 2008, Price et al. 
2008, Cauchi et al. 2009, Stutzmann et al. 2009).  Although our wild-type genotype frequency of 21% falls 
just below the range (23-27%) reported in obese samples, both these are lower than the range (34-38%) 
found in non-obese samples.  The frequency of the heterozygous genotype (55%) was the highest in our 
sample, which is in line with ranges of 44-55% previously reported by all studies independent of obesity 
status (Dina et al. 2007b, Attaoua et al. 2008, Do et al. 2008, Peeters et al. 2008, Price et al. 2008, Cauchi et 
al. 2009, Stutzmann et al. 2009).  Furthermore, the high mutant C-allele frequencies (48-52%) that have 
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been reported for these obese samples (Dina et al. 2007b, Attaoua et al. 2008, Peeters et al. 2008, Price et 
al. 2008, Stutzmann et al. 2009) are similar to the frequency of 52% that was found in this study, which is 
higher than the 37-41% that has been reported for non-obese samples (Dina et al. 2007b, Attaoua et al. 
2008, Do et al. 2008, Peeters et al. 2008, Price et al. 2008, Cauchi et al. 2009, Stutzmann et al. 2009).  
 
A similar picture emerges when considering the FTO rs17817449 polymorphism.  The mutant allele 
frequency of 55% in our subjects was just higher but still in line with the reported mutant allele frequency 
of 48-51% for obese samples (Dina et al. 2007b, Price et al. 2008), while a lower range of 36-40% was 
previously found in non-obese samples (Dina et al. 2007b, Do et al. 2008, Price et al. 2008).  The frequency 
of the mutant genotype (40%) was the highest in our sample, while the wild-type and heterozygous 
genotype frequencies were similar at 29.5 and 30.5% respectively.  The heterozygous genotype frequencies 
were found to be higher at 42-52% in other samples, while the frequency of the wild-type genotype at 23-
27% in obese samples were more in line with ours than the 8-18% reported for non-obese samples (Dina et 
al. 2007b, Do et al. 2008, Price et al. 2008).  Although these discrepancies in genotype and allele 
frequencies of the FTO rs17817449 polymorphism between this study and previous reports were found, it 
must be borne in mind that only three studies that included Caucasian samples could be traced, which 
narrowed the reported frequency ranges compared to the other polymorphisms for which 15 or more 
studies were available.   
 
The wild-type Trp64Trp genotype frequency of the ADRB3 Trp64Arg polymorphism was very high (90%) in 
our sample, while no subjects had the mutant Arg64Arg genotype.  Similar patterns were reported for 
other Caucasian samples, with the wild-type genotype ranging between 82-90% and the mutant genotype 
between 0-1%.  The frequency of the mutant Arg-allele (5%) was also in line with the 5-9% reported by 
others (Corella et al. 2001, Ramis et al. 2004, Kurokawa et al. 2008, Zafarmand et al. 2008). 
 
For the ADRB2 Arg16Gly polymorphism the frequency of the heterozygous genotype was the highest at 
48%, followed by the mutant genotype at 34%.  These genotype frequencies fall within the respective 
ranges of 37-53% and 32-46% reported for other Caucasian samples.  The frequency of the mutant Gly16-
allele (58%) was higher than that of the wild-type allele in our sample, but is similar to the range of 55-66% 
reported for Caucasian samples (Meirhaeghe et al. 2000, Oberkofler et al. 2000, Ellsworth et al. 2002, 
Dallongeville et al. 2003, Tafel et al. 2004, Mattevi et al. 2006).   
 
The wild-type genotype and allele of the GNB3 C825T polymorphism were the most frequent in our sample.  
The wild-type and heterozygous genotype frequencies of 49% and 34% fall within the respective ranges of 
40-60% and 32-46% that was reported for other Caucasian samples.  The mutant allele frequency (35%) is 
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similar to the range of 27-36% reported for other Caucasian populations (Brand et al. 2003, Wascher et al. 
2003, Andersen et al. 2006, Danoviz et al. 2006, Grove et al. 2007, Renner et al. 2007, Casiglia et al. 2008).   
 
In summary, with the exception of the FTO rs17817449 polymorphism, all other genotype and allele 
frequencies are similar to those reported for other Caucasian samples.  The FTO rs17817449 genotype and 
allele frequencies best reflect the frequencies reported for the obese Caucasian subjects compared to the 
non-obese subjects in the two case-control and one population study cited earlier in this section.  For the 
FTO rs1421085 polymorphism it was also evident that the frequencies found in this overweight/obese 
sample were in line with other obese Caucasian samples and are different from those reported for non-
obese samples.   
 
Genotype associations with BMI. 
No differences in BMI between the genotype groups or additive allelic variable were found for any of the 
polymorphisms investigated in this sample of overweight/obese subjects.  Our finding that the FABP2 
Ala54Thr polymorphism is not associated with BMI is line with the results of the majority of association 
studies that included Caucasian populations and several large cross-sectional samples (Galluzzi et al. 2001, 
Damcott et al. 2003, Helwig et al. 2007).  However, there were studies that found that the mutant Thr54-
allele was associated with obesity (Morcillo et al. 2007, Travidou et al. 2009) and a higher BMI (Fisher et al. 
2006) in Caucasian populations.  The discrepancy in results may be attributed to the use of different study 
designs, genetic models in statistical analyses as well as subject heterogeneity for different diseases or 
metabolic conditions such as type 2 diabetes (Travidou et al. 2009). 
 
The reported associations between the INSIG rs7566605 polymorphism and BMI or obesity have been 
conflicting. Although, the mutant CC genotype has been associated with an increased risk for obesity or 
with a higher BMI in case-control and cross-sectional studies, the majority of studies reported no 
association.  A recent meta-analysis (Heid et al. 2009) that included 34 studies and 74345 subjects 
confirmed that there is no association when obese and normal weight controls were compared.  However, 
these authors indicated that the INSIG rs7566605 polymorphism may play a role in extreme obesity as 
significant results were found when comparing normal weight controls to subjects with more extreme 
obesity (i.e. BMI>32.5; 35 or 40).  In the latter subgroup analysis the CC genotype frequencies increased in 
each higher obese BMI category and consequently higher ORs and more significant p-values were reported 
for more obese subjects (Heid et al. 2009).  The fact that we did not include a normal weight control group 
as well as our limited sample size may explain why we did not find a significant association with BMI.   
 
Consistent evidence from small and large-scale studies shows that the mutant CC genotype or C-allele of 
the FTO rs1421085 polymorphism (Dina et al. 2007b, Attaoua et al. 2008, Do et al. 2008, Peeters et al. 2008, 
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Price et al. 2008, Cauchi et al. 2009, Stutzmann et al. 2009) and the mutant GG genotype or G-allele of the 
FTO rs17817449 polymorphism (Dina et al. 2007b, Do et al. 2008, Price et al. 2008) are associated with 
obesity and BMI in Caucasian populations with European ancestry.  Study design limitations may explain 
why we could not repeat these reported associations as all the previous reports used case-control, cohort 
(BMIs ranged from underweight to obese) or family-based designs and none compared the association 
within an overweight/obese group only.   
 
Our results are in line with those from the most recent meta-analyses in Caucasian populations that 
indicated no association between BMI and the ADRB3 Trp64Arg polymorphism (Kurokawa et al. 2008).  
Although it was indicated that the mutant Arg64-carriers had a higher BMI compared to the Trp64Trp 
homozygotes in the overall sample that included 97 studies and 44833 subjects, population heterogeneity 
effects were detected and subgroup analysis revealed that this association is only true for East Asian 
populations and not for Caucasians (Kurokawa et al. 2008).  
 
In line with our findings, no association was reported between BMI and the ADRB2 Arg16Gly polymorphism 
in a study that included 7808 Caucasian subjects (Gjesing et al. 2007), a meta-analysis that included 13 
studies with populations of different ethnicities (Gjesing et al. 2007) as well as other population-based 
(Meirhaeghe et al. 2000, Lima et al. 2007) and case-control studies (Large et al. 1997, Oberkofler et al. 2000, 
Terra et al. 2005) in Caucasians.  Furthermore, the results of the positive association studies were equivocal 
with some linking the Gly16-allele or Gly16Gly genotype with a higher BMI (Ehrenborg et al. 2000) or with 
weight gain over a seven year period (Van Rossum et al. 2002) while others linked this genotype with a 
lower BMI (Meirhaeghe et al. 2001) or obesity prevalence (Ukkola et al. 2000).  These discrepancies in the 
results may be explained by the different sample sizes included, study-designs used and the fact that some 
studies included only male subjects who were non-obese (Ehrenborg et al. 2000), while others included 
family based (Ukkola et al. 2000) or population-based (Meirhaeghe et al. 2001) samples. 
 
Our results are in line with those from Rydén et al. (2002) who also reported no association between the 
GNB3 C825T polymorphism and BMI in a sample of obese Caucasians. Similar results were also reported for 
several population-based cross-sectional studies that included Caucasians (Benjafield et al. 2001, Rydén et 
al. 2002, Wascher et al. 2003, Martín et al. 2005, Terra et al. 2005, Andersen et al. 2006, Renner et al. 
2007).  In contrast, it has been found that the mutant TT homozygous genotype or T-allele carriers of the 
GNB3 C825T polymorphism are associated with a higher BMI (Siffert et al. 1999a, Siffert et al. 1999b, 
Benjafield et al. 2001, Poch et al. 2002, Stefan et al. 2004, Casiglia et al. 2008).  A recent meta-analysis 
including 18903 subjects from 18 studies (of which 12 studies were performed in Caucasians, three in 
Asians, one in Africans and two in subjects with mixed ancestry) indicated a non-significant trend (p=0.053) 
towards a higher BMI in TT homozygotes (Souza et al. 2008).   
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Genotype associations with health and lifestyle indicators. 
The significant associations that were found between genotype and perceived weight history, MetS traits, 
physical activity levels, dietary intake as well as eating behaviour and psychological health variables 
(secondary and exploratory hypotheses) are summarized in Table 4.15.  The table also includes the 
significant modelled effect of the interaction between genotype and specified variables on BMI.  In the 
sections following Table 4.15 the significant results reported in the table are discussed for each 
polymorphism.  To provide context in the discussion reference is mostly made to relevant findings in other 
Caucasian populations.  However, in some instances reference is also made to findings reported for 
populations from Asian or African ancestry.  The ADRB3 Trp64Arg polymorphism is not included in the table 
or discussion as no associations were found between this polymorphism and the mentioned variables.  
 
Table 4.15: Summary of the significant associations between specified variables and genotypes of each polymorphism 
as well as significant modelled effect of the interaction between genotype and specified variables on BMI. 
Gene and  Genotype 
polymorphism Wild-type Mutant 
FABP2 Ala54Thr Ala54Ala (GG) Thr54Thr (AA) 
 *↑ BMI = ↑↑ triglycerides  
 (GG+GA): ↓ intake of take-away food ↑ intake of take-away food 
 ↓ self-esteem§ (AA+AG): ↑ self-esteem§ 
INSIG2 rs7566605 GG CC 
 
                               (GG+GC): ↑ HDL  
(GG+GC): ↓ number of MetS traits 
↓ HDL 
↑ number of MetS traits 
 ↓ leisure-time activity score 
*↑ leisure-time activity = ↓↓ BMI 
(CC+CG): ↑ leisure-time activity score 
 (GG+GC): ↑ self-regulation (restraint subscale) ↓ self-regulation (restraint subscale) 
  *↑ situational disinhibition = ↑↑ BMI 
FTO rs17817449 TT+TG GG 
  *↓ BMI =  ↑↑ HDL§ 
 ↓ intake of high fat foods§ ↑ intake of high fat foods§ 
 
↓ Rigid control (restraint subscale) † 
↓ Habitual disinhibition† 
↑ Rigid control (restraint subscale) †  
↑ Habitual disinhibition† 
 ↓ BDI score ↑ BDI score 
FTO rs1421085 TT CC 
 ↓ % perceived adolescent weight as normal ↑ % perceived adolescent weight as normal 
  *↓ BMI =  ↑↑ HDL 
 ↑ intake of take-away foods (CC+CT): ↓ intake of take-away foods 
 ↓ Hunger score 
↓ Internal locus for hunger 
↓ emotional disinhibition§ 
↓ flexible control (restraint subscale)§ 
*↑ self-regulation = ↓↓ BMI 
 
(CC/ CC+CT): ↑ Hunger score 
↑ Internal locus for hunger 
(CC+CT): ↑ emotional disinhibition§ 
↑ flexible control (restraint subscale)§ 
 
*↑ rigid control = ↑↑ BMI 
 *↑ GHQ = ↑↑ BMI  
FTO haplotypes *T-T vs. T-G: ↑ sport index score = ↓ BMI      *T-G vs. T-C haplotype: ↑ GHQ = ↑ BMI and 
↓ self-regulation = ↑ BMI 
C-G vs. T-T: *↓ BMI =  ↑↑ HDL § 
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Table 4.15: (continued) 
Gene and  Genotype 
polymorphism Wild-type Mutant 
ADRB2 Arg16Gly Arg16Arg (AA) Gly16Gly (GG) 
 
↑ % Perceived childhood weight as overweight  (Gly16Gly+Arg16Gly): ↑ % Perceived childhood 
weight as normal 
 *↑ flexible control = ↓↓ BMI  
GNB3 C825T CC TT 
 
CC: ↑ % Perceived childhood weight as normal 
CT: ↑ % Perceived childhood as overweight 
↑ % Perceived childhood weight as normal 
 (CC+CT): ↓ triglycerides§ 
↓ glucose 
(CC+CT): ↓ number of MetS traits 
(CC/CT): ↓ % diagnosed with MetS 
↑ triglycerides§ 
↑ glucose 
↑ number of MetS traits 
↑ % diagnosed with MetS 
 *↑ leisure-time activity = ↓↓ BMI  
 *↑ high fat/carbohydrate snacks = ↑↑BMI 
↑ high fat foods  
↑ non-alcoholic drinks 
 
(TT+TC): ↓ high fat foods  
(TT+TC): ↓ non-alcoholic drinks 
 ↑ BDI score 
(CC+CT): ↓ self-esteem 
↓ BDI score 
↑ self-esteem 
*Reflects the modelled effect of the interaction between genotype and specified variables on BMI; all other entrees in 
the table indicate associations between genotype and specified variables only.  
All results are significant for unadjusted and gender-adjusted analyses unless indicated as follows: 
§Only significant for gender-adjusted results 
†Only significant for unadjusted results 
 
 
The FABP2 Ala54Thr polymorphism 
The significant associations that were found for the FABP2 Ala54Thr polymorphism involve TG levels, 
frequency of intake of take-away foods and self-esteem (Table 4.17).   
 
The results show that a modelled increase in BMI of the wild-type Ala54Ala homozygotes was associated 
with an increase in TG levels.  The opposite of this association can also be interpreted, namely that a 
modelled decrease in BMI is associated with a decrease in TG levels.  It can therefore be suggested that 
weight loss may help to decrease TG levels in overweight/obese Ala54Ala homozygotes and consequently 
decrease their MetS risk profile.  However, the same beneficial effect of weight loss on TG levels may not 
be observed for the mutant Thr54-allele carriers as no such association was found in these subjects.  
Although the exact physiological functions of FABP2 are not yet fully elucidated (Helwig et al. 2007, 
Montoudis et al. 2008), it is known that the FABP2 proteins are expressed in the enterocytes of the GIT 
where they bind to dietary long chain saturated and unsaturated fatty acids and transport them from the 
brush border membrane to the ER, mitochondria, Golgi-apparatus and perinuclear area (Weiss et al. 2002, 
Cianflone et al. 2008, Karsenty et al. 2009).  In the mitochondria FABP2 influences cholesterol biosynthesis 
as well as β-oxidation of fatty acids by regulating the expression of key enzymes. The Thr54 amino acid 
causes small structural changes in the portal region of FABP2 affecting its binding affinity to dietary fatty 
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acids (Zhang et al. 2003).  The fact that the mutant Thr54 containing FABP2 protein has been found to have 
a greater binding affinity for dietary fat in the GIT (Baier et al. 1995) and has been associated with increased 
ApoBI and increased lipid synthesis, specifically with increased TG and phospholipid esterification and TG 
secretion (Baier et al. 1996, Levy et al. 2001), could explain our findings. It can be argued that a weight loss 
diet that results in weight loss and consequently decreased TG levels in Ala54Ala will not exert similar 
beneficial effects on TG levels of the Thr54-carriers, as they still absorb more dietary fat and secrete more 
TG than the Ala54Ala homozygotes.  It can be hypothesized that the involvement of the FABP2 protein in 
gene expression of key β-oxidation and lipogenic enzymes may differentially change as a consequence of 
the mutant FABP2 protein, thus affecting blood lipid levels.  The work by Marín et al. (2005) and Morcillo et 
al. (2007) further points to the possibility that the fatty acid composition of the diet may be more 
important to consider in weight loss than the total fat content.  These authors have shown that Thr54-
carriers experienced higher post-prandial lipid levels and decreased insulin sensitivity following diets high in 
SFAs, whereas diets low in total fat and SFAs or high in MUFAs were found to counter these effects (Marín 
et al. 2005).  Morcillo et al. (2007) indicated that Thr54-carriers who regularly consumed sunflower oil 
(PUFA) had higher insulin resistance than those who regularly consumed olive oil (MUFA).  The observation 
in rats that the Fabp2 protein has a greater affinity for linoleic acid (PUFA) than for oleic acid (MUFA) 
(Richieri et al. 1994) may elucidate these findings to some extent.  When considering the intake of indicator 
food groups in our subjects, it was evident that the Thr54Thr homozygotes had a higher frequency of intake 
of take-away foods.  This may compound the effect found on the TG levels of Thr54Thr homozygotes as 
described above as these foods are generally high in SFAs, PUFAs and TFAs.  Although not reflected in the 
genotype differences for TG levels in our study or other studies that included Caucasian populations 
(Tahvanainen et al. 2000, Berthier et al. 2001, Damcott et al. 2003), a number of studies did report an 
association that points to the fact that Thr54Thr homozygotes have higher TG levels and a more 
unfavourable lipid profile compared to their wild-type counterparts (Agren et al. 1998, Carlsson et al. 2000, 
Georgopoulos et al. 2000, Galluzzi et al. 2001, Stan et al. 2005).   
 
The currently known physiological functions of FABP2 do not provide a plausible explanation for the 
association found with self-esteem.  It is thus possible that this result is a false positive and should thus be 
confirmed in further research.  
 
In summary, novel findings for the FABP2 Ala54Thr polymorphism that warrant further investigation 
include that 1) a modelled decrease in BMI of wild-type Ala54Ala subjects is associated with the most 
pronounced decrease in TG levels, while this may not be true for the mutant Thr54-carriers and 2) Thr54Thr 
homozygotes may have a higher frequency of intake of energy-dense foods that may compound the 
problem.  These findings are supported by existing evidence indicating a higher fat absorption, specifically 
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SFA and PUFA absorption, in Thr54-allele carriers.  The mutant Thr54Thr subjects also had a higher self-
esteem, but this exploratory novel finding should be further investigated. 
 
The INSIG rs7566605 polymorphism 
The significant associations that were found for the INSIG2 rs7566605 polymorphism involve HDL levels, the 
number of MetS traits diagnosed, leisure-time physical activity and certain eating behaviour variables. 
 
Only one study (Pollex et al. 2007) could be traced that investigated the association between MetS and the 
INSIG2 rs7566605 polymorphism.  In line with our results, these authors reported no association between 
this polymorphism and MetS as diagnosed with the ATP NCEP III criteria in six Canadian populations with 
different ancestries (Pollex et al. 2007).  Research on individual MetS traits in Caucasian populations 
showed no associations between this polymorphism and blood pressure, waist circumference, glucose, HDL 
and other blood lipids (Pollex et al. 2007, Andreasen et al. 2008, Boes et al. 2008, Chu et al. 2008, Peeters 
et al. 2009, Vimaleswaran et al. 2009).  In contrast, our results show that subjects with the mutant CC 
genotype had significantly lower HDL levels compared to the G-allele carriers.  The CC subjects also had a 
higher number of traits that met the criteria for the diagnosis of MetS.  These associations might indicate 
that subjects with the mutant genotype have a higher risk to develop MetS.  It can be argued that the 
associations with MetS traits seen in our CC subjects are supported by previous findings that show that 
Caucasians with the CC genotype have a higher BMI (Herbert et al. 2006, Lyon et al 2007, Rosskopf et al. 
2007, Liu et al. 2008, Andreasen et al. 2008) and subcutaneous adipose tissue and fat volume (Franks et al. 
2008, Orkunoglu-Suer et al. 2008).  Furthermore, a recent meta-analysis (Heid et al. 2009) confirmed that 
the CC genotype frequencies are significantly higher in subjects with more extreme obesity (i.e. BMI>32.5; 
35 or 40) when compared to normal weight controls.  It is a known fact that a higher BMI and/or increased 
abdominal fat content increase MetS prevalence (Stolar 2007).   
 
Insight in the physiological functioning of INSIG2 supports the possibility that the CC genotype’s ability to 
block cholesterol and fatty acid synthesis as well as lipogenesis may be compromised, contributing to the 
development of MetS.  It is known that the wild-type INSIG2 protein blocks the transcription of several 
genes of which the resulting protein products are required in the biosynthetic pathways of fatty acids, 
triglycerides, phospholipids, cholesterol, the NADPH cofactor and the LDL-receptor (Horton et al. 2002, 
DeBose-Boyd 2008).  The wild-type INSIG2 protein therefore contributes to decreased synthesis of these 
lipids and thus lower plasma cholesterol and triglyceride levels (Yabe et al. 2002, Yang et al. 2002, Sun et al. 
2005, Goldstein et al. 2006).  It has also been indicated that Insig2 expression in target cells increases 
following the consumption of a high fat diet, consequently blocking the activation of target lipogenic 
enzymes resulting in decreased preadipocyte differentiation and lipogenesis (Li et al. 2003, Takaishi et al. 
2004).  Gong et al. (2006) showed that a variant Insig2 protein investigated by their group lost the ability to 
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block gene transcription of enzymes required for biosynthetic pathways for cholesterol.  However, it must 
be borne in mind that it is still unknown whether the INSIG2 rs7566605 polymorphism results in the 
expression of such a variant INSIG2 protein.  Furthermore, as the INSIG2 rs7566605 polymorphism is 
located 10 kb upstream of the transcription start site of the INSIG2 gene (Herbert et al. 2006), it is also still 
a question whether this variant itself or maybe another variant in strong LD leads to the expression of a 
variant INSIG2 protein.  Hotta et al. (2008a) argue that the INSIG2 rs7566605 polymorphism may affect the 
transcriptional activity of INSIG2 and may therefore have an impact on its expression.  Although many of 
the functional effects of this polymorphism still need to be elucidated, it is speculated that the mutant 
rs7566605 C-allele encodes a variant INSIG2 protein.  This might explain why the mutant CC subjects in our 
study showed a stronger risk to develop MetS. 
 
When considering physical activity levels, the C-allele carriers in our study were significantly more active 
during their leisure-time7 than the GG homozygotes.  Interestingly, the GG homozygotes experienced a 
pronounced decrease in BMI in response to a modelled increase in the leisure-time index score.  This 
decrease in BMI in response to an increase in the leisure-time index score was less pronounced in the 
heterozygous subjects, while no association was found for the mutant CC homozygotes.  These results 
firstly suggest that overweight/obese GG subjects may benefit more from interventions with a stronger 
focus on physical activity in order to achieve or maintain a lower weight; and secondly, they may find it 
easier to maintain weight or to lose weight as they respond to increased leisure-time physical activity.   
 
The interaction between the INSIG2 rs7566605 polymorphism and physical activity has also been 
investigated by others as INSIG2 plays a role in adipocyte metabolism which in turn is affected by physical 
activity levels.  Although these studies did not focus on leisure-time activity as such, but rather on total 
physical activity levels or specific exercise interventions, it was deemed valuable to consider the results of 
these reports in this discussion.  It can be argued that the reduction in subcutaneous fat levels in the non-
dominant arm of GG Caucasian men following a 12-week resistance exercise intervention focused on the 
mentioned arm (Orkunoglu-Suer et al. 2008) supports our finding that exercise has a more pronounced 
effect on decreasing fat levels and consequently weight in the GG genotype.  This notion is further 
supported by the results of two weight loss interventions that included physical activity components and 
were targeted at obese Caucasian children aged between six to 16 years (Reinehr et al. 2008, Reinehr et al. 
2009).  In both studies, the G-allele carriers lost more weight after following the one-year intervention 
programme than CC homozygotes who gained weight during this period (Reinehr et al. 2008, Reinehr et al. 
2009).  However, the work by Franks et al. (2008) refutes this notion.  These researchers found that CC 
homozygotes lost more weight compared to G-allele carriers after a one-year weight loss intervention that 
                                                 
7 The leisure-time index of the Baecke physical activity questionnaire covers the amount of physical activity, other than sport, 
performed during leisure-time.  The sport index of this questionnaire covers the duration and type of formal exercise or sport that a 
subject practice per week, however no associations with genotype were found. 
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included 150 min of physical activity per week (Franks et al. 2008).  Furthermore, Andreasen et al. (2008) 
reported that the BMI of G-allele carriers was not affected by their physical activity levels.  These authors 
hypothesized that physical activity may help CC homozygotes to achieve a lower BMI, as they found that 
physically passive CC homozygotes had a higher BMI than the physically active CC subjects (Andreasen et al. 
2008).  The discrepancy in the results could be explained by the fact that different study designs and 
interventions were used and subjects from different age groups and from different weight categories were 
involved.  Franks et al. (2008) also indicated that various factors could be responsible for the disparate 
findings reported in their study compared to those on obese children (Reinehr et al. 2008, Reinehr et al. 
2009), including the possibility that the results of both or one of these studies are false-positives. 
 
While manipulation of physical activity levels based on the genotype of an individual may be considered as 
part of weight management interventions, the effect of dietary intake, especially fat and energy intake on 
energy balance, within the context of genotype, may also need to be considered.  Animal studies have 
illustrated that INSIG mRNA expression is nutritionally regulated and is increased in response to high fat or 
energy diets (Li et al. 2002, Li et al. 2003) or is decreased in response to food restriction (Li et al. 2003).   
Although no association between the intake of high fat foods and energy-dense snacks and the INSIG2 
genotypes was found in our study, significant associations between these genotype groups and eating 
behaviour indicators that may result in a higher fat and energy intake, were found.  The mutant CC subjects 
had a lower attitude to self-regulation (subscale of dietary restraint) score, which reflects poorer self-
regulation of food intake.  Furthermore, a modelled increase in the situational susceptibility to disinhibition 
score (reflects an increased tendency to overeat at social occasions, when food tastes good and when in 
the company of someone who overeats) was associated with the most pronounced increase in BMI in the 
mutant CC homozygotes.  As no such association was found for the GG homozygotes and CC subjects were 
found to be more likely to have a poorer self-regulation of food intake, it can be speculated that this could 
result in CC subjects being more likely to consume excessive amounts of food, possibly higher in total fat 
and energy.  This may result in a more pronounced increase in BMI of CC subjects, which is supported by 
the previously mentioned possibility that the mutant C-allele may result in a variant INSIG2 protein that is 
unable to block certain lipogenic enzymes, consequently leading to increased preadipocyte differentiation 
and lipogenesis in the presence of a high fat and energy diet.  No previous reports investigating the effect 
of the INSIG2 rs7566605 polymorphism on eating behaviour could be traced and our results therefore need 
to be confirmed by futher research.   
 
In summary, our results indicate that the mutant CC homozygotes of the INSIG rs7566605 polymorphism 
may have a higher risk to develop MetS as they had lower HDL levels and a higher number of traits that met 
the diagnostic criteria of MetS.  It is argued that our results are supported by the higher BMI in CC subjects 
found by others as well as the effect of a possible variant INSIG protein on changes in its physiological 
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function.  Although the C-allele carriers had higher leisure-time physical activity levels, it was evident that 
the GG homozygotes could possibly decrease their BMI by increasing their leisure-time physical activity 
levels.  Three of the published physical activity/weight loss intervention studies that included physical 
activity components support this possibility, while two refute it.  We therefore suggest that although there 
are indications that the INSIG2 protein may be involved in MetS and the interaction between physical 
activity and BMI, more evidence supporting our findings is necessary before genotype specific 
recommendations can be made in this regard.  Novel findings that warrant further investigation include the 
findings that mutant CC homozygotes have a lower attitude to self-regulation score and they may be more 
likely to experience an increase in BMI as their situational disinhibition score increases. It is argued that the 
proposed changes in the physiological functioning of a possible variant INSIG2 protein may result in an 
inability to block lipogenesis, which could be to the disadvantage of CC subjects who are more likely to 
exhibit poor eating behaviours, which may result in increase fat and energy intakes and consequently 
leading to a higher BMI.   
 
The FTO rs1421085 and rs17817449 polymorphisms 
The significant associations that were found for the two FTO polymorphisms involved perceived weight 
history, MetS traits, physical activity levels, food intake, a number of eating behaviour indicators and 
indicators of depression and general psychological well-being. 
 
It was evident from our study that fewer subjects with the mutant CC genotype of the FTO rs1421085 
polymorphism thought they were overweight during adolescence, while there were no differences 
between genotypes for perceived weight during childhood or young adulthood and for current weight.  If it 
is assumed that perceived weight is a proxy for actual weight, these results are in contrast with published 
trends that indicate consistently that the C-allele is associated with a higher BMI and with early-onset 
obesity in Caucasians (Dina et al. 2007b, Scuteri et al. 2007, Attaoua et al. 2008, Do et al. 2008, Peeters et al. 
2008, Price et al. 2008, Cauchi et al. 2009, Stutzmann et al. 2009).  However, it must be borne in mind that 
even though perceived weight has been suggested to be a valid proxy for actual weight (Munoz et al. 1996, 
Koprowski et al. 2001, Must et al. 2002), it may not have been sensitive enough to detect genotype 
differences regarding weight history for this polymorphism.   It is also possible that this result is a false 
positive. 
 
Associations between the two FTO polymorphisms and MetS traits were found for HDL.  For the 
homozygous mutant subjects of the two FTO polymorphisms as well as the mutant C-G haplotype a 
modelled decrease in BMI was associated with an increase in HDL.  It can thus be hypothesized that weight 
loss may help overweight/obese homozygous mutant subjects to achieve higher HDL levels.  No previous 
studies could be traced that reported on the association between MetS or lipid profile and these two FTO 
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polymorphisms in Caucasians.  However, the mutant allele carriers of both polymorphisms have been 
associated with higher LDL and triglyceride levels in Asians (Tan et al. 2008).  Research has shown that FTO 
is expressed inside the cell nucleus of almost all human tissues including adipocytes (Dina et al. 2007b).  
Although the exact physiological role of the FTO protein is still under investigation (Gerken et al. 2007, 
Fischer et al. 2009), recent research indicates that FTO probably encodes a 2-OG dependent nucleic acid 
demethylase.  It is known that 2-OG dependent oxygenases are involved in DNA repair, fatty acid 
metabolism, and posttranslational modifications (Hausinger 2004, Clifton et al. 2006). The results of in vitro 
experiments indicated that FTO possibly exert gene regulation at RNA level in humans (Gerken et al. 2007, 
Jia et al. 2008).  Furthermore, as a 2-OG dependent oxygenase it might play a potential role in adaptation to 
hypoxia and lipolysis (Gerkin et al. 2007, Sanchez-Pulido & Andrade-Navarro 2007).   
 
According to Frayling et al. (2007) the highest levels of FTO expression are found in the brain, specifically in 
the arcuate nucleus of the hypothalamus, which is known to play a major role in controlling energy 
homeostasis and eating behaviour.   Studies performed on humans, mice and rodents have shown that Fto 
mRNA expression is nutritionally regulated (Gerken et al. 2007, Fredriksson et al. 2008, Stratigopoulos et al. 
2008, Wahlen et al. 2008, Zabena et al. 2009) and that it is possibly involved in the regulation of energy 
expenditure (Stratigopoulos et al. 2008, Fischer et al. 2009). As eating behaviour and resulting dietary 
intake as well as physical activity are major factors in determining energy homeostasis, it is a matter of 
course that the association between these variables and the FTO polymorphisms be investigated.  Our 
research showed clearly that such associations are prevalent.  It must be borne in mind that the exact 
physiological explanations for these associations still need to be elucidated. 
 
We found that a modelled increase in the sport index score was associated with a significant decrease in 
the BMI of subjects with the wild-type T-T haplotype compared to the C-T haplotype.  This implies that 
subjects with both wild-type alleles of the two FTO polymorphisms could benefit more from increasing their 
physical activity levels to lose or maintain weight.  It can also be speculated that mutant allele carriers may 
find it more difficult than the wild-type T-T carriers to manage their weight or to lose weight when their 
physical activity levels are similar.  Therefore, if mutant allele carriers employ physical activity as a weight 
loss strategy, they would need to train harder than subjects with the wild-type haplotype.  If this is not 
possible, they would need to consider restricting their energy intake more than the wild-type haplotypes.  
The notion that mutant allele carriers may need additional increases in physical activity levels or decrease 
energy intake more strictly compared to subjects with the wild-type haplotype in order to maintain or lose 
weight, may explain current findings that the mutant alleles of both FTO polymorphisms have consistently 
been associated with a higher BMI or obesity prevalence (Dina et al. 2007b, Scuteri et al. 2007, Attaoua et 
al. 2008, Do et al. 2008, Peeters et al. 2008, Price et al. 2008, Cauchi et al. 2009, Stutzmann et al. 2009).  
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A number of significant associations between the two FTO polymorphisms and food intake, eating 
behaviour as well as psychological health of overweight/ obese subjects were found in this study, more so 
than for any of the other polymorphisms tested.  A modelled increase in the attitude to self-regulation 
score (subscale score of dietary restraint, reflecting a better eating behaviour) of wild-type TT subjects of 
the FTO rs1421085 polymorphism was associated with a decrease in BMI.  These subjects may thus benefit 
from increasing their attitude to self-regulation if they attempt to achieve a lower BMI, however the same 
beneficial effect may not be experienced by the mutant allele carriers.  The mutant CC subjects of the FTO 
rs1421085 polymorphism may further be challenged by the fact that a modelled increase in the rigid 
control score (subscale score of dietary restraint) was associated with an increase in BMI.  Higher rigid 
control reflects an all-or-nothing approach to dieting, with “fattening foods” or high energy containing 
foods being totally avoided.  This type of dieting is very difficult to maintain over the long-term, often 
resulting in frequent lapses or total relapse, thus increased intake of fattening foods.  It is thus not 
surprising that other researchers have found a positive association between rigid control scores and BMI, as 
well as a higher total energy intake and less success with weight loss in those with high scores 
(Westenhoefer et al. 1999).   
 
Other significant associations from our study point to the possibility that the mutant C-allele carriers of the 
FTO rs1421085 polymorphism may have poorer eating behaviours.  The mutant CC subjects of the FTO 
rs1421085 polymorphism were characterized by a higher hunger score, which reflects a higher 
susceptibility to general subjective feelings and perceptions of hunger which may result in higher food 
intake.  Subscale analysis of the hunger score revealed that CC subjects’ hunger was internally interpreted 
and regulated (higher internal locus for hunger score).  This implies that CC subjects perceive to be hungry 
more often, resulting in eating more frequently during the day, often finding themselves “just having to eat 
something at anytime”.  The C-allele carriers were also characterized by a higher emotional disinhibition 
score, which is associated with experiencing disinhibition due to emotional feelings such as loneliness, 
anxiousness or feeling depressed (Bond et al. 2001).   
 
However, in contrast to these results the mutant CC genotype was also associated with having a higher 
flexible control (subscale score of dietary restraint), which indicates a better approach to dieting and thus a 
better eating behaviour.   Subjects with a higher score eat foods perceived to be fattening in small amounts, 
but without feelings of guilt and thus without losing control over food intake (Westenhoefer et al. 1999).  
Furthermore, it was also evident that the C-allele carriers had a lower intake of take-away foods compared 
to TT subjects.   
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When considering the interaction between food intake, eating behaviours and the FTO rs17817449 
polymorphism the results support those of the FTO rs1421085 polymorphism that indicate that the mutant 
allele carriers may have poorer eating behaviours.  The mutant GG subjects of the FTO rs17817449 
polymorphism were characterized by higher scores for habitual susceptibility to disinhibition (disinhibition 
subscale) and rigid control (subscale score of dietary restraint).  Habitual susceptibility to disinhibition 
refers to the fact that specific circumstances may predispose GG subjects to experience repeated 
disinhibition.  For instance, when such a subject eats food that is not allowed on a diet, they could 
experience it as a lapse resulting in binging on other high energy containing foods.  Such subjects are also 
likely to eat appropriate “healthy” foods in the presence of others, while splurging when on their own.  
They may also engage in eating binges when they are not hungry (Stunkard & Messick 1985).  All in all these 
subjects may find it particularly difficult to diet due to these lapses.  Typical dieting behaviour in this type of 
subject would involve starting to diet in the morning, but discontinuation thereof at some point in the day, 
therefore starting again the next day (Stunkard & Messick 1985).  It must also be borne in mind that these 
results were dependent on gender as the associations disappeared when analyses were adjusted for 
gender.  However, gender-adjusted results did indicate that the mutant GG subjects had a higher intake of 
high fat foods, which may be due to poorer eating behaviours.  
 
Only one report (Stutzmann et al. 2009) investigating the eating behaviour related associations with the 
FTO rs1421085 polymorphism could be found, while none have been published for the FTO rs17877749 
polymorphism.  In the work by Stutzmann et al. (2009) no associations were found between the FTO 
rs1421085 polymorphism and the scores of the restraint, disinhibition or perceived hunger scales of the 
TFEQ in obese and non-obese French adults.  These authors did not investigate associations with subscale 
scores of these three eating behaviours as was done in our research.  Stutzmann et al. (2009) also did not 
find any associations between the FTO rs1421085 polymorphism and snacking or eating large quantities of 
food at meals in Swiss class III obese adults, or with snacking and bulimia in French adults from a randomly 
selected population sample.  However, our results, as described above, provide support for the notion that 
the FTO gene may be associated with food intake and the regulation of eating behaviour (Speakman et al. 
2008, Wardle et al. 2009).  Furthermore, results from studies that investigated the associations between 
dietary intake or eating behaviours and other FTO polymorphisms that are located in the same LD block as 
the rs1421085 and rs17877749 polymorphisms (Dina et al. 2007b, Frayling et al. 2007, Scuteri et al. 2007) 
seem to support our findings that the mutant alleles of these two polymorphisms may be associated with 
poorer eating behaviours.  Wardle et al. (2008) showed that the mutant genotype or allele of the FTO 
rs9939609 polymorphism in Caucasian children was associated with impaired ability to respond to satiety 
cues (Wardle et al. 2008), a higher intake of highly palatable foods (Wardle et al. 2009) and a higher energy 
intake (Cecil et al. 2008).  These children also experienced more frequent “loss of control” eating episodes 
and ate food that is higher in fat at a lunch buffet (Tanofsky-Kraff et al. 2009).  Although the majority of 
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studies did find positive associations involving the FTO rs9939609 polymorphism, one study was unable to 
replicate these results in children (Hakanen et al. 2009).  In Caucasian adults a higher energy intake was 
also reported for mutant allele carriers of the FTO rs9939609 (Speakman et al. 2008) and rs8050136 
polymorphisms (Haupt et al. 2009).  From the aforementioned discussion it can be concluded that there is 
some support for our findings that mutant allele carriers of the FTO polymorphisms may have poorer eating 
behaviours (reflected by higher hunger, internal locus for hunger, emotional disinhibition, habitual 
disinhibition and rigid control scores).  Within this context it could be possible that our results indicating 
that the mutant genotype has a higher flexible control and lower intake of take-away foods (reflecting 
better eating behaviours) are false positives as no support for this could be found.  It is important to note 
that although a number of researchers have been investigating the associations between the FTO 
polymorphisms and physical activity, eating behaviour and dietary intake the exact physiological 
mechanisms involved are still unknown. 
 
The current study also suggests that the mutant GG subjects of the FTO rs17877749 polymorphism have 
more depressive symptoms (as measured by the BDI).  Furthermore, a modelled increase in psychological 
distress (as measured by the GHQ) was associated with a more pronounced increase in the BMI of the wild-
type TT subjects of the FTO rs1421085 polymorphism.  It is known that various mental and personality 
disorders including mania, anxiety and depression contribute to the hedonic aspects of overeating and may 
predict the development of obesity in both men and women (Ahlberg et al. 2002, Davis 2009).  No other 
reports could be traced that investigated the association between FTO polymorphisms and psychological 
health.  
 
In summary, although the exact physiological function of FTO is still unknown, it is has been recognized that 
it may play an important role in the regulation of food intake, eating behaviours and energy expenditure 
(physical activity), which does support the plausibility of the results of this research.  The wild-type T-T 
haplotype of the two FTO polymorphisms investigated in this study experienced the most pronounced 
decrease in BMI in response to an increase in the sport index score. The mutant allele carriers or mutant 
homozygotes of either the FTO rs1421085 or rs17817449 polymorphisms were associated with a higher 
intake of high fat foods as well as poorer eating behaviours, reflected in higher scores for perceived hunger, 
internal locus for hunger, emotional and habitual susceptibility to disinhibition and rigid control of dietary 
restraint.  Furthermore, an increase in rigid control was also associated with the most pronounced increase 
in the BMI of mutant homozygotes of the FTO rs1421085 polymorphism.  For the wild-type homozygotes of 
the FTO rs1421085 polymorphism the most pronounced decrease in BMI was found for a modelled 
increase in self-regulation.  These results are supported to some extent by associations found between 
food intake or eating behaviour indicators and FTO polymorphisms that are in strong LD with the two FTO 
polymorphisms investigated in this research.   
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Other novel findings that warrant further investigation include: 1) the wild-type T-allele carriers of the FTO 
rs17817449 polymorphism had fewer depressive symptoms; 2) the wild-type TT homozygotes of the FTO 
rs1421085 experienced the most pronounced increase in BMI in response to increase in psychological 
distress and 3) a modelled increase in BMI was associated with the most pronounced decrease in HDL levels 
of the mutant homozygotes of both polymorphisms, which was confirmed with haplotype analysis. 
 
The ADRB2 Arg16Gly polymorphism 
The only significant associations that were found for the ADRB2 Arg16Gly polymorphism involved perceived 
weight history and an eating behaviour related indicator.   
 
If it is assumed that perceived weight history is a proxy for actual weight history (Munoz et al. 1996, 
Koprowski et al. 2001, Must et al. 2002), our results indicate that the wild-type Arg16Arg genotype may 
predispose such individuals to being overweight during childhood, while Gly16-allele carriers were less 
likely to be overweight during childhood.  However, these associations disappeared during adolescence and 
young adulthood.  There was also no association between this polymorphism and actual BMI at the time of 
the study.  It can thus be speculated that the latter outcomes (no differences between genotype groups 
and actual weight at the time of this study or perceived weight during adolescence and young adulthood) 
resulted from more weight gain in the Gly16-allele carriers than Arg16Arg homozygotes during adolescence 
and early adulthood.  This is supported by studies that found a higher frequency of the Gly16Gly genotype 
in Caucasian men (aged 20-40 years old) who gained weight over a seven year period (Van Rossum et al. 
2002) as well as in Japanese overweight/obese men (aged <50 years old) who gained weight over a five 
year period (Kawaguchi et al. 2006) compared to their respective weight stable Caucasian and Japanese 
counterparts.  Further support for increased sensitivity to weight gain in Gly16-allele carriers comes from 
childhood and teenage cohort studies in Caucasian and African Americans.  Although no significant 
associations between the ADRB2 Arg16Gly polymorphism and the weight of newborns and children were 
found, the Gly16-allele carriers gained more weight per annum, which consequently resulted in a higher 
BMI during young adulthood (Ellsworth et al. 2002).  This is also in line with studies that indicate positive 
associations between the Gly16-allele carriers or Gly16Gly homozygotes and a higher BMI in Caucasians 
(Ehrenborg et al. 2000, Meirhaeghe et al. 2001) and Brazilians (Mattevi et al. 2006).  However it must be 
borne in mind that these genotypes have also been linked with a lower BMI in Caucasians (Ukkola et al. 
2000) and that the balance of evidence indicates that there is no association between the ADRB2 Arg16Gly 
polymorphism and BMI or obesity (Large et al. 1997, Meirhaeghe et al. 2000, Oberkofler et al. 2000, 
Rosmond et al. 2000, Terra et al. 2005, Gjesing et al. 2007, Lima et al. 2007).   
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As far as eating behaviour related indicators are concerned, it was found that a modelled increase in the 
flexible control score (subscale of dietary restraint) was associated with a more pronounced decrease in the 
BMI of Arg16Arg homozygotes.  This decrease in BMI was less pronounced in the heterozygotes and non 
existent in the mutant Gly16Gly homozygotes.  These results support the possibility that a focus on 
improving flexible control could help Arg16Arg subjects to achieve a lower BMI or could help them to be 
more effective weight managers and prevent weight gain in the long-term.  The fact that a modelled 
improvement in flexible control did not affect the BMI of the mutant Gly16Gly homozygotes in this study 
may indicate that these subjects may find it more difficult to lose weight than the wild-type Arg16Arg 
homozygotes.  The work by Masuo et al. (2005) possibly supports this notion.  They found that a two year 
intervention consisting of a low fat diet, exercise and nutrition education and behaviour sessions resulted in 
a significant reduction in the weight of Arg16Arg homozygotes, while Gly16-carriers were resistant to 
weight loss (Masuo et al. 2005).  Although eating behaviour indicators were not assessed, it can be 
speculated that the findings from the latter study support a focus on flexible control in Arg16Arg 
homozygotes, as a higher flexible control is necessary to achieve and maintain a weight loss over a long-
term period such as two years.  It can also be argued that these results stem from the changes that occur in 
the physiological functioning of ADRB2 due to the Arg16Gly polymorphism.  It has been shown that the 
Gly16-allele is associated with a higher decrease in ADRB2 expression in adipose tissue due to enhanced 
down-regulation after prolonged agonist stimulation (Green et al. 1994, Green et al. 1995).  This may 
consequently result in reduced receptor function and lower efficiency of lipolysis stimulation, leading to 
excess fat accumulation over time (Ellsworth et al. 2002).    
 
In summary, the perceived weight results from this research indicate that Arg16Arg homozygotes were 
more likely to think that they were overweight during childhood.  As no associations between this 
polymorphism and perceived weight during adolescence or young adulthood or with weight measured at 
the time of this study were found, it is speculated that Gly16Gly homozygotes may be more inclined to gain 
weight during the latter two life-cycle stages. As the literature in this regard is still equivocal, further 
research is necessary to confirm this association.  The novel finding that Arg16Arg homozygotes may 
respond better to weight loss or weight management interventions that place emphasis on improving their 
flexible control of dietary restraint, warrants further investigation.   
 
The GNB3 C825T polymorphism 
For the GNB3 C825T polymorphism several significant associations were found between the genotype 
groups and the investigated variables, including perception of weight, MetS traits, physical activity, dietary 
intake, depression and self-esteem.   
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The CT heterozygous subjects of the GNB3 C825T polymorphism were more likely to perceive themselves 
to be overweight during childhood compared to the CC or TT homozygous subjects.  These differences were 
not evident during adolescence or young adulthood.  There was also no association between the 
polymorphism and actual BMI of subjects at the time of this study.  As no evidence in the literature seems 
to support this association, the possibility that this is a false positive result need to be considered.  
 
Assessment of associations with MetS traits revealed that the mutant TT homozygotes were more at risk to 
develop MetS than the CC homozygotes or C-allele carriers.  The TT homozygotes had higher fasting 
triglyceride, glucose levels, a higher number of traits that met the diagnostic cut-off criteria for MetS and 
higher number of these subjects was diagnosed with MetS.  These findings are in line with associations 
reported for the TT homozygous genotype with higher fasting glucose and insulin levels, HbA1c, insulin 
resistance and Type 2 diabetes prevalence in other Caucasian samples (Poch et al. 2002, Brand et al. 2003, 
Wascher et al. 2003, Andersen et al. 2006).   
 
When considering the physical activity results, it was evident that a modelled increase in leisure-time 
activity resulted in a more pronounced decrease in the BMI in wild-type CC homozygotes.  This association 
was less pronounced in the CT heterozygotes and non-existent in the mutant TT homozygotes.  This finding 
is not supported by the results from two published studies conducted in Caucasian samples, namely that 
the interaction between the GNB3 C825T polymorphism and physical activity levels has no effect on the risk 
to develop obesity (Grove et al. 2007) or on body composition changes after a 20-week endurance exercise 
programme (Rankinen et al. 2002). However, significant associations have been reported for non-Caucasian 
samples.   Rankinen et al. (2002) reported greater decreases in fat mass and percentage body fat after the 
20-week endurance exercise programme in African-American TT homozygotes (Rankinen et al. 2002).  
Grove et al. (2007) pointed out that TT-subjects with low physical activity levels had the highest risk for 
obesity development, while TT subjects with high physical activity levels had the lowest risk for obesity 
development (Grove et al. 2007).   The results regarding the association between this polymorphism and 
physical activity levels are clearly still equivocal.   
 
In terms of dietary intake, the CC subjects had a higher intake of high fat foods and energy-dense drinks.  
Furthermore, a modelled increase in the intake of energy-dense snacks was associated with a more 
pronounced increase in the BMI of CC subjects than the CT heterozygotes, while no such association was 
found in TT subjects.  No other studies could be traced that investigated the association between this 
polymorphism and dietary intake specifically.  It is thus possible that CC subjects may benefit more from 
decreased intake of high fat foods, energy dense snacks and energy-dense drinks, but further research is 
essential to confirm this outcome.   
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The associations between the GNB3 C825T polymorphism and MetS traits, physical activity and dietary 
intake indicators can possibly be explained on the basis of the changes in the physiological function of the 
GNB3 protein associated with the C825T polymorphism.  The GNB3 gene encodes a β-subunit of the 
guanine nucleotide binding proteins (G-proteins) (Milligan & Kostenis 2006, Oldham & Hamm 2006).  G-
proteins are located on the cell membranes of WAT where they transduce signals that stimulate lipolysis in 
the adipocytes (Robidoux et al. 2004).  The 825T-allele of the GNB3 polymorphism has been associated with 
the expression of an altered G-protein (Siffert et al. 1998, Rosskopf et al. 2003a, Rosskopf et al. 2003b), 
decreased G-protein content in adipocytes (Rydén et al. 2002) as well as decreased catecholamine induced 
lipolysis in adipose tissue (Hauner et al. 2002, Rydén et al. 2002).  The lower GNB3 protein levels in 
adipocytes as well as the decreased stimulation of lipolysis in TT subjects may explain why CC subjects 
respond better to physical activity or decreased intake of energy-dense snacks to lose weight, as normal 
lipolysis probably occurs in the CC subjects.  Normal lipolysis stimulation may also explain the more 
favourable MetS profile found in the CC subjects.  It can thus be speculated that TT subjects would need to 
have higher physical activity levels or a lower energy intake than CC subject in order to maintain weight or 
to achieve a negative energy balance and lose weight.  However, more research is required to elucidate the 
exact physiological function of the GNB3 splice variants and how this interacts with lifestyle variables and 
contributes to the development of obesity (Vogler et al. 2008). 
 
The link between the GNB3 polymorphism and psychological well-being has also been investigated by 
others because of the physiological role of the GNB3 protein in serotonin reuptake (Simon et al. 1991).  Our 
results indicate that the mutant TT genotype experienced fewer depressive symptoms and had a higher 
self-esteem compared to the CC genotype or C-allele carriers.  In contrast to our results, a meta-analysis of 
three case-control studies (Lopez-Leon et al. 2008) as well as research on Caucasian (Exton et al. 2003), 
Korean (Lee et al. 2004) and Chinese (Cao et al. 2007) samples found an association between the T-allele 
and having either depression or more depressive symptoms.  However, others reported no association 
between depression and this polymorphism in Asian samples (Lin et al. 2001, Kunugi et al. 2002).  Several 
studies also investigated the influence of the GNB3 C825T polymorphism on antidepressant response in 
patients with major depressive disorder.  Some indicate no association in Korean (Kang et al. 2007) and 
Japanese (Kato et al. 2008) samples, while others find a lack of response to specific anti-depressants in T-
allele carriers (Wilkie et al. 2007, Lin et al. 2009).  Most of these studies were performed in Asian 
populations and although they do contribute to the understanding of the association between the GNB3 
polymorphism and depression, more research is necessary to clarify these associations in Caucasians.    
 
In summary, our results indicate that the mutant TT homozygotes had higher triglyceride and glucose levels, 
a higher number of traits that met the diagnostic cut-offs for MetS and a higher number of subjects were 
diagnosed with MetS.  These findings are in line with other published reports in Caucasian populations.  A 
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modelled increase in physical activity levels was associated with the most pronounced decrease BMI of the 
wild-type CC subjects.  Support for this in the literature is conflicting and more research is necessary to 
clarify the association in Caucasian populations.  The novel findings for the associations between the GNB3 
C825T polymorphism and dietary intake indicate that CC subjects had a higher intake of high fat foods and 
energy-dense drinks and that a modelled decrease in the intake of energy-dense snacks is associated with 
the most pronounced decrease in BMI of CC subjects.  The associations with MetS, physical activity and 
dietary intake can be explained to some extent by the known effect of the GNB3 C825T polymorphism on 
the physiological functioning of the GNB3 protein. The finding that TT subjects in our study had less 
depressive symptoms and a higher self-esteem is not in line with previous reports that there is either no 
association or an association between the T-allele and depression.  As most of the research on 
psychological health involved Asian populations, more research is necessary to elucidate the association in 
Caucasian populations. 
 
 
4.3 Conclusions 
 
The results of this study in overweight/obese Caucasian adults with BMIs ranging from 27 to 52 kg/m2 
emphasize that the higher the BMI, the more compromised the physical health status of subjects, including 
increased MetS prevalence and diagnosed abdominal obesity, dyslipidemia (low HDL) and hypertension.  As 
expected, a higher BMI was characterized by having lower sport and leisure-time physical activity levels; 
higher intakes of high fat foods, energy-dense snacks, take-away foods and energy-dense drinks; higher 
disinhibition, emotional disinhibition and habitual disinhibition, lower dietary restraint; and more 
depressive symptoms.  The modelled relationships that were found between BMI and lifestyle and 
psychological health variables emphasize that these factors should form the foundation of a weight loss 
programme aimed at overweight/obese Caucasians.   
 
The primary null hypothesis, namely that there is no association between genotype and BMI, could not be 
rejected.  A number of the secondary and exploratory hypotheses were rejected (Table 4.16), thus 
reflecting associations between either genotype and variable and/or the effect of the interaction between 
genotype and variable on BMI.  These results were supported by the literature in some instances, but some 
were also novel findings.  A number of findings that are contradictory to the association in the literature or 
known physiological function were found (not included in Table 4.16), and the possibility that they are false 
positives needs to be considered. 
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Table 4.16:  A summary of findings from this study 
Findings from this study Evidence:  
Novel/ supported  
Physiological 
context link 
FABP2 Ala54Thr   
 Mutant Thr54Thr:  ↑ intake of take-away foods.  Novel  unknown 
 Wild-type Ala54Ala: modelled decrease in BMI associated with 
decrease TG levels 
 Novel  Possible 
 Wild-type Ala54Ala: ↓ self-esteem  Novel  unknown 
INSIG2 rs7566605:   
 Mutant CC: ↑ MetS risk as they had ↓ HDL levels & more MetS 
traits 
 Others found no association  Possible 
 Wild-type GG: ↓ leisure-time activity levels  Supported but equivocal 
findings 
 Possible 
 Wild-type GG:  modelled ↑ leisure-time activity levels was 
associated with ↓ BMI 
 
 Mutant CC: lower attitude to self-regulation score & modelled ↑ 
in situational disinhibition score associated with ↑ in BMI  
 Novel  Possible 
FTO rs1421085    
 Mutant CC: modelled ↓ BMI associated with ↑ HDL levels  Novel  Unknown 
 Mutant CC: ↑ perceived hunger, ↑ internal locus for hunger, ↑ 
emotional disinhibition, a modelled ↑ in rigid control resulted in 
a ↑ in BMI 
 Novel, but supported by FTO 
SNPs in LD with this SNP. 
 Possible 
 Wild-type TT: modelled ↑ in attitude to self-regulation of dietary 
restraint ↓ BMI.   
 Novel  Possible 
 Wild-type TT: modelled ↓ in general psychological well-being 
(GHQ) associated with ↓ BMI  
 Novel  Unknown 
FTO rs17817449   
 Mutant GG: ↑ intake of high fat foods, ↑ habitual susceptibility of 
disinhibition, ↑ rigid control (dietary restraint).   
 Novel, but supported by FTO 
SNPs in LD with this SNP. 
 Possible 
 Mutant GG: ↑ depressive symptoms.  
 
 Novel  Unknown 
 Wild-type T-T haplotype: modelled ↑ sport index score 
associated with ↓ BMI 
 Novel  Possible 
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Table 4.16: (continued) 
Findings from this study Evidence:  
Novel/ supported  
Physiological 
context link 
ADRB2 Arg16Gly:   
 Arg16Arg: more thought they were overweight during 
childhood, but not during adolescence/young adulthood & no 
association with current BMI. Possible that Gly16Gly 
homozygotes may be more inclined to gain weight during the 
latter two life-cycle stages 
 Supported but equivocal 
findings 
 Possible 
 Arg16Arg: ↑ flexible control of dietary restraint was associated 
with ↓ BMI 
 Novel  Possible 
GNB3 C825T   
 Mutant TT: higher MetS risk as ↑ glucose, ↑ triglycerides,                 
↑ number of MetS traits & more had MetS. 
 Supported  Possible 
 Wild-type CC: ↑ leisure-time activity was associated with ↓ BMI  Supported, but equivocal 
findings  
 Possible  
 Wild-type CC: ↑ intake of high fat foods, energy-dense drinks, ↓ 
intake of energy-dense snacks was associated with ↓ BMI 
 Novel  Unknown 
 Wild-type CC: more depressive symptoms and lower self-esteem  Contradicts findings in Asian 
samples 
 Possible 
 
 
Bearing in mind the limitations of the study (see Chapter 6, p250-251) it can be concluded that there was 
no association between genotype and BMI in this study sample.  Furthermore, several associations 
between genotype and health and lifestyle related factors were prevalant, of which the most plausible 
associations are that the mutant TT homozygotes of the GNB3 C825T polymorphism may have a higher risk 
to develop MetS and that the mutant alleles of the two FTO polymorphism are associated with poorer 
eating behaviours and higher intake of high fat foods.   
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Chapter 5 
 
 
Intervention study 
Results, discussion and conclusions  
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5.1 Results 
 
Participants in the weight loss programme 
 
Two-thirds (66%) of the 133 subjects included in the cross-sectional sample volunteered to participate in 
the six months weight loss programme.  The subjects who chose not to participate in the programme 
(n=45) had a significantly higher mean±SD baseline weight (105.4±19.3 kg) than the n=88 subjects 
(97.0±20.1 kg) who did continue with the programme (p=0.0224).  The baseline BMI (37.2±6.7 kg/m2) of 
subjects who chose not to participate in the programme was also higher than the BMI (34.2±6.3 kg/m2) of 
those who did continue with the programme (p=0.0135).  No further significant differences between these 
two groups of subjects were found for any other variables, including physical activity, dietary intake, 
psychological health and eating behaviour. 
 
Socio-demographic information 
 
The subjects included in the weight loss programme had a mean±SD baseline age of 32.8±4.1 years, weight 
of 97.0±20.1 kg, height of 1.68±0.08 m and BMI of 34.2±6.3 kg/m2.  Just more than a quarter (26.1%) of 
these subjects was overweight (BMI of 27-29.9 kg/m2), 38.6% were obese class I (BMI of 30-34.9 kg/m2), 
18.2% were obese class II (BMI of 35-39.9 kg/m2) and 17.0% were obese class III (BMI ≥ 40 kg/m2).  Most 
were female, married, Afrikaans speaking, had a tertiary qualification and lived with their partners and 
children (Table 5.1).  The males had a significantly higher baseline weight than the females, although the 
mean BMI was not different.  There were no significant differences in mean BMI between the response 
categories of the socio-demographic variables.    
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Table 5.1: Socio-demographic profile and association with baseline weight and BMI 
 n % Baseline 
weight 
mean±SD 
p-value Baseline 
BMI 
mean±SD 
p-value 
Gender 
 Female 
 Male 
 
75 
13 
 
85.2 
14.8 
 
94.5±19.9 
111.3±15.1 
 
0.0048
†
 
 
 
34.2±6.6 
34.4±4.5 
 
 
0.9156† 
 
Marital status  
 Married / living together 
 Unmarried (including separated/ divorced) 
 
52 
36 
 
59.1 
40.9 
 
96.4±21.0 
98.0±19.0 
 
 
0.7158† 
 
 
33.9±6.1 
34.8±6.7 
 
 
0.5175† 
 
Home language 
 Afrikaans 
 English 
 
78 
10 
 
88.6 
11.4 
 
96.2±19.6 
103.7±23.4 
 
 
0.2639† 
 
 
34.0±6.1 
36.5±7.5 
 
0.2416† 
 
Level of education 
 Completed high school  
 College/Technicon qualification 
 University degree 
 
25 
34 
29 
 
28.4 
38.6 
33.0 
 
92.8±22.0 
101.5±21.7 
95.4±15.6 
 
0.2248§ 
 
33.0±6.7 
36.0±6.9 
33.2±4.7 
 
 
0.1055§ 
Living 
 alone 
 with friends/ parents 
 with a partner 
 with a partner and child(ren) 
 
 
18 
14 
19 
37 
 
20.5 
15.9 
21.6 
42.0 
 
100.2±20.4 
96.6±19.6 
99.3±20.1 
94.5±20.6 
 
0.7374§ 
 
35.5±6.9 
34.1±6.7 
33.6±5.1 
34.0±6.6 
 
0.8120§ 
† Independent Samples t-test 
§ One-way ANOVA 
      
 
 
Drop-outs  
 
No significant differences between the drop-outs (n=47, 53%) and subjects who completed the full 24 
weeks (n=41, 47%) of the study were found for the following cross-sectional assessments: age, height, 
weight, BMI and the scores of the physical activity, eating behaviour and psychological health 
questionnaires (Table 5.2).  There were also no differences between weight and BMI measured at each 
follow-up point as well as mean perceived compliance scores of drop-outs (who were still in the 
programme at that specific follow-up point) and non-drop-outs.  There were also no signifcant differences 
between subjects who remained in the four month active intervention phase of the programme but did not 
attend the six months follow-up (n=55, 63%) and drop-outs at four months (n=33, 37%) for all these 
baseline variables and follow-up weights and BMIs (results not included in a Table). 
 
 
 
 220
Table 5.2: Comparison of the mean±SD between the baseline data as well as weight, BMI and perceived compliance 
follow-up data of drop-out and non-drop-outs during the 24 week intervention period. 
Variables  Non-drop-outs Drop-outs  
  n* Mean±SD n* Mean±SD p-value† 
Baseline age (years)  41 33.5±4.1 47 32.1±4.0 0.0925 
Baseline height (m)  41 1.7±0.1 47 1.7±0.1 0.5361 
Baseline weight (kg)  41 97.3±19.0 47 96.8±21.2 0.8956 
Baseline BMI (kg/m2)  41 34.5±5.5 47 34.0±7.0 0.7027 
Perceived dietary compliance 27 5.6±1.5 29 4.9±2.1 0.2068 
Perceived physical activity compliance 27 5.1±1.7 29 4.4±1.9 0.1253 
Perceived behavioural compliance 27 5.0±1.5 29 4.4±2.1 0.2398 
Total perceived compliance 27 5.2±1.2 29 4.6±1.8 0.1244 
Baseline physical activity scores      
Work index  
Sport index  
 41 2.3±0.6 46 2.4±0.6 0.7058 
 41 2.0±0.6 46 2.1±0.7 0.3871 
Leisure-time index  41 2.0±0.6 46 2.0±0.5 0.8651 
Total physical activity  41 2.1±0.4 46 2.2±0.4 0.4725 
Baseline TFEQ scores       
Dietary restraint  41 8.6±3.8 45 7.9±4.6 0.4911 
Disinhibition  41 10.7±3.7 45 9.7±3.7 0.2296 
Perceived hunger  41 7.2±3.4 45 6.8±3.5 0.6160 
Baseline scores of psychological health variables      
Beck depression inventory 
General health questionnaire 
Rosenberg self-esteem scale 
41 13.9±11.0 46 13.2±8.1 0.7225 
41 14.3±5.1 45 16.3±5.5 0.0944 
41 19.8±5.8 46 19.2±4.9 0.5839 
TFEQ = three-factor eating questionnaire 
*n vary due to missing values 
† Independent Samples t-test 
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Perceived compliance with the weight loss programme 
 
The subjects’ mean perceived compliance scores for each of the three components of the weight loss 
programme as well as the total perceived compliance score are presented in Table 5.3.  These mean 
compliance scores were all around 50% (a score of 5 out of 10).   
 
The correlation matrix that was constructed to assess the associations between compliance scores and 
weight variables indicates that the scores were not associated with baseline weight or BMI (Table 5.3).  
Weight and BMI changes from baseline to follow-up were also not associated with physical activity or 
behavioural compliance scores.  However, higher weight and BMI losses were significantly associated with 
higher dietary compliance and total compliance scores. 
 
 
Table 5.3:  Mean±SD perceived compliance scores and correlation matrix of perceived compliance scores and baseline 
weight and BMI as well as change in weight and BMI overtime (24 weeks). 
Perceived  Compliance scores Correlation matrix 
compliance 
variable 
out of 10 
 
Mean±SD 
 Baseline 
weight 
Baseline  
BMI 
Weight change 
(Baseline – 
Follow-up) 
BMI change 
(Baseline – 
Follow-up) 
       
Dietary  5.2±1.8 r -0.1107 0.0130 0.6157 0.6294 
compliance  p 0.416 0.924 0.001 <0.0001 
       
Physical activity  4.7±1.9 r 0.0537 0.1024 0.2548 0.2413 
compliance  p 0.694 0.453 0.200 0.225 
       
Behavioural  4.7±1.8 r 0.0061 0.0583 0.3479 0.3208 
compliance  p 0.965 0.670 0.075 0.103 
       
Total  4.9±1.6 r -0.0193 0.0672 0.5131 0.5013 
compliance  p 0.888 0.623 0.006 0.008 
       
 
 
Differences between Baseline and Follow-up weight and BMI 
 
The subjects had a mean (SE) weight loss of 8.07 (0.72) kg (p<0.0001) and BMI loss of 2.92 (0.26) kg/m2 
(p<0.001) over the total study period of 24 weeks.  This reflects a mean percentage weight loss of 8.6% 
over 24 weeks. The modelled time trajectories for weight and BMI measured every second week from 
baseline for the duration of the programme are depicted in Table 5.4.  The difference between baseline and 
follow-up weight at 24 weeks was significant, whereas the difference between baseline BMI and follow-up 
BMI was significant at 14, 16 and 24 weeks.   
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Table 5.4: Unadjusted mean (SE) for weight and BMI change from baseline to 24 weeks. 
  ∆ Weight (kg)  ∆ BMI (kg/m2) 
Weeks in 
programme n 
Difference from baseline 
(standard error) p-value
†
  
Difference from baseline 
(standard error) p-value
†
 
2 83 -0.82 (3.08) 0.7908  -0.28 (0.95) 0.7665 
4 80 -1.01 (3.11) 0.7464  -0.42 (0.96) 0.6624 
6 70 -4.51 (3.22) 0.1625  -1.67 (0.99) 0.0922 
8 69 -2.95 (3.24) 0.3625  -1.33 (0.99) 0.1809 
10 62 -3.72 (3.34) 0.2655  -1.21 (1.03)  0.2375 
12 57 -3.81 (3.42) 0.2659  -1.19 (1.05) 0.2566 
14 48 -6.92 (3.61) 0.0559  -2.63 (1.11) 0.0180 
16 55 -5.15 (3.46) 0.1366  -2.14 (1.06) 0.0448 
24 41 -7.76 (3.81) 0.0417  -2.65 (1.17) 0.0240 
*n reflects drop-out during intervention;  
†Linear mixed-effects model with weeks as fixed effect and individual as random effect.  
 
 
 
Differences between Baseline and Follow-up scores in physical activity, eating behaviour and 
psychological health variables 
 
Significant changes from Baseline to the 16 week Follow-up assessment were evident for all the mentioned 
variables except for the work index score (Table 5.5).  The changes included significant increases in the 
scores of the sport and leisure-time indices as well as the total physical activity score of the Baecke physical 
activity questionnaire, and significant improvements in the scores for depression (BDI), general 
psychological well-being (GHQ), self-esteem (RSES) and all the scales and subscales of eating behaviour 
(TFEQ) (Table 5.5).   
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Table 5.5: Mean (SE) difference in Baseline to 16-weeks Follow-up scores of physical activity, eating behaviour and 
psychological well-being variables. 
 Variable (score range) 
 
n* 
 
Follow-up minus Baseline 
mean (standard error) 
p-value
†
 
 
Physical activity ∆ Sport index score  52 0.39 (0.10) 0.0002 
 ∆ Work index score 52 -0.02 (0.06) 0.7628 
 ∆ Leisure-time index score 52 0.38 (0.08) <0.0001 
 ∆ Total physical activity score 52 0.25 (0.06) 0.0001 
      
Eating behaviour ∆ Factor I: Dietary restraint (0-21) 51 4.96 (0.62) <0.0001 
 ∆ Factor II: Disinhibition (0-16) 51 -3.22 (0.50) <0.0001 
 ∆ Factor III: Perceived hunger (0-14) 51 -3.24 (0.45) <0.0001 
      
 Dietary restraint subscales: ∆ Flexible control (0-7) 51 1.67 (0.29) <0.0001 
 ∆ Rigid control (0-7) 51 1.63 (0.25) <0.0001 
 ∆ Strategic dieting (0-4) 51 0.96 (0.21) <0.0001 
 ∆ Self-regulation (0-5) 51 1.29 (0.20) <0.0001 
 ∆ Avoidance of fattening foods (0-4) 51 0.63 (0.19) 0.0020 
      
 Disinhibition subscales: ∆ Habitual disinhibition (0-5) 51 -1.12 (0.22) <0.0001 
 ∆ Emotional disinhibition (0-3) 51 -0.67 (0.16) 0.0001 
 ∆ Situational disinhibition (0-5) 51 -1.31 (0.20) <0.0001 
      
 Perceived hunger subscales: ∆ Internal locus (0-6) 51 -1.59 (0.25) <0.0001 
  ∆ External locus (0-6) 51 -1.47 (0.24) <0.0001 
      
Psychological well-being ∆ Beck depression inventory (0-63) 52 -8.35 (1.34) <0.0001 
 ∆ General health questionnaire (0-30) 51 -5.90 (1.00) <0.0001 
 ∆ Rosenberg self-esteem scale (10-40) 52 1.54 (0.59) 0.0117 
*n vary due to missing values; †Linear model of 16-week follow-up as a function of baseline variable 
 
 
Genotype and allele frequencies 
 
The genotype and allele frequencies of the 88 participants in the intervention are presented in 
Table 5.6.  No mutant genotype was found in this sample for the ADRB3 Trp64Arg polymorphism.  The 
frequencies of the mutant alleles were higher than the wild-type alleles for the ADRB2 Arg16Gly and FTO 
rs17817449 polymorphisms.   
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Although the genotype frequencies of the GNB3 C825T and FTO rs17817449 polymorphisms were not in 
HWE, it must be borne in mind that all subjects were overweight/obese and not representative of a random 
population.     
 
Table 5.6: Genotype and allele frequencies for overweight/obese Caucasian subjects in a weight loss 
programme 
Gene Polymorphism Genotype frequency Allele frequency HWE 
  Base pair n* % Allele % p-value
†
 
 
FABP2 
 
Ala54Thr 
 
GG (wild-type) 
GA 
AA 
 
 
28 
28 
16 
 
38.9 
38.9 
22.2 
 
G-allele 
A-allele 
 
58.3 
41.7 
 
0.0930 
INSIG2 rs7566605 GG (wild-type) 
GC 
CC 
 
30 
39 
6 
40.0 
52.0 
8.0 
G-allele 
C-allele 
66.0 
34.0 
0.2084 
FTO rs1421085 TT (wild-type) 
TC 
CC 
 
18 
36 
14 
26.5 
52.9 
20.6 
T-allele 
C-allele 
52.9 
47.1 
0.8074 
FTO rs17817449 TT (wild-type) 
TG 
GG 
 
24 
22 
26 
33.3 
30.6 
36.1 
T-allele 
G-allele 
48.6 
51.4 
0.0010 
ADRB3 Trp64Arg TT (wild-type) 
TC 
CC 
 
54 
6 
0 
90.0 
10.0 
0 
T-allele 
C-allele 
95.0 
5.0 
1.0000 
ADRB2 Arg16Gly 
 
AA (wild-type) 
AG 
GG 
 
10 
38 
23 
14.1 
53.5 
32.4 
A-allele 
G-allele 
40.8 
59.2 
0.4644 
GNB3 C825T CC (wild-type) 
CT 
TT 
 
31 
25 
14 
44.3 
35.7 
20.0 
C-allele 
T-allele 
62.1 
37.9 
0.0449 
*n vary due to missing values 
† R exact test 
 
 
 
Effect of genotype on weight and BMI changes 
 
Total compliance and gender-adjusted p-values for genotype and additive allelic effect on time trajectories 
(change in weight and BMI) for different follow-up periods from baseline are presented in Table 5.7.   
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Table 5.7: Total compliance and gender-adjusted p-values for genotype and additive allelic effect on time trajectories 
(change in weight and BMI) for different time periods from baseline. 
Polymorphisms p-values adjusted for gender and compliance 
 ∆ BMI ∆ Weight 
 genotype† additive allelic§ genotype† additive allelic§ 
1st month     
FABP2 Ala54Thr 0.8446 0.5568 0.8372 0.5485 
INSIG2 rs7566605 0.1910 0.0673 0.3218 0.1309 
FTO rs1421085 0.7029 0.4681 0.5422 0.2977 
FTO rs17817449 0.0619 0.7786 0.1197 0.8215 
ADRB3 Trp64Arg 0.9913 0.9913 0.9519 0.9519 
ADRB2 Arg16Gly 0.0228 0.0114 0.0179 0.0087 
GNB3 C825T 0.2131 0.4134 0.2216 0.5508 
2 months     
FABP2 Ala54Thr 0.9675 0.8123 0.9687 0.8127 
INSIG2 rs7566605 0.3544 0.1893 0.3821 0.2132 
FTO rs1421085 0.5394 0.2623 0.3507 0.1445 
FTO rs17817449 0.0398 0.8549 0.0576 0.9730 
ADRB3 Trp64Arg 0.8509 0.8509 0.8989 0.8989 
ADRB2 Arg16Gly 0.1002 0.0754 0.0741 0.0503 
GNB3 C825T 0.3648 0.2511 0.3765 0.2818 
3 months     
FABP2 Ala54Thr 0.8338 0.6398 0.8099 0.5989 
INSIG2 rs7566605 0.6771 0.3737 0.7333 0.4276 
FTO rs1421085 0.9637 0.9532 0.8877 0.6773 
FTO rs17817449 0.1903 0.6230 0.2531 0.6905 
ADRB3 Trp64Arg 0.4883 0.4883 0.5526 0.5526 
ADRB2 Arg16Gly 0.4281 0.2343 0.3203 0.1628 
GNB3 C825T 0.7442 0.4377 0.8025 0.5070 
4 months     
FABP2 Ala54Thr 0.7964 0.5727 0.7725 0.5435 
INSIG2 rs7566605 0.6072 0.3148 0.6359 0.3378 
FTO rs1421085 0.9933 0.9146 0.9819 0.8451 
FTO rs17817449 0.3078 0.9372 0.3572 0.9890 
ADRB3 Trp64Arg 0.4169 0.4169 0.4719 0.4719 
ADRB2 Arg16Gly 0.4742 0.3000 0.3841 0.2320 
GNB3 C825T 0.7241 0.5073 0.7875 0.5763 
6 months     
FABP2 Ala54Thr 0.8879 0.6760 0.8598 0.6562 
INSIG2 rs7566605 0.5969 0.3649 0.6326 0.3943 
FTO rs1421085 0.9474 0.8771 0.9626 0.8972 
FTO rs17817449 0.5305 0.9997 0.6180 0.9506 
ADRB3 Trp64Arg 0.3618 0.3618 0.4253 0.4253 
ADRB2 Arg16Gly 0.3838 0.2578 0.2969 0.2025 
GNB3 C825T 0.7868 0.6697 0.8431 0.7742 
†Linear model of genotype groups (categorised as wild-type, heterozygous and mutant genotypes) on BMI/ weight. 
§Linear model of the additive allelic variable (numerically categorised as 0, 1 and 2 minor alleles) on BMI/ weight. 
 
 
The gender-adjusted and total compliance adjusted genotype and additive allelic effect on weight and BMI 
time trajectories for the first four weeks on the weight loss programme was significant for the ADRB2 
Arg16Gly polymorphism (Table 5.7).  This significant difference for weight change during the first month 
 226
(p=0.0087) is depicted in the slopes of the lines in Figure 5.1, which shows the modelled trajectories, from 
an additive allelic model, for a woman with an average compliance of 4.9, stratified by genotype. The 
modelled weekly weight loss for mutant Gly16Gly (GG) homozygotes is 0.38 kg for the first month, which is 
significant.  For the heterozygotes (GA) the weekly loss is 0.28 kg more, thus 0.66 kg and for the wild-type 
Arg16Arg (AA) homozygotes it is 0.84 kg (a further additional 0.28 kg).  Thus the mutant Gly16Gly 
homozygotes lost weight at a significantly slower rate than the heterozygotes whose weight loss was 
slower than that of the wild-type homozygotes (Figure 5.1).  As the modeled additive allelic effect is the 
same for BMI, it was not depicted in a graph.  The significant genotype effects are similar to the additive 
allelic effects for both weight and BMI, and are therefore also not depicted in separate graphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1:  Plot of modelled weight against time (in weeks) for the first month on the weight loss 
programme.  Lines show the modelled trajectories, from an additive allelic model, for a woman with 
average compliance of 4.9, for the genotypes of the ADRB2 Arg16Gly polymorphism.   
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The gender and compliance adjusted genotype effect on BMI time trajectories for the first eight weeks on 
the weight loss programme was significant for the FTO rs17817449 polymorphism (Table 5.7).  The 
modeled weight loss for the wild-type TT homozygotes was -1.67 kg during the first eight weeks of the 
programme, which is significantly more than the weight loss of -0.059 kg for GT or -0.175 kg for GG subjects 
(Figure 5.2).  It is clear from Figure 5.2 that there is no additive allelic effect.  It is also important to note 
that the additive allelic effect on weight change was not significant, therefore the possibility that the 
modeled significant effect on BMI change is a false positive result, needs to be considered.   
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Figure 5.2:  Plot of modelled BMI against time (in weeks) for the first two months on the weight loss 
programme.  Lines show the modeled trajectories, from the genotype model, for a woman with average 
compliance of 4.9, for the genotypes of the FTO rs17817449 polymorphism.   
 
 
None of the other polymorphisms had an effect on weight or BMI change during the first eight weeks of the 
weight loss programme.  Furthermore, none of the polymorphisms had an effect on weight or BMI change 
from baseline to 12, 16 or 24 weeks (Table 5.7).    
 
Effect of gene-gene interactions for all allelic combinations on ∆ BMI 
An interaction between the ADRB2 Arg16Gly and INSIG2 rs756605 polymorphisms had a significant 
(p=0.0028) effect on ∆ BMI during the six month programme.  Table 5.8 depicts the significant effects that 
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were found for all the allelic combinations of this gene-gene interaction.  Each effect size presented in this 
table represents the average difference in ∆ BMI for the specific allele combination compared to the 
reference combination which was G-G.  The average difference in ∆ BMI between subjects with both 
mutant alleles (G-allele of ADRB2 and C-allele of INSIG2) and those with the G-G allelic combination is -2.6 
kg/m2.  Thus the change in BMI for those with the mutant G-C alleles is -2.6 kg/m2 less, on average, than for 
subject with the with G-G alleles. The average difference in ∆ BMI between subjects with both wild-type 
alleles (A and G) is -1.59 kg/m2 compared to subjects with the G-G alleles.  The change in BMI for the A-C 
allelic combination does not differ significantly from the G-G allelic combination.  None of the other gene-
gene interactions were significant and therefore not included in the table. 
 
 
Table 5.8: The effect of all allelic combinations of the gene-gene interaction between the ADRB2 Arg16Gly 
and INSIG2 rs7566605 polymorphisms on ∆BMI during the 24 week programme (gender and compliance 
adjusted). 
ADRB2 Arg16Gly 
A= wild-type allele 
G= mutant allele 
INSIG2 rs7566605 
G= wild-type allele 
C= mutant allele 
Allelic 
combination 
frequency 
Effect size 
(kg/m
2
) SE p-value 
A C 0.19 -0.10 0.67 0.8798 
A G 0.20 -1.59 0.74 0.0460 
G C 0.11 -2.60 0.95 0.0137 
G G 0.51 haplotype base   
 
 
Effects of the interaction between ∆ variable and polymorphism on ∆ BMI 
 
The gender and compliance-adjusted significant effects of the interactions between ∆ variable (Baseline 
minus follow-up scores) and polymorphism on ∆ BMI (Baseline minus follow-up BMIs) for the additive 
allelic model are illustrated in Figures 5.3 to 5.5.   
 
The modelled rate of change in ∆ BMI in response to a change in ∆ emotional disinhibition score differed 
significantly between the genotype groups of the FTO rs1421085 polymorphism (Figure 5.3).  The modelled 
rate of increase in BMI loss in response to an increased reduction in the emotional disinhibition score was 
more pronounced in the TT than TC subjects. As there were only a few mutant CC subjects and they had 
mostly a difference of zero or two on the emotional disinhibition score, the resulting modelled line in 
Figures 5.3 was not useful for interpretation purposes. 
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Figure 5.3:  Plot of ∆ BMI against ∆ Emotional disinhibition score.  Symbols represent individual observed values and 
regression lines show the expected relationships, from the additive allelic model, for a woman with average 
compliance of 4.9, for each genotype of the FTO rs1421085 polymorphism (p=0.0017).  ∆ = Baseline minus Follow-up 
values. 
 
 
 
 
The rate of change in ∆ BMI in response to a change in ∆ BDI score differed significantly between the 
genotype groups of the GNB3 C825T polymorphism (Figure 5.4).  A modelled rate of increase in BMI loss 
over the 24 week intervention period in response to an increased reduction in BDI score was observed for 
the CC subjects but not for the CT subjects, while the association was in the opposite direction for the TT 
subjects.  
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Figure 5.4:  Plot of ∆ BMI against ∆ Beck depression inventory.  Symbols represent individual observed values and 
regression lines show the expected relationships, from the additive allelic model, for a woman with average 
compliance of 4.9, for each genotype of the GNB3 C825T polymorphism (p=0.0291).  ∆ = Baseline minus Follow-up. 
 
 
 
The rate of change in ∆ BMI in response to a change in ∆ GHQ score differed significantly between the 
genotype groups of the FABP2 Ala54Thr polymorphism (Figure 5.9).  The modelled rate of increase in BMI 
loss over the 24-weeks intervention period in response to an increased reduction in the GHQ score was 
more pronounced in the mutant AA homozygotes than the heterozygotes, which was more pronounced 
than the wild-type GG homozygotes.   
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Figure 5.5:  Plot of ∆ BMI against ∆ General health questionnaire.  Symbols represent individual observed values and 
regression lines show the expected relationships, from the additive allelic model, for a woman with average 
compliance of 4.9, for each genotype of the FTO rs1421085 polymorphism (p=0.0261).  ∆ = Baseline minus Follow-up. 
 
 
There were also significant differences between the modelled rate of change in ∆ BMI in response to a 
change in the ∆ work index score (p=0.0327), ∆ disinhibition score (p=0.0331), ∆ habitual disinhibition score 
(p=0.0150) and ∆ avoidance of fattening food score (a subscale score of dietary restraint) (p=0.0238) for the 
FTO rs1421085 polymorphism.  Figures for these results were not included as the exact nature (significant 
vs. non-significant) of the differences between the genotype groups are not evident from the genotype 
graphs.   
 
5.2 Discussion 
 
This discussion firstly focuses on the effectiveness of the conservative weight loss programme used in this 
study.  Secondly, the influence of genotype on changes in weight loss treatment and process outcomes for 
each of the seven polymorphisms included in the study, are discussed.   
 
Effectiveness of the weight loss programme 
To investigate the effect of genotype on weight loss outcomes it was firstly important to establish whether 
the weight loss programme had been effective in inducing weight loss in the study sample.  The energy 
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intake recommendations for weight loss were individually calculated for each subject included in this study 
to induce a 0.5 kg loss per week.  This equates to an expected 12 kg weight loss over a six month time 
period.  Although this is theoretically possible, the review of actual weight loss interventions by Franz et al. 
(2007) points to the fact that a lower mean weight loss over a six month period of 7.9 kg or 8.5% should be 
expected for interventions that include a diet and physical activity component and aim to achieve a 0.5 to 1 
kg weight loss per week.  As the mean significant weight loss in the current study of 7.8 kg or 8.6% is in line 
with the suggestions by Franz et al. (2007), we can conclude that our weight loss programme was effective 
in inducing significant and expected weight loss over the six months intervention period.  The percentage 
weight loss also falls within the recommended range of 5 to 10% of initial body weight to ensure 
improvement in risk factors for comorbidities associated with excess weight (Seagle et al. 2009).   
 
Significant changes in specific lifestyle and psychological health indicators that were the focus of strategies 
included in the programme, indicate that the success in terms of weight loss can be attributed to the 
strategies included in the programme.  These changes include highly significant increases in leisure-time, 
sport and total physical activity levels and improvements in dietary restraint, disinhibition and perceived 
hunger as well as all subscale scores of these three eating behaviours.  The subjects also experienced fewer 
depressive symptoms, a better general psychological well-being as well as a higher self-esteem.  Such 
changes in physical activity levels, eating behaviours and psychological health have been noted as 
predictors of weight loss in obese patients on weight loss programme (Dalle Grave et al. 2009, Savage et al. 
2009).   
 
Attrition from the weight loss programme 
It is important to consider the fact that there was a drop-out of 38% over the four months active 
intervention period and 53% for the six month follow-up assessments that could have resulted in bias in the 
data, although most weight-management intervention studies have to contend with the same problem 
(Pratt 1990, Yeh et al. 2003).  To address this limitation time-trajectories were used to analyse the effect of 
genotype on weight loss outcome, with all individuals from the baseline sample (n=88) being included in 
the statistical models. It can also be argued that the bias in our study was limited by the fact that there 
were no significant differences between the genotype groups of each polymorphism as well as all other 
baseline variables between drop-outs and non-drop-outs.  Furthermore, the final sample at four months 
(n=55) and six months (n=41) in our study is comparable to the samples that have typically been used in 
most of the 23 previous studies that investigated the effect of the polymorphisms included in this research 
on weight loss outcome.   The sample size of 15 of these 23 studies were between 24 and 90, while four 
studies had samples between 111 and 185, three between 204 and 304 and one study included 3533 
subjects.  Despite the limitations imposed by the attrition rate, we feel that the results of this study make 
an important contribution to knowledge in the field of nutritional genomics, as very little in this regard has 
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been published on the FABP2, INSIG2, ADRB2 and GNB3 polymorphisms and no such information for the 
FTO polymorphisms included in this study has been published. 
 
FABP2 Ala54Thr polymorphism  
No associations were found between the FABP2 Ala54Thr polymorphism and weight loss during the six 
month intervention period in the current study.  These results are in line with the results from all previous 
studies that report on this association in Caucasian subjects after bariatric surgery (De Luis et al. 2008b) or 
after following weight loss interventions consisting of dietary, physical activity and behavioural components 
and lasting either two months (De Luis et al. 2008a), three months (De Luis et al. 2006), or six months in 
Japanese subjects (Takakura et al. 2005).  Evidence from these studies does however, point to the 
possibility that the FABP2 Ala54Thr polymorphism influences the outcome of other obesity phenotype 
indicators following a weight loss interventions.  For instance, Ala54Ala homozygotes achieved a lower fat 
mass and leptin levels after three months (De Luis et al. 2006), lower leptin levels after two months (De Luis 
et al. 2008a) and a lower waist circumference after six months (Takakura et al. 2005) of intervention.  
However, it was also reported that the FABP2 Ala54Thr polymorphism did not result in changes in waist 
circumference (De Luis et al. 2006, De Luis et al. 2008a) and fat mass (De Luis et al. 2008a, De Luis et al. 
2008b) in Caucasian subjects following weight reduction.  It is thus evident that although no association 
with weight or BMI loss is generally found, more specific phenotype indicators of body fat distribution and 
metabolism point to an association.  The question can thus be asked whether BMI/weight is a sensitive 
marker for detecting changes in adiposity following weight loss interventions.   
 
A novel finding from the current study indicates that an improvement in the psychological well-being (GHQ) 
of mutant Thr54Thr homozygotes over the first four months of the intervention period may have helped 
them to achieve a greater BMI loss over the total six months, compared to the other genotype groups. The 
currently known physiological functions of FABP2 do not provide a possible explanation for the association 
found with psychological well-being.  It is thus possible that this result is a false positive and should thus be 
confirmed in further research.  
 
INSIG2 rs7566605 polymorphism 
No associations were found between the INSIG2 rs7566605 polymorphism and weight loss during the six 
month intervention period in the current study.  When considering gene-gene interactions it was found 
that subjects with a mutant C-allele of the INSIG2 rs7566605 polymorphism and a mutant Gly16-allele of 
the ADRB2 Arg16Gly polymorphism lost significantly less weight over the six month intervention period.  
This indicates that the C-allele carriers of the INSIG2 rs7566605 polymorphism may be more resistant to 
weight loss on a conservative weight loss programme when they also have a mutant ADRB2 allele.   
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When considering the effect of the INSIG2 rs7566605 polymorphism on weight loss outcomes in the 
literature, most evidence points to the possibility that C-allele carriers are resistant to weight loss, while GG 
homozygotes are more likely to experience weight loss on a conservative weight loss programme.  Two 
studies on independent samples of obese Caucasian children found that CC subjects lost less weight in the 
one year “Obeldicks” intervention programme that included nutrition education, physical exercise, 
behaviour therapy (covered in group sessions) and an individualized psychological care component 
(Reinehr et al. 2008, Reinehr et al. 2009). The results from a physical activity intervention in Caucasian men 
also indicated that GG subjects experienced a decrease in subcutaneous fat levels in their non-dominant 
arm following the 12-week resistance exercise intervention focused on this arm, while C-allele carriers were 
resistant to such fat losses (Orkunoglu-Suer et al. 2008).  In contrast, Franks et al. (2008) found that 
overweight Caucasian adults with the CC genotype lost more weight than G-allele carriers after a one year 
lifestyle intervention as part of the Diabetes Prevention Programme.  The discrepancy in the results could 
be explained by the fact that different study designs and interventions were used and subjects from 
different age groups and from different weight categories were involved.  Franks et al. (2008) also indicated 
that various factors could be responsible for the disparate findings reported in their study compared to 
those on obese children (Reinehr et al. 2008, Reinehr et al. 2009), including the possibility that the results 
of both or one of these studies are false-positives. 
 
FTO rs1421085 and rs17817449 polymorphisms  
Although the function of FTO and its role in obesity development still needs to be elucidated, it has been 
proposed that FTO’s expression in the hypothalamus (Dina et al. 2007b, Frayling et al. 2007, Gerken et al. 
2007) is nutritionally regulated (Stratigopoulos et al. 2008) and that FTO is possibly involved in energy 
homeostasis by influencing energy expenditure (Fischer et al. 2009) as well as energy intake and eating 
behaviour (Speakman et al. 2008, Wardle et al. 2009).  No previous reports on the association between the 
FTO rs1421085 and rs17817449 polymorphisms and weight loss outcomes could be traced.  Two reports 
that focussed on another FTO polymorphism, namely FTO rs9939609 (also found in intron 1 of FTO and in 
strong LD with FTO rs1421085 and rs17817449), found no association between the polymorphism and 
weight loss outcomes in obese Caucasian children following the one year “Obeldicks” intervention 
programme (Müller et al. 2008) or in overweight American adults in the Diabetes Prevention Programme 
(DPP) (Franks et al. 2008). The finding in the current study that the wild-type TT homozygotes of the FTO 
rs17817449 polymorphism experienced a significantly greater reduction in BMI during the first two months 
of the intervention period compared to the heterozygotes or mutant homozygotes, is thus novel.  This 
finding needs to be interpreted with care as it may be a false positive result as indicated in the results 
section and needs to be confirmed in further research.   
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It was evident that an improvement in emotional disinhibition in the wild-type TT subjects of the FTO 
rs1421085 polymorphism was associated with a more pronounced decrease in BMI over the six month 
weight loss period compared to CT subjects.  Significant interaction effects for the genotype model were 
also found between the FTO rs1421085 polymorphism and changes in other eating behaviour scales 
(disinhibition, habitual disinhibition and avoidance of fattening foods [subscale of dietary restraint 
indicating better eating behaviour]) as well as changes in the work index scores on BMI losses during the six 
months intervention period.  Although the latter results were not significant for the additive allelic variable 
thus only for the genotype model, it could be argued that it supports the possibility of FTO’s involvement in 
the regulation of eating behaviours and warrants further investigations.   
 
The results of this study therefore indicate that the wild-type homozygotes of the FTO polymorphisms 
might experience greater weight losses during the initial two months of a weight loss programme, while an 
improvement in eating behaviour may specifically help them to achieve greater weight losses over the total 
duration of the programme.  These novel findings warrant further investigation.  
 
ADRB3 Trp64Arg polymorphism 
No associations were found between the ADRB3 Trp64Arg polymorphism and weight loss during the six 
month programme in the current study.  A total of 13 other published studies could be traced that also 
investigated the association between the ADRB3 Trp64Arg polymorphism and weight loss outcome.  Three 
studies that included Caucasian populations showed no association between this polymorphism and weight 
loss after two 12-month interventions (Tchernof et al. 2000, Rawson et al. 2002) and one three-month 
weight loss intervention (De Luis et al. 2007).  Another study reported that subjects who were carriers of 
the mutant ADRB3 Arg64 allele and the mutant UCP1 A/G allele were not able to maintain their weight loss 
during the 40-week weight maintenance phase after the 12-week weight loss phase of the programme 
(Fogelholm et al. 1998).  Four of the seven weight loss interventions carried out in Japanese showed that 
wild-type Trp64Trp homozygotes experienced a more pronounced weight loss after following low energy 
diets and exercise recommendations (Kogure et al. 1998, Yoshida et al. 1995, Sakane et al. 1997b) or using 
a weight loss drug (Mazindol) (Shimizu et al. 2007) for three months.  No associations with weight loss 
outcome were reported in the other three studies in Japanese (Nakamura et al. 2000, Shiwaku et al. 2003, 
Kuriyama et al. 2008), although one study did indicate that wild-type Trp64Trp homozygotes experienced 
decreases in visceral fat area and visceral-to-subcutaneous fat ratio (Nakamura et al. 2000).  In Koreans no 
association between the ADRB3 Trp64Arg polymorphism and weight loss outcome was found, but Trp64Trp 
homozygotes experienced greater decreases in total, visceral and subcutaneous fat areas (Kim et al. 2003).  
Finally, Trp64Trp homozygous Chinese obese children benefited more from a three-month intervention 
aiming at decreasing their fat and cholesterol intake to limit weight gain (Xinli et al. 2001).  The 
improvements reported for other obesity related phenotype indicators in Trp64Trp homozygotes also raise 
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the question whether BMI is a sensitive marker for detecting changes in adiposity following weight loss 
interventions.  The disparate findings that were reported for the Japanese subjects could be explained by 
the fact that the four studies finding an association only included obese (BMI≥30) subjects, while the three 
studies finding no associations  included subjects with BMIs as low as 21.   
 
Our finding of no association between the ARDB3 Trp64Arg polymorphism and weight loss outcome is thus 
supported by the other work done in Caucasians.  However, the same is not true for the work done in Asian 
populations, where some associations have been reported.   
 
ADRB2 Arg16Gly polymorphism 
It was evident that participants with the mutant Gly16Gly genotype of the ADRB2 Arg16Gly polymorphism 
in our study lost significantly less weight during the first month of the programme than the heterozygotes 
or wild-type homozygotes, although this association disappeared subsequently.  When considering the 
gene-gene interactions it was also found that subjects with a mutant Gly16-allele of the ADRB2 Arg16Gly 
polymorphism and a mutant C-allele of the INSIG2 rs7566605 polymorphism lost significantly less weight 
over the six month intervention period.  This finding does support the possibility that the Gly16-allele of 
ADRB2 may be resistant to weight loss on a conservative weight loss programme when combined with a 
mutant C-allele of the INSIG2 rs7566605 polymorphism. 
 
Only one report could be traced that investigated the effect of this polymorphism on weight loss outcomes 
(Masuo et al. 2005).  It can be argued that the result of the latter study is in agreement with our results as 
these authors reported a higher frequency of the Gly16-allele in overweight Japanese men who were 
resistant to weight loss during a 24 month weight loss programme compared to the men who lost weight.  
The results of two exercise interventions consisting of cycling sessions on ergometers three times a week 
for 20 weeks may also support our findings (Garenc et al. 2003, Ukkola et al. 2003).  It was found that Black 
Arg16-allele carriers experienced greater decreases in fat mass and abdominal total fat area (Ukkola et al. 
2003), while Caucasian white Arg16Arg homozygous females experienced greater reductions in BMI, fat 
mass and body fat percentage following the 20-week exercise programme (Garenc et al. 2003).  It can be 
argued that the effect of the Arg16Gly polymorphism on the physiological function of ADRB2 also supports 
our findings.  The ADRB2 Gly16-allele has been associated with a more pronounced decrease in ADRB2 
expression in adipose tissue due to enhanced down-regulation after prolonged agonist stimulation (Green 
et al. 1994, Green et al. 1995).  This may consequently result in reduced receptor function and lower 
efficiency of lipolysis stimulation (Ellsworth et al. 2002), which may explain lower weight loss rates over 
time.   
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Thus, although no association was evident between this polymorphism and weight loss over the total six 
months period it is argued that the association found for the first month is supported by our gene-gene 
interaction analysis, existing intervention evidence as well as the reported physiology of the mutant ADRB2.  
Further investigation of the association between this polymorphism and weight loss outcomes is therefore 
deemed necessary. 
 
GNB3 C825T polymorphism 
No associations were found between the GNB3 C825T polymorphism and weight loss during the six month 
intervention period in the current study.  This is in line with the results reported by Potoczna et al. (2004) 
who also found no association between this polymorphism and weight loss over a period of three years 
following bariatric surgery in Caucasian subjects.  However, in contrast to these results Hauner et al. (2003) 
reported that Caucasian T-allele carriers benefited from a 54-week conservative weight loss intervention 
without pharmacotherapy to lose weight, while CC homozygotes benefited from the same conservative 
weight loss intervention if a weight loss drug (Sibutramine) was added.  The latter study suggests that wild-
type CC homozygotes will probably not lose weight on a programme consisting of a low energy, low fat diet; 
physical activity and behaviour modification recommendations only, and that they may need additional 
pharmacotherapy to achieve weight loss.  However, the decreased GNB3 protein content found in 
subcutaneous adipocytes of TT homozygous Caucasian subjects compared to the wild-type CC subjects, 
with associated decreases in catecholamine induced lipolysis in TT subjects (Rydén et al. 2002) or T-allele 
carriers (Hauner et al. 2002), refutes the findings of Hauner et al. (2003).  It can thus be argued that the 
findings of Hauner et al. (2002) and Rydén et al. (2002) suggest that CC subjects will respond better to a 
negative energy balance induced either by an increase in physical activity or a decrease in energy intake or 
a combination of the two because normal levels of lipolysis can occur in these subjects.   
 
In the current study it was also found that a decrease in depressive symptoms in the CC subjects over four 
months resulted in a reduction in BMI that was not observed in the other genotype groups.  The association 
between depression or response to anti-depression treatment and GNB3 has been investigated by others 
(Lopez-Leon et al. 2008, Exton et al. 2003, Lee et al. 2004, Cao et al. 2007, Lin et al. 2001, Kunugi et al. 2002, 
Kang et al. 2007, Kato et al. 2008, Wilkie et al. 2007, Lin et al. 2009).  However, these studies did not 
include weight loss outcome variables and therefore can not be used to elucidate the effect of the 
association between the CC genotype and depression on BMI in our study.   
 
It is evident from the above discussion that the association between the GNB3 C825T polymorphism and 
weight loss outcome is still equivocal and further investigation is necessary.  The novel finding from this 
research that CC subjects may experience greater weight losses if an improvement in depressive symptoms 
occurs, warrants further investigation.  
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5.3 Conclusions 
 
The weight loss programme used in this research was effective in inducing significant weight loss over a 
period of six months in overweight/obese subjects included in the study.  The subjects also experienced 
significant improvements in specific lifestyle behaviours and psychological health indicators that can be 
attributed to the strategies included in the weight loss programme.   
 
The primary null hypothesis, namely that there is no association between genotype and weight loss 
outcome, could not be rejected for the FABP2 Ala54Thr, INSIG2 rs7566605, FTO rs1421085, ADRB3 
Trp64Arg and GNB3 C825T polymorphisms (Table 5.9).   
 
However, the primary hypothesis was rejected for the FTO rs17817449 and ADRB2 Arg16Gly 
polymorphisms as well as the gene-gene interaction between the INSIG2 rs7566605 and ADRB2 Arg16Gly 
polymorphisms, as the following was found (Table 5.9): 
 The wild-type TT homozygotes of the FTO rs17817449 polymorphism lost significantly more weight 
during the first two months of the program compared to the mutant allele carriers. This is a novel 
finding. 
 The wild-type Arg16Arg homozygotes of the ADRB2 Arg16Gly polymorphism lost significantly more 
weight during the first month of the program compared to the mutant allele carriers. This finding is 
supported by one other intervention study. 
 Subjects with a mutant C-allele of the INSIG2 rs7566605 polymorphism and a mutant Gly16-allele of the 
ADRB2 Arg16Gly polymorphism lost significantly less weight over the six month intervention period.  
This is a novel finding. 
 
The secondary/exploratory hypotheses that were rejected are also depicted in Table 5.9.  These were all 
novel findings and thus need further investigation for confirmation.  
 
 
Table 5.9:  A summary of findings from this study. 
Findings from this study Evidence:  
Novel/ supported 
FABP2 Ala54Thr  
 Did not influence weight loss  Supported 
 Mutant Thr54Thr: improved general psychological well-being 
(GHQ) = ↓ weight during 6 months 
 Novel 
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Table 5.9:  (continued) 
Findings from this study Evidence:  
Novel/ supported 
INSIG2 rs7566605  
 Did not influence weight loss on own  Support conflicting, most point to C-allele = 
resistant to weight loss 
 
 Haplotype: mutant C-allele of INSIG2 & Gly16-allele of ADRB2 = ↓ 
weight loss during 6 months 
FTO rs1421085  
 Did not influence weight loss  Novel 
 Wild-type TT: improved emotional disinhibition = more 
pronounced ↓ in weight during 6 month period. 
 Novel 
 Changes in physical activity at work and eating behaviours e.g. 
disinhibition, habitual disinhibition and avoidance of fattening 
food (dietary restraint) influence weight loss during 6 months 
period 
 Novel 
FTO rs17817449  
 Wild-type TT: ↑ weight loss during first 2 months of programme.  Novel 
ADRB3 Trp64Arg:  
 Did not influence weight loss  Supported by research in Caucasians, may 
influence weight loss in Asians.  
ADRB2 Arg16Gly  
 Wild-type Arg16Arg:  ↑ weight losses during first month.   Supported by existing evidence 
 Haplotype: mutant C-allele of INSIG2 & Gly16-allele of ADRB2 = ↓ 
weight loss during 6 months 
 
GNB3 C825T:    
 Did not influence weight loss  Equivocal support 
 Wild-type CC: ↓ in depressive symptoms = ↓ in weight during 6 
months period. 
 Novel 
 
 
Bearing in mind the limitations of this study (see Chapter 6, p250-251), it can be concluded that the FTO 
rs17817449 and ADRB2 Arg16Gly polymorphisms and the interaction between the INSIG2 rs7566605 and 
ADRB2 Arg16Gly polymorphisms may influence weight loss outcomes in Caucasians.  Furthermore, 
interactions between the FTO rs1421085 polymorphism and changes in emotional disinhibition, the FABP2 
Ala54Thr polymorphism and changes in general psychological well-being as well as the GNB3 C825T 
polymorphism and changes in depressive symptoms may also influence weight loss.   
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Chapter 6 
 
 
Final conclusions and  
recommendations 
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6.1 Integrated discussion  
 
This chapter firstly focuses on perspectives on personalization of dietary intake and other health and 
lifestyle recommendations based on genetic screening for improved weight management and health. 
Secondly, perspectives on the level of evidence required to consider genetic screening in evidence based 
practice in dietetics is discussed. The question whether the associations found between genotypes of the 
seven polymorphisms included in this study and BMI, health and lifestyle indicators as well as weight loss 
outcomes, are robust enough for inclusion in genetic screening for personalization of weight management 
guidelines is also argued by integrating the findings from the cross-sectional and intervention studies as 
well as published evidence.  Finally, conclusions and recommendations are provided. 
 
It has been proposed that nutritional genomics and more specifically, genetic screening, will ensure that 
dietitians and other health professionals will ultimately move away from generalized nutrition 
recommendations to prescribing more genotype-based personalized diets and other lifestyle 
recommendations to prevent/treat chronic diseases (DeBusk et al. 2005, Trujillo et al. 2006, Boehl 2007).  
The potential benefits of such recommendations include early identification and prevention, cost-effective 
and targeted interventions (DeBusk et al. 2005, Joost et al. 2007, Stover & Caudill 2008) and increased 
motivation of individuals to follow the specified guidelines (Joost et al. 2007).   
 
Although very promising, the negative implications of genetic screening also need to be considered.  Joost 
et al. (2007) maintain that one of the main risks of personalized genotype-based nutrition is that 
recommendations that are not supported by sufficient robust evidence may be made to vulnerable 
individuals.  Furthermore, the long-term safety of recommendations that are made may not have been 
tested in long-term follow-up studies (Joost et al. 2007).  The issues of confidentiality of results, access to 
certain insurance products and discrimination in the workplace have also been raised (Gable et al. 2007).  
However, Castle and Ries (2007) maintain that specific strategies can be employed to overcome the rising 
ethical and legal issues and that this should not pose a problem.   
 
Sanderson and Michie (2007) point out that it is also important to take into account the possible 
psychological and behavioural impact of genetic screening.  While genetic screening may lead to less 
healthy behaviour in individuals who are not genetically susceptible to develop chronic diseases such as 
obesity (Frosch et al. 2005), preliminary research also indicates increased motivation to change behaviour 
and improvements in obese subjects’ beliefs that changing behaviour will reduce disease risk (Harvey-
Berino et al. 2001). Furthermore, Arkadianos et al. (2007) indicated that genotype tailored diets resulted in 
better compliance and weight loss over a one year period in screened individuals compared to the control 
group.  
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Genetic screening has been used effectively in the past to screen for relatively uncommon monogenic 
disorders, but has now become increasingly available on the market for chronic disease 
prevention/management.  In many countries, including South Africa, companies have started marketing 
genetic screening for chronic disease prevention/treatment through health care providers or directly to the 
public, even in the form of home-testing kits (DeBusk et al. 2005, www.dnadiet.co.za).  Research shows 
that there is a high level of interest among the public in genetic testing for multifactorial diseases such as 
cancer and heart disease risk (Graham et al. 1998, Sanderson et al. 2004, Sanderson & Wardle 2008).  This 
is facilitated by the lay media’s promotion of new concepts and research findings to be on the frontline of 
reporting (Boehl 2007).  Such direct marketing of tests for which sufficient research to support the claims is 
not yet available, may be harmful to the public, who may be unable to make informed choices in this regard 
(Gollust et al. 2002, Sanderson et al. 2004). Marketing of genetic screening tests and consequent 
personalization of dietary recommendations for obesity prevention/treatment should only take place if it is 
evidenced-based and has clinical utility (Evans et al. 2001, Gray & Gray 2002).  To ensure evidence based 
practice, research should thus provide evidence that the recommended dietary guidelines or other lifestyle 
recommendations for a genotype group are linked to a robust increase or decrease in disease risk.  
Furthermore, repeatable evidence from genotype-based interventions should be available to prove that the 
suggested genotype specific recommendations reduce the risk factors for a specific disease, the disease 
itself or will maximize treatment outcome (Evans et al. 2001, Joost et al .2007).   
 
In 2005 Kaput et al. pointed out that no internationally uniform standards existed for the design of gene-
diet-disease research (Kaput et al. 2005) and for the interpretation of the results derived from current and 
future research (Kaput et al. 2005, Joost et al. 2007).  In 2007, Joost et al. proposed the following guidelines 
for research design: Firstly, the sample should be selected in such a way that it includes equal numbers of 
subjects carrying the wild-type, heterozygous and mutant homozygous genotypes.  Secondly, each genetic 
group should follow each specific lifestyle intervention, which should be rotated across the interventions 
(Joost et al. 2007).  However, the practicality and effectiveness of the latter recommendation for research 
on weight loss outcomes is questionable bearing in mind that obese individuals usually lose weight in the 
beginning of a weight reduction programme, but often reach a weight loss plateau after time as the body 
defends its own weight set-point (Peters 2006).  Guidelines for interpretation of results suggested by Joost 
et al. (2007) are as follow:  Firstly, if there is a small variation in the results of a study, thus most individuals 
in a genotype group lost weight, personalized recommendations could probably be made.  However, if 
there is a large variation in results, too many unknown factors (genetic or environmental) may have played 
a role and personalized recommendations may not be warranted (Joost et al. 2007).   
 
At this point in time evidence regarding the association between genotype, obesity and weight loss 
outcomes seems to be equivocal for most investigated genes (Rankinen et al. 2006, Hainer et al. 2008). It is 
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argued that this situation is due to a lack of homogeneity in the different study samples regarding ethnicity, 
gender, age differences, differences in adiposity levels, absence or presence of concomitant disorders 
(Hainer et al. 2008, Tiwari et al. 2008).  The results can also be affected by the use of different study designs 
as well as power estimates, population stratification, genome wide association vs. candidate/pathway 
approach, Hardy Weinberg Equilibrium, genotyping success and errors, frequency of studied genetic 
variants (Lewis et al. 2002, Andersson et al. 2009) and the different statistical tests and models used across 
studies (Jakobsdottir et al. 2009).  Furthermore, contradictory results can also be attributed to false-
positive findings as multiple comparisons are often used in genetic association studies, which increase the 
likelihood of a significant association occurring once in every 20 tests (Andersson et al. 2009).   Lastly, the 
fact that the sum of a number of diet-gene-risk factor interactions that vary amongst individuals are 
probably involved in the beneficial effects associated with a particular lifestyle intervention (Joost et al. 
2007), compound the issue.   
 
With this research we set out to provide further evidence on the associations between genotype and BMI 
(primary hypothesis), health and lifestyle indicators (secondary and exploratory hypotheses) as well as 
weight loss outcomes (primary hypothesis) for the seven polymorphisms included in this study.  In the 
following sections the results of the cross-sectional and intervention studies are integrated with relevant 
published evidence to provide the robustness of the evidence for inclusion in genetic screening.    
 
The FABP2 Ala54Thr polymorphism 
The fact that the current study and four other previously reported studies found no association between 
the FABP2 Ala54Thr polymorphism and weight loss outcome after following a conservative weight loss diet 
(current study, De Luis et al. 2006, De Luis et al. 2008a, Takakura et al. 2005), bariatric surgery (De Luis et al. 
2008b) or a low carbohydrate diet (De Luis et al. 2008a) may indicate that this polymorphism is not 
important to be considered for personalized weight loss recommendations based on genotype. However, 
published evidence does point to the possibility that the FABP2 Ala54Thr polymorphism influences the 
outcome of other health and obesity phenotype indicators following weight loss interventions, favouring 
mostly the Ala54Ala subjects, although results are still equivocal.  The modelled results from our cross-
sectional sample support the notion that weight loss could be beneficial for the wild-type Ala54Ala subjects 
in terms of decreasing their TG levels, which was not found for the mutant Thr54-allele carriers.  This 
finding is supported by De Luis et al. (2008a) but no association was found by De Luis et al. (2008b).   
 
As existing evidence also indicates that Thr54-allele carriers may have a higher fat absorption, specifically 
for SFA and PUFA (Richieri et al. 1994, Baier et al. 1995, Marín et al. 2005), it is proposed that specific 
macronutrient modifications may be necessary for Thr54-allele carriers in a weight loss programme.  The 
literature points to the possibility that Thr54-allele carriers will benefit from a low fat, SFA and PUFA diet or 
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a higher MUFA intake.  The fact that Thr54Thr homozygotes in our cross-sectional study were found to 
have a higher frequency of intake of take-away foods that are typically high in fat, SFA and PUFA 
emphasises the need for such subjects to focus on healthier fat choices.  Further investigation into the 
response of each FABP2 genotype to diets with different fatty acid contents therefore seems justified.  
However, at this stage it must be borne in mind that low fat recommendations would benefit all individuals 
regardless of genotype, although it may benefit the Thr54-allele carriers most.   
 
The novel findings in this research point to the possibility that Thr54Thr subjects have a higher self-esteem 
and that they experienced the most pronounced weight loss over the six months intervention period in 
response to improvements in psychological health.   To eliminate the possibility that these findings are false 
positives further investigation into the physiological explanation thereof as well as the replication of our 
findings in independent weight loss intervention and case-control studies, is necessary.   
 
The INSIG rs7566605 polymorphism 
The INSIG2 rs7566605 polymorphism did not influence weight loss outcome in the current study. However, 
with gene-gene interaction analysis it was found that subjects with a mutant C-allele of the INSIG2 
rs7566605 polymorphism and a mutant Gly16-allele of the ADRB2 Arg16Gly polymorphism lost significantly 
less weight over the six month intervention period.  This is a novel finding that indicates that the two 
polymorphisms have a combined effect on weight loss.  The evidence from other intervention studies 
regarding the association between the INSIG2 rs7566605 polymorphism and weight loss outcome is 
equivocal studies (Reinehr et al. 2008, Franks et al. 2008, Orkunoglu-Suer et al. 2008, Reinehr et al. 2009).  
The majority of these studies point to the possibility that C-allele carriers are resistant to weight loss, while 
GG homozygotes experience weight loss on a conservative weight loss programme.  It can also be argued 
that the findings from our cross-sectional sample support this possibility, as GG homozygotes experienced 
the most pronounced modelled decrease in BMI in response to an increase in leisure-time physical activity.  
Furthermore, although we found that C-allele carriers in the cross-sectional sample had higher leisure-time 
physical activity levels, there were no differences in the mean BMI between the genotype groups, 
supporting the notion that C-allele carriers may be resistant to weight loss when increasing physical activity 
levels.  The possibility that C-allele carriers do not respond to conservative weight loss treatment may also 
explain our results from the cross-sectional sample, indicating that the mutant CC homozygotes had a 
higher risk to develop MetS.  It is also argued that these results are supported by previous reports 
indicating a higher BMI in CC subjects (Herbert et al. 2006, Lyon et al 2007, Rosskopf et al. 2007, Liu et al. 
2008, Andreasen et al. 2008), as well as the possible effect of a variant INSIG protein and associated 
changes in the physiological function thereof (Gong et al. 2006).  However it must be borne in mind that 
the INSIG2 rs7566605 polymorphism is located 10 kb upstream of the transcription start site of the INSIG2 
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gene (Herbert et al. 2006) and it is still a question whether this variant itself or maybe another variant in 
strong LD leads to the expression of a variant INSIG2 protein. 
 
The novel findings from the cross-sectional study that the mutant CC homozygotes had a lower attitude to 
self-regulation score and that they are likely to experience a modelled increase in BMI as their situational 
disinhibition score increases, warrant further investigation. It is argued that the proposed changes in the 
physiological functioning of a variant INSIG2 protein may result in an inability to block lipogenesis, which 
could be to the disadvantage of CC subjects, as the latter were shown to be more likely to exhibit poor 
eating behaviours, which may result in increased fat and energy intakes, consequently resulting in a higher 
BMI, MetS risk as well as resistance to weight loss interventions.   
 
The FTO polymorphisms 
Several novel findings for the FTO polymorphisms that warrant further investigation were found in the 
current study.  These findings include the following:  
 The wild-type TT homozygotes of the FTO rs17817449 polymorphism experienced a greater weight loss 
over the first two months of the programme.  This can also be interpreted as a resistance to weight loss 
on a conservative weight loss programme in the mutant allele carriers, at least during the first two 
months of treatment.  As this is a novel finding, which was only significant for the genotype model and 
no association between weight loss outcome and another FTO polymorphism (in strong LD with the 
FTO rs17817449 polymorphism) has been reported by two other studies (Müller et al. 2008, Franks et 
al. 2008) the possibility that this may be a false positive needs to be considered.  
 An improvement in emotional disinhibition resulted in the most pronounced BMI loss over a six month 
period in the wild-type TT subjects of the FTO rs1421085 polymorphism.  This finding was supported by 
the modelled cross-sectional data indicating that a modelled improvement of the attitude to self-
regulation was associated with the most pronounced modelled decrease in BMI of the wild-type TT 
subjects. On the other hand a modelled increase in rigid control was associated with the most 
pronounced increase in BMI of the mutant CC homozygotes of the FTO rs1421085 polymorphism.  
Genotype interaction effects from the intervention study between the FTO rs1421085 polymorphism 
and changes in eating behaviours (including disinhibition, habitual disinhibition and avoidance of 
fattening foods) on BMI loss over a six months period are also evident.  Furthermore, the results from 
the cross-sectional sample also showed various significant associations between the FTO 
polymorphisms and eating behaviour including the following: the mutant allele of either the FTO 
rs1421085 or rs17817449 polymorphism were associated with a higher intake of high fat foods as well 
as with poorer eating behaviours as reflected in higher scores for perceived hunger, internal locus for 
hunger, habitual and emotional susceptibility to disinhibition and rigid control of dietary restraint.  
These associations are supported by the associations found by others between food intake or eating 
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behaviour and FTO polymorphisms (Bray et al. 2004a, Rosmond et al. 2004, Malik et al. 2006, Gibson 
2008, Wolff & Dansinger 2008) that are in strong LD with the two FTO polymorphisms investigated in 
this research.  It is thus evident that the mutant alleles of the two FTO polymorphisms included in this 
study may predispose individuals to having poorer eating behaviours, while an improvement in eating 
behaviour may specifically benefit the wild-type homozygotes to lose weight. Although the function of 
FTO and its role in obesity development still need to be elucidated, it has been proposed that FTO’s 
expression in the hypothalamus (Dina et al. 2007b, Frayling et al. 2007, Gerken et al. 2007) is 
nutritionally regulated (Stratigopoulos et al. 2008) and that FTO is possibly involved in energy 
homeostasis by influencing energy expenditure (Fischer et al. 2009) as well as energy intake and eating 
behaviour (Speakman et al. 2008, Wardle et al. 2009) 
 The findings from the cross-sectional study showed that the T-T haplotype of the two FTO 
polymorphisms experienced a modelled decrease in BMI in response to an increase in the sport index 
score.  This finding may be supported by that fact that a significant genotype interaction effect was also 
found between this polymorphism and the work index score on BMI losses over the six month 
intervention period.  The proposed physiological function for FTO supports the involvement thereof in 
energy expenditure.  
 Further novel findings from the cross-sectional study indicate that a modelled increase in BMI was 
associated with the most pronounced decrease in HDL levels of the mutant homozygotes of both FTO 
polymorphisms, which was confirmed with haplotype analysis.  The physiological context for these 
findings still needs to be elucidated. 
 The results from the cross-sectional sample also indicate that the mutant GG subjects of the FTO 
rs17817449 polymorphism may have more depressive symptoms while a modelled improvement in 
general psychological well-being was associated with the most pronounced decrease in BMI in the wild-
type TT subjects of the FTO rs1421085 polymorphism.   The physiological context for these novel 
findings still needs to be elucidated. 
 
The ADRB3 Trp64Arg polymorphism 
This polymorphism did not influence weight loss outcome in the current study, which is in line with the 
results of three published weight loss interventions performed in Caucasian populations (Tchernof et al. 
2000, Rawson et al. 2002, De Luis et al. 2007).  In Asian samples, seven of the nine published weight loss 
interventions found that the wild-type Trp64Trp homozygotes experienced greater reductions in weight or 
fat area, while the Arg64-allele carriers were resistant to weight loss (Kogure et al. 1998, Yoshida et al. 1995, 
Sakane et al. 1997b, Nakamura et al. 2000, Xinli et al. 2001, Kim et al. 2003, Shimizu et al. 2007).  It can be 
argued that the latter findings are supported by the latest meta-analysis that included 97 studies, which 
found that the Arg64-allele predisposes Asians to having a higher BMI or obesity prevalence, but no 
association was found for Caucasians (Kurokawa et al. 2008).  It must be noted that 90% of the current 
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sample were wild-type Trp64Trp homozygotes, 10% were heterozygotes and none were mutant 
homozygotes, leading to a mutant allele frequency of 5%.  This is in line with the genotype and allele 
frequencies reported for other Caucasian populations, while it is a fact that Asian populations have a higher 
mutant allele frequency of ~20%.   Yang et al. (2005) proposed that fewer genes can be included in a 
personalized screen for polygenic diseases if the frequencies of predisposing genotypes are common in the 
specific population.  They recommend that “only around 20 genes are usually needed to explain 50% of the 
burden of a disease in the population if the predisposing genotypes are common (>25%), even if the 
individual risk ratios are relatively small (i.e. increasing the risk by only 20-50%)”.  In comparison to all the 
other polymorphisms included in this research, the ADRB3 had the lowest mutant allele frequency, while 
those for the other polymorphisms were definitely more “common” (34 to 58%).  We propose that this 
polymorphism could thus be included in an investigation of weight loss outcomes for the South African 
Asian/Indian race group as well as Black South Africans as a mutant allele frequency of 28% has previously 
been reported for the latter group.  However, due to the fact that no associations in the cross-sectional as 
well as the intervention sample with the ADRB3 Trp64Arg polymorphism were found and the fact that a 
low mutant allele frequency was found, it is suggested that ADRB3 may not be an important gene to be 
considered for personalization of weight loss guidelines for Caucasian South Africans.  
 
The ADRB2 Arg16Gly polymorphism 
In the current study it was found that the wild-type Arg16Arg homozygotes of the ADRB2 Arg16Gly 
polymorphism experienced greater weight losses, especially during the first month of treatment.  This 
finding is supported by existing evidence from one weight loss (Masuo et al. 2005) and two physical activity 
interventions (Garenc et al. 2003, Ukkola et al. 2003) as well as the changes in the physiological function of 
ADRB2 that occur as a result of the mutant allele (Green et al. 1994, Green et al. 1995, Ellsworth et al. 
2002).  The findings from the gene-gene interaction analysis further indicate that subjects with the mutant 
Gly16-allele of ADRB2 and the mutant C-allele of INSIG2 lost significantly less weight over the six month 
intervention period.   
 
It can further be argued that the Gly16Gly homozygotes may be more inclined to gain weight during 
adolescence and young adulthood.  This is based on the premises that more Arg16Arg homozygotes 
thought they were overweight during childhood, an association that was not evident any more during 
adolescence, young adulthood and at the time of the study.  As the literature in this regard is still equivocal, 
further research is necessary to confirm this association.   
 
The novel finding from the cross-sectional sample that Arg16Arg homozygotes experienced the most 
pronounced decrease in BMI in a response to an improvement of their flexible control of dietary restraint 
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needs to be confirmed as no association study or physiological context link has been identified to support 
the possibility that it is a true association.   
 
The GNB3 C825T polymorphism 
No association between the GNB3 C825T polymorphism and weight loss was found in the current study, 
which is in line with the finding of one published weight loss intervention (Potoczna et al. 2004).  However, 
the results from another published weight loss intervention reported increased weight loss in T-allele 
carriers on a conservative weight loss programme, with CC subjects responding if Sibutramine was added 
(Hauner et al. 2003).  The latter finding can not be explained within the context of the known physiological 
function of the variant GNB3 protein in adipocytes. It is also in contrast with the novel findings from the 
cross-sectional sample that suggest that CC subjects may respond more effectively to a conservative weight 
loss diet that places emphasis on increasing leisure-time physical activity as well as decreasing intake of 
high fat foods, energy-dense snacks and drinks.  The lower GNB3 protein levels in adipocytes as well as the 
decreased stimulation of lipolysis in mutant allele carriers (Hauner et al. 2002, Ryden et al. 2002) may 
explain why the CC subjects respond better to physical activity or decreased energy-dense snacks to lose 
weight, as normal lipolysis probably occurs in CC subjects.   
Normal lipolysis stimulation may also explain the more favourable MetS profile found in the CC subjects.  
The cross-sectional results indicate that mutant TT homozygotes had higher triglyceride and glucose levels, 
a higher number of traits that met the diagnostic cut-offs for MetS and a higher number who were 
diagnosed with MetS.  These findings are in line with other published reports in Caucasian populations 
(Poch et al. 2002, Brand et al. 2003, Wascher et al. 2003, Andersen et al. 2006) and can be explained by the 
possible.   
 
Another novel finding from the intervention sample indicates that CC subjects may experience greater 
weight losses over a six month period if an improvement in depressive symptoms occurs. The novel finding 
from the cross-sectional sample indicates that CC subjects may have a lower self-esteem.  The finding from 
the cross-sectional sample that CC subjects in our study had more depressive symptoms is not in line with 
previous reports that indicate either no association or an association between the T-allele and depression 
(Exton et al. 2003, Lee et al. 2004, Cao et al. 2007, Lopez-Leon et al. 2008).  As most of this research 
involved Asian populations, more research is necessary to elucidate the association between depressive 
symptoms and this polymorphism in Caucasian populations.  
 
 
 
 
 
 249
6.2 Final conclusions and recommendations 
 
Bearing in mind the limitations of the current study, the following conclusions can be made regarding the 
primary hypotheses of the cross-sectional and intervention studies: 
 There is no association between the BMI of overweight/obese subjects and all the polymorphisms 
investigated.  These results were confirmed by meta-analyses for the INSIG2 rs7566605, ADRB3 
Trp64Arg, ADRB2 Arg16Gly and GNB3 C825T polymorphisms. For the FTO rs1421085 and rs17817449 
polymorphisms current literature consistently link the mutant genotype with a higher BMI.  The 
published results for the FABP2 Ala54Thr are still equivocal.  
 There is no association between weight loss outcome and the FABP2 Ala54Thr and ADRB3 Trp64Arg 
polymorphisms, which is supported by published findings in Caucasian populations. 
 There is no association between weight loss outcome and the GNB3 C825T polymorphism.  Literature in 
this regard is still equivocal and thus warrants further investigation.  
 The wild-type TT homozygotes of the FTO rs17817449 polymorphism lost significantly more weight 
during the first two months of the program compared to the mutant allele carriers. As this is a novel 
finding, which was only significant for the genotype model and no association between weight loss 
outcome and another FTO polymorphism has been reported by two other studies the possibility that 
this may be a false positive needs to be considered. 
 The wild-type Arg16Arg homozygotes of the ADRB2 Arg16Gly polymorphism lost significantly more 
weight during the first month of the program compared to the mutant allele carriers. This finding is 
supported by one other intervention study. 
 Subjects with a mutant C-allele of the INSIG2 rs7566605 polymorphism and a mutant Gly16-allele of the 
ADRB2 Arg16Gly polymorphism lost significantly less weight over the six month intervention period.  
This is a novel finding that warrants further investigation as an association with the individual genes 
and weight loss has been indicated as well as a physiological context link supports this possibility. 
 
The secondary and exploratory hypotheses that were formulated for the cross-sectional and intervention 
studies were rejected in a number of instances.  The main findings that stood out in terms of support from 
the literature and a plausible physiological explanation include: 
 The mutant TT homozygotes of the GNB3 C825T polymorphism may have a higher risk for the 
development of MetS and MetS traits. 
 The mutant allele carriers of the FTO rs1421085 and rs17817449 polymorphisms may have poorer 
eating behaviours while an improvement in eating behaviour may specifically benefit the wild-type 
homozygotes to lose weight. 
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It is important to consider that the cross-sectional results are limited by the fact that a normal weight 
control group was not included.  It is therefore necessary to emphasize that the cross-sectional results 
pertain to overweight/obese individuals only and should be confirmed in further case-control and 
intervention studies for broader application.  
 
It is also important to bear in mind that BMI (the obesity phenotype indicator used in this study) seems to 
have limitations as a general indicator of adiposity.  It is thus possible that using more specific phenotype 
indicators of adiposity e.g. subcutaneous/ abdominal fat area, body fat % etc. may have resulted in 
different outcomes.  
 
As most obesity related polymorphisms are expected to have a small effect on obesity development or 
weight loss outcome, the small sample size as well as the fact that only an average of 80% genotyping 
success rate was achieved in the current study restricted statistical power of analyses. The high attrition 
rate in the intervention study compounded the problem.  From the literature review it is clear that only a 
limited number of studies have been performed on the association between genotype and weight loss 
outcomes.  From our experience it is clear that this could be ascribed to the complexity and time-
consuming aspects of weight loss interventions, which may also explain the small sample sizes included in 
many of these studies.  However, investigations in larger samples that ensure appropriate statistical power 
are essential to ensure that evidence re the investigated associations is robust before application in clinical 
practice is warranted. 
 
The fact that no follow-up blood values were collected may be seen as a limitation of the intervention study.  
However, the decision to exclude MetS diagnosis at follow-up was made because the aim of the 
intervention study was to assess the association between genotype and weight loss outcomes, not 
associated physical health indicators. The same can be said for the fact that dietary intake was only 
assessed at baseline and not at follow-up.  This decision was based on the need to decrease respondent 
burden. Past experiences in this regard guided this decision as the completion of lengthy questionnaires 
was stated as a reason for not returning to follow-up measurements (Cilliers 2004).  For the same reason 
the questionnaires on the other psychological health and lifestyle variables were only administered at 16 
week follow-up and not again at 24-weeks.  It was also argued that the time-period between the 16 and 24 
weeks was too short for measurable changes to occur in these variables.  A further drop-out was also 
expected at 24 weeks compared to 16 weeks, which would have resulted in an even smaller sample size.   
 
As many variables were self-reported (in this research: physical activity, dietary intake, eating behaviour 
and psychological health), it needs to be mentioned that self-reported data is always limited in that it has 
to be assured that the reported information is the truth. 
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The use of multiple comparisons as performed in this thesis may be seen as a limitation as it is difficult to 
distinguish between false positive and true associations.  Multiple comparisons are however recognized as 
a common phenomenon in genetic association studies (Andersson et al. 2009).  Perneger (1998) 
recommends that it is important to consider the results from all association tests and that each significant 
p-value should rather be interpreted with caution, taking into account the plausibility of the finding.  In the 
current study, the replication of previously reported results as well as functional explanation of the 
association between the polymorphism and phenotype (Andersson et al. 2009) where considered as factors 
that strengthens the possibility that the specific finding may be a true association.  The novel associations 
found in the current study should thus be viewed as “hypotheses generating” findings that should be 
replicated and further investigated to establish the functional plausibility and clinical value for 
implementation as part of weight management interventions.      
 
Finally, although the FTO rs17817449 and ADRB2 Arg16Gly polymorphisms as well as the gene-gene 
interaction between the ADRB2 Arg16Gly and INSIG2 rs7566605 polymorphisms influenced weight loss 
over the short-term in the current study, it would be premature to conclude that these polymorphisms can 
be included as part of an evidence-based personalized weight loss recommendation program.  Within this 
context it must also be borne in mind that genotype only explains one component of the phenotypic 
expression of multifactorial diseases such as obesity or the response to weight loss treatment.  Effective 
obesity prevention/treatment interventions should thus address the spectrum of causes of the condition 
that can include any combination of genetic, biochemical, psychological, physiological and environmental 
factors.  Furthermore, with the known fact that multiple polymorphisms play a role in the development of 
complex diseases such as obesity, more research such as the current study is necessary, but with the 
inclusion of investigating more polymorphisms and larger samples. If affordable, this requires more 
extensive analyses techniques such as DNA chip analysis or exome or whole genome sequencing.  
 
Based on the results and conclusions of this study it is recommended that the following associations should 
be viewed as priority in future research: 
 The GNB3 C825T polymorphism and physical health indicators (MetS/MetS traits). 
 The FTO rs1421085 and rs17817449 polymorphisms and weight loss outcome and eating behaviours. 
 The gene-gene interaction between the INSIG2 rs7566605 and ADRB2 Arg16Gly polymorphisms and 
weight management. 
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Addendum A: Screening questionnaire 
 
Screening Questionnaire 
     
Today’s date   /   /  2 0 0       
 d d  m m  y y y y       
   
Name  Surname:   
   
Date of birth   /   / 1 9    Age:   years  
 d d  m m  y y y y       
      
Weight    ,  kg  Height  ,   m BMI   ,   
    
    
Highest academic qualification achieved      
   
What is your profession currently      
     
Please answer yes or no to the following questions     
     
 Are you currently pregnant  1.  Yes         2. No    3. Not applicable   
     
 Are you currently breast feeding 1.  Yes         2. No    3. Not applicable   
     
 Have you ever been diagnosed with Anorexia 1.  Yes         2. No      
     
 Have you ever been diagnosed with Bulimia 1.  Yes         2. No      
     
 Have you ever been diagnosed with a Psychiatric illness 1.  Yes         2. No      
  If yes, specify:   
    
 Do you have a history of drug or alcohol abuse 1.  Yes         2. No     
    
 Do you suffer from Graves disease 1.  Yes         2. No     
    
 Do you use weight reduction aids on a regular basis 1.  Yes         2. No     
  If yes, specify: Name(s) of aids:  
   How often using it:  
    
    
Contact details of potential subject  
    
Telephone (home) (        ) Cell phone   
    
Telephone (work) (        ) E-mail   
    
In which town/ city/ suburb do you live? Stellenbosch  Somerset-West  Strand/ G’bay  Paarl   
    
 Other, specify      
    
In which town/ city/ suburb do you work? Stellenbosch  Somerset-West  Strand/ G’bay  Paarl   
    
 Other, specify      
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Addendum B: Consent form 
 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM  
 
TITLE OF RESEARCH PROJECT: Association between conventional (dietary, physical activity and behavioural) 
treatment outcome (weight loss) in overweight/obese adults and genotype. 
 
REFERENCE NUMBER: 
 
PRINCIPAL INVESTIGATOR:  Dr Marjanne Senekal 
ADDRESS:  Department of Physiological Sciences 
 University of Stellenbosch 
 Private Bag X1, Matieland, 7602 
 
CONTACT NUMBER: (021) 8083631 
 
We would like to invite you to participate in a research study that involves DNA (genetic) analysis and possible long-term 
storage of blood or tissue specimens.  Please take some time to read the information presented here which will explain 
the details of this project.  Please ask the study staff or doctor any questions about any part of this project that you do 
not fully understand.  It is very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free to decline to participate.  
If you say no, this will not affect you negatively in any way whatsoever.  You are also free to withdraw from the study at 
any point, even if you do agree to take part initially.  
 
This research study has been approved by the ethics Committee for Human Research at Stellenbosch University 
and it will be conducted according to international and locally accepted ethical guidelines for research, namely the 
Declaration of Helsinki, Guidelines on Ethics for Medical and Genetic Research of the Medical Research Council of 
South Africa (MRC). 
 
WHAT IS DNA ANALYSIS OR GENETIC RESEARCH? 
Genetic material, also called DNA, is usually obtained from a small blood sample.  Occasionally other tissues may be 
used.  DNA consists of numerous genes, strung together in long strands and found in every cell in the human body.  
Genes determine who we are, what we look like and sometimes what kind of diseases we may be susceptible to.  
Worldwide research in this field is continuously discovering new information that may be of great benefit to future 
generations and also that may benefit people today, who suffer from particular diseases or conditions. 
 
What does this particular research study involve? 
The aim of this research is to look at the success (=weight loss) of treatment of overweight adults with a conventional 
weight reduction program (including dietary, physical activity and behavioural components) and their genotype. We also 
want to identify appropriate predictors of long-term success of such conventional treatment. This will help to improve the 
matching of patients with treatment and thus the eventual success with treatment. As part of this project genetic material 
(blood) will be collected and analysed for the presence of certain genetic alterations that have previously been studied in 
overweight adults.  These genetic alterations are most probably not associated with any negative effect(s) when present 
on their own, which means that they will only have an effect when combined with other genetic alterations and/or specific 
lifestyle patterns.   
 
Why have you been invited to participate? 
You fit the criteria for this study and were therefore invited to participate. 
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What procedures will be involved in this research? 
You will be requested to: 
• Provide information about your medical history, weight history, family’s weight history, eating behaviour, dietary 
intake, physical activity, mental health and brief socio-demographic information by completing questionnaires, which 
will take 30-45 minutes;   
• Keep record of everything that you eat and drink for 3 days on dietary record forms that will be provided to you (at 
the beginning of the project and then every two weeks for a period of six months); 
• Keep a simple daily record (tick of activities as you did it) of your physical activity for the entire six month period; 
• Give consent for the drawing of blood (15ml, about 3 teaspoonfuls) for the determination of a fasting (after 12-14 
hours fast) blood HDL, triglyceride and glucose levels and for DNA-analysis; 
• To obtain written permission from your general practitioner to participate in this research on the provided form; 
• Be available for the assessment of the following anthropometric measurements: weight, height, waist circumference, 
hip circumference and triceps skin fold; 
• Place a piece of blotting paper (3 cm diameter), which is saturated with a chemical compound that can have a bitter 
taste for some, on your tongue so that your taste sensitivity can be tested; 
• Follow an individualized weight loss program, including a group session every two weeks for a period of six months 
that will include dietary, exercise, behavioural and cognitive restructuring components. 
 
Are there any risks involved in genetic research? 
• You may experience minor pain or bruising at the site where blood is taken; 
• You may feel some discomfort when tasting the piece of paper, which is saturated with a harmless chemical 
compound that may taste bitter for some; 
• You may feel some discomfort during the assessment of the anthropometric measurements and during the 
assessment of resting energy expenditure; 
• Some insurance companies may mistakenly assume that taking part in genetic research indicates a higher risk for 
disease.  Thus no information about you or your family will be shared with such companies; 
 
Are there any benefits to your taking part in this study and will you get told your results? 
You will gain scientific knowledge about weight management, you will receive a published weight management manual 
and will lose weight if you follow the program.  After all the results of all the tests from all the study participants are 
known, a study conclusion written in layman terms will be provided to you.   
 
How long will your blood be stored and where will it be stored? 
Your blood will be stored for a period of 5 years at the Department of Physiological Sciences, University of Stellenbosch. 
 
If your blood is to be stored is there a chance that it will be used for other research? 
Your blood and DNA will only be used for genetic research that is directly related to the treatment of overweight or 
obesity.  Also if the researchers wish to use your stored blood for additional research in this field they will be required 
to apply for permission to do so from the Human Research Ethics Committee at Stellenbosch University. 
 
If you do not wish your blood specimen to be stored after this research study is completed you will have an opportunity 
to request that it be discarded when you sign the consent form. 
 
How will your confidentiality be protected? 
Your identity will be kept confidential throughout and information will not be associated with your name.  The research 
staff will use only a coded number, access will be limited to authorized scientists and any scientific publications, lectures 
or reports resulting from the study will not identify you by name.  
 
Will you or the researchers benefit financially from this research? 
You will not be paid to take part in this study and will not be compensated for travelling costs to attend the initial 
assessments and group sessions every two weeks.   
 
In the unlikely event that the research leads to the development of a commercial application or patent you or your family 
will not receive any profits or royalties.  However profits will be reinvested to supporting the cause of further research, 
which may bring benefits to your family or community in the future. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a genetic research study entitled: 
Association between conventional (dietary, physical activity and behavioural) treatment outcome (weight loss) in 
overweight/obese adults and genotype. 
 
I declare that: 
• I have read or had read to me this information and consent form and it is written in a language with which I 
am fluent and comfortable.   
• I have had a chance to ask questions and all my questions have been adequately answered. 
• I understand that taking part in this study is voluntary and I have not been pressurised to take part. 
 
 I agree that my blood or tissue sample can be stored, but I can choose to request at any time that my 
stored sample be destroyed.  I have the right to receive confirmation that my request has been carried out. 
OR 
 Please destroy my blood sample as soon as the current research project has been completed.  (Tick the 
option you choose) 
 
 
Signed at (place) ......................…........……………………………………… on (date) ………………………....……….. 2006. 
 
 
 
 ...................................................................................   ................................................................................. 
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) …………………………………………………………………………… declare that: 
 
• I explained the information in this document to …………………..……………............................... 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research as discussed above. 
• I did/did not use a translator.  (If a translator is used then the translator must sign the declaration below). 
 
 
Signed at (place) ......................…........…………………………….….. on (date) …………....……………….…….. 2006. 
 
 
 
 ...................................................................................   ................................................................................. 
Signature of investigator Signature of witness 
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Addendum C: Questionnaires 
 
Sociodemographic & weight questionnaire 
Date   /   / 2 0 0 7  Code     
 d d  m m  y y y y       
  
  
Name & Surname  
  
    
1. Gender  1. Male  
2. Female  
    
2. Marital status 1. Unmarried  
2. Married    
3. Divorced    
4. Separated    
5. Widowed    
6. Living together  
    
3. Home language 1. Afrikaans  
2. English    
3. Zulu  
4. Other, specify :   
 
                           …................................................................. 
    
4. Highest level of education completed 1. Matric  
2. College certificate/ diploma  
3. Technikon diploma/ degree  
4. University degree   
5. Other, specify :   
 
                      ……………………………………………………. 
    
5. Do you live 1. alone  
2. with friends  
3. with your husband/ wife/ partner  
4. with your husband/ wife/ partner and children  
5. With your parents  
6. Other, please specify:   
 
…………………………………………………………….. 
    
6. In which of the following areas do you stay? 1. Stellenbosch/ Somerset-West/ Strand/ Gordonsbay  
2. Northern suburbs: Durbanville, Brackenvelle, Bellville etc.  
3. Southern suburbs: ??  
4. Cape Town: city centre  
5. Other, please specify:  
 
   ………………………………………………………………………. 
    
7. Would you describe your weight during most of your childhood years (ages 2 to 10) as: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
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8. Would you describe your weight during most of your adolescent years (ages 11 to 19) as: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
    
9. When you were between the ages of 20 to 25 years would you describe your weight as: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
5. Not applicable  
    
10. When you were between the ages of 25 to 30 years would you describe your weight as: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
5. Not applicable  
    
11. When you were between the ages of 30 to 35 years would you describe your weight as: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
5. Not applicable  
    
12. Would you consider your mother for most of your adolescent years to be: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
5. Did not know her      
    
13. Would you consider your father for most of your adolescent years to be: 1. Underweight  
2. Normal weight  
3. Overweight  
4. Obese  
5. Did not know him     
    
14. How would you describe the weight of your living biological parents at present  
 14.1 Your father presently is  
   
1. Underweight   
2. Normal weight   
3. Overweight   
4. Obese   
5. Did not know him  
   
 14.2 Your mother presently is  1. Underweight   
2. Normal weight   
3. Overweight   
4. Obese   
5. Did not know him  
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Food Frequency Questionnaire 
 
 
 
Instructions 
 Look at the food item list (column 1)   
 Think back carefully over the past month and determine how often you ate each item   
 If you eat/drink a specific item less than once a month, mark the Never/<1/ month 
column. 
 If you do eat/drink it more regularly, decide how often you eat it per month, OR per 
week, OR per day and make a cross (X) in the column which best applies to each item 
in the food list. 
 Only make one cross (X) for each item in the list e.g. for each row in the table. 
 
 Never/  
<1/ month 
1-3/ 
mth 
1/ 
week 
2-4/ 
week 
5-6/ 
week 
1/ 
 day 
2-3/ 
day 
4-5/ 
day 
6+/ 
day 
STARCHES 
         
White or brown bread and/or buns/ 
rolls 
         
Whole wheat, health, Low GI, seed 
etc. bread and/or rolls 
         
Breakfast cereals or porridge such as 
All bran, high bulk bran, Muesli, Weet-
bix, Pronutro, Oats etc. 
         
Breakfast cereals such as  Rice 
crispies, Cornflakes, Coco pops, Fruit 
loops, Maize porridge etc. 
         
Rice, mealie rice, samp 
 
         
Pasta:  macaroni, spaghetti, noodles 
 
         
Potato:  cooked, baked, mashed   
 
         
Potato:  cooked, baked, mashed  with 
fat added or potato salad 
         
Legumes:  baked beans, lentils, 
harricot beans, split peas, broad 
beans, kidney beans, sugar beans, 
dried bean salad/soup etc. 
         
VEGETABLES 
         
Cooked vegetables: any type. (no 
sugar/ fat/ sauce added) 
         
Vegetables: any type prepared with 
sugar/ fat/ sauces e.g. white sauce. 
         
Mixed salad: lettuce, cucumber, 
tomato, peppers, onions, mushrooms, 
carrots in any combination or alone. 
         
FRUIT 
         
Fresh fruit (any type) 
 
         
Dried fruit  (any type) 
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 Never/  
<1/ month 
1-3/ 
mth 
1/ 
week 
2-4/ 
week 
5-6/ 
week 
1/ 
 day 
2-3/ 
day 
4-5/ 
day 
6+/ 
day 
Fruit juice 
 
         
Fruit salad:  fresh or tinned 
 
         
MILK, YOGHURT AND CHEESE 
         
Full cream: milk, yogurt, sour milk 
(maas) 
         
Skimmed/ low fat/2%: milk, yogurt, 
sour milk (maas)  
         
Coffee creamer: in tea/coffee e.g. 
cremora 
         
Milk drinks:  Milo, Nesquik, Horlicks 
 
         
Cheese:  gouda, cheddar, camembert, 
brie, edam etc. (except low fat/ fat-free 
cottage cheese) 
         
MEAT, FISH, CHICKEN 
         
Snitzels, gorden bluer 
 
         
Red meat e.g. beef, mutton, pork.  (Eat 
meat and visible fat)  
         
Red meat e.g. beef, mutton, pork.  (Eat 
meat, but remove visible fat)  
         
Red meat e.g. venison & ostrich.   
 
         
Chicken/turkey:  with skin 
 
         
Chicken/turkey:  without skin 
 
         
Fried fish in any fat or oil, with or 
without batter/crumbs. 
         
Fish:  steamed, grilled, braaied (fire) 
 
         
Fish:  tinned sardines, pilchards, 
salmon, tuna 
         
Sausages:  Vienna’s, russians, 
frankfurter 
 
         
Cold meat:  polonie, salami, etc. & 
bacon 
 
         
Eggs:  cooked or poached 
 
         
Eggs:  scrambled, baked, omelettes 
 
         
FATS 
         
Soft margarine  
 
         
Butter/hard margarine 
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 Never/  
<1/ month 
1-3/ 
mth 
1/ 
week 
2-4/ 
week 
5-6/ 
week 
1/ 
 day 
2-3/ 
day 
4-5/ 
day 
6+/ 
day 
Salad dressing, mayonnaise: normal 
fat 
         
Salad dressing, mayonnaise: lite/ low 
fat 
         
FAST FOODS AND TAKE AWAYS          
Pizza 
 
         
Pies & Sausage rolls 
 
         
Potato chips (French fries)  
 
         
Kentucky Fried Chicken 
 
         
Hamburgers (= bun and meat or 
chicken patty) e.g. McDonalds, Steers, 
Wimpy, Spur, other restaurants etc. 
         
OTHER 
         
Vetkoek, samoosas, koeksister, 
doughnuts 
         
Muffin, scones, cake, tart  
 
         
Rusks:  commercial or homemade e.g. 
bran, buttermilk, white, whole wheat 
etc. 
         
Cookies: commercial or homemade: 
e.g. oat, crunchies, shortbread 
         
Chips:  niknaks, simba etc. 
 
         
Energy bars, health bars, breakfast 
bars 
 
         
Chocolate 
 
         
Ice cream 
 
         
Cheese sauce, white sauce, meat 
sauces 
 
         
Tomato sauce, chutney, mustard, 
sweet chilli sauce 
         
Sweets e.g. jelly tots, sour worms, 
super-C’s etc. 
         
Nuts and peanuts  
 
         
Peanut butter 
 
         
Chocolate spread 
 
         
Jam, syrup, honey 
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 Never/  
<1/ month 
1-3/ 
mth 
1/ 
week 
2-4/ 
week 
5-6/ 
week 
1/ 
 day 
2-3/ 
day 
4-5/ 
day 
6+/ 
day 
DRINKS 
         
Wine:  red or white 
 
         
Port, sherry, liqueur 
 
         
Beer, cider, coolers e.g. castle, black 
label, hunters dry, savanna, smirnoff 
etc. 
         
Bier, cider, cooler diet/ light  e.g.  
Savanna light 
         
Spirits:  e.g. brandy, whisky, rum, 
vodka, gin.  
         
Fizzy soft drinks: e.g. coke, fanta 
 
         
Fizzy diet soft drinks: e.g. coke lite etc. 
 
         
Energy drinks e.g. energade, 
powerade 
 
         
Milkshake 
 
         
EATING PLACE 
         
In general, how often do you eat out 
e.g. restaurant, take-aways, hotel, 
prepared food/ meals from Spar, 
Checkers etc. 
         
If you work during the day (away from 
your home), how often do you take 
food from your home with you to eat 
during the day. 
         
If you work during the day (away from 
home), how often do you buy food to 
eat during the day. 
         
 
 
 
 
 
 
 
